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CHAPTER I 
 
NATURALLY OCCURRING AROMATIC POLYKETIDES 
 
Secondary Metabolites and Their Medicinal Properties 
 
The medicinal properties of secondary metabolites have been known for 
thousands of years.1 The Inca civilization chewed the leaves of coca plants, which 
produce cocaine (1.1) and cause feelings of intense euphoria.1 Secretions of the opium 
poppy, which produces morphine (1.2), codeine, and other alkaloid metabolites, have 
found use as analgesics and anxiolytics since the time of Homer, and pure morphine, first 
isolated in 1806 by Friedrich Wilhelm Adam Sertürner, aided minor surgical procedures 
beginning in the mid-nineteenth century.2 In 1928, Alexander Fleming noted the absense 
of Staphylococcus aureus colonies surrounding the mould Penicillium notatum, the now 
famous producer of penicillin G (1.3), and thus began the modern era of antibiotic drug 
treatment.3 Many subsequent anecdotes similar to these have shaped the history of 
medicine, and microbial secondary metabolism remains an important source of 
treatments for prominent twenty-first century diseases. 
 
 
Figure 1.1. Historically important secondary metabolites. 
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Organisms synthesize natural products through secondary metabolism which 
exists as a close extension of primary metabolism. The pathways responsible for 
converting key dietary components such as carbohydrates, sugars, fats, and proteins into 
energy are described as primary metabolic pathways and are common to all organisms.4 
In contrast, secondary metabolism produces compounds of varying amount and utility 
under specific environmental conditions and lacks consistency across species. While few 
compounds have known purposes, self-defense, mating, and camouflage are among the 
common elucidated uses for certain classes of secondary metabolites. Compounds 
involved in and produced by primary metabolism provide many of the biosynthetic 
intermediates necessary for secondary metabolism, and acetyl coenzyme A (CoA), 
shikimic acid, and mevalonate are important examples.4  
Specifically, the acetate pathway for secondary metabolism utilizes acetyl CoA to 
synthesize natural products such as polyketides, phenols, prostaglandins, and fatty acids.4 
These classes of natural products have found many uses as medicinal therapies such as 
antibiotics, immunosuppressants, and antitumor agents.5 Acetyl CoA is produced through 
oxidative decarboxylation of pyruvic acid via the glycolytic pathway, which utilizes 
dietary D-glucose as its input.4 Cellular machinery then uses acetyl CoA as a key 
building block for production of important secondary metabolites. 
 
Aromatic Polyketide Biosynthesis 
 
Polyketides are a large and diverse class of natural products that can be divided 
into subcategories including macrolides (erythromycin, 1.10), polyenes (amphotericin, 
 3 
1.7 and rapamycin, 1.9), polyethers (monensin, 1.6), and aromatics (tetracycline, 1.8) as 
shown in Figure 1.2 and the selected polyketides have a rich history of clinical use.6 
Erythromycin (1.10), a common broad-spectrum antibiotic, has been used in the 
treatment of upper and lower respiratory infections for more than 50 years, and it is a 
common alternative for penicillin-alergic patients.7 Monensin (1.6) and tetracycline (1.8) 
are commercially marketed antibiotic therapies, while amphotericin is a widely used 
antifungal treatment.8 Rapamycin (1.9) is an immunosuppressant utilized to prevent 
transplanted organ rejection, and lovastatin (1.5) is a cholesterol-lowering agent.8 
Resveratrol (1.4), a stilbene polyketide found in red wine, has produced much debate 
over its reported anti-aging effects, and calicheamicin γ1 (1.11), one of the most potent 
antitumor agents known, is an enediyne natural product that has been developed as part 
of several monoclonal antibody constructs for cancer treatment.9,10 The classification of 
polyketides arises from the biosynthetic machinery utilized in their synthesis, all of which 
derive from the acetate pathway of secondary metabolism.  
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Figure 1.2. Biologically important examples of polyketide natural products. 
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 5 
workup surprisingly led to the aromatic compound orcinol (1.15). While simply 
determining the structure of the reaction product was no small task at the time, the key 
point to his groundbreaking hypothesis involved proposing the triketone 1.13 as an 
intermediate in the transformation. Thus, the biosynthetic pathway was proposed to 
involve addition of water followed by dehydration and tautomerization to the aromatic 
product. Despite the importance of Collie’s findings, acceptance of his hypothesis did not 
come until Robert Robinson revived the conversation with his publication of the 
biosynthesis of tropinone.12 Arthur Birch also played in important role in developing the 
basis for polyketide biosynthesis in the 1950’s.12 Birch hypothesized that the polyketone 
intermediate proposed by Collie could arise from the condensation of acetate units, and 
he confirmed his theory by determining the pattern of acetate incorporation into the 
natural product 6-methylsalicylic acid with isotopic labeling. These studies laid the 
groundwork for the extensive research that followed and formed the basis of our current 
understanding of polyketide biosynthesis. 
 
 
Scheme 1.1. Collie’s proposed biosynthesis of orcinol. 
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in unison. Type I polyketide synthases (PKS) are large proteins with many enzymatic 
active sites performing all necessary functions for metabolite synthesis.11 Type I PKS’s 
have been identified in bacteria, plants, and fungi, and the type I PKS mechanism 
produces macrolides, polyethers, and polyenes.6 The minimal domains necessary for type 
I synthesis include ketosynthase (KS), acyltransferase (AT), and acyl carrier protein 
(ACP).12 Optional subunits provide variation along the growing linear chain, which 
include ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER).12 The type I 
PKS builds a linear chain with a terminal β-diketone through a decarboxylative 
condensation between enzyme-associated starter and extender units, acetyl CoA being the 
simplest.13 Through each round of chain extension, varying levels of ketone reduction 
occur based on the use of optional domains listed above.6 In this way, the level of 
oxidation in type I products directly correlates to the domains utilized in their synthesis; 
however, post-PKS modification can alter the oxidation state of the final product.13 
Finally, a thioesterase (TE) enzyme is responsible for releasing the polyketide chain from 
the complex with either an acid or acyl ester terminus.12 
 In contrast to the type I PKS enzyme complex, type II polyketides arise from the 
coordinated action of individual enzymes acting as a large complex and are generally 
produced by bacteria.6 Aromatic polyketides are produced by type II PKS machinery, and 
the minimal type II PKS complex includes KS, ACP, and chain length factor (CLF).11 
Unlike the varying states of reduction found along the extending chain in type I PKS 
synthesis, the linear polyketide chain associated with the type II PKS often remains in the 
ketone oxidation state and is stabilized by a complex between the CLF and KS, which 
allows for ultimate cyclization and aromatization.11 Synthetic studies by Tom and 
 7 
Constance Harris in 1977, in which they prepared linear polyketone chains through 
polyanion additions to polyketoesters, importantly confirmed that the biosynthetic 
cyclization of these linear chains must be under enzymatic control due to the formation of 
isomeric products in solution.14 In addition to the optional enzymes involved in type I 
PKS’s, type II synthesis utilizes enzymes such as cyclases (CYC) and aromatases (ARO) 
to effect formation of the hallmark fused aromatic polycyclic structures of aromatic 
polyketides.6 
 The final subgroup of polyketides is synthesized by chalcone and stilbene 
synthases which are categorized as type III PKS’s. These PKS’s exist primarily in plants 
but also in bacteria, and fungi.5 Type III PKS’s do not utilize an ACP in contrast to the 
first two types and function as iterative homodimers in the production of aromatic 
polyketides.15 Importantly, consideration must be given to the numerous examples that do 
not strictly follow the paradigm laid out by the rather rigid definitions of the type I, II, 
and III PKS’s.15 
 Actinorhodin (1.23), a blue-pigmented antibiotic, is a classic example of a type II 
aromatic polyketide. 16  Isolated from the actinomycete Streptomyces coelicolor A3, 
actinorhodin is the first antibiotic for which its entire gene cluster was cloned.16 These 
studies determined that actinorhodin is produced iteratively by a single set of biosynthetic 
enzymes, and therefore it has become one of the most well studied type II PKS systems.16 
 The initial steps involved in actinorhodin biosynthesis are shown in Figure 1.3. 
The minimal type II PKS system, which consists of KS, CLF, and ACP, utilizes acetyl 
CoA as the starter unit and seven malonyl CoA extender units to synthesize the linear 
polyketide chain 1.18, where bolded bonds indicate the two-carbon unit incorporation 
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pattern.12 The minimal PKS machinery has also been implicated in the first cyclization 
step, which yields 1.19, and KR then regioselectively effects ketone reduction in 
preparation for aromatization.12 Aromatase forms the phenol 1.21 which then undergoes a 
second cyclization performed by CYC. From 1.22, the biosynthetic steps are less well 
characterized; however, stereoselective reduction of the β-keto-thioester in 1.22 by KR 
provides the first chiral intermediate leading to the outer ring stereochemistry.16 
Actinorhodin biosynthesis provides a relatively general template for the assembly of 
many related aromatic polyketides, in which a linear polyketide undergoes a series of 
reductions, cyclizations, and aromatizations. 
 
 
Scheme 1.2. Biosynthetic pathway of the aromatic polyketide actinorhodin. 
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Synthetic Approaches to Aromatic Polyketides 
 
Following seminal work by Collie and Birch, much of the early synthetic research 
toward aromatic polyketides involved accessing clinically relevant compounds. Notably, 
the tetracycline family of antibiotics, which represent canonical aromatic polyketides 
with their linear tetracyclic backbone, garnered much attention in the 1950’s and 1960’s 
following their isolation from various strains of Streptomyces actinobacteria. 17 
Aureomycin (1.24), also termed chlorotetracycline, was the first family member to be 
isolated and identified as a potent antibacterial agent, and Lloyd Conover at the Charles 
Pfizer Co., Inc. first produced tetracycline (1.8) through catalytic hydrogenation of 
aureomycin. Following fevered studies, Pfizer in collaboration with R. B. Woodward 
determined the structure of terramycin (1.25), also known as oxytetracycline. 
Tetracycline (1.8) was approved by the FDA in 1954 and has enjoyed widespread success 
as a broad-spectrum antibiotic since its first use in the clinic.17 
 
 
Figure 1.3. Examples of tetracycline family members. 
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and Fields, Kende, and Boothe in the United States was superseded by completion of the 
total synthesis of 6-demethyl-6-deoxytetracycline by R. B. Woodward in 1962. 18 
Woodward’s synthesis was quickly followed by Shemyakin’s synthesis of tetracycline 
(1.8) in 1963 and Muxfeltd’s assembly of 6-demethyl-6-deoxytetracycline in 1965. Later, 
Muxfeltd succeeded in the total synthesis of the much more complicated terramycin 
(1.25) in 1968. 
Owing to their importance as medicinal agents and their often-scarce availability, 
many other aromatic polyketides have been the subjects of many modern total synthesis 
efforts. While the aldol reaction is the linchpin reaction for synthesis of macrocyclic 
polyketide type I natural products and the Dieckmann condensation the linchpin of 
aromatic polyketide biosynthesis, a wide variety of approaches have been utilized for the 
total synthesis of type II aromatic polyketides, and an examination of the key backbone-
forming reactions can provide insight into the most effective methods for consideration in 
synthetic planning. The fused polycyclic structures lend themselves to a range of ring 
formation methodologies, including Diels-Alder, electrocyclization, radical ring closure, 
and multi-step cyclizations. Examples shown encompass the recent literature and focus 
on the enabling step in ring-structure formation. 
 After a half-century of clinical use, tetracycline antibiotic resistance has become a 
serious issue, and Myers and co-workers have led the field in producing synthetic routes 
to tetracycline derivatives aimed at circumventing resistance.19 Key to their approach is 
the unification of two halves through an electrocyclic ring opening of a benzocyclobutane 
followed by intermolecular Diels-Alder cycloadditon. This method has proven rather 
general toward accessing aromatic polyketides and has been implemented in numerous 
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other syntheses. Therefore, Myers’ total synthesis of (−)-tetracycline truly set the state of 
the art by introducing important alternative methods for the antibiotic’s production. 
 
 
Scheme 1.3. Myers’ synthesis of (–)-tetracycline. 
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 Starting with large-scale microbial whole-cell dihydroxylation of benzoic acid 
(1.26), optically pure 1.27 was then regio- and stereoselectively epoxidized with m-
CPBA.19 Methyl ester formation was followed by treatment with TBSOTf under basic 
conditions which effected epoxide rearrangement and subsequent bis-silylation to arrive 
at 1.28. Nucleophilic addition of the lithiated isoxazole 1.29 into the methyl ester yielded 
ketone 1.30, which set the stage for the first ring closure step. Heating in the presence of 
LiOTf caused SN2’ epoxide opening by the tertiary amine functionality followed by a 
[2,3]-sigmatropic rearrangement of the resultant nitrogen ylide to arrive at the tricyclic 
1.31. Reductive olefin transposition successfully installed the necessary olefin 
regioisomer for upcoming Diels-Alder unification. Silyl deprotection and oxidation to the 
enone produced a common intermediate utilized by Myers for synthesis of a large 
number of tetracycline derivatives, whereas continuation in Scheme 1.2 describes the 
group’s route to the natural (−)-tetracycline (1.8).20 Installation of an α-thiophenyl enone 
set the stage for intermolecular Diels-Alder reaction with the stereochemically-defined 
benzocyclobutane 1.34 which provided the highly-elaborated 1.35 in good yield. TES-
ether deprotection was followed by IBX oxidation, and m-CPBA oxidation of the 
thiophenyl group to a sulfoxide then led to sulfoxide elimination and air oxidation to 
hydroperoxide 1.38. Finally, global hydrogenolysis led to (−)-tetracycline (1.8) through 
benzyl ether deprotection, isoxazole cleavage, and hydroperoxide reduction. Myers’ 
clever approach allowed rapid buildup of complexity with an efficient route to the broad-
spectrum antibiotic tetracycline and opened access to a wide range of analogs to combat 
problems of antibiotic resistance. 
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Isolated in 1983 from the tropical marine sponge Xestospongia exigua, 
halenaquinone (1.47) exhibits in vitro biological activity against Staphylococcus aureus 
and Bacillus subtilis and represents a unique pentacyclic polyketide-derived structure.21 
Although it had succumbed to total synthesis three times prior, Trauner and co-workers 
offered an elegant entry into the pentacyclic core of halenaquinone through a unique 
vinyl-quinone Diels-Alder.22  
 
 
Scheme 1.4. Trauner’s total synthesis of (–)-halenaquinone. 
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installed the quaternary center with the pendant vinyl dienophile found in 1.47. Tin-
lithium exchange with 1.42 and addition into the furanal 1.41 afforded the advanced 
intermediate as an inconsequential mixture of diastereomers. Silyl deprotection, bis-
oxidation under Ley conditions, and oxidation to the vinyl quinone produced the Diels-
Alder precursor 1.44. The key pentacycle-forming step involved a high-pressure inverse-
demand intramolecular Diels-Alder reaction with concomitant tautomerization to the 
vinyl hydroquinone 1.46. Lastly, oxidation with MnO2 completed the synthesis of (−)-
halenaquinone (1.47). Trauner’s use of the intramolecular Diels-Alder reaction for multi-
cyclic ring system installation exemplifies one major strategy for the assembly of 
aromatic polyketide natural products. 
The aflatoxin family of mycotoxins was originally identified in 1960 as the 
common mutagens produced by a number of Aspergillus molds that contaminate grains 
and nuts in the food supply.23 Aflatoxin B1 (not shown), the most toxic of the family, 
undergoes P450-mediated epoxidation at the outer ring dihydrofuran moiety which 
readily undergoes DNA alkylation. Numerous syntheses of aflatoxin family members 
preceded Corey’s enantioselective route in 2005, but the simplicity of an asymmetric 
[3+2] cyclization to establish three of the five rings sets this approach apart from others 
in addition to its brevity.24 
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Scheme 1.5. Corey’s total synthesis of aflatoxin B2. 
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 One of the more unusual aromatic polyketides known, cavicularin (1.63) was 
isolated from the liverwort Cavicularia densa and possesses a dihydrophenanthrene 
moiety within a macrocyclic structure containing two other aryl rings.25 Interestingly, the 
immense macrocyclic ring strain causes the ether-linked arene to adopt a boat-like 
conformation, and this fact played a large part in Harrowven’s synthetic design. To this 
point, an ingenious radical-mediated transannular ring contraction was planned to 
alleviate issues related to ring strain until the final steps of the synthesis.  
 
 
Scheme 1.6. Harrowven’s synthesis of (±)-cavicularin and (±)-riccardin C. 
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Thus, starting from the two advanced building blocks 1.58 and 1.59, synthesized 
in six and four steps respectively, a modified Wittig protocol provided the stilbene 1.60 
as an inconsequential mixture of E and Z isomers. Hydrogenation of the resultant olefin 
was followed by regioselective basic aryl iodination, phenol methylation, and bis-acetal 
deprotection to arrive at 1.61 in high yield. Macrocyclization under McMurray-type 
conditions was followed by diimide reduction to provide 1.62, which was set up for the 
key ring contraction reaction. Radical initiation with tris(trimethylsilyl)silane and AIBN 
successfully effected transannular ring contraction at 90 °C through radical combination 
into the adjacent aryl ring, although a large majority of the material underwent 
dehalogenation toward riccardin C (1.64). The inseparable mixture was subjected to 
demethylation conditions which led to a separable mixture of (±)-cavicularin (1.63) and 
(±)-riccardin C (1.64) in a 1:2 ratio. Harrowven’s use of a radical-mediated ring 
contraction truly enabled the assembly of this highly strained macrocyclic system. 
The kinamycin family of aromatic polyketides, whose original members A-D 
were isolated by Ōmura from Streptomyces murayamaensis, contains a unique 
diazotetrahydrobenzo[b]fluorene skeleton and includes numerous other members varying 
in alcohol acetylation level.26 The kinamycins exhibit potent anticancer activity across a 
range of cell lines and have been shown to act as DNA damaging agents. Although 
various kinamycin family members have succumbed to synthesis, Nicolaou’s approach to 
kinamycin F highlights the usefulness of multi-step cyclization sequences in the assembly 
of aromatic polyketides.27 
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Scheme 1.7. Nicolaou’s total synthesis of kinamycin F. 
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78% yield. With the kinamycin backbone synthesized, functional group manipulation 
began with tertiary alcohol acetylation and reduction, which was followed by base-
mediated olefin isomerization to provide 1.71. Stereoselective allylic oxidation with SeO2 
installed the final oxygen functionality, and the sequence of concomitant silyl and 
acetonide deprotection, triacetylation, and benzyl deprotection arrived at 1.72 in excellent 
yield. Phenol silylation set up for diazo moiety incorporation, which was effected by 
formation of the tosyl-hydrazone and CAN oxidation to form the protected kinamycin 
product 1.73. Finally, silyl and acetate group deprotection led to kinamycin F (1.74). 
While utility overrules elegance in the two-step cyclization approach to aromatic 
polyketides, Nicolaou and co-workers effectively demonstrated the importance of its 
consideration during synthetic planning through their successful assembly of kinamycin F 
(1.74). 
 Aromatic polyketide natural products have played an important role as medicinal 
agents, and thus synthetic access holds the potential to continue impacting human health. 
While many structural scaffolds exist, all aromatic polyketides can be related by common 
biosynthetic synthesis by type II polyketide synthases. Numerous strategies for their 
synthetic assembly have emerged, and the examples shown above seek to highlight the 
main methods used as key cyclization steps. Myers’ use of an intermolecular Diels-Alder 
reaction toward (−)-tetracycline (1.8) allowed for rapid unification of two highly 
functionalized subunits, while Trauner’s synthesis of halenaquinone (1.47) showcases the 
power of the intramolecular Diels-Alder reaction to build multi-ring systems in one single 
step. The linchpin [3+2]-electrocyclization in Corey’s approach to aflatoxin B2 (1.57) 
highlights the value of simplicity in the first synthetic step which provided three of the 
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five rings found in the natural product with the correct functionalization and 
stereochemistry. The unusual natural product cavicularin (1.63) shows the wide range of 
possible aromatic polyketides synthesized by microorganisms, and Harrowven’s elegant 
implementation of a radical-mediated macrocyclic ring contraction overcame innate 
structural limitations to arrive at the desired product. Finally, Nicolaou’s approach to 
kinamycin F (1.74) underscores the value and utility of multi-step ring formation, as its 
use can be equally successful in comparison with single-step cyclizations such as the 
Diels-Alder. With the importance of aromatic polyketide and methods for their formation 
in mind, the hibarimicin aromatic polyketide natural products constitute an important 
family of biologically important compounds in which a total synthetic effort holds 
promise in furthering the field of natural product therapeutics. 
 
Angelmicins A and B 
  
Oncogene-transformed cells exhibit lower growth requirements and continue to 
grow and thrive in a serum-free medium, while normal cells require specific growth 
factors for proliferation.28 Therefore, selective inhibitors of oncogenesis should display 
growth inhibition of transformed cells in serum-free medium but not in serum-containing 
medium, and an IC50 shift should be observable. Using this paradigm, Uehara and co-
workers screened the culture broth of a rare actinomycete Microbispora sp. AA9966 for 
selective growth inhibition and in 1993 reported the isolation of substances that potently 
inhibited the growth of src and abl oncogene-transformed NIH3T3 cells. 29  The 
microorganism was isolated from a soil sample collected at Mt. Tennyo in Gunma 
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Prefecture, Japan, and the substances were termed angelmicins A and B (1.75). The red 
powders were determined to have molecular formulae of C85H112O38 and C85H112O37 
respectively and were determined to have general structures including one anthraquinone 
and six sugar moieties for each compound. 
Angelmicin B was found to shift IC50 values of growth inhibition of src and abl-
transformed mouse NIH3T3 cells between serum-free and serum-containing media 7- and 
10-fold respectively, while in ras-transformed cells, angelmicin B caused only a 2.5-fold 
change in IC50.29 Comparatively, common chemotherapeutics such as doxorubicin and 
vinblastine showed no such selectivity in the developed assay indicating that the activity 
of angelmicins may be attributed to novel modes of action directly involving oncogenic 
signaling pathways. To further validate the activity of angelmicins on oncogene-derived 
signaling, p60v-src autophosphorylation was probed, and it was determined that 
angelmicins reduced activity in a dose dependent manner. Thus, angelmicins selectively 
inhibit the growth of oncogene-transformed cells without affecting the growth of normal 
cells, and through a single assay testing for direct inhibition of various protein kinases, 
angelmicins were characterized as selective inhibitors of tyrosine kinase without affecting 
protein kinase A or C. 
With knowledge of its activity toward src tyrosine kinase, it was postulated that 
angelmicin B could be utilized as a differentiation agent for acute leukemia.30 This 
indication is based on the premise that unchecked cell proliferation results from aberrant 
signaling due to the action of oncogenes, and chemical agents can induce terminal 
differentiation of immature malignant cell lines to abate cancerous growth. Therefore, 
because src is known to be a proto-oncogene implicated in numerous forms of cancer, 
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angelmicin B could potentially act as a chemotherapeutic, and the HL-60 leukemia cell 
line was chosen based on its previously reported ability to differentiate into a mature 
lineage with the addition of chemical agents. Thus, angelmicin was determined to inhibit 
HL-60 cell line growth with an IC50 of 58 nM while other leukemia cell lines were less 
responsive. Differentiation induction was also evaluated, and angelmicin B showed 
significant ability to effect differentiation of the HL-60 cell line which is indicated by 
NBT reduction and morphological changes, at a concentration of approximately 175 nM. 
Additionally, angelmicin B was found to act synergistically in effecting HL-60 
differentiation when co-treated with retinoic acid, TNFα, and vitamin D3. And while most 
chemotherapeutics effect differentiation at cytotoxic concentrations, all angelmicin B-
treated cells that underwent differentiation were not apoptotic, indicating that the 
mechanism of differentiation induction may be novel and may implicate angelmicin B as 
an effective therapy for myeloid leukemia. 
Several other angelmicin family members that were isolated from the same 
actinomycete culture broth but not reported in the initial isolation paper, which include 
angelmicins A1, A2, C, and D, were also tested for their ability to inhibit HL-60 cell 
growth and differentiation.30 Angelmicin B most potently inhibited tyrosine kinase 
activity and HL-60 growth, while angelmicin A2 was determined to be the most effective 
differentiation inducer. Also, from these studies, some important inconsistencies 
regarding the activity of angelmicin B arose. Most importantly, the concentrations of 
angelmicin B required for src tyrosine kinase inhibition were 20 to 200-fold higher than 
the concentrations necessary for growth inhibition. This indicates that tyrosine kinase 
may not be the responsible mechanism for the observed growth inhibition; however, 
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these events may be closely linked through a yet unknown pathway. Additionally, 
topoisomerase II was postulated as an alternative target that could be responsible for HL-
60 growth inhibition, of which known tyrosine kinase inhibitors have been shown to also 
effect topoisomerase inhibition. Finally, angelmicin B was studied as a differentiation 
inducer in freshly isolated leukemia cells, and while angelmicin B alone did not effect 
differentiation, it greatly improved the differentiation induction in unison with retinoic 
acid in acute promyelocytic leukemia. 
Three years removed from the publication of angelmicin isolation and 
characterization as selective tyrosine kinase inhibitors, the structure of angelmicin B was 
reported.31 Based on UV and visible spectra, which indicated absorbance at 511 nm that 
disappeared in a basic methanol solution, and an IR spectrum with peaks at 3450, 1705, 
and 1620 cm-1, angelmicin B was identified as containing a phenolic quinone structure. 
Beyond these studies, extensive 1D and 2D NMR spectroscopy was utilized to determine 
the complete carbon structure. The presence of six anomeric methine carbons indicated 
six sugar moieties, while two similar halves of the aglycon were assigned based on 
COSY and HMBC spectra. Each half contained a tertiary n-propyl unit, of which the 
tertiary oxygen of one half formed an ether bridge. Through NOESY and HMBC spectra, 
the sugar incorporation appeared symmetrical with equivalent disaccharides attached at 
both C-12 and C-12’ and a monosaccharide connected to C-10 and C-10’. Specifically, 
angelmicin B contains a β-amicetopyranose (AM) directly attached to the C-12 and C-12’ 
hydroxyl groups and an α-4-C-acetyl-2,3,6-trideoxyhexopyranose (AT) linked to both 
AM’s. Connected to the C-10 and C-10’ hydroxyl groups is an α-digitoxopyranose (DG) 
moiety. Anomeric configurations were determined by coupling constants and relative 
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sugar stereochemistry was reported; however, absolute sugar configurations were not 
determined. Three aryl methoxy groups reside on the A-ring, and the remaining methoxy 
group was assigned to the C-3’ quinone carbon based on comparison with a similar 
compound, O-methyllapachol. Finally, the remaining assignment involved attachment of 
the two similar halves through a carbon-carbon bond between the aryl C-2 and quinone 
C-2’. The originally assigned two-dimensional structure of angelmicin B, which did not 
include relative or absolute stereochemical assignments, is shown in Figure 1.4. 
 
 
Figure 1.4. Two-dimensional structure of angelmicin B. 
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hibaria TP-A0121.32 The microorganism was isolated from a soil sample collected at 
Hibari, Toyama Prefecture, Japan, in 1995, and the species was identified based on 
growth characteristics and DNA-DNA homology studies. Fermentation, ethyl acetate 
extraction, and chromatographic separation yielded more than ten components which 
were termed hibarimicins. Of these ten hibarimicins, physicochemical properties were 
reported for hibarimicins A, B, C, D, and G, all of which were red powders with an 
indicative UV absorbance at 511 nm in MeOH, properties that for B and D were noted in 
the publication to be identical to angelmicins B and A. 
 The multi-kinase assay utilized in the isolation of the hibarimicins involved 
detection of protein kinase A, protein kinase C, protein tyrosine kinase, and calmodulin-
dependent protein kinase III. By screening all four kinases within the same assay, Kajiura 
and co-workers were able to determine that the hibarimicins were selective inhibitors of 
protein tyrosine kinase activity without inhibiting the activity of protein kinases A or C. 
In vitro IC50 values for hibarimicins A-D were reported to range from 580 nM 
(hibarimicin A) to 2.32 µM (hibarimicin B) against src tyrosine kinase. And MIC’s for in 
vitro inhibitory activity against Gram-positive bacteria for hibarimicins A-D ranged from 
464 nM to 7.25 µM. Finally, in vitro cytotoxicity against B16-F10 (murine melanoma) 
and HCT-116 (human colon carcinoma) cells ranged from 406 nM to 1.01 µM. 
Therefore, the hibarimicin natural products exhibit a broad range of biological activity 
that centers around their roles as protein tyrosine kinase inhibitors. 
 The second publication in the series with Kajiura’s report in 1998 involved the 
structural determination of hibarimicins A-D and G highly relying on 1-D and 2-D NMR 
spectroscopic techniques.33  Based on the identically characteristic UV absorbances and 
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IR stretches across the family, the determination was made that the compounds all 
contained the same chromophore. Basic NMR spectroscopy identified the presence of 
carbohydrate moieties, and further investigation indicated their attachment in pairs for a 
total of six sugars. Thus, utilizing COSY, HMBC, NOESY, and TOCSY NMR, the 
sugars and their connectivities were assigned as β-amicetosyl (2,3,6-trideoxy-β-erythro-
hexopyranose), α-digitoxosyl (2,6-dideoxy-α-ribo-hexopyranose), and 4-C-acetyl-2,3,6-
trideoxy-threo-hexopyranose moieties. While the relative stereochemistry of the sugars 
was determined through coupling constants and comparison with synthetic versions, the 
absolute stereochemistry of all sugars remained undetermined. 
 Assignment of the hibarimicin aglycon again involved extensive 2-dimensional 
NMR spectroscopy. The molecule was divided roughly into halves, and two spin systems 
for each side were determined through COSY correlations. Complimentary HMBC 
established the carbon framework, and NOE and NOESY experiments confirmed these 
connectivities. Importantly, the six and seven contiguous stereocenters of the western and 
eastern tetracycles, respectively, were assigned primarily by coupling constants, which 
confirmed the cis relationship of the decalin ring systems and the trans-trans orientation 
of the triol systems. NOE and NOESY correlations further reinforced these 
stereochemical findings. And while the ether linkage in the eastern tetracycle aided in 
assigning the relative stereochemistry of the C-13’ center, no related assignment could be 
made at C-13 purely based on spectroscopic data. Additionally, although relative 
stereochemistry for the aglycon was successfully determined, the absolute configuration 
remained to be elucidated. 
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Figure 1.5. Key COSY and NOE/NOESY correlations for hibarimicin B. 
 
 With the carbohydrates and aglycon for hibarimicin B (1.78) assigned, it was 
confirmed that hibarimicin B was identical to the previously reported angelmicin B. And 
from the structural knowledge of hibarimicin B, the final assignments were made for the 
remaining members of the family. Ultimately, it was determined that the hibarimicins all 
retained the same aglycon core and AM and DG sugar patterning while differentiation 
occurred at the terminal carbohydrate moieties X and Y, as shown in Figure 1.6. 
Hibarimicins A, B, C, D, and G were reported in the 1998 structure elucidation paper, 
and E, H, and I were disclosed in a later publication. As shown, a few structural features 
are worth noting. While the absolute stereochemistry was not determined for the aglycon, 
the relative stereochemistry was initially represented in early reports as the enantiomer 
shown in Figure 1.6. Importantly, the tetra ortho-substituted aryl-quinone bond 
connecting the western and eastern halves of the aglycon has the potential to exhibit 
hindered rotation due to steric repulsion of the ortho substituents (atropisomerism); 
however, this possibility was not addressed in the structure elucidation paper. 
Nevertheless, one could reasonably assume that any isolated mixture of atropisomers 
would relay to a mixture of diastereomers visualized in the proton NMR spectrum, or 
readily interconvertible atropisomers would potentially cause line broadening. Thus, if 
O
OH
OH
O
O
DG'
AM'
O
NOE/NOESY
COSY
O
HO
O
O
OH
H
H
DG
AM
HO
OHOH
OMe
OMe OH
OH
O
O
MeO
O
AT
A'B'C'D'DCBA
O
AT'
WEST (1.76) EAST (1.77)
 28 
the hibarimicins do display atropisomerism, a single natural atropisomer would be a fair 
assumption for the family. 
 
 
Figure 1.6. The hibarimicin family of natural products. 
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to simple aromatic PKS patterning, determining their biosynthetic pathway remained an 
intriguing proposal. In 2002, led by Hori, Kajiura, and Igarashi, a series of three 
publications addressed this interest through two different approaches. 
Utilizing the methodology originally developed by Birch, Hori and co-workers 
reported the use of isotopic labeling of precursor units to unravel important portions of 
the pathway.34 By fermentation of Microbispora rosea subsp. hibaria TP-A0121 with [1-
13C], [2-13C], or [1,2-13C2] acetates, isotopically labeled hibarimicin B was produced and 
analyzed by 13C NMR. These studies revealed that aside from three methoxy carbons and 
the carbohydrate moieties, all carbons of the hibarimicin B aglycon were derived from 
acetate units and thus confirming its biosynthesis from a polyketide pathway. 
Incorporation patterns indicated two symmetric polyketide chains attached at the C-2/C-
2’ aryl-quinone bond, which supports a pathway involving oxidative dimerization of two 
half-fragments, biosynthesized from a linear undecaketide, to provide the bis-tetracyclic 
carbon framework. Additionally, irregular two carbon unit incorporation was observed at 
carbons 10, 14, and 15, implying the possibility of a rearrangement and decarboxylation 
sequence. Specifically, C-10 and C-15 were proposed to be derived from a single acetate, 
while decarboxylation at C-14 would account for the remaining missing carbon. 
Importantly, by proposing an oxidative dimerization of two equal tetracycles, the 
assumption can be made that the previously unassigned C-13 tertiary center should 
exhibit the same stereochemistry as the C-13’ tertiary ether. 
 The hypothesized rearrangement necessary to account for the results of isotope 
labeling studies is shown in Scheme 1.8. From acetyl CoA (1.16) fragments, a linear 
undecaketide 1.86 is assembled, in which purple bolded bonds represent the 
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incorporation of a single acetate. Cyclization and aromatization of the first two rings 
occurs with standard Claisen condensation reactions and ketone tautomerization. 
Intermediate 1.87 has been shown suggestively to account for C-10/C-15 incorporation 
from a single acetate unit, and Claisen condensation of C-14 onto the C-15 ketone is 
proposed to initiate the rearrangement cascade to provide 1.88. A second Claisen of C-10 
onto the C-9 ketone provides an unstable four membered ring that should undergo a retro-
Claisen to arrive at 1.90. Finally, addition of C-14 to the C-13 ketone forms the A ring 
and is followed by C-14 decarboxylation and further oxidation steps to arrive at the 
monomeric unit (1.92) utilized in the proposed oxidative dimerization. 
 
 
Scheme 1.8. Proposed biosynthetic rearrangement producing tetracycle 1.92. 
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incubation of strain TP-A0121 with NTG, the surviving spores were further incubated for 
14 days to produce colonies that were chosen based on pigment color. Fermentation of 
the chosen colonies produced mutant products that provided insight into the order of 
dimerization and glycosylation. 
 Of the stable isolated mutant lines, mutant AN-0416 produced the most important 
blocked mutant compound which was termed HMP-Y6 (1.93). HMP-Y6, where Y 
describes the color of the product (yellow), was determined to be a dimer of the west half 
of hibarimicin B, where presumably mutagenesis affected PKS enzymes responsible for 
the east half oxidation state.36 HMP-Y6 was converted to HMP-Y1 (1.94) by acidic 
methanolysis to provide the aglycon, and one of these two metabolites was proposed as a 
biosynthetic intermediate to hibarimicin B. To test this hypothesis, cosynthesis, or direct 
addition of HMP-Y6 and HMP-Y1 to the fermentation broth of mutant strains, was 
performed with the expectation that a true intermediate would be indicated by the 
production of hibarimicins. With HMP-Y6 and HMP-Y1, cosynthesis experiments 
confirmed that HMP-Y1, not the glycosylated form HMP-Y6, was a biosynthetic 
intermediate of the hibarimicins. Additionally, the HMP-Y6 producing strain was further 
mutated to glean insight into the order of cyclization to produce the tetracycle 1.92. 
Isolated mutant products confirmed that cyclization of the aromatic rings occurs under 
the traditional Claisen cyclization paradigm and is followed by rearrangement and 
decarboxylation. 
 
 32 
 
Scheme 1.9. Identification of HMP-Y1 as a biosynthetic intermediate. 
 
 The resulting biosynthetic pathway for the hibarimicins is proposed in Scheme 
1.10. From the monomeric tetracycle 1.92, oxidative dimerization arrives at the C2-
symmetric intermediate HMP-Y1 (1.94). Because HMP-Y1 and not HMP-Y6 produced 
hibarimicins in the cosynthesis experiment, dimerization and oxidation were confirmed to 
occur prior to glycosylation. Thus, HMP-Y1 undergoes ether-bridge formation and 
oxidation to the naphthoquinone to provide the hibarimicin aglycon, which was termed 
hibarimicinone (1.96). Hibarimicinone undergoes a first round of glycosylation, installing 
amicetoses at C-12 and C-12’ and digitoxoses at C-10 and C-10’, then the second round 
of glycosylation provides the hibarimicin family of natural products. 
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Scheme 1.10. Biosynthetic pathway of hibarimicin B. 
 
Atropisomerism and Natural Product Total Synthesis 
 
Due to the scarcity of natural products displaying the tetra-ortho substituted aryl-
quinone bond found in the hibarimicins, minimal precedent exists for evaluating the 
possibility of atropisomerism in this system. However, axial chirality is a prevalent 
feature of natural products, drug molecules, and ligands such as BINAP (1.99), which 
most commonly exist in biaryls and trisubstituted amide functionalities.37,38 The natural 
product vancomycin (1.98) has been used in the clinic as the antibiotic of last resort since 
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generation of enantiomerically pure materials, initially used in pioneering work by Ryōji 
Noyori in his development of an asymmetric hydrogenation reaction that garnered him a 
Nobel Prize in 2001. Atropisomerism also plays an important role within drug molecules, 
exemplified by telenzepine (1.100), which exhibits atropisomerism about its trisubstituted 
amide bond that undergoes conversion between isomers with a half life of 1000 years.37 
 
 
Figure 1.7. Important compounds exhibiting atropisomerism. 
 
Atropisomerism is defined as the restricted bond rotation about a covalent bond 
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interconversion of 1000 seconds, or 16.7 minutes at a certain temperature.39 This roughly 
correlates to an energy barrier of ΔG = 22.3 kcal/mol at 27 °C. 
Two related naming conventions exist for indicating axial chirality. The most 
common notation utilizes the standard R and S nomenclature used for linear chirality, 
which is denoted by aR and aS for atropisomers. By viewing the Newman projection of 
the biaryl bond, the ortho substituents are assigned Cahn-Ingold-Prelog priorities, and a 
270 ° path from the highest priority substituent of the front ring to the highest priority 
substituent on the back ring in a clockwise direction denotes the aR configuration, while 
the counter-clockwise direction indicates the aS configuration. Conversely, a direct 90 ° 
path from highest priority substituent on the front ring to the highest priority substituent 
on the back ring in a counter-clockwise direction is defined as the M (minus) orientation, 
and the clockwise direction indicates the P (plus) orientation. For the remainder of this 
document, the aR/aS notation will be utilized exclusively. 
 
 
Figure 1.8. Nomenclature standards for atropisomers. 
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 Gossypol is one of the most well known atropisomeric natural products, which 
exhibits antispermatogenic, antimalarial, and antitumor properties based on its 
atropisomeric orientation.40 Originally isolated in 1886 by Longmore, its structure wasn’t 
determined until 1938 by Adams and ultimately not confirmed until Edwards published 
its first total synthesis in 1957.41 Its C2-symmetric bis-naphthalene structure represents 
one of the most common and simplest forms of biaryl atropisomerism. And its 
atroposelective synthesis by Meyers in 1997 represents one of the key synthetic 
approaches to enantiopure atropisomers. 
 From naphthalene acid 1.101, formation of the oxazoline auxiliary with the acid 
chloride and (S)-tert-leucine was followed by regioselective bromination to arrive at 
1.103. Refluxing this compound in DMF with Cu(0) effected asymmetric Ullmann 
coupling to arrive at a 17:1 diastereomeric mixture of 1.104, where the use of a 
removable auxiliary successfully effected the formation of a single isomer. Three step 
removal of the oxazoline functionality provided the primary alcohol, which was 
converted to the bis-tolyl product 1.106 under hydrogenolysis conditions. Finally, global 
demethylation and Swern oxidation yielded essentially atropisomerically pure gossypol 
(1.107) as a 99.2:0.8 mixture of aS to aR conformations. This method provides a 
powerful approach for the synthesis of single atropisomers, and the substitution of (R)-
tert-leucine for the (S)-form should switch the selectivity of the asymmetric Ullmann 
coupling. 
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Scheme 1.11. Meyers’ synthesis of atropisomerically pure (S)-gossypol. 
 
 In contrast to the bis-phenolic structure of gossypol, bismurrayaquinone A (1.110) 
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of the natural product for these studies. Starting from the functionalized carbazole 1.108, 
oxidative dimerization under radical conditions effected regioselective coupling yielded 
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with PCC.42,43 The two atropisomeric enantiomers were separated by chiral HPLC, thus 
confirming the existence of a stable stereoisomeric bis-quinone bond, and the 
experimental circular dichroism (CD) spectra were compared with computationally 
generated CD spectra to assign the absolute orientation of each enantiomer. This method 
of separating a racemic mixture of atropisomers and correlation with either a natural 
sample or a computational experiments has played an important role in the assignment of 
many axially chiral natural products. Additionally, the oxidative dimerization method for 
synthesizing biaryl bonds represents one of the major approaches to these types of natural 
products. 
 
 
Scheme 1.12. Bringmann’s first synthesis of racemic bismurrayaquinone A. 
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1.113 as a single atropisomer determined by the stereochemistry of the conjugate 
addition. This approach to the natural product also hinged upon a contrasting approach to 
Bringmann’s original synthesis shown above. By forming the central bond first, as 
opposed to Bringmann’s late-stage oxidative dimerization, Thomson demonstrated the 
use of a two-directional synthesis, where each transformation after forming a central core 
occurs at both ends of the molecule. 
 From the bis-phenol 1.113, phenol methylation was followed by Buchwald-
Hartwig amination, first with aniline to cleanly provide 1.114 (X = H). By performing 
demethylation and air oxidation of 1.114 first, the bis-quinone was finally transformed to 
bismurrayaquinone A by palladium-catalyzed C-C bond formation. However, upon 
product analysis, it was determined that the product had racemized along the synthetic 
route. Ultimately, it was determined that 1.115 could undergo room-temperature 
racemization through the N-O tautomer (1.116) on the order of weeks at room 
temperature, and the refluxing conditions of the final step highly increased the rate of 
racemization. 
 Thomson and co-workers reasoned that because the bis-phenol intermediate did 
not undergo racemization, palladium-catalyzed C-C bond formation could occur first 
followed by oxidation. Utilizing chloro-aniline in the Buchwald-Hartwig amination to 
improve the reactivity of the bis-phenol 1.114 (X = Cl) toward C-C bond formation, the 
two step sequence provided (+)-aR-bismurrayaquinone A in 99% ee. Ultimately, it was 
determined that a combination of shorter C-O bond lengths between the quinones and 
phenols respectively and an out-of plane distortion of the biquinone bond in 1.115 
compared to that in bismurrayaquinone A accounted for the differences in racemization 
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potential. Finally, Thomson and co-workers determined that the barrier to rotation in 
bismurrayaquinone A (1.110) was 54 kcal/mol whereas that of a model biquinone was 13 
kcal/mol and a model biphenol was essentially inert to racemization. 
 
 
Scheme 1.13. Thomson’s enantioselective synthesis of bismurrayaquinone A. 
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stereoselectivity and Bringmann’s lack of a chiral element led to a racemic mixture.45 
Next, two major approaches to symmetric natural products are highlighted by Meyers’ 
and Bringmann’s dimerizations and Thomson’s two-directional synthesis. Finally, while 
many tetra-ortho substituted biphenols exhibit stable atropisomerism, other mechanisms 
evident in Thomson’s synthesis lead to a case-by-case evaluation of the stability of 
compounds such as biquinones. 
 Very few aryl-quinone natural products have been identified to date. In fact, to the 
author’s knowledge, only three other natural products contain this motif, namely 8’-
hydroxyisodiospyrin (1.122), the xanthoviridicatin family (not shown), and the 
belamcandaquinone family (not shown).46,47 In contrast to the xanthoviridicatins and 
belamcandaquinones, which were not investigated for the possibility of atropisomerism, 
8’-hydroxyisodiospyrin (1.122) has been isolated separately in both atropisomeric forms 
from the Diospyros and Euclea species but had not undergone studies to probe the 
stability of aryl-quinone atropisomers.48 In 1998, Sargent and co-workers reported the 
atroposelective synthesis and absolute stereochemical confirmation of (+)-aS-8’-
hydroxyisodiospyrin (1.122) by regioselective nucleophilic aromatic substitution with an 
internal Meyers’ chiral oxazoline auxiliary to arrive at a 7:1 biaryl mixture of aS and aR 
atropisomers 1.119. Four step conversion of the oxazoline auxiliary to the tolyl moiety in 
1.121 led to completion of the synthesis by CAN oxidation to provide a 7:1 mixture of 
aS:aR 8’-hydroxyisodiospyrin. Importantly, while the tetra-ortho substituted biaryl 1.121 
would be expected to exist as a stable atropisomer, conversion to the aryl-quinone 
product 1.122 retained the same mixture and thus confirmed the stable axially chiral aryl-
quinone linkage. However, despite 8’-hydroxyisodiospyrin sharing a similar structural 
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feature with the hibarimicins, applying lessons of its atropisomeric stability to the 
hibarimicin system may be of limited value considering the differences in symmetric 
versus unsymmetric linkages. 
 
 
Scheme 1.14. Sargent’s synthesis of aS-8’-hydroxyisodiospyrin. 
 
Atropisomerism and the Hibarimicins 
 
 Synthetic interest in the hibarimicins had grown by the beginning of the new 
millennium, and in light of the previously highlighted investigations into atropisomerism 
stability, interest existed to determine the properties of the aryl-quinone bond found in the 
hibarimicins. No mention had been made regarding the possibility for atropisomerism in 
the isolation reports for either the angelmicins or the hibarimicins, and therefore, our 
laboratory initiated this study with the synthesis of an aryl-quinone model system.49 By 
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targeting a D-D’ model system that incorporated stereogenic centers, the evaluation of 
axial chirality would thus be simplified by the existence of atropodiastereomers that 
could be easily visualized by proton NMR. 
 Although transition metal-mediated cross couplings are the method of choice for 
forming the biaryl functionality, formation of highly hindered biaryl bonds with this 
approach is often difficult, and thus another method was utilized. Starting from 
dibenzofuran (1.123), fourteen steps arrived at the functionalized monoketal quinone 
1.124. Using 1,3-cyclopentadiene, room temperature intermolecular Diels-Alder provided 
the bridged bicyclic monoketal, which was hydrolyzed with LiBF4 in aqueous acetonitrile 
to provide the quinone phenol. Finally, MOM protection of the free phenol provided the 
aryl-quinone model system 1.125. 
 
 
Scheme 1.15. Sulikowski’s model of aryl-quinone atropisomerism. 
 
 Interestingly, upon generation of the phenol quinone prior to MOM protection, 
NMR analysis indicated a single isomer at room temperature, which would indicate rapid 
interconversion between the two possible isomers. Conversely, the MOM-protected 
model 1.125 was observed as an approximately 1:1 mixture of interconverting 
atropisomers. Spectroscopically, heating of a mixture of atropisomers to the temperature 
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at which they can freely rotate between isomers should result in observation of a single 
set of peaks as seen with the free phenol. However, heating the MOM-protected model 
1.125 to a temperature of 148 °C did not result in coalescence of the diastereomeric 
mixture, which was taken to imply that 1.125 does exhibit atropisomerism with a barrier 
to rotation of approximately 20-25 kcal/mol. 
 When the high rate of interconversion for the phenol quinone was compared to 
the relative stability of 1.122 atropodiastereomers, it was unlikely that the extra steric 
hindrance provided by the MOM-ether can fully account for these differences. Thus, a 
tautomeric pathway, as shown in Scheme 1.16, was proposed that should greatly lower 
the activation energy necessary for aryl-quinone bond rotation. And because the MOM-
ether 1.125 cannot access this tautomeric pathway, the difference in interconversion 
between the two compounds could be rationalized. While these studies do indicate the 
potential for alternate aryl-quinone racemization pathways, it remained unknown what 
insights from the model 1.125 could be applied to the atropisomeric stability of the 
hibarimicins considering 1.125 lacks their C-3’ methoxy group. 
 
 
Scheme 1.16. Proposed mechanism of phenol quinone interconversion. 
 
 In 2004, Roush and co-workers reported the synthesis of a similar model system 
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concerns regarding atropisomerism.50 As previously mentioned, metal-catalyzed cross 
coupling reactions of sterically hindered and highly electron rich aryl rings for biaryl 
bond formation is commonly met with difficulty, and thus Roush and co-workers were 
unsuccessful at performing Suzuki, Stille, and Ullmann couplings between a variety of 
functionalized naphthalene partners. In contrast, synthesis of bromoquinone 1.129 
impressively provided a suitable partner with favorable electronics for oxidative 
insertion, which provided aryl-quinone 1.130 through Suzuki coupling with the aryl 
boronic acid 1.128 in good yield. 
 With aryl-quinone 1.130 in hand, evaluation of its atropisomeric stability 
commenced. Although no other chiral centers exist in 1.130 to produce spectroscopically 
discernable diastereomers, the splitting pattern observed for the aryl benzyl methylene 
existed as an AB quartet which indicated some amount of asymmetry present and 
allowed for variable temperature NMR studies. Heating 1.130 to 150 °C did not cause 
any change in the splitting pattern, and thus the barrier to rotation was estimated to be 
greater than 22 kcal/mol, or roughly in agreement with Sulikowski’s estimate. 
Additionally, computational studies were carried out with the slightly modified methyl 
ether 1.131, and the barrier to rotation was calculated to be 25.6 kcal/mol. Considering 
this information in concert with Sulikowski’s estimates, it appeared that the hibarimicins 
should exhibit reasonable atropisomeric stability to allow for resolution at room 
temperature; however, the contribution of alternate tautomerization pathways remained to 
be determined with the nature product family itself. 
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Scheme 1.17. Roush’s aryl-quinone model system. 
  
The model system studies by Sulikowski and Roush were followed by numerous 
efforts toward hibarimicin fragments, which will be discussed in further detail in the 
following chapter. These studies generally focused on the synthesis of the A’B’ ring 
system and did not discuss issues of atropisomerism. Finally, our laboratory published the 
determination of the natural hibarimicin atropisomer in 2011 by utilizing a chromophore 
model system of HMP-Y6 1.132.51 
 Circular dichroism (CD) measures the differential absorption of plane polarized 
light by a chiral molecule and thus operates based on the absorption of molecular 
chromophores. This method is well suited for observation of axial chirality, where 
atropisomeric biaryls show opposing CD spectra. With this method, we reasoned that 
synthesis of a suitably similar model system of HMP-Y6, whose CD spectrum was 
available through correspondence with Professors Hori and Igarashi, would enable 
comparison of a known model atropisomer with the HMP-Y6 spectrum to unequivocally 
assign the hibarimicin atropisomer. The synthesis of (+)-aR-1.132 and (–)-aS-1.132, 
which will be addressed in chapter III, was followed by recording of each compound’s 
CD spectrum, as shown in Figure 1.9. Although an intermediate of aS-1.132 was 
confidently assigned an absolute configuration through X-ray crystallography, we also 
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confirmed the correlation of the computational CD spectrum of aR-1.132 with its 
experimental spectrum prior to using this data for drawing conclusions. A negative 
Cotton effect (negative band on the long wavelength side and a positive band on the short 
wavelength side) was observed for aR-1.132, and a positive Cotton effect was observed 
for aS-1.132. The computational data for aR-1.132 were in agreement with experimental 
data, predicting a negative Cotton effect. 
 With this data in hand, we then compared both the aR-1.132 and aS-1.132 CD 
spectra to the CD spectrum for HMP-Y6 (1.93, not shown), which exhibited a negative 
Cotton effect. Therefore, the CD spectrum of HMP-Y6 matched the torsional angle of 
aR-1.132, and HMP-Y6 could be assigned as having the aR configuration. This 
assignment could be applied directly to HMP-Y1 which presumably exists as the 
biosynthetic precursor of the blocked mutant HMP-Y6. And assuming atropisomeric 
retention in the conversion of HMP-Y1 to hibarimicin B and the rest of the family 
members, hibarimicin B could be assigned a configuration of aS. 
 
 
Figure 1.9. Computational and experimental model system CD spectra. 
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Conclusion 
 
Secondary metabolites have a rich history as medicinal agents, and aromatic 
polyketides have greatly contributed to the treatment of human disease. The biosynthesis 
of aromatic polyketides generally utilizes the acetate pathway, and many diverse 
structures can be produced through this biosynthetic mechanism. Despite their biological 
importance, scant natural quantities of many aromatic polyketides preclude their 
medicinal use, and thus total synthetic efforts have attempted to alleviate this issue. 
Various synthetic approaches have been developed for the assembly of aromatic 
polyketides, and the Diels-Alder reaction has found great utility for this purpose. 
Hibarimicin B is one of the most complicated aromatic polyketides isolated to date, and 
its interesting biological activity makes it an intriguing candidate for a total synthesis 
effort. Its biosynthesis goes through a homodimerization step to form the key 
intermediate HMP-Y1, and the hibarimicins have been determined to exist as stable 
atropisomers. 
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CHAPTER II 
 
THE DIELS-ALDER REACTION IN NATURAL PRODUCT TOTAL SYNTHESIS 
 
Origin and History of the Diels-Alder Reaction 
 
Nearly a century removed from the publication of their groundbreaking research, 
the memories of Otto Diels and Kurt Alder live on through the widespread use of the 
chemical reaction that bears their names. And one of its many uses includes enabling the 
assembly of complex natural products such as aromatic polyketides. 
Beginning with Zincke in 1892, as well as Lebedev, von Euler, Josephson, and 
Albrecht through the beginning of the new century, numerous studies began to track 
down the now famous cycloaddition reaction; however, not until 1928 did Diels and 
Alder publish their successful identification of the products of what at the time was 
referred to as the diene synthesis.1 Thus, it was noted that mixing of cyclopentadiene 
(2.1) and quinone (2.2) formed a 1:1 and a 2:1 adduct, which were identified as the 
bridged cyclic structures 2.3 and 2.4, respectively.2 And although the products were 
correctly identified, much mechanistic investigation remained. 
 
 
Scheme 2.1. The original Diels-Alder reaction. 
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 The importance of their findings was apparently not lost on Diels and Alder, as 
they made several illuminating concluding statements. On the potential scope of the diene 
synthesis, “Thus it appears to us that the possibility of synthesis of complex compounds 
related to or identical with natural products such as terpenes, sesquiterpenes, perhaps also 
alkaloids, has been moved to the near prospect.”2 And in a curious move to claim their 
territory, “We explicitly reserve for ourselves the application of the reaction discovered 
by us to the solution of such problems.”2 Thus, the Diels-Alder era of synthetic chemistry 
opened, and due to the impact of their research, they received the 1950 Nobel Prize in 
chemistry. 
  
Diels-Alder Mechanistic Details 
 
Numerous guidelines have been identified that govern current understanding and 
analysis of the Diels-Alder reaction. The canonical example utilizes a diene, which 
contains a conjugated system of 4 π electrons, that reacts in an intermolecular fashion 
with a dienophile, a minimal 2 π system, in a pericyclic, concerted manner.3 If carbon 
atoms in the diene or dienophile are substituted for alternative atoms, the reaction is 
termed a hetero-Diels-Alder. The reaction constitutes the height of atom economy, in 
which full conservation exists from starting materials to product, and complex molecular 
architecture can be arrived at with the formation of a six-membered ring with up to four 
new stereocenters.4 
Reactivity in the Diels-Alder [4+2]-cycloaddition follows frontier molecular 
orbital (FMO) patterns. The Diels-Alder reaction operates by the interaction between 
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filled and unfilled orbitals in the two reactants, where the closest energy highest occupied 
molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) in the 
diene and dienophile interact to determine the nature of the resultant product.3 Electron 
releasing substituents increase the energy level of the HOMO, while electron 
withdrawing substituents lower the LUMO energy level; therefore, in the normal electron 
demand Diels-Alder, an electron rich diene reacts with an electron poor dienophile to 
form a six-membered ring. Conversely, an inverse demand Diels-Alder utilizes an 
electron deficient diene and an electron rich dienophile. And the energy gap between 
these interacting molecular orbitals determines the activation energy required to drive the 
reaction forward. 
 
 
Figure 2.1. Fronteir molecular orbital analysis of Diels-Alder electronics. 
 
Beginning with Alder’s follow-up investigations, factors that govern the regio- 
and stereoselectivity of the reaction have been proposed. Specifically, unsymmetrical 
dienes and dienophiles react with preference for formation of the ortho and para adducts 
HOMO
LUMO
normal demand
LUMO
HOMO
inverse demand
HOMO
LUMO
diene dienophile
HOMO
LUMO
diene dienophile
 57 
over the meta regioisomer in a manner consistent with the requisite partial charges, and 
this mnemonic is consistent with an FMO analysis utilizing orbital coefficients.3 Scheme 
2.2 demonstrates the so-called “ortho rule” where partial charges can be used to 
rationalize the preference for this effect with the example of methoxybutadiene 2.5 
reacting with methyl acrylate (2.6) to form the ortho-substituted cyclohexene 2.8.5 
Intermediate 2.7 importantly indicates that although symmetrical dienes and dienophiles 
react in a synchronous concerted manner, where sigma bond formation occurs equally, 
polar unsymmetrical partners undergo asynchronous bond formation, and all points along 
the continuum between concerted and fully stepwise can be accessed based on the nature 
of the reactants. The reaction shown in Scheme 2.2 shows formation of the ortho-adduct 
2.8, and in this example, no meta-product formation occurs. 
 
 
Scheme 2.2. Regiochemical preferences in the intermolecular Diels-Alder. 
 
 Alder’s subsequent research culminated with a stereochemical analysis of the 
reaction. Specifically, the Alder-Stein rule indicates that olefin geometry in the starting 
materials relays in a stereospecific manner to the stereochemistry observed in the 
product. This principle was demonstrated by the reaction of cyclopentadiene (2.1) with 
maleic acid (cis-1,4-butenedoic acid, 2.11) and fumaric acid (trans-1,4-butenedoic acid, 
2.9).6 While both reactions yield the bridged products 2.12 and 2.10, the fumaric acid 
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product was found to not undergo anhydride formation, which is consistent with a trans 
orientation of the requisite diacid. Conversely, the maleic acid product successfully 
formed the anhydride 2.13, which indicated a cis relationship between the viscinal acid 
functionalities. In this way, the correlation could be made that the olefin geometry of the 
dienophile directly affected the relative stereochemistry found in the product. Similarly, 
olefin geometry of substituted dienes also relays into the product’s relative 
stereochemistry. 
 
 
Scheme 2.3. Alder and Stein’s cis principle. 
 
One of the more important features of the Diels-Alder reaction that exerts a 
profound effect on product stereochemistry is the Alder endo rule. Because the diene and 
dienophile do not approach each other head on due to the lack of orbital overlap, the 
spatial interaction of reactants within the transition state can be described by the 
orientation of their requisite appendages. Therefore, for example, as the dienophile 
approaches the diene from below, the dienophile substituents can align either directly 
under the conjugated diene system forming the endo transition state, or they can orient 
away from the diene to form the exo transition state. While the exo approach can logically 
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be assumed the favored orientation based on a steric argument, Alder and co-workers 
determined that the endo transition state is preferred in many Diels-Alder reactions.7 The 
basis for this seemingly counterintuitive result has been determined to arise from 
stabilization of the endo transition state by secondary non-bonding orbital interactions 
that overcome the perceived destabilizing steric effect. 
Using the example from Scheme 2.2, the reaction of methoxybutadiene (2.5) with 
methyl acrylate (2.6) can provide two distinct relative stereochemical outcomes, namely 
cis-2.8 or trans-2.8. Steric repulsion of the reactant appendages can account for the exo 
transition state leading to the trans product; however, the secondary orbital interaction 
between the blue orbitals in Scheme 2.4 stabilizes the transition state energy and leads to 
the Diels-Alder favoring the endo approach that leads to cis-2.8 in many cases. It is 
noteworthy that the endo transition state represents formation of the kinetic product, and 
with appropriately high temperatures, retro Diels-Alder can ultimately favor the 
thermodynamic exo product over longer reaction times.3 
 
 
Scheme 2.4. Stereochemical outcomes due to the Alder endo rule. 
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In the years since its discovery, the Diels-Alder has enjoyed widely successful 
application, and ever more variations on its original form continue to be investigated. As 
mentioned previously, the hetero-Diels-Alder has added a new dimension to the 
possibility of ring products. Additionally, modern Diels-Alder research continues to push 
the boundaries of the reaction’s versatility, and the applications of Lewis acids can 
greatly impact its successful implementation into synthetic applications. However, two 
other forms of the Diels-Alder require further discussion, namely the intramolecular 
(IMDA) and transannular (TADA) versions. 
 The intermolecular version of the Diels-Alder utilizes a diene and dienophile that 
can incorporate substituents at all carbon locations. The intramolecular Diels-Alder 
reaction links the diene and dienophile through a covalent tether, and various attachment 
points lead to differing product structures. With the increasing complexity of the Diels-
Alder starting material, significant complexity can be added to the resulting product: in 
addition to the four stereocenters created, two new rings are formed, where the second 
ring derives from the length of the covalent tether. 
 The most traditional application of the IMDA is shown as the type I motif in 
Figure 2.2, where the diene attachment point occurs at the 4-position and the dienophile 
orients itself in the lowest energy linear conformation shown as 2.14.8 In special cases, 
which necessarily require a longer linker unit, the type I system can form bridged 
products that arise from an oppositely oriented dienophile (2.15). The type II IMDA is 
the more energetically favorable method for formation of bridged products, where the 
dienophile approaches in the linear fashion of 2.14 but the linkage point to the diene 
occurs at the 3-position. Again, shorter tether lengths may preclude the necessary 
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transition state, but many successful examples of the type II IMDA have emerged in the 
literature in the past two decades. Finally, as a further extension of the molecular 
complexity produced by the IMDA, the transannular Diels-Alder (TADA) increases the 
number of rings produced to three by tethering the diene and dienophile at both ends to 
produce a macrocyclic precursor 2.17.9 Due to macrocyclic strain energy, mode 2.17 
predominates in the chemical literature; however, a handful of type II TADA reactions, 
such as Shair’s total synthesis of (–)-longithorone A, have confirmed the possibility of its 
success.10 And while the TADA offers one of the most extensive ring formation patterns 
available in one single transformation, synthesis of the requisite macrocycles has limited 
its widespread and practical application in total synthesis. 
 
 
Figure 2.2. Diels-Alder motifs of increasing molecular complexity. 
 
 The early years following the first IMDA reports in the early 1950s focused on 
evaluation of simplistic substrates for general parameters and stereochemical outcomes 
which were nicely reviewed by Fallis in 1983.4 Of note from these studies is the 
stereoselectivity of the resulting products, where two similar IMDA reactions are shown 
in Scheme 2.5. Although the 6-5 ring structure between the two reactions remains 
conserved, the trans-fused product 2.19 is favored in the first reaction, while the second 
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reaction favors the cis-fused product 2.23 by a similar margin. As previously mentioned, 
the trans products arise from an exo transition state, which interestingly indicates that 
other factors, mainly sterics within the transition state and olefin geometry, affect the 
stereochemical outcome of the IMDA. 
 
 
Scheme 2.5. Early IMDA example substrates. 
 
 Initial work by Deslongchamps indicated similar stereochemical effects within the 
TADA manifold relying heavily on the olefin geometry to relay into relative orientation 
of substituents in the resulting products.9 For example, the trans-trans-cis geometry 
(TTC) macrocycle 2.24 could be predicted to have access to two possible transition 
states, 2.25 and 2.27. Upon heating in refluxing benzene, however, only the tricycle 2.28 
with trans-syn-trans ring juncture orientation was isolated. This result can be rationalized 
through likely 1,3-diaxial interactions in the transition state 2.25 between the two pseudo-
axial methyl ester substituents and 1,4-diene hydrogens. Therefore, the example shown in 
Scheme 2.6 highlights various stereochemical considerations necessary for TADA 
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analysis, and steric factors and inherent olefin geometries play integral roles in the 
formation of relative stereochemistry. Related work by Jacobsen takes TADA 
stereochemistry to a new level with application of asymmetric catalysis to the system 
allowing for stereocontrol and even altering inherent macrocyclic stereochemical bias.11 
 
 
Scheme 2.6. Stereochemical outcome of a representative TADA. 
 
Applications of the Diels-Alder to Total Synthesis 
 
In the two decades between Diels and Alder’s initial publication of their reaction 
and their receipt of the Nobel Prize in 1950, the reaction struggled to take hold in the 
synthetic community. However, almost coinciding with their international recognition, 
the Diels-Alder reaction finally began featuring in prominent total syntheses of the 1950s, 
which included the first synthesis of morphine and Stork’s synthesis of cantharidin.12 But 
its truly enlightening incorporation into complex molecule total synthesis did not appear 
until R. B. Woodward harnessed the Diels-Alder’s potential in his syntheses of cortisone 
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(2.33) and cholesterol (2.34) which were reported in 1952.13 Utilizing the disubstituted 
quinone 2.29 as the dienophile and butadiene (2.30), the cycloaddition was effected by 
heating in benzene for four days which produced the endo product in high yield. Two 
features of this reaction remain impressive even today: Woodward recognized that the 
differing electronics of the two quinone olefins could direct the regioselectivity of the 
reaction, and considering that the C-ring exists in a trans orientation with the appended 
cyclopentane, that the cis product 2.31 arising from the endo transition state was the 
kinetic product that could be equilibrated to the thermodynamic trans product 2.32 by 
treatment with base.12 This product was then elaborated into both cortisone (2.33) and 
cholesterol (2.34), a truly monumental feat in the history of organic total synthesis. 
 
 
Scheme 2.7. Woodward’s total syntheses of cortisone and cholesterol. 
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array of potential ring systems and has opened new doors to various stereochemical 
motifs. This fact is highlighted by Corey’s synthesis of forskolin (2.39), which was 
reported in 1988 and utilized a tethered IMDA to quickly form the 6,6-core ring system.14 
 Forskolin (2.39), which was isolated from Coleus forskohlii, is an activator of 
adenylyl cyclase which catalyzes the conversion of ATP to cAMP causing an variety of 
important physiological responses. Corey strategically positioned his IMDA strategy 
toward the beginning of the synthesis, and in setting the key trans ring juncture of the 
first two rings, he was able to utilize substrate control to direct the formation of many of 
the remaining chiral centers. Central to the synthetic strategy was the selective formation 
of the methyl-substituted quaternary ring juncture carbon, and for this approach, the 
IMDA proved well-suited. The stereochemically defined 2.35 was directly esterified with 
the propargylic acid, and the intermediate ester underwent spontaneous Diels-Alder 
reaction to form the tricyclic lactone 2.36. Thus, the secondary alcohol stereocenter in 
2.35 directed the dienophile from the α-face of the diene and provided the correct 
quaternary methyl stereochemistry found in 2.39. In this total synthesis, Corey 
successfully demonstrated the power of the IMDA at the beginning of a synthesis which 
relayed into the subsequent necessary stereochemistry-forming reactions. 
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Scheme 2.8. Corey’s IMDA-enabled total synthesis of forskolin. 
 
 In contrast to Corey’s strategy of an early-stage IMDA, the reaction can also 
provide much benefit when utilized at the end of a synthesis. In this mode, depending on 
the specific structure, a central core with appendages can simplify the early 
transformations, and with a well-planned strategy, the natural product structure can be 
rapidly assembled through a single intramolecular step such as in Rychnovsky’s synthesis 
of (–)-colombiasin A (2.44).15 Synthesis of the IMDA precursor 2.43 notably proceeded 
through the synthesis of decalin 2.42 which was assembled by an intermolecular Diels-
Alder between chiral diene 2.40 and quinone dienophile 2.41. As noted in previously in 
Corey’s synthesis of forskolin, the IMDA benefits the relay of existing stereochemistry 
into the stereochemical outcome of the cycloaddition, and in the case of colombiasin A, 
the tethered diene approached the internal quinone dienophile from the β-face due to the 
chirality of its decalin attachment point. In this way, the complex ring structure of 
colombiasin A (2.44) arose from the much simpler precursor 2.43, which was synthesized 
in fifteen linear steps. Final demethylation with AlCl3 provided the natural product. 
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Scheme 2.9. Rychnovsky’s late-stage IMDA toward colombiasin A. 
 
 In much the same way as the IMDA can efficiently form complicated ring 
structures, as seen in Scheme 2.9, the transannular Diels-Alder strategy can render 
difficult triene systems labile to cycloaddition due in part to the proximity effect.16 
Schreiber’s synthesis of dimethyl dynemicin A (2.49) exemplified this principle, in which 
the advanced intermediate acid 2.45 was macrocyclized using PyBroP in CH2Cl2, and 
after 13 hours at room temperature, the TADA product 2.46 was directly isolated in good 
yield.17 In comparison, the related IMDA of a protected form of 2.45 resulted in slow 
decomposition at or above 180 °C, thus lending support to the proximity effect 
mentioned above. 18  Following lactone epimerization and benzylic oxidation, an 
interesting sequence of hydroxyl ionization and hyrazide trapping led to the intermediate 
diazene 2.47 which underwent stereospecific sigmatropic rearrangement to 2.48, the core 
of the dynemicins. Final appending of the remaining two rings led to dimethyl dynemicin 
A (2.49).19 
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Scheme 2.10. Schreiber’s TADA toward dimethyl dynemicin A. 
 
 Reported in 2002, Sorensen’s synthesis of (+)-FR182877 (2.53) stands near the 
pinnacle of complexity-driven Diels-Alder capability.20 The 19-membered macrocycle 
2.50 was assembled in seven steps from advanced convergent building blocks, and 
miraculously, by gentle heating in chloroform, 2.50 underwent a double TADA, first 
forming the cyclohexene intermediate 2.51 then a hetero-TADA with the remaining 
enone to form five new rings with seven new contiguous stereocenters. Completion of the 
target molecule required simple deprotection steps followed by lactonization to provide 
(+)-FR182877 (2.53). Sorensen’s use of the TADA perfectly showcases the power of a 
reaction that only requires shrewd synthetic planning and execution of macrocycle 
formation. 
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Scheme 2.11. Sorensen’s double TADA toward (+)-FR182877. 
 
 The highlighted examples of the Diels-Alder reaction in total synthesis serve to 
illustrate not only the history and breadth of its application but also its importance as an 
enabling step toward complicated molecular structures. The focus on IMDA and TADA 
approaches above is also meant to provide context for a discussion of synthetic routes 
toward the hibarimicins, of which all but one has incorporated in some capacity the 
Diels-Alder reaction. 
 
Previous Synthetic Studies Toward the Hibarimicins 
 
Several research laboratories have reported efforts toward the hibarimicin natural 
products, beginning in 2002, and although the they have targeted differing members of 
the family, the common linking bond is the general consensus for a two-directional 
synthetic approach. The retrosyntheses initially targeted hibarimicinone (1.96), and 
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O
MeMe
TESO OTES
Me
O
OtBu
Me OTMS
2.50
CHCl3, 40 °C
4 hours
O
MeMe
TESO OTES
Me
O
OtBu
Me OTMS
2.5140%
O
Me
TESO O
Me
2.52
Me
TES O OtBu Me
OTMS
1) PPTS, MeOH
2) TFA, CH2Cl2
3) EDCI, DMAP, CH2Cl2
62% three steps
H
H
O
Me
HO OH
Me
(+)-FR182877 (2.53)
Me
O
MeO
H
H
 70 
intermediate HMP-Y1 (1.94) could provide a biomimetic intermediate target. From either 
the semi-C2-symmetric hibarimicinone (1.96) or C2-symmetric HMP-Y1 (1.94), based on 
the principle championed by Schreiber of double processing from the center of a 
molecule outward, a biaryl 2.55 could be annulated with appropriately functionalized 
enones 2.54 and 2.56 toward hibarimincone or in a symmetrical fashion with two 
equivalents of enone 2.54 toward HMP-Y1. 21 Varying functionalities at X and Y in 2.55 
were proposed to allow differential functionalization toward the semi-symmetric 
hibarimicinone. Thus much of the early work toward the hibarimicins focused on the 
synthesis of the A’B’-decalinic ring system (2.56). 
 
 
Scheme 2.12. Retrosynthetic consensus for early work toward hibarimicinone. 
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 The first synthetic report toward the synthesis of hibarimicinone came from our 
laboratory in 2002, in which routes were proposed from a single intermediate for 
synthesis of 2.54 and 2.56 toward hibarimicinone. 22  This approach relied on the 
elaboration of enantiomeric decalins into the AB- and A’B’-ring systems, and thus 
racemic Diels-Alder cyclization of quinone (2.57) and 1-acetoxybutadiene (2.58) 
provided the cis-deaclin 2.59. Complete reduction and 1,3-diol protection provided 
racemic 2.60. Lipase resolution enabled separation of the mixture in high enantiomeric 
excess for both 2.61 and 2.62, where the free alcohol 2.62 was to become the A’B’ 
hibarimicin decalin 2.56, while the acetate 2.61 was to be elaborated to the AB decalin 
2.54. 
 
 
Scheme 2.13. Sulikowski’s route to divergent hibarimicinone precursors. 
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the cerium reagent led to the tertiary alcohol in a 5:1 diastereomeric ratio, and p-
toluenesulfonic acid then removed the acetonide protecting group. Acetylation led to an 
intermediate ripe for cycloetherification which was attempted with palladium 
tetrakis(triphenylphosphine); however, cyclization unexpectedly occurred through an 
SN2’-type addition to the C-16 carbon with olefin migration and acetyl ejection yielding 
2.64. 
 
 
Scheme 2.14. Cycloetherification toward the A’B’-decalin system. 
 
 Reasoning that the trans diol at C-11/12 in 2.56 may affect the cycloetherification 
outcome, the C-7/16 olefin was masked by bromoetherification with the C-10 secondary 
alcohol to provide 2.66 followed by epoxidation and retro-bromoetherification and acidic 
solvolysis for diol installation. The three secondary alcohols were acetylated to 2.68 for 
the purpose of obtaining an X-ray crystal structure, and ultimately not only did the 
resulting triol exist as the incorrect relative stereochemistry but a presumed 
cyclodehydration occurred yielding the same undesired furan product as previously 
observed in 2.64. 
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Scheme 2.15. Trans diol installation and attempted cycloetherification. 
 
 A final attempt was made toward the AB-ring system 2.54 based upon the logic of 
installing the C-15 ketone earlier in the sequence, which involved using the opposite 
enantiomer: the free alcohol version of 2.61. TIPS protection of the secondary alcohol 
was thus followed by acetonide deprotection, bis-Jones oxidation and tertiary alcohol 
installation to yield 2.70. Unfortunately, all attempts at regioselective alkylation toward 
2.71 were unsuccessful. 
 
 
Scheme 2.16. Attempted synthesis of the AB-decalin system. 
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system 2.54. Therefore, based on literature precedent, it was reasoned that the β-OPiv 
group in 2.73 would direct formation of the C-9 stereochemistry and thus compound 2.73 
was the first to be investigated.23 While the lithiated form of ethynyl p-tolylsulfone was 
ineffective in the addition to aldehyde 2.72, Kuwajima’s conditions effected reasonable 
conversion to the diastereomeric mixture of secondary alcohols 2.73. Oxidation with 
Dess-Martin periodinane then led to the intermediate alkynone, which underwent 
spontaneous IMDA to the bicycle 2.74 with formation of the undesired C-9 
stereochemistry. Carrying the opposing α-OPiv series (not shown) through the same 
sequence again led to the undesired C-9 stereochemistry and thus required altering of the 
synthetic plan. 
 
 
Scheme 2.17. Sulikowski’s alkynyl IMDA toward the AB-decalin system. 
 
 In hopes of switching the Diels-Alder selectivity, a simple enone dienophile 2.76 
was prepared utilizing the α-OPiv series in which vinyl Grignard addition to the aldehyde 
2.75 and subsequent Dess-Martin oxidation led to the Diels-Alder precursor 2.76. Indeed, 
when heated at 90 °C for 40 hours, the desired ring junction stereochemistry emerged in 
2.77 leading to an interesting comparison between the cycloadditions of 2.73 and 2.76 
which vary only in the structure of the dienophile. Further studies by our laboratory 
OH
O
OTs
OPiv
O
O
O
OPiv
H
TBAF, THF, –78 °C
then SiO2
Ts TMS
58%2.72 2.73
DMP, CH2Cl2
0 °C to RT
60%
Ts O
H
O
O
OPiv
2.74
 75 
suggest that altering the nature of alcohol protecting groups within the IMDA linking 
chain influence precursor orientation and thus stereoselectivity observed in the product.24 
 
 
Scheme 2.18. Altering dienophile structure leads to different stereochemistry. 
 
 Roush and co-workers reported the first successful synthesis of the A’B’-decalin 
of hibarimicinone in 2005.25 Their strategy involved assembling the two six-membered 
rings from a pre-formed furan. The furan was derived from their previously developed 
three component coupling of γ-silylallylboranes through hydroboration of allene 2.78 and 
subsequent addition to the aldehyde 2.79. Following silylation, the furan 2.83 was formed 
through a [3+2] cycloaddition with aldehyde 2.82. A modified Tamao-Fleming oxidation 
yielded the desired alcohol diastereomer 2.84 which was subjected to a series of 
protection and deprotection to arrive at the selectively TIPS-protected diol 2.85. Swern 
oxidation led to the keto-aldehyde intermediate that when treated under basic conditions 
effected aldol cyclization to the bicyclic system 2.86 in a 1.3:1 diastereomeric ratio, 
where the undesired diastereomer could be converted under the same reaction conditions 
to the 1.3:1 ratio favoring the desired diastereomer. Protection of the newly present 
alcohol was followed by regioselective debenzylation to yield the primary alcohol 2.87. 
A sequence of Swern oxidation, Wittig olefination, and olefin hydrogenation led to 2.88 
which set up for the final ring forming reaction. Thus, pinacol-enabled ring closure by 
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treatment with Bu3SnH and AIBN in refluxing benzene successfully effected formation 
of the A’B’-decalinic ring system found in hibarimicinone. The remaining steps to the 
fully functionalized A’B’-system involved Swern oxidation of the secondary alcohol and 
enone installation through α-phenylselenation and oxidation with hydrogen peroxide to 
arrive at 2.89. Roush’s synthesis of the A’B’-decalin of hibarimicinone required 16 linear 
steps and utilized the unique approach of forming the furan ring system first as a scaffold 
for decalin formation. 
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Scheme 2.19. Roush’s synthesis of the A’B’-decalin system. 
 
 In contrast to Roush’s strategy through the furan moiety, Mootoo and co-workers 
reported the synthesis of the A’B’-decalin unit in 2008 that focused on formation of the 
decalin functionality followed by installation of the bridging furan.26 This approach 
centered on a key IMDA to quickly provide the functionalized decalin structure. Thus, 
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the lactone 2.90, which derived from methyl-α-D-glucopyranoside, was bis-alkylated, 
first with propylmagnesium chloride then with the lithium salt of TMS acetylene in a 5:1 
diastereomeric ratio favoring the desired α-tertiary alcohol. TMS alkyne deprotection 
provided the key intermediate 2.91 which was subjected to Grubbs second generation 
catalyst under an atmosphere of ethylene to effect a ring closing enyne metathesis, 
smoothly arriving at the highly functionalized A’-ring precursor 2.92. Installation of the 
dienophile by esterification with acryloyl chloride provided the proposed IMDA substrate 
which was successfully cyclized in refluxing xylene to form the decalin 2.93. Mootoo 
and co-workers then shrewdly exploited the decalin conformation for stereoselective 
dihydroxylation on the convex face of the trisubstituted olefin followed by silyl 
protection. For the dual purpose of removing the extra lactone carbon and furan 
formation, the lactone was reduced to the lactol 2.94 with DIBAL, and under radical-
mediated conditions with phenyliodonium diacetate (PIDA) and iodine, carbon-carbon 
bond fragmentation and intramolecular capture with the tertiary alcohol resulted in 
formation of the furan ring. The resulting formate was removed with potassium carbonate 
in methanol to yield the free secondary alcohol 2.95. The final steps necessary for 
formation of the A’B’-ring system required a regioselective protection/deprotection 
sequence, and 2.96 was converted to the enone through IBX oxidation to the ketone 
followed by phenylselenation/oxidation to arrive at the A’B’-decalin 2.97. Mootoo’s 
route to this key building block toward hibarimicinone established two important 
precedents for future synthetic approaches, namely the use of an IMDA rapidly form the 
decalinic structure and a method for removing the unwanted lactone carbon while 
concomitantly forming the key ethereal linkage found in the A’B’-ring structure. 
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Scheme 2.20. Mootoo’s synthesis of the A’B’-decalin toward hibarimicinone. 
 
 Considering Roush’s and Mootoo’s syntheses of the A’B’-ring system toward 
hibarimicinone, these approaches also require the assembly of the AB-decalin 2.54 for 
differential bis-annulation with the biaryl core 2.55. Toward this end, two separate 
publications have addressed this need, first by Mootoo and co-workers utilizing the same 
manifold employed in their synthesis of the A’B’-system.27 Thus, from the previously 
synthesized IMDA product 2.93, slight modification of the previously published route led 
to the AB-ring system. 
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 While attempting direct radical fragmentation of the lactol form of 2.93, it was 
determined that the ring strain of the trans lactol negatively affected the success of the 
reaction. Therefore, DBU-mediated epimerization to the cis lactone and reduction to the 
lactol yielded 2.98, which proved to be a superb substrate for the fragmentation reaction. 
And unlike in their synthesis of the A’B’ subunit, intramolecular oxygen capture did not 
occur, with the substrate striking a balance between reactivity and conformation 
necessary for cycloetherification. With the epimeric mixture of iodides 2.99, tributyltin 
hydride-mediated dehalogenation provided 2.100 which was subjected to formate 
removal and TBS protection to provide the key intermediate 2.101. In a four step 
sequence similar to their previously utilized strategy, dihydroxylation and IBX oxidation 
were followed by phenylselenation/oxidation to provide the target enone 2.103 in good 
yield. In this work, Mootoo and co-workers effectively diverged from their previously 
successful approach to synthesize the remaining outer core partner for the two-directional 
bis-annulation sequence outlined in Scheme 2.12. To date, no further reports from the 
Mootoo laboratories have appeared describing their work toward the central biaryl core. 
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Scheme 2.21. Mootoo’s modified route to the AB-decalin system. 
 
 Shortly following Mootoo’s report of their unified strategy toward the AB-ring 
system of hibarimicinone, Shair and co-workers published the gram-scale synthesis of a 
variably protected AB-decalin with the same key functionalities as synthesized by 
Mootoo.28 Key to their strategy was an intermolecular Diels-Alder reaction to form the 
decalin system and a silyl-zincate conjugate addition/oxidation sequence to install 
functionality for further oxidation. 
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presence of cerium trichloride to yield the inconsequential mixture of diastereomeric 
alcohols 2.106. Ring closing metathesis with Grubbs first generation catalyst and Parikh-
Doering oxidation led to the Diels-Alder precursor 2.107. By Lewis-acid complexation, 
the desired intermolecular Diels-Alder with butadiene occurred with high 
diastereoselectivity through transition state 2.108, where a purely steric analysis would 
suggest its unfavorable interactions with the OTBS and OPiv groups; however, 
rationalization by Cieplak theory would suggest stabilization of forming σ*-orbital 
adjacent to the OTBS group by electron donation from the axial hydrogen. Thus, the cis 
decalin 2.109 was carried forward through silyl-enol ether formation and oxidation to the 
dienone 2.110, which when subjected to the silyl zincate, underwent 1,6-conjugate 
addition and the resulting zinc enolate was oxidized with MoOPh to provide the α-
hydroxyketone 2.111 as a single diastereomer. Due to the favorable conformation of the 
cis decalin, nucleophilic addition of the propyl unit afforded a single diastereomer of the 
tertiary alcohol while concomitantly removing the pivaloyl protecting group. Acetonide 
formation between the free secondary and tertiary alcohols led to 2.112, and m-CPBA 
epoxidation of the disubstituted olefin led to 1,5-silyl migration forming the allylic silyl 
ether 2.113. Finally, TBAF-mediated silyl deprotection followed by Swern oxidation led 
to the protected AB-subunit 2.114 containing the same key functionalities targeted by the 
Mootoo group. Importantly, the Shair group’s approach was carried out completely on 
gram scale allowing for synthesis of large quantities of material for further studies toward 
HMP-Y1 and hibarimicinone. Their intermolecular Diels-Alder strategy highlights the 
versatility of various forms of the Diels-Alder reaction toward synthesis of 
hibarimicinone intermediates. 
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Scheme 2.22. Shair’s synthesis of the AB-decalin unit. 
 
 The absolute stereochemistry of the hibarimicins remained unknown through the 
publication of Roush, Mootoo, and Shair’s work, and the arbitrarily-depicted absolute 
orientation shown in Figure 1.6 continued as the general consensus through 2011. 
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O
O O
OBn
OMe
OPiv
Ph
2.104
1) AcOH, H2O, 80 °C
2) I2, PPh3, imidazole, toluene
3) TBSOTf, 2,6-lutidine, 0 °C
90% three steps
O
OTBS
OBn
OMe
OPiv
2.105
I
1) Zn(0), THF, H2O, ))), 40 °C
2) vinyl MgBr, CeCl3, THF, –78 °C
75% two steps
OH
OPiv
OTBS
OBn
2.106
1) Grubbs I, CH2Cl2
    RT, 18 hours
2) SO3•pyridine, DIPEA, 
    DMSO, CH2Cl2 0 °C
82% two steps
O
OPiv
OTBS
OBn
2.107
TiCl4, toluene
–78 °C to 5 °C
76%, >10:1 d.r.
O
OPivOBn
O TBS
Cl4Ti
2.108
O
H
H
OBn
OPiv
OTBS
2.109
1) TMSCl, NaI, HMDS
    MeCN, 82 °C
2) DDQ, CH2Cl2
78% two steps
O
H
OBn
OPiv
OTBS
2.110
Me2PhSLi, Et2Zn, THF, –78 °C
then MoOPh, –78 °C to –20 °C
82%
O
H
OBn
OPiv
OTBS
2.111
OH
PhMe2Si
1) propyl MgCl, CeCl3, LiCl
    THF, –78 °C to 0 °C
2) 2-methoxypropene, PPTS
    toluene, RT
71% two steps
H
OBn
O
OTBS
2.112
OH
PhMe2Si
O
m-CPBA, NaHCO3
CH2Cl2, –78 °C to –5 °C
85%
H
OBn
O
OTBS
2.113
OH O
PhMe2SiO
1) TBAF, THF, –78 °C
2) (COCl)2, DMSO, CH2Cl2
    –78 °C, then Et3N
91% two steps
H
OBn
O
OTBS
2.114
OH O
O
AB
 84 
beginning with a little-noticed abstract in the Japanese abstracting service Tennen Yuki 
Kagobutsu Toronkai Koen Yoshishu reported in 2004.29 Our laboratory obtained a copy 
of the abstract through our ongoing collaboration with Professors Hori and Igarashi in 
Japan, which outlined the determination of the absolute stereochemistry of the 
hibarimicins through Mosher ester analysis and sugar moiety synthesis.  
 
 
Figure 2.3. Determination of hibarimicinone absolute stereochemistry. 
 
Specifically, Mosher ester analysis was performed at the C-1, C-11, and C-10’ 
hydroxyl groups shown in Figure 2.3, although details and experimental methods for 
these studies were not included. Additionally, the circular dichroism spectrum for 
hibarimicinone was used for postulation of the absolute atropisomerism about the highly 
congested aryl-quinone bond. Taken in concert with data determined by the model 
system synthesis by our laboratory shown in Figure 1.9, the absolute stereochemistry of 
hibarimicin B was determined to be opposite of the stereochemistry reported in previous 
synthetic efforts and is shown in Figure 2.4. This information proved vital in the two total 
syntheses of hibarimicinone that were reported in 2012. 
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Figure 2.4. Absolute stereochemistry of hibarimicin B. 
 
Total Syntheses of HMP-Y1 and Hibarimicinone 
 
The determination of the absolute stereochemistry of the hibarimicins proved to 
be a turning point in the history of the hibarimicins: Hosokawa and co-workers reported 
the first total synthesis of hibarimicinone with the correct absolute stereochemistry early 
in 2012.30 Their route resembled a combination of the retrosyntheses presented in 
Scheme 2.12, in which a differentially functionalized biaryl core was elaborated through 
a two-directional bis-annulation sequence with two equivalents of a decalinic enone in a 
manner similar to the retrosynthetic disconnection of HMP-Y1. The approach relied upon 
formation of a single atropisomer of the biaryl core, differential functionalization of the 
bis-tetracycle, and formation of the furan linkage through an ortho-quinone methide. 
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trimethylsiloxybutadiene (2.116) in the presence of di-t-butylcatechol (DTBC) which 
arrived at the desired cis-decalin 2.118 regio- and stereoselectively. Jones oxidation 
provided the enone, and reductive samarium enolate formation with SmI2 was followed 
by enolate oxidation with Oxone to provide the tertiary alcohol 2.119. Regioselective 
desilylation with SnCl4 removed only the C-10 TBS-ether, and the resulting alcohol was 
oxidized with IBX. The triketone was regio- and stereoselectively reduced with 
NaBH(OAc)3 to provide the correct regiochemistry of the triol system, and the remaining 
secondary and tertiary alcohols were protected as TMS ethers while concomitantly 
forming the extended silyl enol ether 2.120. The remaining steps toward the AB-ring 
system involved stereoselective allylation with allyl Grignard, tertiary alcohol protection, 
reformation of the enone with DBU, and regioselective hydrogenation of the allyl 
functionality provided the protected AB-decalin 2.121. 
 
 
Scheme 2.23. Hosokawa’s synthesis of the AB-decalin system. 
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 For the two-directional strategy toward hibarimicinone, a biaryl ring system was 
needed that contained varying functionalities on either end for regioselective 
manipulation later in the synthesis. Thus, the acid 2.122 was transformed to the amide 
followed by regioselective lithiation and reaction with methyl iodide. Boron trichloride-
mediated regioselective demethylation provided the phenol 2.123 which was converted to 
the methyl ester. The key step involved oxidative dimerization with silver triflate to form 
the racemic bis-phenol which was protected as the bis-benzoate 2.124. Radical bis-
bromination was followed by displacement with potassium thioacetate, thiolactone 
formation, and concomitant benzoate cleavage. By forming the mono-camphanic ester, 
the diastereomeric mixture became separable, and the desired aR atropisomer could be 
carried forward through ester removal to arrive at the atropisomerically enriched bis-
phenol 2.125. Bis-MOM protection was followed by breaking of the biaryl core 
symmetry through mono-bromination and displacement with n-butanol to provide the 
unsymmetrical diastereomeric mixture 2.126 which was properly functionalized for the 
proposed bis-annulation sequence with the previously synthesized AB-ring system 2.121. 
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Scheme 2.24. Synthesis of the unsymmetrical biaryl D-D’ moiety. 
 
 The remaining steps necessary for synthesis of hibarimicinone involved the 
linchpin bis-Michael-Dieckmann condensation between the biaryl 2.126 and the enone 
2.121, which was effected with NaHMDS and followed by methylation of the thiolate 
intermediate to form the basic bis-tetracyclic core of the target. Interestingly, the 
annulation sequence was favored for the unsubstituted thiolactone in THF while the 
Michael-Dieckmann condensation with the substituted thiolactone was most effective in 
toluene, and thus the two-directional annulation was performed in the mixture of 
solvents. Enolization of the resulting bis-β-diketone formed bis-enol 2.127, and 
hydrolysis of the semithioacetal and formation of the hydroquinone was effected by a 
sequence of silver nitrate then DBU. By treating the hydroquinone with silver carbonate, 
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provide the quinone 2.128. The important furan linkage was then installed by formation 
of the quinone methide with lithium iodide which allowed for Michael addition of the C-
13’ tertiary alcohol, and MOM ether deprotection also occurred. Treatment with DDQ 
oxidized the resulting hydroquinone back to the quinone oxidation state, and a final step 
involving heating with 1 N HCl in methanol led to global silyl deprotection and 
tautomerization of the C’-D’ ring system to afford hibarimicinone (1.96). Hosokawa’s 
first total synthesis not only confirmed the absolute stereochemistry of hibarimicinone 
but also validated the two-directional annulation sequence that had been the cornerstone 
of all synthetic efforts to that point. Additionally, Hosokawa’s synthesis proved the 
validity of a biomimetic ether linkage formation through an ortho-quinone methide 
intermediate. 
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Scheme 2.25. Hosokawa’s first total synthesis of hibarimicinone. 
 
 A second total synthesis of hibarimicinone, as well as the synthesis of the 
biosynthetic intermediate HMP-Y1, appeared from the Shair laboratory during the 
writing of this document. 31  Drawing on the previously determined hibarimicinone 
absolute stereochemistry and utilizing a similar two-directional approach to Hosokawa, 
Shair and co-workers also reported extensive studies regarding the atropisomerism of 
HMP-Y1 and hibarimicinone. 
O
OTBS
H
OTBS
2.121
OTMS
OTMS
AB
OMOM
MeO
OMe
2.126
MOMO
OMe
OMe
S
S O
O
OBu
D
D'
O
TBSO
H
TBSO
OTMS
TMSO
A B
2.121
1) NaHMDS, MeI, THF
    toluene, pyridine, –20 °C
2) LiCl, THF, RT
56% two steps
TBSO
H
TBSO
OTMS
TMSO
2.127
OH O
SMe
O
OMe
OMe
MeO
OMe
O
OMe
MeO
O OH
MeS OBu
OTBS
H
OTMS
OTBS
OTMS
1) AgNO3, toluene, acetone, H2O, 40 °C
2) DBU, toluene, 0 °C
3) Ag2CO3, toluene, acetone, H2O, 40 °C
    then MeI
63% three steps
TBSO
H
TBSO
OTMS
TMSO
2.128
O OH O
OMe
OMe
MeO
OMe
O
OMe
MeO
O O
OTBS
H
OTMS
OTBS
OTMS
O
HO
H
HO
OH
HO
hibarimicinone (1.96)
O OH OH
OMe
OMe
MeO
O
O
OH O
OH
H
OH
OH
O
OH
1) LiI, MeCN, DCE, 50 °C
2) DDQ, THF, toluene, 0 °C
3) 1 N HCl, MeOH, 40 °C
56% three steps
OH
OH A'B'C'D'
DCBA
O
O
TMS
TMS
O
O
TMS
TMS
O
O
TMS
TMS
 91 
 Following the publication of the Shair laboratory’s gram-scale synthesis of the 
AB-decalin unit 2.114 shown in Scheme 2.22, it became apparent that the absolute 
configuration of 2.114 corresponded to the unnatural enantiomer of hibarimicinone, and 
thus for their total synthesis, Shair and co-workers modified their initial assembly of the 
AB-decalin to arrive at the desired enantiomer. Derived from the same starting material 
as in their synthesis of 2.114, methyl-α-D-glucopyranoside, 2.129 was subjected to a 
series of functional group interconversions and protection steps to form the primary 
iodide 2.130. To switch the absolute stereochemistry of the AB-subunit previously 
synthesized through a Vasella fragmentation, the primary iodide was eliminated to form 
the exocyclic olefin 2.131 which was subjected to a type-II Ferrier rearrangement with 
Hg(OCOCF3) and converted to the enone 2.132. The enone 2.132 corresponds to the 
enantiomer of 2.107 synthesized in the Shair group’s previous report and thus was 
elaborated to the AB-decalin 2.133 using the same sequence as shown in Scheme 2.22.  
 
 
Scheme 2.26. Shair’s synthesis of the natural AB-decalin enantiomer. 
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 Shair’s proposed two-directional synthesis of the bis-tetracyclic ring system of 
HMP-Y1 and hibarimicinone hinged upon an improved benzylic fluoride-mediated 
Michael-Dieckmann cyclization, and therefore an appropriately functionalized D-D’ 
biaryl core required assembly. Starting from 5-methylvanillin (2.134), a three step 
sequence involving phenol methylation, Baeyer-Villiger oxidation, and MOM protection 
led to the toluene derivative 2.135. Regioselective aryl lithiation and treatment with iron 
trichloride effected homodimerization to the racemic biaryl 2.136. Installation of a bis-
methyl ester required bis-bromination, lithiation, and addition to methyl chloroformate 
leading to 2.137. Finally, bis-benzylic fluoride incorporation for the upcoming bis-
Michael-Dieckmann cyclization occurred through bis-benzylic bromination followed by 
fluoride displacement with TBAT to yield the symmetrical D-D’ biaryl core 2.138. 
 
 
Scheme 2.27. Synthesis of a symmetrical D-D’ biaryl core for bis-annulation. 
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2.138 with LiTMP (lithium tetramethylpiperidine) followed by Michael addition into 
enone 2.133 and subsequent Dieckmann condensation to form the C-rings. Notably, 
addition of MgBr2•OEt2 was essential to the Dieckmann condensation’s completion. In a 
novel method, treatment of the bis-cyclic benzylic fluorides with trifluoroethanol (TFE) 
effected C-ring aromatization, likely through hydrolysis of a hydrogen-bound fluorine-
TFE complex which provided the protected HMP-Y1 2.139. At this point, the racemic 
mixture of atropisomers became chromatographically separable, and each atropisomer 
was carried forward separately. Acetonide, MOM, and silyl ether deprotection with 
aqueous HF was finally followed by hydrogenolysis of the benzyl ethers to provide both 
atropisomers of HMP-Y1 (1.94). Attempted thermal interconversion failed when heated 
at 90 °C, and thus confirmation was provided for the proposal that atropostereochemistry 
is retained during the biological conversion of HMP-Y1 to hibarimicinone. Therefore, the 
aR atropisomer was validated as the correct axial stereochemistry for HMP-Y1, and its 
conversion to hibarimicinone with retention of axial chirality confirms the absolute biaryl 
stereochemistry of aS for hibarimicinone, which was synthetically validated by 
Hosokawa’s total synthesis. 
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Scheme 2.28. The first total synthesis of HMP-Y1. 
 
 Shair and co-workers originally intended for a biomimetic synthesis of 
hibarimicinone that utilized the biosynthetic intermediate HMP-Y1 as a key precursor. In 
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this point, and each was carried through the remaining steps separately. Phenyl sulfide 
elimination led to aromatization of the C-ring affording 2.141, which was oxidized to the 
C’-ring mono-quinone. In the key furan linkage forming step, addition of anhydrous HCl 
led to ether 2.142 through a presumed quinone methide intermediate with tertiary alcohol 
Michael addition and reformation of the hydroquinone. The final deprotection steps 
simply required aqueous HF-mediated removal of the silyl ether and acetonide protecting 
groups and was followed by hydrogenolysis of the remaining benzyl ethers to provide the 
natural (aS 1.96) and unnatural (aR 1.96) forms of hibarimicinone. Interestingly, an axial 
interconversion pathway was identified based on treatment with either pH 7.5 buffer at 
room temperature or with 1 N HCl in methanol at 60 °C. Considering these results, a 
proposed mechanism for interconversion relies upon the same proposal set forth in 
Scheme 1.16 in which formation of a planar conjugated tautomer allows for transition 
between the two atropisomers with a lower barrier to rotation. Ultimately, the Shair 
laboratory’s total synthesis of hibarimicinone has provided important information 
regarding the nature of hibarimicin atropisomers and along the way has demonstrated 
novel methods for performing bis-annulation sequences, either to form symmetrical or 
unsymmetrical products. 
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Scheme 2.29. Shair’s completion of the total synthesis of hibarimicinone. 
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of the HMP-Y1 and hibarimicinone axial chirality. With this knowledge, the remaining 
chapters highlight the studies toward total synthesis of HMP-Y1 and hibarimicinone that 
have occurred in our laboratories in the recent past. 
The remaining chapters of this dissertation detail the application of the 
intramolecular Diels-Alder reaction in the development of two differing approaches to 
the natural product hibarimicin B and its biosynthetic intermediates HMP-Y1 and 
hibarimicinone.  
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CHAPTER III 
 
A TWO DIRECTIONAL SYNTHETIC APPROACH 
 
Synthetic Analysis Toward HMP-Y1 and Hibarimicinone 
 
From the beginning of our group’s interest in the hibarimicins, our synthetic 
strategy hinged upon the use of a two-directional bis-annulation sequence. Numerous 
benefits existed with this aim, beginning with a plan to derive the complex semi-C2-
symmetric hibarimicinone (1.96) through a biomimetic conversion of HMP-Y1 (1.94). 
Because HMP-Y1 exhibits C2-symmetry, we reasoned that the two-directional bis-
annulation could occur between two equivalents of an appropriately functionalized enone 
by way of a Michael-Dieckmann condensation cascade, and thus our plan would only 
require synthesis of two key coupling partners. Additionally, much benefit existed in 
targeting a highly functionalized biaryl core. 
At the outset of our studies toward the hibarimicins, the absolute stereochemistry 
of the AB- and A’B’-ring systems remained unresolved, and questions still remained 
regarding the existence and nature of atropisomerism in HMP-Y1 and the aryl-quinone in 
hibarimicinone. With this in mind, our two-directional strategy sought to identify the 
natural atropisomer of both of our synthetic targets by elaboration of the aR and aS biaryl 
cores to the natural product for spectroscopic correlation. Thus, we reasoned that a rapid 
synthesis and evaluation of optically pure biaryls 3.1 would benefit the overall strategy of 
assigning hibarimicinone axial chirality. These principles become apparent with the 
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general synthetic approach outlined in Scheme 3.1, and for the sake of clarity, the AB- 
and A’B’-absolute stereochemistry are denoted as historically accurate for our work. 
 
 
Scheme 3.1. Two-directional synthetic analysis toward HMP-Y1. 
 
Romaine’s Work Toward the Biaryl Core 
 
 Two former members of our laboratory played key roles in initiating our 
hibarimicin studies. Ian Romaine’s pioneering work toward the biaryl core, which no 
other research groups had previously given focus despite their interest in the AB and 
A’B’ subunits, proved the feasibility of the two-directional approach, and his efforts 
require summarizing for contextual purposes. We thus proposed arrival at both aR-3.2 
and aS-3.2 which would derive from a racemic mixture of a biaryl intermediate through 
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provide access to the symmetric biaryl, and 3.3 was proposed to derive from vanillin 
(3.4). 
 
 
Scheme 3.2. Biaryl core retrosynthetic analysis. 
 
 Synthesis of the biaryl core began from vanillin (3.4) by regioselective aromatic 
bromination followed by Baeyer-Villiger oxidation to hydroquinone 3.5.1 Bis-methyl 
ether formation was followed by lithium-halogen exchange and methylation with methyl 
iodide to provide the desired toluene derivative 3.3 as a key precursor for oxidative 
dimerization. Using Spring’s oxidative homodimerization procedure, by aryl 
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by lithium-halogen exchange and addition to phenyl chloroformate to provide a racemic 
mixture of the biaryl bis-phenyl ester 3.2. For the purpose of ultimately determining the 
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determination for each atropisomer was performed by bis-Mosher ester synthesis of a C-
1,1’ bis-phenol derivative of 3.7. Serendipitously, crystallization of one of the Mosher 
ester samples allowed for X-ray structure determination, ultimately assigning the 
crystallized sample as aS. With access to atropisomerically pure biaryls aR 3.2 and aS 
3.2, we then only needed to synthesize the enone coupling partner; however, first, we 
investigated model Staunton-Weinreb annulation conditions for both mono- and bis-
annulation with simple enones. 
 
 
Scheme 3.3. Romaine’s synthesis of the HMP-Y1 biaryl core. 
 
 We were interested in the possibility of mono- as well as bis-annulations, and thus 
phenyl ester 3.8 was synthesized through a modified procedure from that shown in 
Scheme 3.3. Toluate anion formation with 3.8 following Staunton’s method was effected 
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tricycle 3.10 was treated with DDQ in refluxing benzene to arrive at the model BCD-ring 
system 3.11 in good yield. Similarly, performing the Michael-Dieckmann sequence with 
the β-phenylsulfonylenone 3.12 led directly to the desired naphthalene product 3.11 but 
in lower yield than the two step procedure.4 With conditions worked out for mono-
annulation, we moved to perform a bis-annulation with the related biaryl bis-phenyl ester 
3.2 and cyclohexenone (3.9). After extensive experimentation, we were unable to 
improve the yield of bis-tricycle beyond 32%. These results, while confirmatory, loomed 
large over the big picture approach to HMP-Y1 and hibarimicinone by way of a bis-
annulation sequence. Subsequent bis-oxidation with DDQ led to the racemic bis-tricycle 
3.13 which constituted the BCD-BCD ring system found in HMP-Y1; however, again, 
the yield of this sequence remained concerning. 
 
 
Scheme 3.4. Annulation model systems with cyclohexenone. 
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Engers’ Work Toward the AB-Decalin 
 
 With both pure biaryl atropisomers in hand, a route to the AB-decalinic enone 
2.54 was designed based on our laboratory’s previous experiences highlighted in Chapter 
II. Thus, a key intramolecular Diels-Alder reaction was posed as a stereochemistry-
defining step for the C-9 bridgehead hydrogen that would direct formation by tethering 
with the adjacent chiral secondary alcohol at C-10 from an IMDA precursor 3.14. In this 
manner, the dienophile would be installed through an esterification reaction, and the 
terminal diene would arise from a palladium-mediated Suzuki cross coupling to arrive at 
enone 3.15. The A-ring subunit 3.15 was proposed to derive from a linear precursor 
through a ring closing metathesis reaction, and the three stereochemically defined 
secondary alcohols would be available directly from the chiral feedstock methyl-α-D-
glucopyranoside (3.16).  
 
 
Scheme 3.5. Retrosynthetic analysis toward the AB-ring system subunit. 
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glucopyranoside (3.16), we arrived at the primary iodide 3.17 which was treated with 
zinc dust with sonication to effect Vasella fragmentation to the intermediate aldehyde. 
The aldehyde reacted in situ with allylzinc bromide to afford the homoallylic alcohol 3.18 
in good yield. 5  The four step sequence of alcohol oxidation, terminal olefin 
isomerization, ring closing metathesis, and enone α-iodination arrived at the iodo-enone 
3.19.6 Installation of the diene through a Suzuki cross coupling reaction then led to a key 
substrate 3.21 for three-carbon unit addition. Unfortunately, our best results came with 
allyl Grignard with concomitant benzoate deprotection to provide the tertiary alcohol 
3.22 as a 2:1 mixture of inseparable diastereomers in relatively low yield. Despite this 
disappointing result, the mixture of diastereomers was subjected to esterification with the 
propargylic acid 3.23 which led to separable diastereomers of 3.24, of which the desired 
was carried forward. Again, we encountered only disappointment when all attempts at 
IMDA cyclization failed to afford the decalin 3.25. It was reasoned that the locked 
conformation of 3.24 imparted by the acetonide protecting group led to poor orbital 
overlap, and thus the free diol was targeted as a potential solution to the problem. 
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Scheme 3.6. Engers’ early approach toward the AB-decalin. 
 
 To test the potential adverse conformational effects of the acetonide in the IMDA, 
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Scheme 3.7. IMDA followed by attempted hydroxy-ketone installation. 
 
 Toward the end of his tenure, Dr. Engers contributed a highly effective route to 
large quantities of the benzyl-protected glucose derivative 3.32, which was available in 
five steps from methyl-α-D-glucopyranoside (3.16) as reported by Liotta and co-
workers.7 Thus, regioselective benzylidene acetal formation was followed by benzylation 
of the remaining secondary alcohols and in situ HI formation effected acetal removal to 
provide 3.30. Primary alcohol iodination was finally followed by benzoate protection of 
the remaining secondary alcohol yielding 3.32 in high yields throughout the entire 
sequence. This route reliably provided greater than 60 grams per single batch; however, 
the necessity for flash column chromatographic purification of each step on large scale 
proved highly cumbersome. Nevertheless, access to stockpiles of advanced material 
allowed for effective large scale throughput to later synthetic stages. 
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Scheme 3.8. Synthesis of the benzyl-glucopyranoside series. 
 
 Following precedent set with the acetonide series, Vasella fragmentation and in 
situ addition of allylzinc bromide to the intermediate aldehyde 3.34 led to the homoallylic 
alcohol 3.35 with quantities of the protonated methyl byproduct 3.36 detected by NMR as 
an inseparable mixture with the desired product. Oxidation of the inconsequential mixture 
of diastereomers provided the ketone 3.37, and although a yield was not determined for 
the formation of the impurity 3.36, it likely significantly contributed to the low two-step 
yield of 3.37. The previously developed three-step sequence to iodo-enone 3.19 involving 
olefin transposition, ring closing metathesis, and α-iodination was utilized to arrive at 
3.38 in low yield. Suzuki cross coupling with the cyclic vinyl-boronate 3.20 again 
occurred in less than desirable yield to nevertheless arrive at the dienone 3.39. 
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Scheme 3.9. Engers’ route to the benzyl-protected dienone. 
 
 Despite low yields leading to the dienone 3.39, we forged ahead with the 
previously established allyl Grignard addition to form the C-13 tertiary alcohol with 
concomitant benzoate deprotection to arrive at the inseparable mixture of diastereomers 
of 3.40. Esterification with acryloyl chloride afforded the IMDA precursor 3.41 at which 
point the undesired diastereomer became chromatographically separable. We were 
pleased to observe clean cycloaddition to the decalin product upon heating in benzene at 
160 °C in a sealed tube, and regioselective terminal olefin hydrogenation led to 3.42 in 
high yields. This application of the IMDA perfectly highlights the enabling nature of such 
a simple transformation, where the key C-9 ring juncture stereochemistry was set in a 
predictable and specific manner. 
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Scheme 3.10. Engers’ acrylate IMDA toward the decalinic enone. 
 
An analysis of the key tertiary alcohol-forming step with allyl Grignard, which 
remained the weak point in our sequence toward Diels-Alder product 3.42, indicated the 
delicate balance of steric and electronic effects at play and the overriding substrate 
control in the diastereoselectivity. First, based on the relative stereochemistry found in 
2.54 and considering the conformation of the dienone 3.39, a pseudo-equatorial attack on 
the ketone is necessary. When analyzing the facial addition based on the Burgi-Dunitz 
angle, the pseudo-axial attack suffers from a detrimental 1,3-diaxial interaction with the 
axial hydrogen, whereas the pseudo-equatorial addition encounters an unfavorable 
Gauche interaction, both shown in 3.43. These effects manifest in varying levels based on 
the size of the nucleophile. Additionally, while axial attack to cyclohexanones is favored, 
this preference increases when compared to cyclohexenones because of a large change in 
internal dihedral angle, from 51° to 22°, that exacerbates the aforementioned Gauche 
interaction.8 One other stereoselecting factor involves the Cieplak effect, shown in 3.44 
which exhibits a stabilizing effect on the forming σ*-orbital from the adjacent C-H σ-
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orbital through hyperconjugation.9 Ultimately, the equatorial versus axial orientation of 
the nucleophilic unit in the products α-3.40 and β-3.40 respectively also play into the 
final stereoselectivity of the reaction, and all of these factors affect the observed low 
diastereoselectivity of the allyl addition to 3.39 slightly favoring the desired pseudo-
equatorial addition. Finally, further evidence for strong substrate control included 
attempted Schaus allylation with an allyl borane-BINOL complex that led to high yields 
but exclusively the undesired diastereomer.10 
 
 
Scheme 3.11. Stereochemical effects in the nucleophilic addition. 
 
With the trisubstituted olefin in 3.42, significant experimentation was required to 
determine the best conditions for hydroxy-ketone installation. It was proposed that the 
stereochemistry of the resulting tertiary alcohol should be set by substrate control, where 
oxidation of the olefin would occur from the convex face of the molecule. Attempts 
included dihydroxylation, as in Scheme 3.7, as well as epoxidation; however, our most 
successful results came by treatment with in situ generated RuO4 in the presence of 
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excess Oxone. Initially reported by Plietker, the method takes advantage of the 
mechanistic pathway innate to OsO4 dihydroxylation.11 In the same manner that OsO4 
undergoes a [3+2]-addition to olefins to form an osmate ester, RuO4 forms the ruthenate 
ester 3.46. With excess Oxone present, the ruthenate ester is oxidized by Oxone to 
Ru(VIII)-complex 3.47. At this point in the OsO4-mediated dihydroxylation mechanism, 
water serves to break down the osmate ester to the requisite diol; however, with excess 
Oxone and a low volume of water present, the Ru(VIII)-ester preferentially reacts with 
the oxidant following protonation to reach the intermediate 3.49, which effects substrate 
oxidation to the hydroxy-ketone 3.50 and regenerating RuO4. With symmetrical olefinic 
substrates, regioselectivity does not present an issue, but when R and R’ are not equal, 
regioselectivity is at least partly governed by substituent electronics, in which the 
hydroxyl-functionality is directed toward electron withdrawing groups.12  
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Scheme 3.12. Mechanism of RuO4-mediated ketohydroxylation. 
 
 Thus, ketohydroxylation of the trisubstituted olefin 3.42 successfully installed the 
necessary α-hydroxy-ketone to provide 3.51 with complete stereoselectivity for the 
convex-face addition. In addition, keeping in mind the regioselectivity observed for 
ruthenate ester opening by Oxone as shown in Scheme 3.12, formation of the tertiary 
alcohol is favored at lower temperatures. This method proved highly successful in 
providing rapid generation of two functionalities present in hibarimicinone with 
stereoselectivity for the bridgehead tertiary alcohol. Unfortunately, all attempts at 
installing the necessary enone failed, likely due to the small reaction scales resulting from 
difficulties with material throughput. Therefore, we returned to our synthetic strategy in 
hopes of improving our ability to arrive at a related enone precursor to 3.51 in higher 
overall yield. 
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Scheme 3.13. Failed enone installation approach. 
 
An Improved Route to the AB-Enone Precursor 
 
We originally identified four major points of necessary improvement in our 
approach to the AB-decalin 2.54. The five-step sequence from the functionalized glucose 
3.32 to iodo-enone 3.38 proved problematic in yield and the formation of inseparable 
impurities. Next, the Suzuki cross coupling to install the required diene functionality 
remained low yielding and appeared ripe for optimization. Although the limiting step in 
our sequence remained the C-13 tertiary alcohol formation, we saw few options left 
following Engers’ extensive investigation, and we thus settled for moving quantities of 
material through this step, where we could reliably isolate and functionalize the resulting 
product. Finally, while keeping in mind difficulties encountered with enone formation 
from 3.51, we sought to incorporate functionality that would facilitate enone installation 
outside of the realm of traditional enone-generating reactions. 
Therefore, inspired by reports of direct vinyl additions to Vasella products, we 
moved to modify this procedure to allow large-scale transformation.13 The previously 
developed in situ allylzincation was hampered by scale limitations with sonication, and 
thus we developed a procedure that utilized refluxing the primary iodide 3.32 in the 
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presence of zinc dust to effect Vasella fragmentation to the linear aldehyde 3.34. Instead 
of utilizing in situ nucleophilic addition to the intermediate aldehyde, we elected for 
quick isolation and immediate reaction with vinylmagnesium bromide at –78 °C to arrive 
at the inconsequential mixture of allylic alcohol diastereomers 3.53, and satisfactorily, 
minimal formation of the methyl impurity 3.36 was observed. 
Ring closing metathesis of 3.53 occurred readily with both diastereomers to 
provide the cyclic allylic alcohol 3.54, and it became apparent that the allylic alcohol was 
a superior substrate for the necessary reaction when compared to the α,β-unsaturated 
ketone in Scheme 3.9. This effect should not be surprising when considering work by 
Hoye and co-workers that showed preferential reaction of allylic alcohols in the ring 
closing metathesis manifold by presumed pre-association or ligand exchange of the 
catalyst with the alcohol substituent.14 Therefore, the two lowest yielding steps in the 
previous sequence, Vasella fragmentation/nucleophilic addition and ring closing 
metathesis, were improved to an overall three step yield of 46%. Subsequent IBX 
oxidation and α-iodination provided the desired iodo-enone 3.38 in high yield. 
 
 
Scheme 3.14. Improved route to the iodo-enone. 
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Ring closing metathesis has revolutionized organic chemistry in the past two 
decades, and the three major players in its development, Schrock, Grubbs, and Chauvin 
were awarded the Nobel Prize in Chemistry for 2005. For synthetic chemists, it has 
enabled ring formation where few robust methods existed previously, and 
mechanistically it draws on the electronic properties of the transition metal catalysts 
molybdenum and most commonly ruthenium. While the molybdenum catalysts suffer 
from high sensitivity to air and water, Grubbs’ first generation catalyst,  
(PCy3)2RuCl2CHPh, exhibits excellent stability, and the incorporation of an imidazole-
derived N-heterocyclic carbene in Grubbs’ second generation catalyst (3.56) further 
improved the reactivity.15 The cycle shown in Scheme 3.15 illustrates the ring closing 
metathesis of the ideal 1,7-octadiene substrate (3.57), which first undergoes a [2+2]-
cyclization with the ruthenium alkylidene to form the four-membered ruthenium 
intermediate 3.58 which decomposes through a pericyclic process to the substrate-derived 
ruthenium alkylidene 3.59. Association and cycloaddition with the remaining terminal 
olefin provides the bicyclic intermediate 3.60, which finally undergoes pericyclic 
decomposition and ligand exchange to regenerate a form of the catalyst and provide the 
cyclohexene (3.61). The efficiency, high compatibility with many functional groups, and 
versatility makes the ring closing metathesis reaction a highly important reaction in the 
repertoire of the synthetic organic chemist. 
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Scheme 3.15. Catalytic cycle for ring closing metathesis. 
 
 With the newly improved synthesis of iodo-enone 3.38, we set forth to optimize 
reaction conditions for installation of the terminal diene for the IMDA reaction. Original 
conditions developed by Engers involved the use of tetrakis(triphenylphosphine) 
palladium(0) with triphenylarsine and silver(I) oxide in a mixture of THF and water. 
Additionally, the cyclic boronate-pyridine complex 3.20 provided a stable source of three 
equivalents of vinyl boronic acid.16 The modest 44% yield of 3.39 was gratifyingly 
improved to 73% when changing to Fu’s catalyst, palladium bis(tri-t-butylphosphine), 
with cesium carbonate in a mixture of THF and water, and this procedure could be 
effectively scaled to multi-gram reactions with only minor drop in yield.17,18 From 3.39, 
we decided to move forward through the allyl addition step to form 3.40, which occurred 
in 44% yield as a 2:1 mixture of inseparable diastereomers. 
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 At this point, in contrast to the acrylate dienophile utilized previously by Engers, 
we elected to utilize the 3-phenylsulfonylacrylic ester, in which the phenylsulfone 
substituent would provide a leaving group for easy enone formation. Therefore, 
esterification with 3-phenylsulfonylacrylic acid (3.63) under Mukaiyama’s conditions 
effectively formed the desired IMDA precursor α-3.64, at which point the undesired 
diastereomer β-3.64 became chromatographically separable.19,20 
 
 
Scheme 3.16. Improved synthesis of a modified IMDA substrate. 
 
 We finally arrived at the proposed IMDA precursor 3.64 as a single diastereomer 
in an improved 8 steps from iodide 3.32, and we reasoned that not only would the 
phenylsulfone functionality play an important role in enone formation but also in the 
IMDA reaction. As described in Figure 2.1, addition of an electron withdrawing group to 
the dienophile has the effect of lowering the dienophile LUMO and thus should improve 
the reactivity. And we were excited to observe clean cycloaddition to the desired decalin 
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3.65 by heating in toluene at 70 °C for 2 days. Extensive 1D and 2D NMR spectroscopy 
allowed structure assignment, and two key NOESY correlations between C-9/C-10 and 
C-10/C-12 confirmed the desired stereochemistry at the bridgehead C-9 hydrogen. 
Importantly, the correct C-9 stereochemistry validated the IMDA approach toward the 
decalin, and we next targeted enone 3.52. 
 
 
Scheme 3.17. Key IMDA toward the AB-decalin. 
 
 Analogous to Engers’ approach to the enone, we first performed regioselective 
hydrogenation on the terminal olefin which required only 30 minutes before over-
reduction began to occur at the trisubstituted olefin. Subsequent ketohydroxylation 
successfully provided the key substrate 3.66; however, attempts at purification with a 
variety of solid phases led only to decomposition. Despite this fact, the reaction 
proceeded cleanly enough to compare 1H NMR spectra with the previously synthesized 
acrylate IMDA analog 3.51 to confirm that the reaction had again occurred with complete 
stereoselectivity for the correct C-14 orientation. 
 Finally, we had arrived at an enone precursor that only required base-mediated 
elimination of the sulfone. Unfortunately, treatment of 3.66 initially with DBU and later 
with varying bases such as potassium tert-butoxide at low temperature led exclusively to 
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the undesired olefin regioisomer 3.67. This product was easily assigned by 1H NMR due 
to the difference in the number and splitting patterns of olefinic protons of the two 
possible products. We reasoned that the undesired product formation may be a result of 
altered pKa’s arising from ring strain in the lactone, and retrospectively, this regioisomer 
could be expected to be the thermodynamic product as effected by the cis-ring fusion and 
observed by Ziegler and co-workers in their efforts toward forskolin.21 We thus moved to 
relieve this ring strain by opening the lactone functionality. 
 
 
Scheme 3.18. Failed sulfone elimination to the AB-enone. 
 
 Through a straightforward sequence, lactone opening with K2CO3 in methanol led 
to the methyl ester and free secondary alcohol which was silyl protected and subjected to 
ketohydroxylation conditions to arrive at the fully functionalized enone precursor 3.69. 
Again, because of the sensitivity of the sulfone moiety, this product was unstable to 
chromatographic purification; however, we utilized the relatively clean crude material for 
base-mediate enone formation. Treatment of 3.69 with DBU at low temperature formed a 
highly unexpected product, which we ultimately identified as the caged ether 3.70. This 
compound presumably arose by enone formation and subsequent Michael addition of the 
C-13 tertiary alcohol. We were unable to suppress this secondary reaction, and because 
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3.70 was isolated as a single diastereomer, no absolute determination regarding the 
regioselectivity of elimination could be made. 
 
 
Scheme 3.19. An unexpected etherification of an enone intermediate. 
 
 Due to our difficulty arriving at meaningful quantities of enone precursors 3.66 
and 3.69 but considering our interest in probing the elimination regioselectivity, we 
quickly synthesized the reported IMDA product 3.71 which perfectly suited our needs for 
an elimination model system. 22  The racemic 3.71 contained all of our necessary 
functionality without the extraneous oxygenation, and we attempted ketohydroxylation 
with the intent of studying the subsequent base-mediated elimination regioselectivity. 
Interestingly, based on analysis of a 1H NMR mixture of products, we determined that 
our desired product 3.73 was highly labile to the ketohydroxylation conditions and 
provided a mixture of predominantly the undesired olefin regioisomer 3.72. When taken 
in consideration with results leading to the formation of 3.67, this lends further support 
the concept that the α,β-unsaturated lactone is the thermodynamic product. Ultimately 
because we were unable to isolate pure 3.73 without in situ elimination, this system was 
of little use for our purposes. 
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Scheme 3.20. A sulfone elimination model system. 
 
These three major results proved disconcerting and caused a complete rethinking 
of our synthetic strategy. However, we were also concurrently attempting a tangential 
reworking of a substrate for C-13 tertiary alcohol formation that we hoped would impress 
strong substrate control toward the desired stereochemical orientation and improve the 
remaining limiting step in material throughput for our synthetic route. 
 
Toward a Substrate-Controlled Tertiary Alcohol Formation 
 
In our work toward the enone 3.52, tertiary alcohol formation presented the 
remaining complication for producing quantities of an enone precursor for extensive 
enone formation studies. Therefore, we devised a synthetic route that would diverge from 
a previously synthesized intermediate and would install the C-13 propyl unit in high yield 
and stereoselectivity. This approach hinged upon using the cis-decalin substrate 
conformation to direct the face of nucleophilic addition to a decalinic ketone 3.75, which 
would be assembled in analogy to our previous work and would diverge from 3.77, where 
X could equal H, I, or vinyl as previously synthesized. 
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Scheme 3.21. Synthetic strategy for a substrate controlled propyl addition. 
 
 We believed that the C-13 ketone in 3.38 would require masking for the sequence 
of reactions necessary to arrive at 3.75, and thus we targeted the series of enones 
previously synthesized as substrates for reduction and protection. We initially attempted 
Luche reduction on our most advanced amenable intermediate, dienone 3.39, however 
primary attempts with NaBH4, CeCl3•7H2O, and MeOH failed to deliver the desired 
allylic alcohol likely caused by the starting material’s insolubility in methanol. 23 
Changing the reaction solvent to a 1:1 mixture of ethanol and THF provided the desired 
product, albeit in low yield. Finally, we met success when taking a step back and utilizing 
Luche conditions on the iodo-enone 3.38, where we arrived at a diastereomeric mixture 
of allylic alcohols in 86% yield.24 
 
 
Scheme 3.22. Encountered difficulties with a modified Suzuki coupling substrate. 
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 Silyl protection of the allylic alcohol mixture cleanly provided 3.78 which we 
subjected to our standard Suzuki cross coupling conditions. Interestingly, the two 
diastereomers exhibited differential reactivity, and we isolated primarily the α-OTES 
product 3.79 with larger amounts of unreacted β-OTES starting material 3.78. Despite 
attempts to improve this reactivity with other conditions, we resorted to carrying forward 
only α-3.79, and even resubjection of β-3.78 to the reaction conditions never provided 
greater than 50% conversion to product. Unfortunately, our ability to reliably produce 
large amounts of vinyl iodide 3.78 became overshadowed by the unexpected problems 
encountered with relying on a mixture of diastereomers through our proposed sequence 
of reactions. 
 
 
Scheme 3.23. Synthesis of the proposed decalinic enone 3.75. 
 
 Moving forward with the single diastereomer 3.79 in spite of our Suzuki cross 
coupling complications, the benzoate protecting group was effectively removed with 
DIBAL at low temperature and was followed by esterification as previously developed to 
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arrive at the desired IMDA precursor 3.81. When considering the optimal solvent for this 
cycloaddition, we turned to work by Jung and Gervay regarding the reactive rotamer 
effect as seen in the IMDA in Scheme 3.24.25 
 
 
Scheme 3.24. The reactive rotamer effect in the IMDA. 
 
 For the prototype IMDA of the furan diene with the methyl fumarate dienophile 
3.83, various substitutions at the R and R’ locations failed to produce a significant effect 
on the rate of the IMDA reaction, as was proposed based on the gem-dialkyl effect. The 
original postulate involving the gem-dialkyl effect relied upon Thorpe-Ingold bond angle 
compression and a resultant lower entropy of activation. However, ultimately the reactive 
rotamer effect and activation enthalpy lowering explained the observed results. Thus, the 
most stable s-trans conformation 3.83 is expected to be the predominant conformation in 
solution, whereas the higher energy s-cis conformation 3.84 must be accessible for the 
IMDA to occur. This conformation results in a highly polar transition state 3.85 as shown 
with the indicated dipole moments, and thus the reactive rotamer effect for IMDAs 
involving an ester-linked diene and dienophile can be exploited by stabilization of the 
transition state with polar solvents. Indeed, in the system shown in Scheme 3.24, a 
significant rate enhancement was observed when changing from toluene to acetonitrile 
and even greater with DMSO. Therefore, we chose acetonitrile as an optimal solvent for 
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the desired IMDA, and we successfully arrived at the decalin 3.82 in reasonable yield by 
heating 3.81 in refluxing acetonitrile for 60 hours. 
 We had finally arrived at our proposed Diels-Alder product 3.82 as shown in 
Scheme 3.23; however, serious complications remained regarding material throughput 
with the Suzuki cross coupling reaction. We successfully found deprotection conditions 
for the TES-ether involving treatment with acetic acid and THF and water, and the allylic 
alcohol was oxidized in mediocre yield with IBX. Ultimately, the limited amounts of 
material past the IMDA reaction never allowed for full characterization of the free allylic 
alcohol or ketone 3.75, and we never produced enough 3.75 to reasonably probe its 
reactivity and the resulting stereoselectivity of a 1,2-nucleophilic addition. We had 
effectively managed to trade one significant problem for another, as is often too much of 
a reality in complex molecule total synthesis, and we again had to reimagine our 
synthetic strategy to account for our previous results. 
 
Conclusion 
 
Our proposed two-directional annulation strategy toward HMP-Y1 and 
hibarimicinone aimed to allow straightforward manipulation of each biaryl atropisomer 
for ultimate assignment of the natural product axial chirality. While we could reliably 
produce the racemic biaryl core 3.2 and perform chiral chromatographic separation, 
preliminary studies indicated low yielding bis-annulation reactions. Additionally, 
multiple routes were devised to arrive at the proposed decalinic enone 2.54; however, we 
consistently encountered problems at varying points in the synthetic sequences. First, 
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traditional enone installation attempts with the hydroxy-ketone 3.51 failed, and two 
substrates with a sulfone leaving group led only to unexpected and undesired products. 
Finally, our attempt to improve the limiting propyl unit-appending step led to problems 
earlier in the route which rendered the sequence useless. These results taken together 
pointed to the need for a complete overhaul of our approach to HMP-Y1 and 
hibarimicinone that would subvert issues encountered in the crux of the two-directional 
strategy. 
 
Experimental Methods 
 
General Procedure. All non-aqueous reactions were performed under an argon 
atmosphere in flame-dried glassware. Stainless steel syringes or cannula were used to 
transfer air- and moisture-sensitive liquids. Reaction temperatures were controlled using 
a thermocouple thermometer and analog hotplate stirrer. Reactions were conducted at 
room temperature (RT, approximately 23 °C) unless otherwise noted. Analytical thin-
layer chromatography was performed on E. Merck pre-coated silica gel 60 F254 plates 
and visualized using UV, ceric ammonium molybdate (CAM) and potassium 
permanganate (KMnO4) stains. Flash column chromatography was conducted as 
described by Still et. al. using indicated solvents and Dynamic Adsorbents silica gel 60 
(230-240 mesh).26 Where necessary, silica gel was neutralized by treatment of the silica 
gel prior to chromatography with the eluent containing 1% triethylamine (Et3N). Where 
necessary, silica gel was treated prior to chromatography with the eluent containing 1% 
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glacial acetic acid (AcOH). Yields were reported as isolated, spectrocopically pure 
compounds. 
 
Materials. Reagents were purchased at the highest commercial quality and used without 
further purification unless otherwise stated. When necessary, intermediates were dried by 
azeotropic removal of water by evaporation from benzene (three iterations) and further 
dried on high-vacuum for the indicated amount of time. Toluene and dichloromethane 
(CH2Cl2) were obtained by passing commercially available solvents through activated 
alumina columns (MBraun MB-SPS solvent system). Tetrahydrofuran (THF) was 
purified by distillation from sodium metal with benzophenone indicator, and when 
necessary, was further dried over activated 4 Å molecular sieves under an atmosphere of 
argon. Triethylamine (Et3N) was distilled from calcium hydride and stored over sodium 
hydroxide. The molarity of commercial n-butyllithium solutions was determined by 
titration using diphenylacetic acid as an indicator (average of three determinations). 
 
Instrumentation. Optical rotations were obtained using a Perkin Elmer 341 polarimeter 
and zeroed with the pure solvent, spectrophotometric-grade chloroform. 1H NMR spectra 
were recorded on Bruker 300, 400, 500, or 600 MHz spectrometers and are reported 
relative to deuterated solvent signals (CDCl3: 7.26; C6D6: 7.16). Data for 1H NMR 
spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sept. = septet, m = multiplet, br = broad, app = 
apparent), coupling constants (Hz), and integration. 13C NMR spectra were recorded at 
100, 125, or 150 MHz and are reported relative to deuterated solvent signals (CDCl3: 
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77.0; C6D6: 128.1). Infrared spectra were obtained as thin films on NaCl plates using a 
Thermo Electron IR100 series instrument and are reported in terms of frequency of 
absorption (cm-1). High-resolution mass spectra were obtained from the Department of 
Chemistry and Biochemistry, University of Notre Dame using either a JEOL AX505HA 
or JEOL LMS-GCmate mass spectrometer. 
 
Preparative Procedures 
 
Methyl-α,D-glucopyranoside (40.0 g, 206 mmol, 1.0 eq) was dissolved in 
acetonitrile (1.00 L), and to the solution was added benzaldehyde dimethyl 
acetal (40.2 mL, 268 mmol, 1.3 eq) and camphorsulphonic acid (1.91 g, 8.24 
mmol, 0.04 eq) and the reaction was stirred at RT for 18 h. Triethylamine (20.0 mL) was 
added and stirred for one hour, and the reaction mixture was concentrated to a slurry and 
purified by flash column chromatography (25% then 90% EtOAc/hexanes) yielded 3.29 
as a white solid (40.5 g, 143 mmol, 70%). Spectral data were consistent with reported 
literature values.27 
 
A solution of 3.29 (36.9 g, 131 mmol, 1 eq), KOH (50.6 g, 902 mmol, 6.9 
eq), and benzyl bromide (108 mL, 902 mmol, 6.9 eq) in toluene (470 mL) 
was heated at reflux for 2.5 h. At RT toluene (750 mL) was added and the 
mixture was washed with H2O (2 x 750 mL) and evaporated to an oil. The oil was twice 
dissolved in toluene (300 mL) and evaporated to dryness. Purification by flash column 
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chromatography (11:1, 10:1, and 9:1 hexanes/acetone) yielded S3.1 as a white solid (50.8 
g, 110 mmol, 84%). Spectral data were consistent with reported literature values.7 
 
A solution of S3.1 (68.2 g, 147 mmol, 1 eq) and I2 (13.9 g, 54.6 mmol, 0.37 
eq) in methanol (1.50 L) was heated at reflux for 6 h. At RT, 10% aqueous 
Na2S2O3 was added (400 mL) and the mixture was evaporated to an oil. The 
oil was dissolved in water (500 mL) and extracted with CH2Cl2 (3 x 600 mL), and the 
organic layers were combined, dried (MgSO4), filtered and concentrated. Purification by 
flash column chromatography (20%, 40% and 60% acetone/hexanes) provided 3.30 as a 
white solid (46.1 g, 123 mmol, 83%). Spectral data were consistent with reported 
literature values.7 
 
To a solution of 3.30 (43.6 g, 116 mmol, 1.0 eq) in toluene (1.19 L), I2 
(44.3 g, 175 mmol, 1.5 eq), triphenylphosphine (42.8 g, 163 mmol, 1.4 eq), 
and imidazole (23.8 g, 349 mmol, 3.0 eq) were added and the reaction was 
heated at 50 °C for 2.5 h. At RT methanol (900 mL) was added and the mixture was 
concentrated to an oil. The mixture was diluted with 10% aqueous Na2S2O3 (350 mL) and 
extracted with CH2Cl2 (3 x 350 mL). The organic layers were combined, dried (MgSO4), 
filtered and concentrated to a yellow oil. Purification by flash column chromatography 
(5%, 8% and 11% acetone/hexanes) resulted in 3.31 as a clear oil (54.7 g, 129 mmol, 
97%). Spectral data were consistent with reported literature values.7 
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To a solution of 3.31 (54.1 g, 112 mmol, 1.0 eq) in pyridine (1.12 L) at 0 
°C was added benzoyl chloride (30.8 mL, 265 mmol, 2.4 eq) dropwise, 
followed by removal of the ice bath after 30 min and the reaction was 
stirred at RT for 18 h. The reaction was poured over ice (2000 mL) and extracted with 
CH2Cl2 (3 x 1.0 L). The combined organic layers were washed with ice cold 6 M aqueous 
HCl (4 x 1.0 L), saturated aqueous NaHCO3 (1 x 1.0 L) and water (4 x 1.2 L). The 
organic layer was dried (MgSO4), filtered and concentrated. The crude material was 
purified by flash chromatography (5-15% acetone/hexanes) to yield 3.32 as a white solid 
(63.3 g, 108 mmol, 96%). Spectral data were consistent with reported literature values.7 
 
A solution of 3.32 (15.0 g, 25.5 mmol, 1.0 eq) and zinc dust (33.3 g, 510 
mmol, 20 eq) in THF/H2O (4:1, 1.02 L) was heated at reflux. After 2 h the 
reaction was removed from heating, and once at RT the mixture was filtered 
through a plug of celite and THF was removed in vacuo. The remaining aqueous solution 
was diluted with EtOAc/H2O (3:1, 400 mL), separated and the aqueous layer extracted 
with EtOAc (3 x 300 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated to provide crude 3.34 as a yellow oil. Material was immediately taken 
forward crude, except for characterization purposes. 1H NMR (400 MHz, CDCl3): δ 9.69 
(d, J = 1.1 Hz, 1H), 8.01 (d, J = 7.7 Hz, 2H), 7.57 (t, J = 7.7 Hz, 1H), 7.44 (t, J = 7.7, 
2H), 7.38-7.31 (m, 5H), 7.29-7.20 (m, 5H), 5.97-5.85 (m, 2H), 5.39 (d, J = 16.4 Hz, 1H), 
5.28 (d, J = 10.3 Hz, 1H), 4.74 (d, J = 11.8 Hz, 1H), 4.71 (d, J = 11.3 Hz, 1H), 4.62 (d, J 
= 11.3 Hz, 1H), 4.56 (d, J = 11.8 Hz, 1H), 4.05 (dd, J = 5.6, 4.2 Hz, 1H), 3.96 (dd, J = 
4.1, 1.2 Hz, 1H); 13C NMR (CDCl3, 100 MHz): δ 202.4, 165.1, 137.2, 136.7, 133.2, 
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132.6, 129.7, 128.6, 128.5, 128.4 (2C), 128.3, 128.2, 128.0, 119.3, 82.4, 80.4, 74.5, 74.2, 
73.4; IR (film) νmax 3064, 3032, 2870, 1724, 1268 cm-1; HRMS (ESI) m/z calcd. for 
C27H26NaO5 [M+Na]+ 453.1672, found 453.1661. 
 
A crude solution of 3.34 in THF (644 mL) was cooled to −78 °C and vinyl 
magnesium bromide (1M in THF, 80.6 mL, 80.6 mmol, 2.5 eq) was added 
dropwise. The −78 °C bath was allowed to warm to −20 °C over 3 h, and to 
the reaction was added saturated aqueous NH4Cl (500 mL). The −20 °C bath was 
removed and once at RT the mixture was diluted with EtOAc/H2O (4:1, 500 mL). The 
aqueous layer was extracted with EtOAc (3 x 375 mL), and the combined organic layers 
were dried (MgSO4), filtered and concentrated to provide 3.53 as a yellow oil. The 
mixture of crude diastereomers was taken forward without further purification. 
 
A solution of crude 3.53 (13.5 g, 29.5 mmol, 1.0 eq) and Grubbs second 
generation catalyst (750 mg, 0.884 mmol, 0.03 eq) in toluene (589 mL) was 
heated at 70 °C. After 24 h the reaction was removed from heating, and at RT 
the mixture was filtered through a plug of silica with EtOAc washes, and the filtrate was 
concentrated. The crude residue was purified by column chromatography (5-25% 
EtOAc/hexanes) to yield 3.54 as a light brown solid (5.09 g, 11.8 mmol, 46% three steps) 
as a 1.3:1 mixture of diastereomers. MP: 75-77 °C; 1H NMR (400 MHz, CDCl3): major 
diastereomer δ 8.01-7.98 (m, 2H), 7.58 (dt, J = 7.2, 0.4 Hz, 1H), 7.43 (dt, J = 8.0, 0.8 Hz, 
2H), 7.37-7.32 (m, 5H), 7.25-7.23 (m, 2H), 7.22-7.19 (m, 3H), 5.84-5.80 (m, 2H), 5.72-
5.67 (m, 1H), 5.00 (d, J = 11.6 Hz, 1H), 4.85 (d, J = 11.2 Hz, 1H), 4.78 (d, J = 11.2, Hz 
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1H), 4.73 (dd, J = 12.0, 2.8 Hz, 1H), 4.40-4.36 (m, 1H), 3.97 (dd, J = 9.6, 7.2 Hz, 1H), 
3.73-3.67 (m, 1H), 2.29 (d, J = 4.8 Hz, 1H); minor diastereomer δ 8.01-7.98 (m, 2H), 
7.58 (dt, J = 7.2, 0.4 Hz, 1H), 7.43 (dt, J = 8.0, 0.8 Hz, 2H), 7.37-7.32 (m, 5H), 7.25-7.23 
(m, 2H), 7.22-7.19 (m, 3H), 5.96 (ddd, J = 10.0, 4.4, 1.6 Hz, 1H), 5.84-5.80 (m, 1H), 
5.72-5.67 (m, 1H), 4.85 (d, J = 11.2 Hz, 2H), 4.78 (d, J = 11.2 Hz, 1H), 4.73 (dd, J = 
12.0, 2.8 Hz, 1H), 4.40-4.36 (m, 1H), 4.15 (dd, J = 9.6, 7.2 Hz, 1H), 3.73-3.67 (m, 1H), 
2.78 (d, J = 3.6 Hz, 1H); IR (film) νmax 3451, 3063, 3032, 2880, 1717 cm-1; HRMS (ESI) 
m/z calcd. for C27H26NaO5 [M+Na]+ 453.1672, found 453.1635. 
 
To a 1 L 3-necked flask with a mechanical stirrer attached open to the air was 
added 2-iodobenzoic acid (25.0 g, 101 mmol, 1.0 eq) and tap water (325 mL). 
The suspension was slowly stirred and Oxone (89.9 g, 146 mmol, 1.5 eq) was added. The 
reaction was heated in an oil bath to 89 °C (internal temperature 70-73 °C) then heated 
for 3 h with vigorous stirring. Stirring was stopped and the reaction was removed from 
heating. At RT, the reaction was cooled to 0 °C and allowed to sit for 1 h. The reaction 
precipitated a white solid, which was collected by filtration, and the solid was washed 
with H2O (6 x 50 mL) and acetone (3 x 50 mL). The reaction yielded 2-iodoxybenzoic 
acid (S3.2) as a free-flowing white crystalline solid (22.0 g, 78.5 mmol, 78%). Spectral 
data were consistent with reported literature values.28 
 
A solution of 3.54 (4.26 g, 9.90 mmol, 1.0 eq) in CH2Cl2/DMSO (98.0 mL, 
1:1) was cooled to 0 °C, at which point 2-iodoxybenzoic acid (4.16 g, 14.8 
mmol, 1.5 eq) was added and stirred for 15 min followed by removal of the ice 
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bath and stirring at RT. After 12 h, the mixture was diluted with CH2Cl2/H2O (500 mL, 
1:1). The aqueous layer was extracted with CH2Cl2 (3 x 250 mL), and the combined 
organic layers were washed with H2O (2 x 300 mL). The organic layer was dried 
(MgSO4), filtered and concentrated to a clear oil. Purification by flash column 
chromatography (5-20% EtOAc/hexanes) gave 3.55 as a white solid (3.69 g, 8.61 mmol, 
87%). MP: 63-66 °C; [α]  −198 (c 0.36, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 7.97 
(dd, J = 8.4, 1.6 Hz, 2H), 7.60 (dt, J = 7.2, 1.2 Hz, 1H), 7.47-7.43 (m, 4H), 7.37-7.30 (m, 
3H), 7.18-7.14 (m, 5H), 6.78 (dd, J = 10.4, 2.4 Hz, 1H), 6.15 (dd, J = 10.4, 2.4 Hz, 1H), 
6.00 (dt, J = 8.4, 2.4 Hz, 1H), 5.12 (d, J = 11.2 Hz, 1H), 4.89 (d, J = 11.2 Hz, 1H), 4.80 
(d, J = 11.2 Hz, 1H), 4.74 (d, J = 11.2 Hz, 1H), 4.21 (d, J = 10.4 Hz, 1H), 4.14 (dd, J = 
10.8, 8.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz): δ 196.8, 165.6, 145.5, 137.5 (2C), 
133.5, 129.8, 129.2, 129.1, 128.5, 128.4, 128.3, 128.2 (2C), 127.9, 127.7, 83.7, 81.8, 
75.2, 74.6, 73.0; IR (film) νmax 3088, 3063, 3032, 2916, 2873, 1723, 1699 cm-1; HRMS 
(FAB+) m/z calcd. for C27H23O5 [M+H]+ 427.1545, found 427.1534. 
 
To a solution of 3.55 (4.29 g, 10.0 mmol, 1.0 eq) in CH2Cl2 (92.4 mL) was 
added pyridine (46.2 mL) and DMAP (4.00 mg, 0.033 mmol, 0.0033 eq) and 
the solution was cooled to 0 °C. To the cooled solution was added I2 (6.35 g, 
25.0 mmol, 2.5 eq) in CH2Cl2/pyridine (61.6 mL, 1:1) slowly by cannula. The reaction 
was stirred at 0 °C for 30 min and the ice bath was removed. After 18 h stirring at RT, the 
solution was added to 1:1 Et2O/H2O (600 mL) and the organic layer was washed with 
10% aqueous HCl (3 x 250 mL), H2O (1 x 250 mL), 10% aqueous Na2S2O3 (3 x 250 mL) 
and brine (2 x 250 mL), then dried (MgSO4), filtered and concentrated. Purification by 
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flash column chromatography (5-30% EtOAc/hexanes) provided 3.38 as a yellow solid 
(4.70 g, 8.48 mmol, 85%). MP: 120-122 °C; [α]  −108 (c 0.19, CHCl3); 
1H NMR (400 
MHz, CDCl3): δ 7.95 (dd, J = 8.4, 1.2 Hz, 2H), 7.61 (dt, J = 7.2, 0.8 Hz, 1H), 7.54 (d, J = 
2.4 Hz, 1H), 7.47-7.43 (m, 4H), 7.37-7.32 (m, 3H), 7.19-7.14 (m, 5H), 5.89 (dd, J = 8.4, 
2.4 Hz, 1H), 5.12 (d, J = 11.2 Hz, 1H), 4.88 (d, J = 11.6 Hz, 1H), 4.77 (d, J = 11.2 Hz, 
1H), 4.73 (d, J = 11.6 Hz, 1H), 4.27 (d, J = 10.4 Hz, 1H), 4.14 (dd, J = 10.8, 8.4 Hz, 1H); 
13C NMR (100 MHz, CDCl3): δ 191.4, 165.5, 153.3, 137.3, 137.1, 133.7, 129.9, 128.8, 
128.5 (2C), 128.4, 128.3, 128.2, 128.1, 127.9, 103.5, 82.1, 80.9, 75.2, 75.7, 74.0; IR 
(film) νmax 2929, 1726, 1707, 1450, 1313, 1251 cm -1; HRMS (ESI) m/z calcd. for 
C27H24IO5 [M+H]+ 555.0663, found 555.0638. 
 
To a solution of 3.38 (4.00 g, 7.22 mmol, 1.0 eq) in THF/H2O (144 mL, 
2:1) was added Cs2CO3 (3.53 g, 10.8 mmol, 1.5 eq) and 2,4,6-trivinyl-
1,3,5,2,4,6-trioxatriborinane•pyridine (3.20, 1.31 g, 5.41 mmol, 0.75 eq), 
and the mixture was degassed (3x) with liquid N2. To the flask was added Pd[P(t-Bu)3]2 
(369 mg, 0.722 mmol, 0.10 eq) and the reaction was stirred at RT. After 4 h, the mixture 
was diluted with EtOAc (500 mL) and washed with brine (2 x 500 mL). The combined 
aqueous layers were extracted with EtOAc (1 x 500 mL), and the combined organic 
layers were dried (MgSO4), filtered and concentrated to a brown oil. Immediate 
purification by flash column chromatography (5% and 10% EtOAc/hexanes) gave 3.39 as 
a white solid (1.90 g, 4.18 mmol, 58%). MP: 52-56 °C; [α]  −54.4 (c 0.31, CHCl3); 
1H 
NMR (500 MHz, CDCl3): δ 7.98 (dd, J = 8.0, 1.0 Hz, 2H), 7.61 (app. t, J = 7.0 Hz, 1H), 
7.48-7.44 (m, 4H), 7.39-7.30 (m, 3H), 7.20-7.14 (m, 5H), 6.73 (d, J = 2.5 Hz, 1H), 6.50 
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(dd, J = 17.5, 11 Hz, 1H), 6.04 (dd, J = 8.5, 2.0 Hz, 1H), 5.83 (d, J = 18.0 Hz, 1H), 5.35 
(d, J = 11.5 Hz, 1H), 5.12 (d, J = 11.5 Hz, 1H), 4.91 (d, 11.5 Hz, 1H), 4.79 (d, J = 11.5 
Hz, 1H), 4.75 (d, J = 11.5 Hz, 1H), 4.23 (d, J = 10.5 Hz, 1H), 4.13 (dd, J = 10.5, 8.0 Hz, 
1H); 13C NMR (125 MHz, CDCl3): δ 195.7, 165.7, 139.0, 137.6, 136.0, 133.5, 129.9, 
129.3, 129.1, 128.5, 128.4, 128.3, 128.2 (2C), 127.9, 127.7, 119.3, 84.1, 81.3, 75.1, 74.5, 
72.9; IR (film) νmax 3063, 3031, 2911, 1721, 1697 cm -1; HRMS (ESI) m/z calcd. for 
C29H26NaO5 [M+Na]+ 477.1672, found 477.1645. 
 
To a solution of 3.39 (1.90 g, 4.18 mmol, 1.0 eq) in THF (209 mL) at −78 
°C was added allyl magnesium chloride (2 M in THF, 6.27 mL, 12.5 
mmol, 3.0 eq) dropwise. The −78 °C bath was replaced after 3 h with an 
ice bath, and the reaction was stirred at 0 °C for 1.5 h. To the mixture was added 
saturated aqueous NH4Cl (200 mL) and the ice bath was removed. At RT the mixture was 
extracted with EtOAc (3 x 400 mL), and the combined organic layers were dried 
(MgSO4), filtered and concentrated. Purification by flash column chromatography (5-
30% EtOAc/hexanes) yielded 3.40 as a clear oil (727.0 mg, 1.852 mmol, 44%) in a 2:1 
mixture of inseparable diastereomers. IR (film) νmax 3400, 3064, 3030, 2910, 1110 cm -1; 
HRMS (ESI) m/z calcd. for C25H29O4 [M+H]+ 393.2060, found 393.2069. 
 
To a solution of allyl phenyl sulfone (5.00 mL, 32.6 mmol, 1.0 eq) in DCE 
(25 mL) was added m-CPBA (11.3 g, 65.3 mmol, 2.0 eq) and the reaction 
was heated at reflux for 2.5 h. At 0 °C, which caused the reaction to solidify, 10% 
aqueous Na2S2O3 (100 mL) and CH2Cl2 were added and the mixture was extracted with 
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CH2Cl2 (3 x 75 mL). The combined organic layers were washed with saturated aqueous 
NaHCO3 (1 x 50 mL), and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The 
combined organic layers were dried (MgSO4), filtered, and concentrated. Purification by 
flash column chromatography (33% EtOAc/hexanes) provided S3.3 as a clear oil (5.78 g, 
29.2 mmol, 89%). Spectral data were consistent with reported literature values.19 
 
To a solution of S3.3 (5.78 g, 29.2 mmol. 1.0 eq) in CH2Cl2 (35 mL) at     
–10 °C was added a solution of DBU (4.44 g, 29.2 mmol, 1.0 eq) in CH2Cl2 (18 mL) via 
syringe pump over 3 h while remaining at –10 °C. The reaction became a thick solid 
slurry, and at 0 °C, 20% aqueous HCl (50 mL) was added and the thick mixture was 
extracted with CHCl3 (5 x 25 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated. Material was taken to the next step crude. 
 
To a solution of crude S3.4 (4.43 g, 22.3 mmol, 1.0 eq) in acetone (175 
mL) was added Jones’ reagent [prepared by addition of concentrated H2SO4 (3.9 mL) to 
CrO3 (3.35 g, 33.5 mmol, 1.5 eq) then at 0 °C addition of H2O (11 mL)] dropwise until 
the reaction remained orange/brown for 15 min. To the reaction was added i-PrOH until 
the reaction turned green, and the mixture was filtered through a plug of celite with 
EtOAc washes. The filtrate was concentrated, and the white solid (containing green 
liquid) was recrystallized from toluene (green liquid was removed by pipette once all 
material solubilized) to yield 3.63 as a white solid (2.40 g, 11.3 mmol, 51%). Spectral 
data were consistent with reported literature values.19 
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To a solution of 3.40 (727 mg, 1.85 mmol, 1.0 eq) in CH2Cl2 (41.0 
mL) was added (E)-3-(phenylsulfonyl)acrylic acid (3.63, 393 mg, 
1.85 mmol, 1.0 eq) and 2-chloro-1-methylpyridinium iodide (3.62, 
710 mg, 2.78 mmol, 1.5 eq) and the mixture was heated to reflux. To the reaction was 
added Et3N (774 µL, 5.56 mmol, 3.0 eq) by syringe pump over 1 h followed by refluxing 
for an additional 30 min. The flask was removed from heating, and at RT the mixture was 
added to saturated aqueous NaHCO3 (200 mL) and the biphasic mixture was extracted 
with CH2Cl2 (3 x 200 mL). The organic layers were washed with saturated aqueous 
NH4Cl (2 x 200 mL), dried (MgSO4), filtered and concentrated. Purification by flash 
column chromatography (5-30% EtOAc/hexanes) yielded 3.64 as a clear oil (400 mg, 
0.682 mmol, 37%), the undesired diastereomer was separated and discarded. [α]  −63.8 
(c 0.16, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.91 (dd, J = 8.4, 1.2 Hz, 2H), 7.70 (app. 
t, J = 7.6 Hz, 1H), 7.59 (app. t, J = 8.0 Hz, 2H), 7.40-7.32 (m, 7H), 7.22-7.19 (m, 3H), 
6.66 (d, J = 15.2 Hz, 1H), 6.36 (dd, J = 17.6, 11.2 Hz, 1H), 5.61 (d, J = 1.6 Hz, 1H), 
5.54-5.47 (m, 2H), 5.46-5.38 (m, 1H), 5.19 (d, J = 11.2 Hz, 1H), 5.07-4.95 (m, 4H), 4.81 
(d, J = 11.6 Hz, 1H), 4.70 (d, J = 10.8 Hz, 1H), 4.61 (d, J = 11.6 Hz, 1H), 3.97 (dd, J = 
9.6, 8.0 Hz, 1H), 3.65 (d, J = 10.0, 1H), 2.94 (s, 1H), 2.60 (dd, J = 14.0, 5.2 Hz, 1H), 2.47 
(dd, J = 14.0, 9.2 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 163.0, 143.6, 140.8, 138.4, 
137.9, 137.7, 134.4, 133.3, 132.8, 130.4, 129.6, 128.6, 128.5, 128.3, 128.1, 128.0 (2C), 
123.2, 119.3, 117.8, 78.4, 78.3, 75.6, 74.9 (3C), 41.5, 29.7; IR (film) νmax 3529, 3064, 
3032, 2922, 2853, 1729 cm -1; HRMS (ESI) m/z calcd. for C34H35O7S [M+H]+ 587.2098, 
found 587.2072. 
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A solution of 3.64 (400 mg, 0.682 mmol, 1.0 eq) in toluene (40 mL) 
was heated at 70 °C. After 46 h, the solution was removed from 
heating, and at RT was concentrated. Purification by flash column 
chromatography (10-50% EtOAc/hexanes) gave 3.65 as a clear oil (298 mg, 0.508 mmol, 
74%). [α]  −14.7 (c 0.27, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 7.79 (dd, J = 8.4, 1.2 
Hz, 2H), 7.63 (app. t, J = 7.2 Hz, 1H), 7.49 (app. t, J = 8.0 Hz, 2H), 7.40-7.28 (m, 10H), 
5.88 (m, 1H), 5.74 (dddd, J = 17.2, 10.4, 7.2, 7.2 Hz, 1H), 5.09-5.01 (m, 2H), 4.78 (d, J = 
11.6 Hz, 1H), 4.75 (dd, J = 7.6, 1.2 Hz, 1H), 4.61 (d, J = 10.2 Hz, 1H), 4.59 (d, J = 10.6 
Hz, 1H), 4.55 (d, J = 11.6 Hz, 1H), 3.86 (dd, J = 6.4, 2.8 Hz, 1H), 3.73 (dt, J = 9.6, 3.2 
Hz, 1H), 3.59 (d, J = 3.2 Hz, 1H), 3.03 (ddd, J = 17.6, 6.4, 3.2 Hz, 1H), 2.90-2.78 (m, 
3H), 2.41 (dddd, J = 17.6, 9.2, 2.8, 1.2 Hz, 1H), 2.34 (dd, J = 14.4, 7.6 Hz, 1H), 2.24 (dd, 
J = 14.4, 7.2 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 171.1, 141.3, 137.8, 137.1, 136.8, 
133.9, 132.2, 129.1, 128.7, 128.5, 128.2, 128.0, 127.9 (2C), 120.6, 118.5, 84.4, 80.9, 
79.9, 74.7, 73.8, 72.5, 58.6, 43.3, 41.4, 40.2, 29.6, 25.1; IR (film) νmax 3519, 3064, 3030, 
2921, 1790 cm -1; HRMS (ESI) m/z calcd. for C34H34NaO7S [M+Na]+ 609.1917, found 
609.1935. 
 
 To a solution of 3.65 (298 mg, 0.508 mmol, 1.0 eq) in 
heptane/EtOAc (36.3 mL, 3:2) under argon atmosphere was added 5% 
Pd/C (70 mg, 0.14 g/mmol SM) and the reaction mixture was placed 
under H2 atmosphere (balloon). After 20 min, the reaction was filtered through Celite 
with EtOAc, and the filtrate was concentrated to provide 3.68 as a clear oil requiring no 
further purification (256 mg, 0.435 mmol, 86%). [α]  −23.3 (c 0.27, CHCl3); 
1H NMR 
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(400 MHz, CDCl3): δ 7.78 (dd, J = 8.4, 1.2 Hz, 2H), 7.63 (app. t, J = 7.6 Hz, 1H), 7.48 
(app. t, J = 8.0 Hz, 2H), 7.40-7.27 (m, 10H), 5.85 (m, 1H), 4.77 (m, 2H), 4.58 (d, J = 11.6 
Hz, 1H), 4.57 (d, J = 11.6 Hz, 1H), 4.51 (d, J = 11.6 Hz, 1H), 3.84 (dd, J = 6.0, 2.0 Hz, 
1H), 3.72 (dt, J = 9.2, 2.8 Hz, 1H), 3.54 (d, J = 2.0 Hz, 1H), 3.04 (ddd, J = 17.6, 6.4, 2.8 
Hz, 1H), 2.90-2.78 (m, 2H), 2.75 (s, 1H), 2.40 (dddd, 17.8, 9.7, 2.6, 1.7 Hz, 1H), 1.46-
1.40 (m, 2H), 1.27-1.18 (m, 2H), 0.88-0.85 (m, 3H); 13C NMR (100 MHz, CDCl3): δ 
171.3, 141.8, 137.8, 137.2, 136.8, 134.0, 129.1, 128.7, 128.5, 128.3, 128.1, 127.9 (2C), 
120.0, 85.3, 81.0, 80.2, 77.2, 75.0, 73.5, 72.2, 58.7, 43.4, 40.4, 38.6, 25.0, 16.6, 14.3; IR 
(film) νmax 3584, 2959, 2360, 1789, 1447, 1306 cm -1; HRMS (ESI) m/z calcd. for 
C34H36NaO7S [M+Na]+ 611.2074, found 611.2095. 
 
 To a solution of EtOAc/CH3CN/H2O (3.25 mL, 6:6:1) was added 
NaHCO3 (2.50 mg, 0.0297 mmol, 2.5 eq), RuCl3 (0.1 M in H2O, 1.19 
µL, 0.119 µmol, 0.01 eq) and Oxone (37.0 mg, 0.0595 mmol, 5.0 eq) 
and the solution turned yellow. At 0 °C, 3.68 (7.0 mg, 0.0119 mmol, 1.0 eq) was added, 
and after 10 min, the reaction was filtered through Celite with EtOAc, and the filtrate was 
washed with 10% aqueous Na2S2O3 (2 x 15 mL). The combined organic layers were 
dried (MgSO4), filtered and concentrated to yield crude 3.66 as a clear oil (7.00 mg, 
0.0119 mmol, 95%). Attempts at purification resulted in decomposition. 
 
 To a solution of 3.66 (7.0 mg, 0.0113 mmol, 1.0 eq) in CH2Cl2 (1.10 mL) 
at 0 °C was added DBU (1.70 µL, 0.0113 mmol, 1.0 eq). After 20 min, the 
reaction mixture was added to saturated aqueous NH4Cl (15 mL) and 
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extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were washed with 
saturated aqueous NH4Cl (1 x 10 mL), dried (MgSO4), filtered and concentrated. 
Purification by flash column chromatography (5-25% EtOAc/hexanes) provided 3.67. [α]
 −126 (c 0.09, CHCl3); 
1H NMR (600 MHz, CDCl3): δ 7.40-7.21 (m, 10H), 6.81 (dd, J 
= 7.3, 3.7 Hz, 1H), 5.00 (d, J = 10.7 Hz, 1H), 4.97 (d, J = 10.9 Hz, 1H), 4.93 (dd, J = 8.6, 
8.0 Hz, 1H), 4.73 (d, J = 11.1 Hz, 1H), 4.59 (d, J = 10.5 Hz, 1H), 4.26 (s, 1H), 3.99 (dd, J 
= 9.7, 7.7 Hz, 1H), 3.71 (d, J = 9.8 Hz, 1H), 3.59 (ddd, J = 22.3, 4.0, 4.0 Hz, 1H), 3.44 
(ddd, J = 12.3, 3.5, 3.5 Hz, 1H), 3.26 (ddd, J = 22.3, 3.2, 3.1 Hz, 1H), 2.10 (s, 1H), 1.66-
1.49 (m, 2H), 1.39-1.29 (m, 1H), 1.16-1.06 (m, 1H), 0.80 (dd, J = 7.3, 7.3 Hz, 3H); 13C 
NMR (150 MHz, CDCl3): δ 208.7, 167.5, 138.0, 137.7, 132.7, 128.5, 128.4, 128.1, 128.0 
(2C), 127.7, 127.0, 82.7, 81.7, 81.1, 79.5, 77.9, 76.3, 74.8, 48.6, 41.2, 37.1, 16.8, 14.9; IR 
(film) νmax 3460, 2925, 1766, 1714, 1369, 1086 cm -1; HRMS (ESI) m/z calcd. for 
C28H30NaO7 [M+Na]+ 501.1884, found 501.1882. 
 
A solution of 3.68 (128 mg, 0.217 mmol, 1.0 eq) in MeOH (22.0 mL) 
was cooled to −78 °C. To the solution was added K2CO3 (35.0 mg, 
0.250 mmol, 1.2 eq) and the reaction was stirred at −78 °C for 15 h. 
The mixture was added saturated aqueous NaHCO3 (20 mL), followed by removal from 
the −78 °C bath. At RT the mixture was diluted with H2O (20 ml) and extracted with 
CH2Cl2 (4 x 30 mL), and the combined organic layers were dried (MgSO4), filtered and 
concentrated to yield S3.5 as a clear oil (123 mg, 0.197 mmol, 91%) requiring no further 
purification. [α]  −4.0 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.78 (dd, J = 8.4, 
1.2 Hz, 2H), 7.66 (app. t, J = 7.6 Hz, 1H), 7.57 (app. t, J = 7.6 Hz, 2H), 7.38-7.30 (m, 
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7H), 7.26-7.19 (m, 3H), 5.97 (d, J = 6.4 Hz, 1H), 4.54 (d, J = 12.0 Hz, 1H), 4.54 (d, J = 
10.4, 1H), 4.49 (d, J = 12.0 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 3.91 (app. t, J = 2.8 Hz, 
1H), 3.78 (s, 3H), 3.74 (d, J = 11.6 Hz, 1H), 3.57 (dt, J = 12.4, 4.8 Hz, 1H), 3.52 (s, 1H), 
3.28 (dd, J = 12.4, 9.6 Hz, 1H), 2.97 (d, J = 11.6 Hz, 1H), 2.87 (d, J = 9.2 Hz, 1H), 2.59 
(s, 1H), 2.36 (dt, J = 17.2, 5.2 Hz, 1H), 2.17 (dt, J = 14.0, 2.4 Hz, 1H), 1.84 (dt, J = 17.2, 
4.8 Hz, 1H), 1.50 (dt, J = 12.0, 4.6 Hz, 1H), 1.32-1.23 (m, 1H), 1.21-1.08 (m, 1H), 0.83 
(t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 174.2, 137.3, 136.9, 136.3, 135.9, 
133.9, 129.2, 129.1, 128.8, 128.7, 128.6, 128.5, 128.0, 127.6, 121.3, 82.5, 74.8, 74.3, 
74.0, 72.4, 69.7, 61.6, 52.5, 41.9, 41.2, 38.9, 24.9, 16.2, 14.2; IR (film) νmax 3491, 2928, 
1737, 1447 cm -1; HRMS (ESI) m/z calcd. for C35H41O8S [M+H]+ 621.2517, found 
621.2480. 
 
 To a solution of S3.5 (15.0 mg, 0.0242 mmol, 1.0 eq) in DMF (100 
µL) at 0 °C was added 2,6-lutidine (17.0 µL, 0.145 mmol, 6.0 eq), 
DMAP (2 mg, catalytic), and TESOTf (22.0 µL, 0.0967 mmol, 4.0 
eq), and the reaction was removed from the 0 °C bath after 1 h. After 18 h at RT, 
saturated aqueous NH4Cl (10 mL) was added and the mixture was extracted with CH2Cl2 
(3 x 15 mL). The combined organic layers were washed with H2O (4 x 20 mL) and brine 
(1 x 25 mL), then dried (MgSO4), filtered and concentrated. Purification by flash column 
chromatography (10-20% EtOAc/hexanes) provided S3.6 as a light yellow oil (16.0 mg, 
0.0218 mmol, 90%). [α]  −4.4 (c 0.09, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.93 
(app. d, J = 7.6 Hz, 2H), 7.66 (app. t, J = 7.6 Hz, 1H), 7.57 (app. t, J = 7.6 Hz, 2H), 7.39-
7.22 (m, 10H), 5.93 (d, J = 6.8 Hz, 1H), 4.62 (d, J = 11.6 Hz, 1H), 4.53 (d, J = 11.6 Hz, € 
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1H), 4.49 (d, J = 12.0 Hz, 1H), 4.40 (d, J = 12.0 Hz, 1H), 3.86 (br. s, 1H), 3.78 (s, 3H), 
3.68 (t, J = 2.8 Hz, 1H), 3.58 (dt, J = 12.0, 4.4 Hz, 1H), 3.40 (d, J = 3.2 Hz, 1H), 3.18 (s, 
1H), 2.92 (dd, J = 12.4, 9.2 Hz, 1H), 2.77 (app. d, J = 8.8 Hz, 1H), 2.42 (dt, J = 16.8, 5.2 
Hz, 1H), 2.13 (app. t, J = 14.0 Hz, 1H), 1.94 (dt, J = 17.6, 4.4 Hz, 1H), 1.46 (dt, J = 12.0, 
4.0 Hz, 1H), 1.18-0.92 (m, 2H), 0.85-0.79 (m, 12H), 0.53-0.46 (m, 6H); 13C NMR (100 
MHz, CDCl3): δ 173.9, 137.6 (2C), 137.1, 136.8, 133.9, 129.5, 129.1, 128.5, 128.3, 128.0 
(2C), 127.8, 119.9, 81.0, 79.4, 77.9, 74.4, 73.2, 72.0, 70.8, 61.9, 52.4, 41.8, 41.7, 38.9, 
24.8, 16.8, 14.4, 6.8, 4.8; IR (film) νmax 3534, 2954, 2912, 2874, 1739, 1455 cm -1; 
HRMS (ESI) m/z calcd. for C41H54O8NaSSi [M+Na]+ 757.3206, found 757.3253. 
 
 To a solution of EtOAc/CH3CN/H2O (3.25 mL, 6:6:1) was added 
NaHCO3 (4.00 mg, 0.0476 mmol, 2.5 eq), RuCl3 (0.1 M in H2O, 
1.91 µL, 0.191 µmol, 0.01 eq) and Oxone (59.0 mg, 0.0952 mmol, 
5.0 eq) and the solution turned yellow. At 0 °C, S3.6 (14.0 mg, 0.0190 mmol, 1.0 eq) was 
added. After 10 min the reaction was filtered through Celite with EtOAc, and the filtrate 
was washed with 10% aqueous Na2S2O3 (2 x 15 mL). The combined organic layers were 
dried (MgSO4), filtered and concentrated to yield crude 3.69 as a clear oil (13.0 mg, 
0.0170 mmol, 89%). Attempts at purification resulted in decomposition. 
 
 To a solution of crude 3.69 (13.0 mg, 0.0170 mmol, 1.0 eq) in CH2Cl2 
(1.7 mL) at RT was added DBU (3.00 µL, 0.0186 mmol, 1.1 eq) and the 
reaction immediately turned yellow. After 40 min, saturated aqueous  
NH4Cl (5 mL) was added and the mixture was extracted with CH2Cl2 (4 x 10 mL). The 
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combined organic layers were washed with saturated aqueous NH4Cl (1 x 25 mL), dried 
(MgSO4), filtered and concentrated. Purification by flash column chromatography (5-
10% EtOAc/hexanes) provided 3.70 as a clear oil (5.00 mg, 0.00800 mmol, 47%). [α]  
−15.3 (c 0.15, CHCl3); 1H NMR (500 MHz, CDCl3): δ 7.36 (app. d, J = 7.0 Hz, 2H), 7.32 
(app. t, J = 7.0 Hz, 2H), 7.27-7.18 (m, 6H), 4.97 (d, J = 11.5 Hz, 1H), 4.92 (d, J = 11.0 
Hz, 1H), 4.83 (d, J = 11.5 Hz, 1H), 4.60-4.56 (m, 1H), 4.57 (d, J = 11.0 Hz, 1H), 4.30 
(dd, J = 9.5, 5.0 Hz, 1H), 3.88 (t, J = 9.0 Hz, 1H), 3.74 (d, J = 9.0 Hz, 1H), 3.69 (s, 3H), 
3.61 (s, 1H), 3.59-3.58 (m, 1H), 2.73 (ddd, J = 20.0, 3.5, 2.0 Hz, 1H), 2.58 (dd, J = 4.5, 
4.0 Hz, 1H), 2.43 (dd, J = 19.5, 1.5 Hz, 1H), 1.68 (dt, J = 14.0, 3.5 Hz, 1H), 1.50-1.42 
(m, 1H), 1.30-1.23 (m, 2H), 0.90 (t, J = 8.0 Hz, 9H), 0.72 (t, J = 7.5 Hz, 3H), 0.59 (q, J = 
8.0 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 208.4, 172.1, 139.0, 138.2, 128.3, 128.2, 
128.1, 127.6, 127.2, 127.1, 84.3, 81.3, 79.0, 77.6, 76.2, 75.7, 71.4, 67.6, 52.4, 44.9, 43.0, 
40.0, 39.3, 17.9, 14.9, 6.8, 4.8; IR (film) νmax 3473, 2955, 2876, 1741, 1455 cm -1; HRMS 
(ESI) m/z calcd. for C35H48NaO8Si [M+Na]+ 647.3011, found 647.3032. 
 
 To a solution of 3.38 (250 mg, 0.451 mmol, 1.0 eq) in EtOH/THF (9.0 mL, 
1:1) was added CeCl3•7H2O (336 mg, 0.902 mmol, 2.0 eq) and stirred at RT 
for 20 min. To the mixture was added NaBH4 (17.0 mg, 0.456 mmol, 1.0 eq) and the 
reaction was stirred at RT. After 45 min saturated aqueous NH4Cl (100 mL) and H2O (50 
mL) were added and the mixture was extracted with EtOAc (4 x 100 mL). The combined 
organic layers were dried (MgSO4), filtered and concentrated. Purification by flash 
column chromatography (5-15% EtOAc/hexanes) gave S3.7 as a crystalline white solid 
(217 mg, 0.390 mmol, 86%) as a 3.8:1 inseparable mixture of diastereomers. MP: 150-
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154 °C; 1H NMR (400 MHz, CDCl3): major diastereomer δ 7.97 (app. dd, J = 7.2, 1.2 Hz, 
2H), 7.59 (ddt, J = 7.6, 2.8, 1.2 Hz, 1H), 7.45-7.40 (m, 2H), 7.35-7.32 (m, 5H), 7.26-7.20 
(m, 5H), 6.45 (d, J = 3.2 Hz, 1H), 5.53 (ddd, J = 6.8, 2.8, 0.4 Hz, 1H), 4.83 (d, J = 11.2 
Hz, 1H), 4.82-4.77 (m, 1H), 4.76 (d, J = 11.2 Hz, 1H), 4.70 (d, J = 11.2 Hz, 1H), 4.44 (t, 
J = 3.6 Hz, 1H), 4.14 (dd, J = 9.2, 6.8 Hz, 1H), 3.81 (dd, J = 9.2, 4.0 Hz, 1H), 2.90 (d, J = 
3.6 Hz, 1H); minor diastereomer δ 7.97 (app. dd, J = 7.2, 1.2 Hz, 2H), 7.59 (ddt, J = 7.6, 
2.8, 1.2 Hz, 1H), 7.45-7.40 (m, 2H), 7.35-7.32 (m, 5H), 7.26-7.20 (m, 5H), 6.46 (dd, J = 
3.2, 1.6 Hz, 1H), 5.62 (ddd, 6.4, 3.2, 2.4 Hz, 1H), 4.85 (d, J = 7.2 Hz, 1H), 4.83 (d, J = 
7.2 Hz, 1H), 4.82 (d, J = 11.6 Hz, 1H), 4.78 (d, J = 11.6 Hz, 1H), 4.30 (tt, J = 6.4, 2.0 Hz, 
1H), 4.01 (dd, J = 8.4, 6.0 Hz, 1H), 3.85 (dd, J = 8.4, 6.0 Hz, 1H), 2.69 (d, J = 6.4 Hz, 
1H); IR (film) νmax 3543, 3062, 3031, 2924, 2872, 1716, 1452 cm -1; HRMS (ESI) m/z 
calcd. for C27H25INaO5 [M+Na]+ 579.0639, found 579.0649. 
 
 To a solution of S3.7 (217 mg, 0.390 mmol, 1.0 eq) in DMF (780 µL) at 0 
°C was added DMAP (2 mg, catalytic), 2,6-lutidine (136 µL, 1.17 mmol, 3.0 
eq) and TESOTf (176 µL, 0.780 mmol, 2.0 eq) and the reaction stirred at 0 °C and at RT 
for 18 h. To the reaction was added saturated aqueous NH4Cl (100 mL) and the mixture 
was extracted with CH2Cl2 (3 x 150 mL). The combined organic layers were washed with 
H2O (4 x 200 mL) and brine (1 x 250 mL), followed by drying (MgSO4), filtration and 
concentration. Purification by flash column chromatography (7.5% EtOAc/hexanes) 
provided 3.78 as a clear oil (238 mg, 0.355 mmol, 91%) as a 1.9:1 inseparable mixture of 
diastereomers. 1H NMR (400 MHz, CDCl3): major diastereomer δ 7.96 (dt, J = 7.2, 1.2 
Hz, 2H), 7.57 (app. t, J = 7.2 Hz, 1H), 7.42 (app. dt, J = 8.0, 2.4 Hz, 2H), 7.34-7.29 (m, 
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5H), 7.23-7.05 (m, 5H), 6.32 (d, J = 2.8 Hz, 1H), 5.49 (dd, J = 7.2, 2.8 Hz, 1H), 4.87-
4.67 (m, 4H), 4.49 (d, J = 3.2 Hz, 1H), 4.23 (dd, J = 10.0, 7.6 Hz, 1H), 3.66 (dd, J = 10.0, 
3.2 Hz, 1H), 1.03-0.96 (m, 9H), 0.77-0.68 (m, 6H); minor diastereomer δ 7.96 (dt, J = 
7.2, 1.2 Hz, 2H), 7.57 (app. t, J = 7.2 Hz, 1H), 7.42 (app. dt, J = 8.0, 2.4 Hz, 2H), 7.34-
7.29 (m, 5H), 7.23-7.05 (m, 5H), 6.40 (app. t, J = 2.4 Hz, 1H), 5.67 (dt, J = 7.6, 2.4 Hz, 
1H), 5.07 (d, J = 11.6 Hz, 1H), 4.87-4.67 (m, 3H), 4.40 (dt, J = 6.8, 2.4 Hz, 1H), 3.97 
(dd, J = 9.6, 7.6 Hz, 1H), 3.74 (dd, J = 9.6, 7.2 Hz, 1H), 1.03-0.96 (m, 9H), 0.77-0.68 (m, 
6H); IR (film) νmax 3063, 3031, 2953, 2916, 2875, 1723, 1453 cm -1; HRMS (ESI) m/z 
calcd. for C33H39INaO5Si [M+Na]+ 693.1504, found 693.1483. 
 
 To a solution of 3.78 (690 mg, 1.03 mmol, 1.0 eq) in THF:H2O (5.17 mL, 
8:1) was added Ag2O (381 mg, 1.65 mmol, 1.6 eq), Ph3As (19.0 mg, 
0.0617 mmol, 0.06 eq) and 2,4,6-trivinyl-1,3,5,2,4,6-
trioxatriborinane•pyridine (3.20, 187 mg, 0.772 mmol, 0.75 eq). The mixture was 
degassed with liquid N2, then tetrakis (triphenylphosphine) palladium(0) (36.0 mg, 
0.0309 mmol, 0.03 eq) was added and the reaction was stirred at RT. After 20 h, the 
reaction was diluted with EtOAc (200 mL) and washed with brine (2 x 250 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated, and purification 
by flash column chromatography (2-15% EtOAc/hexanes) yielded the α-OTES product 
(3.79, 250 mg, 0.438 mmol, 43%), the unreacted β-OTES SM (3.78, 127 mg, 0.189 
mmol, 18%) and a minor amount of the β-OTES product (3.79, 28.0 mg, 0.0491 mmol, 
5%). Major diastereomer (α-OTES): [α]  −119 (c 0.90, CHCl3); 1H NMR (400 MHz, 
CDCl3): δ 8.00 (dd, J = 7.6, 1.6 Hz, 2H), 7.58 (tt, J = 7.6, 1.2 Hz, 1H), 7.46-7.40 (m, 4H), 
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7.38-7.31 (m, 3H), 7.27-7.25 (m, 2H), 7.17-7.16 (m, 3H), 6.26 (dd, J = 17.6, 10.8 Hz, 
1H), 5.74 (dd, J = 7.6, 2.8 Hz, 1H), 5.70 (d, J = 3.2 Hz, 1H), 5.39 (d, J = 17.6 Hz, 1H), 
5.19 (d, J = 11.2 Hz, 1H), 4.92 (d, J = 11.6 Hz, 1H), 4.91 (d, J = 11.6 Hz, 1H), 4.80 (d, J 
= 11.6 Hz, 1H), 4.78 (d, J = 11.6 Hz, 1H), 4.68 (d, J = 2.8 Hz, 1H), 4.39 (dd, J = 10.4, 7.6 
Hz, 1H), 3.55 (dd, J = 10.4, 3.2 Hz, 1H), 0.97 (t, J = 8.0 Hz, 9H), 0.77-0.60 (m, 6H); 13C 
NMR (100 MHz, CDCl3): δ 166.2, 139.4, 138.5, 138.2, 135.7, 133.0, 130.0, 129.8, 128.3, 
128.2 (3C), 128.0, 127.6, 127.4, 126.2, 115.2, 80.3, 78.0, 75.5, 74.7, 74.0, 67.0, 7.1, 5.4; 
IR (film) νmax 3032, 2953, 2875, 1720, 1267 cm -1; HRMS (ESI) m/z calcd. for 
C35H42NaO5Si [M+Na]+ 593.2694, found 593.2704. Minor diastereomer (β-OTES): 1H 
NMR (400 MHz, CDCl3):  δ 8.01 (dd, J = 8.4, 1.2 Hz, 2H), 7.58 (tt, J = 7.6, 1.2 Hz, 1H), 
7.43 (t, J = 7.6 Hz, 2H), 7.34-7.31 (m, 5H), 7.16-7.10 (m, 5H), 6.32 (dd, J = 17.2, 10.8 
Hz, 1H), 5.90 (app. d, J = 7.2 Hz, 1H), 5.78 (d, J =2.0 Hz, 1H), 5.46 (d, J = 17.6 Hz, 1H), 
5.15 (d, J = 10.8 Hz, 1H), 5.02 (d, J = 11.6 Hz, 1H), 4.76-4.68 (m, 3H), 4.57 (app. d, J = 
6.4 Hz, 1H), 3.92 (app. t, J = 8.8 Hz, 1H), 3.77 (dd, J = 8.8, 6.8 Hz, 1H), 0.96 (t, J = 7.6 
Hz, 9H), 0.66 (q, J = 8.0 Hz, 6H). 
 
 To a solution of 3.79 (54.0 mg, 0.0946 mmol, 1.0 eq) in CH2Cl2 (946 µL) 
at −78 °C was added DIBAL (1.0 M in heptane, 189 µL, 0.189 mmol, 2.0 
eq). After 3 h, MeOH (1 mL) was added, and the −78 °C bath was removed. The reaction 
was stirred at RT in a saturated solution of Rochelle’s salt (sodium potassium tartrate, 20 
mL) and CH2Cl2 (20 mL) for 1 h, and the biphasic mixture was separated and the 
aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were 
dried (MgSO4), filtered and concentrated, and purification by flash column 
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chromatography (10% EtOAc/hexanes) gave 3.80 as a clear oil (35.0 mg, 0.0750 mmol, 
79%). [α]  +21.0 (c 0.19, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.39-7.27 (m, 10H), 
6.27 (dd, J = 17.6, 11.2 Hz, 1H), 5.68 (d, J = 3.2 Hz, 1H), 5.34 (d, J = 17.6 Hz, 1H), 5.14 
(d, J = 10.8 Hz, 1H), 4.98 (d, J = 11.6 Hz, 1H), 4.83 (d, J = 11.2 Hz, 1H), 4.77 (d, J = 
11.6 Hz, 1H), 4.76 (d, J = 11.6 Hz, 1H), 4.62 (d, J = 3.2 Hz, 1H), 4.20 (dd, J = 8.8, 6.0 
Hz, 1H), 4.01 (dd, J = 10.0, 6.8 Hz, 1H), 3.40 (dd, J = 9.6, 2.8 Hz, 1H), 2.18 (d, J = 5.6 
Hz, 1H), 0.93 (t, J = 8.0 Hz, 9H), 0.71-0.56 (m, 6H); 13C NMR (100 MHz, CDCl3): δ 
138.8, 138.3, 138.1, 136.0, 129.1, 128.5, 128.2, 128.0 (2C), 127.7, 127.6, 114.5, 81.4, 
80.5, 74.4, 73.6, 72.6, 66.9, 7.0, 5.3; IR (film) νmax 3413, 3031, 2953, 2875, 1129 cm -1; 
HRMS (ESI) m/z calcd. for C28H39O4Si [M+H]+ 467.2618, found 467.2612. 
 
 To a solution of 3.80 (18.0 mg, 0.0386 mmol, 1.0 eq) in CH2Cl2 (1.0 
mL) was added (E)-3-(phenylsulfonyl)acrylic acid (3.63, 8.20 mg, 
0.0386 mmol, 1.0 eq) and 2-chloro-1-methylpyridinium iodide (3.62, 
15.0 mg, 0.0579 mmol, 1.5 eq) and the mixture was heated at reflux. At 40 °C, Et3N 
(20.0 µL, 0.116 mmol, 3.0 eq) was added in 4 portions over 1 h, followed by refluxing 
for 20 min. The reaction mixture was removed from heating and at RT, saturated aqueous 
NaHCO3 (20 mL) was added and the mixture was extracted with CH2Cl2 (3 x 20 mL). 
The combined organic phases were washed with saturated aqueous NH4Cl (25 mL), dried 
(MgSO4), filtered and concentrated. Purification by flash column chromatography (5% 
and 10% EtOAc/hexanes) yielded 3.81 as a clear oil (17.0 mg, 0.0257 mmol, 67%). [α]  
−37.1 (c 0.32, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.93 (dd, J = 7.2, 1.6 Hz, 2H), 
7.70 (dt, J = 7.2, 1.2 Hz, 1H), 7.60 (app. t, J = 7.6 Hz, 2H), 7.39-7.30 (m, 6H), 7.27-7.24 
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(m, 4H), 7.21 (d, J = 15.2 Hz, 1H), 6.65 (d, J = 15.2 Hz, 1H), 6.18 (dd, J = 17.6, 11.2 Hz, 
1H), 5.48 (dd, J = 10.0, 3.2 Hz, 1H), 5.47 (s, 1H), 5.35 (d, J = 17.6 Hz, 1H), 5.18 (d, J = 
11.2 Hz, 1H), 4.89 (d, J = 12.0 Hz, 1H), 4.87 (d, J = 11.2 Hz, 1H), 4.76 (d, J = 11.6 Hz, 
1H), 4.64 (d, J = 12.0 Hz, 1H), 4.60 (d, J = 2.8 Hz, 1H), 4.21 (dd, J = 10.4, 7.2 Hz, 1H), 
3.44 (dd, J = 10.0, 2.8 Hz, 1H), 0.93 (t, J = 8.0 Hz, 9H), 0.72-0.56 (m, 6H); 13C NMR 
(100 MHz, CDCl3): δ 163.1, 143.3, 140.3, 138.5, 138.3, 138.0, 135.4, 134.4, 130.7, 
129.6, 128.4 (2C), 128.3, 128.2 (2C), 127.9, 127.7, 124.6, 115.8, 80.3, 77.2, 76.4, 74.6, 
74.0, 66.7, 7.0, 5.4; IR (film) νmax 3064, 3032, 2953, 2911, 2875, 1729, 1455 cm -1; 
HRMS (ESI) m/z calcd. for C37H45O7SSi [M+H]+ 661.2656, found 661.2650. 
 
 A solution of 3.81 (11.0 mg, 0.0166 mmol, 1.0 eq) in CH3CN (10 
mL) was heated at reflux for 48 h then removed from heating and 
concentrated. Purification by flash column chromatography (20% and 
25% EtOAc/hexanes) yielded 3.82 as a clear oil (6.0 mg, 9.09 µmol, 55%). [α]  +20.4 (c 
0.22, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.62 (dd, J = 7.4, 1.0 Hz, 2H), 7.57 (app. t, 
J = 7.6 Hz, 1H), 7.41 (app. t, J = 7.8 Hz, 2H), 7.38-7.26 (m, 10H), 6.00 (ddd, J = 9.0, 5.2, 
2.4 Hz, 1H), 4.87 (d, J = 12.2 Hz, 1H), 4.69-4.62 (m, 3H), 4.62 (d, J = 12.2 Hz, 1H), 4.53 
(d, J = 11.7 Hz, 1H), 3.84 (dd, J = 4.4, 1.8 Hz, 2H), 3.70 (dt, J = 10.0, 1.5 Hz, 1H), 3.28 
(dd, J = 13.8, 10.2 Hz, 1H), 3.20 (ddd, J = 17.3, 6.9, 1.4 Hz, 1H), 2.90 (dd, J = 12.2, 10.1 
Hz, 1H), 2.42 (app. dt, J = 13.4, 9.5, 4.8 Hz, 1H), 0.98 (t, J = 8.0 Hz, 9H), 0.64 (q, J = 7.8 
Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 171.8, 139.2, 138.4, 137.6, 137.2, 133.8, 129.2, 
129.0, 128.5, 128.3, 127.9, 127.7, 127.6, 119.2, 82.3, 81.2, 79.4, 73.6, 71.9, 71.3, 59.2, 
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43.0, 41.0, 29.7, 24.4, 6.9, 4.7; IR (film) νmax 3063, 2919, 1789, 1452 cm -1; HRMS (ESI) 
m/z calcd. for C37H44NaO7SSi [M+Na]+ 683.2469, found 683.2484. 
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Appendix A1: 
 
Spectra relevant to Chapter III. 
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Figure A1.1. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.34. 
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Figure A1.2. 1H NMR spectrum (400 MHz, CDCl3) of compound 3.54. 
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Figure A1.3. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.55. 
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Figure A1.4. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.38. 
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Figure A1.5. 1H NMR spectrum (500 MHz, CDCl3) and 13C NMR spectrum (125 MHz, CDCl3) of 
compound 3.39. 
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Figure A1.6. 1H NMR spectrum (500 MHz, CDCl3) and 13C NMR spectrum (125 MHz, CDCl3) of 
compound 3.64. 
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Figure A1.7. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.65. 
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Figure A1.8. COSY spectrum (500 MHz, CDCl3) and NOESY spectrum (500 MHz, CDCl3) of compound 
3.65. 
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Figure A1.9. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.68. 
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Figure A1.10. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 3.67. 
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Figure A1.11. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound S3.5. 
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Figure A1.12. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound S3.6. 
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Figure A1.13. 1H NMR spectrum (500 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.70. 
OBn
OBn
OTES
H
OMeO
O
OH
O
3.70
 168 
  
  
Figure A1.14. 1H NMR spectrum (400 MHz, CDCl3)  of compound S3.7 and 1H NMR spectrum (400 
MHz, CDCl3) of compound 3.78. 
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Figure A1.15. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound α-3.79. 
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Figure A1.16. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.80. 
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Figure A1.17. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.81. 
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Figure A1.18. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 3.82. 
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CHAPTER IV 
 
A TRANSANNULAR DIELS-ALDER-ENABLED  
BIOMIMETIC DIMERIZATION APPROACH 
 
Access to Single Biaryl Atropisomers 
 
At this point in our research, the nature and identity of hibarimicin axial chirality 
was still unknown, and thus a total synthesis of HMP-Y1 (1.94) and hibarimicinone 
(1.96) would require access to both atropisomers; however, our initial efforts involving a 
two-directional synthesis had failed to produce the necessary AB-enone for these 
purposes. We therefore needed to radically rethink our synthetic strategy while keeping 
in mind the atropisomerism limitation, and we became interested in the possibility of 
accessing single atropisomeric products without the need for chromatographic separation 
of a racemic mixture. To this end, we took notice of work developed by Brussee and 
applied by Wulff and co-workers involving the deracemization of BINOL and other 
related biaryl phenol ligands. Brussee and co-workers initially introduced the concept of 
racemic BINOL (4.1) resolution by treatment with a mixture of CuCl2•2H2O and (–)-
sparteine (4.2) in methanol.1 This method produced aS-BINOL (4.1) in 94% isolated 
yield and 80% ee. 
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Scheme 4.1. Brussee’s deracemization of BINOL. 
 
 Decades later, Wulff and co-workers reported an improved procedure utilizing in 
situ air oxidation of Cu(I) which was effectively applied to the resolution of vaulted 
biaryls such as VANOL (4.3).2,3 Thus, with the racemic ligand VANOL (4.3), the aS-
isomer could be isolated in 92% yield and 99.5% ee by deracemization with the Cu(II) 
complex generated from CuCl and (–)-sparteine (4.2). Additionally, by employing the 
(+)-sparteine surrogate O’Brien’s diamine (4.4), the aR-isomer was isolated in similarly 
impressive yield and enantiomeric excess.4 
 
 
Scheme 4.2. Access to pure aR- and aS-VANOL from a racemic mixture. 
 
 As proposed by Wulff, the mechanism of this deracemization is believed to 
follow the concept of dynamic thermodynamic resolution and relies upon an sp3-
hybridized intermediate.5 Kinetic resolution exploits reactivity rates of diastereomeric 
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intermediates formed from racemic mixtures based on effective differences in ΔGactivation 
and results in only one enantiomer preferentially reacting. Conversely, thermodynamic 
resolution involves a mechanism for equilibration between two populations of 
diastereomeric intermediates, which allows almost complete conversion to the 
thermodynamically favored product based on a matched or mismatched diastereomeric 
relationship. 
 For the specific case of aR-VANOL (4.3), association with the pre-formed Cu(II)-
sparteine complex results in the mismatched intermediate 4.5. Two paths for 
interconversion have been proposed based on previously reported analogous systems, and 
likely both paths contribute under differing conditions. In path A, 4.5 undergoes phenol 
tautomerization with the addition of HCl which forms an C-sp3 center that can freely 
rotate into the more thermodynamically stable conformer 4.7. Retautomerization arrives 
at the matched case 4.8, which dissociates from the Cu(II)-sparteine complex and 
liberates aS-VANOL (4.3). Path B alternatively does not require the action of HCl and 
directly forms a C-Cu quaternary center through phenol tautomerization which similarly 
to path A undergoes bond rotation to the more thermodynamically stable 4.10. 
Retautomerization by C-Cu bond cleavage leads to the matched system 4.8. And by 
switching the chiral environment imposed by the ligand, the matched and mismatched 
cases reverse and thus the aR-isomer becomes the thermodynamically favored product. 
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Scheme 4.3. Mechanism of VANOL dynamic thermodynamic resolution. 
 
We believed that the biaryl bis-phenol present in HMP-Y1 provided a perfect 
substrate for exploitation of this methodology. In this way, a diastereomeric mixture of 
HMP-Y1 atropisomers or an adequate precursor could be converted to either the aS- or 
the aR-atropisomer without the need to utilize chromatographic separation or 
stereoselective oxidative dimerization. Therefore, to probe the feasibility of this 
approach, we applied this method to our previously synthesized biaryl bis-phenol 4.11.6 
When racemic 4.11 was treated under deracemization conditions with (–)-sparteine, we 
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O’Brien’s diamine (4.4) led to aR-4.11 in high yield and slightly lower ee; however, we 
were pleased with these results. 
 
 
Scheme 4.4. Dynamic thermodynamic resolution of our model substrate. 
 
Biomimetic Dimerization Synthetic Analysis 
 
 The results shown in Scheme 4.4 proved significant in developing a synthetic 
strategy toward HMP-Y1 and hibarimicinone. Our previous difficulties with a two-
directional approach now required a novel method of single atropisomer synthesis; 
however, we still required access to both hibarimicinone atropisomers. Thus, with the 
developed deracemization protocol, we became free to propose a fresh synthetic scheme 
that followed nature’s lead: a biomimetic oxidative dimerization. 
 Still targeting the C2-symmetric biosynthetic intermediate HMP-Y1 (1.94), we 
proposed the monomeric tetracycle 4.12, which constitutes each half of HMP-Y1, as a 
key intermediate target. We believed this tetracycle could significantly improve the 
efficiency of an ultimate total synthesis of hibarimicinone for a number of reasons. An 
approach to 4.12 would set up a straightforward route with few transformations to HMP-
Y1, in theory only involving oxidative homodimerization. And in order to avoid the 
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necessity of AB-enone 2.54 synthesis, an alternate two-directional strategy from the 
central core biaryl dimer would require a large number of doubly processed reactions. 
Most importantly, our newly developed application of the dynamic thermodynamic 
resolution negated the need for chromatographic separation and opened the door to 
perform an unselective dimerization which we predicted would occur in the absence of 
external chirality, followed by deracemization to both atropisomeric forms. 
 
 
Scheme 4.5. A biomimetic dimerization toward HMP-Y1 and hibarimicinone. 
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secondary alcohol. This Diels-Alder could then be performed in two distinct modes: 
transannular (4.13), or intramolecular (4.14), where the fully functionalized A- and D- 
rings were tethered with a northern and southern carbon linker or just with a southern 
linker, respectively. And we proposed the possibility of varying oxidation states at the X 
variable as well as carbon and non-carbon linkers at the Y position for southern tethering. 
 
 
Scheme 4.6. A Diels-Alder-enabled strategy to tetracycle 4.12. 
 
First Generation TADA Approach 
 
We were drawn initially to the transannular disconnection, not only for its novelty 
and single-step formation of the tetracyclic framework but also due to the perceived 
differences in complexity of northern and southern tether formation. Therefore, we 
targeted formation of the northern bridge first, and we proposed various two and three 
carbon linker units for this purpose; however, we ultimately settled on a bifunctional 
reagent that could participate in cross coupling with the vinyl iodide 3.38 and 
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or cross) of a suitably functionalized olefin 4.18 and attachment with the C-10 secondary 
alcohol. 
 
 
Scheme 4.7. Synthetic analysis for assembly of a TADA precursor. 
 
 To synthesize the functionalized D-ring 4.16, a straightforward five step sequence 
from 2,4-dimethoxybenzaldehyde (4.19) was employed that resembled our previous work 
with the two-directional strategy. Baeyer-Villiger oxidation with m-CPBA with a 
hydrolytic workup provided the phenol which was allylated to provide 4.20.7 We found 
that regioselective Vilsmeier-Haack formylation occurred readily on the allyl ether 4.20, 
and the aryl aldehyde proved stable to high temperatures necessary for inducing a Claisen 
rearrangement. 8  Finally, the resulting phenol was methylated to provide the fully 
functionalized D-ring 4.16 in high yield on decagram scale. 
 
 
Scheme 4.8. Synthesis of the D-ring aryl aldehyde. 
OP
MeO
OMe O
OP
OH
OP
Y
X
D A
4.15
OMe
MeO
OMe
D
I
OBn
OBz
OBn
A
metathesis
cross
coupling
H
O
Y
R
R
M
M
4.16
4.17
4.18
3.38
nucleophilic
addition
O
O
OH
OH
OH
OMe
OH
methyl-α-D-gluco-
pyranoside (3.16)
OMe
MeO
OMe
D
H
O
4.16
OMe
MeO
CHO
1) m-CPBA, CH2Cl2
    reflux
2) allyl Br, K2CO3
    acetone
69% two steps
OMe
MeO
O
1) POCl3, DMF, toluene
2) neat, 200 °C, µW
3) MeI, K2CO3, acetone
62% three steps4.204.19
 181 
 With the aryl aldehyde 4.16 in hand, we sought out the use of a bifunctional 
ethylene reagent for connecting the aldehyde and and vinyl iodide 3.38. And two specific 
pieces of work led us to our first northern tether candidate. In Nicolaou and co-workers’ 
synthesis of rapamycin (1.9), they utilized a highly unique method for macrocyclic ring 
closure, specifically through a “stitching” reaction with trans-1,2-bis(tributylstannyl) 
ethylene (4.22).9 And while our approach did not directly map onto Nicolaou’s precedent, 
we consequently considered Corey’s demonstration that 4.22 could be reliably mono-
lithiated with n-BuLi.10,11 Thus, the homo-disubstituted ethylene reagent suited both of 
our needs for a nucleophilic reagent also capable of undergoing cross coupling. 
 
 
Scheme 4.9. Nicolaou’s “stitching-cyclization” method for rapamycin. 
 
We quickly optimized conditions for mono-lithiation of 4.22 and its addition into 
the aldehyde 4.16 which provided the secondary alcohol 4.23 as an inconsequential 
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to form the terminal olefin. Nevertheless, we attempted Stille coupling with both the free 
I
I
O
O
O
OH
OMe
O
MeO
OH H
O
ON
O
MeO
HO
O
O
O
OH
OMe
O
MeO
OH H
O
ON
O
MeO
HO
rapamycin (1.9)
Bu3Sn SnBu3
4.22
4.21
Pd(MeCN)2Cl2
DIPEA, DMF, THF
28%
 182 
and protected alcohols 4.23 and 4.24, however, no cross coupling of either substrate was 
observed. While this approach ultimately failed, necessary large quantities of the high 
molecular weight bis(tributylstannyl)ethylene 4.22 made the sequence less than 
desireable for long-term application. 
 
 
Scheme 4.10. Unsuccessful Stille coupling toward the northern tether. 
 
 We next turned to an alternative two carbon nucleophile that would require 
elaboration prior to reaction with the vinyl iodide 3.38. Reasoning that an alkyne unit 
could undergo hydroboration for ultimate Suzuki coupling, we considered a publication 
by Singleton and co-workers that demonstrated chemoselective hydroboration of a 
terminal alkyne without reaction with a terminal olefin.12 In this example, hydroboration 
of 4.27 with dicyclohexylborane led to the trans-vinylborane 4.28 which was 
characterized in situ and subsequently heated to effect an IMDA reaction to arrive at the 
trans-decalin 4.29. Finally, oxidation with sodium perborate yielded the secondary 
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alcohol 4.30 in 54% overall yield. We believed a similar approach to an intermediate aryl 
enyne derivative would enable Suzuki coupling with vinyl iodide 3.38. 
 
 
Scheme 4.11. Singleton’s chemoselective hydroboration. 
 
Following Singleton’s precedent, nucleophilic addition of ethynyl Grignard to 
aldehyde 4.16 yielded the propargylic alcohol 4.31 as an inconsequential mixture of 
diastereomers in excellent yield, and the secondary alcohol was protected as its TES ether 
4.32 in analogy to the previous sequence. We then investigated various hydroboration 
conditions with both the free (4.31) and TES-protected (4.32) alcohols hoping to find 
chemoselectivity for the alkyne over the alkene but to no avail.  
 
 
Scheme 4.12. Failed alkyne hydroboration for Suzuki coupling. 
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successes with vinyl iodide cross coupling, we decided to pursue an “A-ring-first” 
strategy where the aryl ring would be appended last. This design, however, would require 
an alternative linker unit if we specifically intended to implement a Suzuki cross coupling 
reaction. 
 
Second Generation TADA Approach 
 
Previous studies had shown robust capability for vinyl iodide 3.38 to undergo 
Suzuki cross coupling reaction with vinyl boronic acid. In analogy to our failed alkyne 
hydroboration approach, a functionalized vinyl boronate could be utilized in a Suzuki 
cross coupling followed by unification with a suitable aryl moiety. We decided to revert 
back to boron as our metal of choice and discounted bis(tributylstannyl)ethylene 4.22 for 
several key reasons. While “stitching” reactions enjoyed various successes, we did not 
believe that a mono-Stille coupling was feasible and would likely result in quantities of 
dimerized products. Additionally, tin-lithium exchange of a more highly functionalized 
vinyl tin substrate with multiple electrophilic centers posed serious challenges. Therefore, 
we targeted 3-boronoacrolein (4.36) and its intermediates as 3-carbon donors for 
unification of the A- and D-rings. 
This strategy required slight modification of our aryl ring substrate to reflect 
switching of the electrophilic and nucleophilic components, and aryl bromide 4.35 was 
proposed. Again, analogous to our first attempts at the TADA precursor 4.15, the order of 
reaction remained flexible and the approach to the southern tether remained unchanged. 
And our confidence with the proposed Suzuki cross coupling meant that our final 
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northern tether hurdle would involve appending the aryl ring 4.35 to the functionalized 
A-ring moiety. 
 
 
Scheme 4.13. Second generation TADA synthetic analysis. 
 
 Synthesis of the modified D-ring closely followed our previous assembly of the 
aryl aldehyde 4.16 starting with 2,4-dimethoxybenzaldehyde (4.19). Baeyer-Villiger 
oxidation provided the phenol which was transformed to the allyl ether 4.37 through 
standard conditions. Heating the neat allyl ether 4.37 at 200 °C via microwave irradiation 
cleanly provided the Claisen-rearranged product, and the resulting phenol was 
methylated. Finally, regioselective bromination with CuBr2 in DME at room temperature 
for 48 hours provided the functionalized D-ring 4.35 with handles for both northern and 
southern tether formation. 
 
 
Scheme 4.14. Synthesis of the aryl bromide. 
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 We now had in hand our proposed A- and D-rings, and we moved to determine 
effective conditions for unification with 3-boronoacrolein (4.36). Thus, Suzuki cross 
coupling with the bifunctional linker 4.38 was effected under two differing sets of 
conditions previously optimized for earlier substrates.13 Ultimately, although Pd(PPh3)4 
provided dienone 4.39 in slightly lower yield, we elected to proceed with these conditions 
due to complications with removal of Pd[P(t-Bu)3]2 and presumed long-term product 
stability in its presence. Surprisingly, we met complications with silyl ether deprotection 
which with either TBAF or HF•pyridine provided the free alcohol in highly variable 
yields. Nevertheless, allylic oxidation with MnO2 arrived at the desired three-carbon 
functionalized aldehyde 4.40 in reasonable yield. This compound contained important 
functionality for upcoming steps, namely the electrophilic aldehyde for aryl ring 
attachment and the diene necessary for our cornerstone transannular Diels-Alder reaction. 
 
 
Scheme 4.15. Synthesis of the tethered A-ring. 
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ether 4.41 required slight modification from literature procedures which traditionally 
utilized immediate TMS-deprotection following hydroboration of the requisite TMS-
propargylic alcohol; however, we found that concentration and direct distillation of the 
reaction mixture provided the desired TMS reagent 4.41 in reasonable reproducibility.14,15 
And with a simple acidic workup following Suzuki coupling, the allylic alcohol 4.42 was 
isolated in good yield for the two steps. In this way, we removed the necessary additional 
deprotection step, and allylic oxidation again arrived at the functionalized aldehyde 4.40 
for coupling. Finally, with both building blocks in hand, we attempted nucleophilic 
addition of an aryl-lithiate of 4.35 to the aldehyde 4.40 and were met with disappointing 
yield for formation of the northern-tethered product 4.43. However, retrospectively, we 
should not have been surprised by this result, as the aldehyde 4.40 contained numerous 
other electrophilic centers that likely contributed to other undesired products. 
 
 
Scheme 4.16. Improved synthesis of the A-ring aldehyde and tethering. 
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 With the results of Scheme 4.16 in mind, we sought to reverse the order of tether 
formation in hopes of improving nucleophilic aryl addition regioselectivity. Aldehyde 
4.36 has a relatively limited scope when considering nucleophilic additions but has been 
more highly utilized in aldol and Diels-Alder chemistry.14,16 However, Vaultier and co-
workers reported on zinc nucleophile addition to aldehyde 4.36, which was synthesized in 
three steps from TMS-propargylic alcohol 4.44 by hydroboration, TMS deprotection, and 
PCC oxidation.17 Addition of phenylzinc chloride provided an intermediate benzylic 
alcohol which was finally oxidized with PCC to the ketone 4.45 in good overall yield. 
Notably, lithium and magnesium nucleophiles suffered poor yields in the addition to 4.36 
presumably due to competitive addition to the electrophilic boronate center. 
 
 
Scheme 4.17. Vaultier’s arylzinc addition to aldehyde 4.36. 
 
 Our synthesis of the aldehyde linker 4.36 was modified slightly from that of 
Vaultier, namely in oxidation to the aldehyde in which we utilized DMP instead of PCC. 
Use of the aldehyde posed numerous technical problems including instability, difficulty 
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23 to 44%. Attempts at alcohol oxidation as shown in Scheme 4.17 were ultimately 
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unsuccessful, and we therefore elected for silyl ether protection to provide 4.47 in 
reasonable yield. We were pleased to finally observe synthesis of the northern-tethered 
product 4.48 through Suzuki reaction of the two coupling partners 4.47 and 3.38 in good 
yield. A big picture view of Scheme 4.18, however, showed problems with aryl addition 
to the aldehyde linker, and we recognized the limitations that this route would impose on 
large scale synthesis of 4.48. Regrettably, we failed to investigate the exact conditions 
laid out by Vaultier for smooth aryl zinc addition to aldehyde 4.36 or their use of PCC for 
pre- and post-nucleophilic addition oxidation. 
 
 
Scheme 4.18. Alternate order for northern tethering. 
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nucleophilic functionalities, but at this point, we had not considered modifications to a 
vinyl iodide A-ring. Thus, we set out to simplify functionalities present in the A-ring to 
facilitate unification with the D-ring for an ultimate transannular Diels-Alder reaction. 
 
A New A-Ring Surrogate from Quinic Acid 
 
Iodo enone 3.38 contained three of the six contiguous stereocenters found in 
HMP-Y1; however, we believed our forward progress toward the macrocyclic TADA 
precursor was hampered by the extensive functionality present including multiple 
electrophilic centers. Additionally, the absolute stereochemistry of HMP-Y1 and 
hibarimicinone remained unknown at this point, and we saw no reason to remain wedded 
to a single final enantiomer when no data existed to suggest one over the other. 
Therefore, we saw numerous advantages to completely reimagining a route to a similar 
vinyl iodide for cross coupling. First, we were eager to shed the five-step sequence from 
methyl-α-D-glucopyranoside to the Vasella precursor 3.32 in which each step required 
large-scale chromatography. Also, we hoped to identify a readily-available starting 
material that contained fewer reactive functional groups and could foreseeably be 
transformed into the desired A-ring. Finally, we sought out a starting material that had 
previously been utilized for synthesis of a similar vinyl iodide to 3.38, and fortunately, 
our laboratory had experience with utilizing (–)-quinic acid in a similar sequence to 
synthesize a highly analogous iodo-enone 4.50. 18  Notably, the C-10 stereocenter 
(hibarimicin numbering) necessitated synthesis of the opposite hibarimicinone 
enantiomer compared to the methyl-α-D-glucopyranoside route, but again at this point in 
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our research, this change was of no consequence considering our lack of absolute 
stereochemical knowledge. Thus, our retrosynthetic analysis toward the macrocyclic 
TADA precursor 4.49 remained largely the same, but several key features were modified. 
We had removed the C-12 secondary alcohol stereocenter, and the C-11 alcohol would 
require inversion to the correct hibarimicinone relative stereochemistry, but most 
importantly, iodo-enone 4.50 contained only minimal necessary functionality for 
speeding our progress toward the macrocycle 4.49. 
 
 
Scheme 4.19. TADA synthetic analysis from (–)-quinic acid. 
 
 Following literature precedent, (–)-quinic acid was subjected to acetonide-
forming conditions on large scale to arrive at the acetonide-lactone 4.52 which was 
followed by global reduction with LAH forming triol 4.53.19 Oxidative cleavage of the 
1,2-diol in 4.53 led to β-hydroxy ketone 4.54, and mesylation/elimination readily 
occurred to form enone 4.55.20 Finally, similar conditions to those utilized in our previous 
approaches installed the α-iodo enone in good yield. Importantly, the five-step sequence 
shown in Scheme 4.20 required only two chromatographic purifications, for the final two 
steps, and we reliably produced decagram quantities of 4.50 for each batch. 
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Scheme 4.20. Synthesis of a (–)-quinic acid-derived iodo-enone. 
 
 Iodo-enone 4.50 highly resembled the previously utilized iodo-enone 3.38 derived 
from methyl-α-D-glucopyranoside, and we were curious about installation of the C-13 
tertiary alcohol present in hibarimicinone. Because we hoped to functionalize the ketone 
in 4.50 prior to northern tether formation, we targeted the iodo-enone for three-carbon 
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as the major product. Seeking modifications, we employed Baran’s use of toluene as a 
solvent for Grignard addition, and we were ecstatic to not only observe primarily 1,2-
addition to 4.50 but also essential formation of a single desired diastereomer.21 This result 
can be easily rationalized due to severe steric interactions with the acetonide moiety in 
the pseudo-equatorial transition state 4.56 for β-face addition.22 Thus, we had overcome 
the major hurdle present in our two-directional strategies and contrastingly directly 
installed the necessary propyl unit in high yield and with complete stereoselectivity. 
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Scheme 4.21. Selective C-13 stereocenter formation. 
 
 Now that we had access to quantities of the (–)-quinic acid-derived A-ring 4.57, 
we elected to attempt northern tether formation with our previously synthesized vinyl 
boronate 4.47 under our standard Suzuki coupling conditions. We were pleased to 
observe high yield for this cross coupling reaction to form the A-D linked product 4.58, 
and we pushed this material forward through silyl ether deprotection and benzylic alcohol 
oxidation to the α,β-unsaturated ketone 4.60. With this northern tethered compound 4.60, 
we envisioned multiple possibilities for macrocyclic closure by southern tether formation; 
however, our major hurdle remained producing quantities of the vinyl boronate 4.47 
which suffered from low yields in the aryl addition to the aldehyde linker 4.36. Thus, we 
reasoned that reversing the order of operations, analogous to Scheme 4.16, could improve 
these problems as long as the route from vinyl iodide 4.57 to an α,β-unsaturated aldehyde 
occurred with good yields. 
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Scheme 4.22. Northern tether formation with the (–)-quinic acid-derived A-ring. 
 
 To reverse operation order, we reverted to Suzuki cross coupling between the 
vinyl iodide 4.57 and the vinyl boronate linker 4.41 which occurred smoothly, and under 
the reaction conditions, some of the TMS ether was deprotected. Therefore, the crude 
reaction mixture was stirred with citric acid in methanol to effect the remainder of TMS 
removal, and the allylic alcohol 4.61 was isolated in high yield. A two step sequence of 
allylic oxidation and tertiary alcohol protection as the TMS ether with TMSTFA worked 
well to arrive at the linker-installed A-ring 4.62 for northern tether formation with the 
aryl bromide 4.35.23 In this way, we now had optimized routes for large scale production 
of both A- and D-ring surrogates in decagram quantities with no severely limiting steps, 
and we were hopeful about our chances to effect tethering with the new minimally 
functionalized A-ring 4.62. 
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drying, and the reaction proceeded slowly enough to require stirring overnight at room 
temperature before full starting material consumption. We were elated by this result, as 
we had finally synthesized an A-D linked intermediate in high yield, and this reaction 
was easily increased to multi-gram scale. We could then foresee numerous paths forward 
for southern tether linking, with the terminal olefin and cis-diol functionalities as key 
handles for macrocycle formation. 
 
 
Scheme 4.23. Improved synthesis of the A-ring aldehyde and tethering. 
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shown to be advantageous in the transmetallation step due to its lower coordinating 
strength to palladium as compared with triphenylphosphine.24 Silver oxide has also been 
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likely mechanism is shown in Scheme 4.24. 25  Beginning with tetrakis 
(triphenylphosphine)-palladium(0), ligand exchange with triphenylarsine provides the 
O
O
4.57
I
OH
A
Pd(PPh3)4, Ag2O, Ph3As
THF, H2O, then
citric acid, MeOH
74%
TMSO Bpin
4.41
O
O
4.61
OH
HO 1) MnO2, CH2Cl2
2) TMSTFA, Et3N
    CH2Cl2 O
O
4.62
OTMS
H
O
60% two steps
OMe
MeO
OMe
Br
4.35
A
O
O
4.62
OTMS
H
O
D n-BuLi, THF–78 °C to RT
75%
A
O
O
4.63
OTMS
OHOMe
MeO
OMe
D
 196 
activated Pd(Ph3As)4 catalyst (4.64) which undergoes oxidative insertion with the vinyl 
halide 4.65. The palladium(II) intermediate 4.66 undergoes anion exchange, and the 
intermediate 4.67 is set up for transmetallation with the boronic acid. The di-
alkylpalladium(II) intermediate 4.68 then undergoes reductive elimination to provide the 
disubstituted olefin 4.69, completing the catalytic cycle, and regenerating the 
palladium(0) catalyst. 
 
 
Scheme 4.24. Mechanism of Suzuki cross coupling of vinyl halides. 
 
 Our southern tether strategy stemmed from precedent shown for previous IMDA 
reactions involving a silicon linker, where the silicon group could be easily removed 
following ring closure. In the case of work by Sieburth and co-workers, primary alcohol 
4.70 was silylated with vinyldiphenylchlorosilane, and the resulting triene 4.71 was 
heated in toluene to effect IMDA reaction.26  The bicyclic product 4.72 was then 
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subjected to Tamao-Fleming oxidation conditions to provide the diol 4.73 in a 1:1 
mixture of diastereomers. And although our strategy would require C-Si bond reduction, 
we hoped to follow this general approach. 
 
 
Scheme 4.25. Sieburth’s silyl-tethered IMDA/Tamao-Fleming sequence. 
 
We first elected to oxidize the resultant mixture of diastereomers through allylic 
oxidation with MnO2 so as to more easily operate with a single diastereomer, and we 
arrived at the α,β-unsaturated ketone 4.74 in high yield. From ketone 4.74, we hoped to 
unmask the cis-diol functionality through acetonide deprotection, and treatment of 4.74 
with 2 N HCl in acetonitrile effectively led to triol 4.75. From this intermediate, we 
hoped to regioselectively install a vinyl moiety for macrocyclic ring closing metathesis. 
A vinyl silicon linker was chosen for its ease of removal following the proposed 
transannular Diels-Alder reaction. Unfortunately, even after sequential investigation of 
the number of silyl chloride equivalents necessary, we observed only formation of the tri-
siloxane 4.76. Undeterred, we reasoned that the two extra vinyl-silane functionalities 
posed minimal threat to a potential ring closing metathesis reaction; however, under 
various tested conditions we never observed an indication of macrocycle formation.  
 Considering that all three alcohols present on the A-ring possessed the correct 
orientation necessary to direct facial selectivity in the TADA, we made a slight leap by 
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forming the tertiary vinyl-silane 4.77 in hopes of effecting formation of a bridged 
macrocycle. Again, we were met with disappointment, and under numerous conditions 
for ring closing metathesis, no macrocycle ever formed. 
 At this point, we acknowledged the difficulty of relying on regioselective vinyl-
moiety attachment on the requisite cis-diol, and we began to investigate terminal olefin 
functionalization. We reasoned that an alkyne would open numerous doors to 
modification due to its ability to undergo deprotonation, and thus we screened 
dihydroxylation conditions including classic Upjohn and Sharpless conditions but to no 
avail. Although the terminal olefin would be predicted to be most reactive on electronic 
and steric rationales, we believe that cross reactivity with the other two olefins in 4.74 led 
to complex mixtures of products. Additionally, attempted cross metathesis with 
vinylchlorosilanes ultimately failed as well.27,28 With these disappointing results, we 
elected to take a step back and focus on a simpler substrate for dihydroxylation which we 
reasoned could ultimately be converted to the desired terminal alkyne to which 4.79 
would ultimately lead. 
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Scheme 4.26. Failed attempts toward southern tether formation. 
 
 Before we abandoned the northern-tethered terminal olefin substrate 4.63, we 
became intrigued to determine the innate stereoselectivity of an intramolecular Diels-
Alder reaction to either confirm or contradict our predictions for the C-9 bridgehead 
center. After some experimentation, we began to observe cyclization of the allylic alcohol 
substrate 4.63 when heated in toluene at 75 °C, and full starting material consumption 
had occurred within 48 hours. The major product of the reaction was isolated in 34% 
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yield (we believe the remainder of the mass balance underwent cyclization followed by 
dehydration of the free secondary alcohol based on crude NMR), and the product was 
acetylated to facilitate characterization. Ultimately, we had formed the ABCD tetracycle 
4.80 with the undesired C-9 stereochemistry which was confirmed by extensive 2-D 
NMR and readily apparent through a NOESY correlation of the C-9 hydrogen with the 
TMS group. Additionally, NOESY correlations and coupling constants were used to 
assign the remaining stereocenters, and noting that 4.80 was isolated as a single 
diastereomer, the β-secondary alcohol presumably made up a portion of the dehydrated 
material. This result confirmed our suspicions regarding facial approach of the olefin 
dienophile in which the acetonide strongly directs the olefin to the α-face of the diene and 
provided further support for the southern tether as imperative to Diels-Alder 
stereochemistry. 
 
 
Scheme 4.27. Incorrect C-9 stereochemistry from a northern-tethered IMDA. 
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dibromination; however, this reaction resulted in concomitant aryl ring halogenation. 
Ozonolysis did effect conversion to the desired aldehyde but also resulted in an unknown 
reaction with the aryl ring as well. Finally, simple dihydroxylation and oxidative cleavage 
with NaIO4 cleanly formed the necessary aldehyde 4.81, and we then converted the 
aldehyde with the Bestmann-Ohira reagent (4.82) to the terminal alkyne 4.83 in high 
yield.29 Notably, single step oxidative cleavage with OsO4 and NaIO4 in one pot resulted 
in lower yield, and thus we elected for a two step procedure without purification of the 
intermediate diol. With the terminal alkyne, we installed various functionality that we 
hoped would allow southern tether formation. Thus, deprotonation of the alkyne with 
ethylmagnesium chloride produced the intermediate alkynyl Grignard which could be 
reacted with either TMSCl or methyl chloroformate to yield 4.84 and 4.85 respectively. 
Additionally, we were able to form the alkynyl bromide 4.86 in excellent yield.  
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Scheme 4.28. Aryl alkyne synthesis and functionalization. 
 
Alkynyl ester 4.85 was initially our preferred functionality for eventual southern 
tethering as it would only require hydrolysis to provide an acid for macrolactonization. 
Unfortunately, we were unable to effect northern tether formation between aryl bromide 
4.85 and the A-ring aldehyde 4.62 as the methyl ester was likely an incompatible 
functionality with n-BuLi. We then turned our attention to the TMS-alkyne 4.84 which 
we reasoned could be deprotected and functionalized post-tethering. We screened a large 
number of conditions with various metals but disappointingly never observed formation 
of the desired product 4.88. 
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Scheme 4.29. Attempted northern tether formation with functionalized alkynes. 
 
 Despite our difficulties at uniting an alkyne-functionalized aryl ring with our A-
ring aldehyde 4.62, we remained convinced that slight modification of our standard n-
BuLi conditions, which reliably underwent deuterium incorporation in test reactions, 
would lead to the desired product. TMS alkyne 4.84 remained our primary aryl bromide 
as we believed that the alkyne would require masking to allow for chemoselectivity upon 
treatment with n-BuLi. We finally glimpsed success when allylic alcohol 4.88 was 
isolated in 43% yield by simply running the reaction at –100 °C instead of –78 °C, but 
the reaction resisted improvement. Faced with these results, we became less convinced 
that a TMS-alkyne functionality truly provided benefit over the free alkyne, and we thus 
attempted formation of the di-lithiate intermediate 4.89 at –100 °C and addition to the 
aldehyde 4.62. Gratifyingly, we isolated the desired product 4.90 as a mixture of 
diastereomers in high yield with complete chemoselectivity for aryl-lithiate addition. In 
this way, we viewed formation of the alkynyl lithiate as a form of in situ protection which 
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was ultimately reprotonated during the workup step. This reaction proved highly scalable, 
and we could produce multiple grams of the allylic alcohol 4.90 in a single reaction. 
 
 
Scheme 4.30. Successful northern tethering with terminal alkyne functionality. 
 
 We immediately converted the diastereomeric mixture of allylic alcohols 4.90 to 
the α,β-unsaturated ketone 4.91 for ease of characterization of further reaction products. 
But this strategy ultimately led to other complications. Our original plans for the terminal 
alkyne involved deprotonation and addition to methyl chloroformate to provide the 
alkynyl ester 4.92. Unfortunately but not surprisingly, we were unable to 
chemoselectively deprotonate the alkyne as our standard bases preferentially underwent 
nucleophilic addition to the ketone moiety. 
 An alternate route to the alkynyl ester 4.92 involved carbonylative cross coupling 
of either the terminal alkyne 4.91 or the halo-alkyne 4.93. While reports of these types of 
transformations remain limited in scope and application and their mechanisms are not 
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well understood, we hoped that a palladium-catalyzed method would overcome inherent 
difficulties of alkynyl nucleophile formation in the presence the ketone functionality. 
Thus, we screened various systems reported by Yamamoto, Tsuji, and Temkin but 
unfortunately failed to observe product formation. 30,31,32 When we attempted to optimize 
conditions on the simpler aryl alkyne 4.83, we observed mixtures of desired product with 
the isomerized allenic ester. In light of these results, we resorted to less traditional 
methods for ester installation. 
 
 
Scheme 4.31. Failed attempts at alkyne functionalization. 
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Yamamoto and co-workers probed the details of the carbonylation of a terminal 
alkyne and proposed a mechanism based on their studies. Starting with a palladium(II) 
catalyst 4.94, formation of the palladium-methoxycarbonyl species 4.95 is followed by 
addition of the terminal alkyne 4.96 to form intermediate 4.97. Reductive elimination of 
the alkynyl ester 4.98 generates a palladium(0) species 4.99 which is oxidized by 
molecular oxygen to complete the catalytic cycle. 
 
 
Scheme 4.32. Proposed mechanism of alkyne carbonylation. 
 
Despite failure with carbonylative methyl ester formation, we were intrigued by 
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the reaction. Nevertheless, we reasoned that with an acetonide-deprotected alkyne 
compound, we could at very least hope for confirmation that our proposed alkynyl 
lactone could indeed be formed. 
 
 
Scheme 4.33. Ogasawara’s carbonylative macrolactonization. 
 
 Treatment of alkynyl ketone 4.91 with 2 N HCl in acetonitrile cleanly effected 
acetonide and TMS ether deprotection to the triol 4.103. From this intermediate, we saw 
two possible, albeit unlikely, routes to forming macrolactone 4.104. In analogy to 
Ogasawara’s carbonylative macrolactonization, we treated alkynyl triol 4.103 with 
palladium-mediated carbonylation conditions with the hope that the alkynyl palladium 
intermediate would be intercepted by the adjacent secondary alcohol; however, we never 
observed any conversion to desired product.  
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Scheme 4.34. Alternate macrolactonization attempts. 
 
Alternatively, we viewed a cyclic carbonate formed from the cis-diol functionality 
of 4.103 as a potential intramolecular electrophilic acceptor of an alkynyl nucleophile. 
This approach stemmed from precedent set by Nicolaou and co-workers in their synthesis 
of taxol in which a cyclic carbonate moiety in 4.106 was opened with phenyllithium to 
install the innate benzoate functionality and arrive at 4.107.34 This example did not 
clearly map onto our substrate, as Nicolaou’s work utilized an intermolecular delivery of 
a nucleophile that was used in large molar excess. 
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Scheme 4.35. Nicolaou’s nucleophilic opening of a cyclic carbonate. 
 
Despite the obvious differences with Scheme 4.35, conversion to the necessary 
cyclic carbonate 4.105 proved straightforward, but again, we were met with failure as all 
conditions utilized to effect cyclization did not lead to the desired macrocycle.35 These 
results were not surprising considering our lack of success with carbonylative methyl 
ester formation and the necessary conformation for alkyne attack of the cyclic carbonate. 
However, we recognized the need to employ a protected version of the allylic alcohol 
4.90 to allow for alkyne deprotonation for functionalization. 
To see this plan through, silyl ether protection of the mixture of secondary 
alcohols yielded 4.108, and we then explored alkyne functionalization. By removing the 
electrophilic center in 4.91, we were pleased to observe chemoselective deprotonation, 
and we optimized conditions to install the desired methyl ester with Manders’ reagent.36 
And despite the mixture of diastereomers, we curiously observed a mixture of the 
uncyclized ester 4.109 and the IMDA product 4.110 by 1H NMR following standard 
workup and purification. To confirm the identity of this new compound, we heated the 
mixture in toluene at 40 °C to effect conversion of the remainder of the uncyclized 
product. Indeed, after 5 hours, the alkynyl ester 4.109 had fully converted to the IMDA 
product 4.110. Tetracycle 4.110 proved difficult to assign by 2-D NMR methods due to 
the unsaturation found in the B-ring. No major NOESY correlations indicated 
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stereochemistry, but the C-9 stereocenter was assigned to be the undesired β-hydrogen 
based on coupling constants with the adjacent α-face hydrogen. This facial selectivity 
came as no surprise based on precedent within the terminal olefin series as well as 
modeling logic with the presence of the acetonide moiety. This result provided even 
further evidence for the necessity of southern tethering to effect formation of the correct 
C-9 stereocenter. However, we were surprised to observe room temperature IMDA of 
4.109. 
An electronic analysis of the alkynyl ester 4.109 reveals a highly activated Diels-
Alder substrate within a normal electron demand paradigm. In contrast to the α,β-
unsaturated ketone 4.91, the allylic-OTES diene serves as a highly electron rich diene 
system. Logically, the terminal alkyne starting material 4.108 does not undergo 
cyclization due to the unfavorable Diels-Alder dienophile electronics; however, 
installation of the methyl ester to arrive at 4.109 significantly lowers the LUMO of the 
dienophile, and the energy necessary to bridge the energy gap is available at room 
temperature. Regrettably, we never investigated the rate of conversion between 4.109 and 
4.110 by simply allowing the mixture to sit at room temperature for an extended period of 
time. 
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Scheme 4.36. Alkyne functionalization and an unexpected IMDA. 
 
 We had planned to attempt macrocyclization of 4.109 to form the southern tether 
which we had now shown as essential for correct stereoselectivity in the Diels-Alder. 
However, room temperature Diels-Alder cyclization provided no reasonable window in 
which to perform the necessary steps for macrocyclization first. Therefore, we were 
forced to redesign our synthetic route once again to account for these results. We 
reasoned that although northern tether formation did not occur with an aryl alkynyl ester 
4.85, we might be able to functionalize the aryl-alkyne with a lower oxidation state group 
so as to allow fine-tuning of Diels-Alder electronics and avoid unwanted cyclization. 
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The Propargylic Alcohol Series for Macrocycle Formation 
 
Drawing on our experience with alkyne functionalization in Scheme 4.36, we 
believed that we could effectively substitute the electrophile to produce a lower oxidation 
state product. We were familiar with the use of paraformaldehyde as an electrophilic 
reagent for carbon elongation, and we succeeded, albeit in very low yield, to produce the 
propargylic alcohol 4.111. Ultimately, if we were to apply this route to a total synthesis 
of hibarimicinone, we would require a much more robust synthetic route. With this in 
mind, we turned back to the aryl alkyne 4.83 which we reasoned could be transformed to 
the propargylic alcohol, and its protected form could be used in northern tethering with 
aldehyde 4.62. Deprotonation of the aryl alkyne 4.83 under our standard conditions was 
followed by the addition of rigorously dry paraformaldehyde, and after 22 hours, 
propargylic alcohol 4.112 was isolated in excellent yield. In preparation for lithium-
halogen exchange, we elected to protect the secondary alcohol as a silyl ether which 
proceeded with similar success to provide the TES-ether 4.113. 
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Scheme 4.37. Synthesis of an aryl propargylic alcohol. 
 
 Aryl bromide 4.113 was treated with n-BuLi at –100 °C in analogy to Scheme 
4.30 followed by addition of the aldehyde 4.62, and again we arrived at the northern-
tethered compound 4.114 in exceptional yield. With the lessons of the undesired IMDA 
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instability of 4.117, we moved material directly to the next oxidation step, and for the 
sake of characterization, we treated the intermediate acid with diazomethane to produce 
the methyl ester 4.118. The three step sequence from the propargylic alcohol 4.116 to 
methyl ester 4.118 occurred in 11% overall yield, which we viewed as unsustainable for 
our purposes considering the remaining steps necessary for southern tether formation. 
 
 
Scheme 4.38. Synthesis of a deactivated alkynyl ester. 
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gained any traction, and we were again forced to confront the serious issues presented by 
functionalization of the A-ring cis-diol and southern tethering. 
 
Conclusion 
 
Despite our lack of success with a two-directional strategy toward HMP-Y1 and 
hibarimicinone, we demonstrated the power of a deracemization protocol that opened the 
door to a biomimetic approach. We identified a monomeric tetracycle that we planned 
would ultimately undergo oxidative dimerization and deracemization, and we evaluated 
numerous synthetic strategies for its synthesis. Formation of the northern tether could 
occur from either direction by building onto either the A- or D-ring, and tethering with 
the methyl-α-D-glucopyranoside-derived A-ring was ultimately met with limitations for 
both synthetic options. Therefore, we identified a (–)-quinic acid-derived A-ring that 
greatly improved the requisite tethering reactions. With various northern-tethered 
substrates at our disposal, we attempted macrocycle formation to no avail, and two 
demonstrations of IMDA reactions confirmed the necessity of the southern tether for 
correct C-9 stereochemistry. As we failed to achieve southern tethering toward the 
proposed tetracycle, we finally recognized the need to directly tackle the difficult task of 
functionalizing the A-ring cis-diol toward a southern-tethered intermediate. These 
experiments are detailed in the following chapter. 
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Experimental Methods 
 
General Procedure. All non-aqueous reactions were performed under an argon 
atmosphere in flame-dried glassware. Stainless steel syringes or cannula were used to 
transfer air- and moisture-sensitive liquids. Reaction temperatures were controlled using 
a thermocouple thermometer and analog hotplate stirrer. Reactions were conducted at 
room temperature (RT, approximately 23 °C) unless otherwise noted. Analytical thin-
layer chromatography was performed on E. Merck pre-coated silica gel 60 F254 plates 
and visualized using UV, ceric ammonium molybdate (CAM) and potassium 
permanganate (KMnO4) stains. Flash column chromatography was conducted as 
described by Still et. al. using indicated solvents and Dynamic Adsorbents silica gel 60 
(230-240 mesh).37 Where necessary, silica gel was neutralized by treatment of the silica 
gel prior to chromatography with the eluent containing 1% triethylamine (Et3N). Where 
necessary, silica gel was treated prior to chromatography with the eluent containing 1% 
glacial acetic acid (AcOH). Yields were reported as isolated, spectrocopically pure 
compounds. 
 
Materials. Reagents were purchased at the highest commercial quality and used without 
further purification unless otherwise stated. When necessary, intermediates were dried by 
azeotropic removal of water by evaporation from benzene (three iterations) and further 
dried on high-vacuum for the indicated amount of time. Toluene and dichloromethane 
(CH2Cl2) were obtained by passing commercially available solvents through activated 
alumina columns (MBraun MB-SPS solvent system). Tetrahydrofuran (THF) was 
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purified by distillation from sodium metal with benzophenone indicator, and when 
necessary, was further dried over activated 4 Å molecular sieves under an atmosphere of 
argon. Triethylamine (Et3N) was distilled from calcium hydride and stored over sodium 
hydroxide. The molarity of commercial n-butyllithium solutions was determined by 
titration using diphenylacetic acid as an indicator (average of three determinations). 
 
Instrumentation. Optical rotations were obtained using a Perkin Elmer 341 polarimeter 
and zeroed with the pure solvent, spectrophotometric-grade chloroform. 1H NMR spectra 
were recorded on Bruker 300, 400, 500, or 600 MHz spectrometers and are reported 
relative to deuterated solvent signals (CDCl3: 7.26; C6D6: 7.16). Data for 1H NMR 
spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sept. = septet, m = multiplet, br = broad, app = 
apparent), coupling constants (Hz), and integration. 13C NMR spectra were recorded at 
100, 125, or 150 MHz and are reported relative to deuterated solvent signals (CDCl3: 
77.0; C6D6: 128.1). Infrared spectra were obtained as thin films on NaCl plates using a 
Thermo Electron IR100 series instrument and are reported in terms of frequency of 
absorption (cm-1). High-resolution mass spectra were obtained from the Department of 
Chemistry and Biochemistry, University of Notre Dame using either a JEOL AX505HA 
or JEOL LMS-GCmate mass spectrometer. 
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Preparative Procedures 
 
To a solution of lithium acetylide ethylene diamine complex (90%, 12.0 g, 
117 mmol, 1.1 eq) in THF (400 mL) at 0 °C was added Bu3SnCl (29.5 mL, 110 mmol, 
1.0 eq) via dropping funnel with vigorous stirring over 45 min then stirred at RT for 22 h. 
The reaction was cooled to 0 °C and H2O (10 mL) was added then the mixture was 
concentrated. The residue was diluted with H2O (75 mL) and extracted with hexanes (4 x 
30 mL), and the combined organic layers were dried (MgSO4), filtered and concentrated. 
Distillation (0.1 mm Hg, 92-95 °C) provided S4.1 as a clear liquid (9.37 g, 29.7 mmol, 
25%). Spectral data were consistent with reported literature values.38 
 
To S4.1 (9.37 g, 29.7 mmol, 1.0 eq) was added AIBN (122 mg, 0.743 
mmol, 0.025 eq) and Bu3SnH (9.60 mL, 35.7 mmol, 1.2 eq) and the reaction was heated 
at 90 °C for 6 h. At RT, distillation (0.1 mm Hg, 190-200 °C) required constant heating 
of the shortpath column and yielded 4.22 as a cloudy white liquid (17.7 g, 29.1 mmol, 
98%). Spectral data were consistent with reported literature values.38 
 
To a solution of 4.22 (1.83 g, 3.02 mmol, 3.0 eq) in THF (9.0 mL) 
at –78 °C was added n-BuLi (2.2 M in hexanes, 1.52 mL, 3.32 
mmol, 3.3 eq) and the reaction was stirred at –40 °C for 30 min. At –78 °C, a solution of 
4.16 (238 mg, 1.01 mmol, 1.0 eq) in THF (1.1 mL) was added dropwise and the reaction 
was stirred at –78 °C for 3 h. To the reaction was added saturated aqueous NH4Cl (20 
mL) and the mixture was extracted with Et2O (3 x 20 mL). The combined organic layers 
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were dried (MgSO4), filtered and concentrated. Purification by flash column 
chromatography (5-15% EtOAc/hexanes) containing 1% Et3N provided 4.23 as a light 
yellow oil (336 mg, 0.607 mmol, 60%). 1H NMR (400 MHz, CDCl3): δ 6.45 (s, 1H), 6.27 
(dd, J = 19.1, 4.4 Hz, 1H), 6.03 (dd, J = 19.0, 1.6 Hz, 1H), 5.95 (ddt, J = 17.1, 10.2, 5.7 
Hz, 1H), 5.24 (ddd, J = 10.8, 4.5, 1.5 Hz, 1H), 5.03 (app. dd, J = 10.2, 1.6 Hz, 1H), 4.96 
(app. dd, J = 17.1, 1.7 Hz, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 3.77 (d, J = 10.9 Hz, 1H), 3.74 
(s, 3H), 3.55 (ddt, J = 15.8, 5.7, 1.6 Hz, 1H), 3.43 (ddt, J = 15.8, 5.5, 1.8 Hz, 1H), 1.55-
1.37 (m, 6H), 1.27 (sex, J = 7.3 Hz, 6H), 0.95-0.75 (m, 15H); 13C NMR (100 MHz, 
CDCl3): δ 154.2, 152.2, 149.6, 141.4, 136.9, 132.1, 126.3, 122.1, 115.6, 96.4, 73.2, 61.0, 
55.9, 55.8, 30.4, 29.1, 27.2, 13.7, 9.4; IR (film) νmax 3555, 2924, 2871, 1598, 1485 cm -1; 
HRMS (ESI) m/z calcd. for C27H46NaO4Sn [M+Na]+ 577.2315, found 577.2293. 
 
To a solution of 4.23 (65 mg, 0.117 mmol, 1.0 eq), imidazole (24 
mg, 0.352 mmol, 3.0 eq), and DMAP (2 mg, catalytic) in DMF (150 
µL) at 0 °C was added TESCl (39 µL, 0.235 mmol, 2.0 eq) and the reaction was stirred at 
0 °C for 1 h and at RT for 20 hours. To the reaction was added saturated aqueous NH4Cl 
(10 mL) and the mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were washed with H2O (1 x 10 mL) and brine (1 x 10 mL) then dried (MgSO4), 
filtered and concentrated. Purification by flash column chromatography (0-1.5% 
EtOAc/hexanes) containing 1% Et3N yielded 4.24 as a light yellow oil (67 mg, 0.100 
mmol, 85%). 1H NMR (600 MHz, CDCl3): δ 6.40 (s, 1H), 6.24-6.07 (m, 2H), 5.92 (ddt, J 
= 16.9, 10.2, 6.1 Hz, 1H), 5.87 (app. d., J = 1.7 Hz, 1H), 4.94 (dd, J = 17.2, 1.9 Hz, 1H), 
4.91 (dd, J = 10.2, 1.8 Hz, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.73 (s, 3H), 3.67 (app. dd, J = 
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14.8, 6.3 Hz, 1H), 3.54 (app. dd, J = 14.7, 5.8 Hz, 1H), 1.54-1.39 (m, 6H), 1.28 (sex, 6H), 
0.94-0.78 (m, 24H), 0.59-0.50 (m, 6H); 13C NMR (150 MHz, CDCl3): δ 152.9, 152.0, 
150.7, 142.6, 138.7, 134.9, 124.9, 123.0, 114.1, 95.6, 69.7, 60.5, 56.4, 55.7, 31.4, 29.1, 
27.3, 13.7, 9.4, 6.8, 4.8; IR (film) νmax 2955, 2929, 1596, 1464, 1326, 1235 cm -1; HRMS 
(ESI) m/z calcd. for C33H60NaO4SiSn [M+Na]+ 691.3181, found 691.3188. 
 
To a solution of 4.16 (500 mg, 2.12 mmol, 1.0 eq) in THF (21 mL) at     
–78 °C was added ethynyl magnesium bromide (0.5 M in THF, 8.5 mL, 
4.23 mmol, 2.0 eq) dropwise and the reaction was stirred at –78 °C for 30 min and at 0 
°C for 1 h. To the reaction was added saturated aqueous NH4Cl (50 mL) and the mixture 
was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried 
(MgSO4), filtered and concentrated. Purification by flash column chromatography (20% 
and 30% EtOAc/hexanes) provided 4.31 as a light yellow oil (498 mg, 1.90 mmol, 90%). 
1H NMR (400 MHz, CDCl3): δ 6.48 (s, 1H), 5.97 (ddt, J = 17.1, 10.3, 5.5 Hz, 1H), 5.50 
(dd, J = 10.7, 2.3 Hz, 1H), 5.05 (ddd, J = 10.2, 3.1, 1.5 Hz, 1H), 4.97 (ddd, J = 17.1, 3.3, 
1.6 Hz, 1H), 3.94 (d, J = 10.7 Hz, 1H), 3.91 (s, 3H), 3.86 (s, 3H), 3.72 (s, 3H), 3.57 (ddt, 
J = 16.1, 5.7, 1.8 Hz, 1H), 3.50 (ddt, J = 16.1, 5.7, 1.7 Hz, 1H), 2.44 (d, J = 2.4 Hz, 1H); 
13C NMR (100 MHz, CDCl3): δ 154.2, 152.9, 141.3, 136.3, 131.4, 120.2, 115.8, 96.5, 
84.6, 71.5, 60.9, 59.2, 56.2, 55.8, 30.1; IR (film) νmax 3530, 3285, 2940, 2840, 1597 cm -
1; HRMS (ESI) m/z calcd. for C15H18NaO4 [M+Na]+ 285.1097, found 285.1090. 
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To a solution of 4.31 (217 mg, 8.27 mmol, 1.0 eq), imidazole (282 mg, 
4.14 mmol, 5.0 eq), and DMAP (2 mg, catalytic) in DMF (827 µL) at 0 
°C was added TESCl (417 µL, 2.48 mmol, 3.0 eq) and the reaction was stirred at 0 °C for 
30 min and at RT for 22 h. To the reaction was added saturated aqueous NH4Cl (25 mL) 
and the mixture was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers 
were washed with H2O (1 x 25 mL) and brine (1 x 25 mL) then dried (MgSO4), filtered 
and concentrated. Purification by flash column chromatography (5% and 10% 
EtOAc/hexanes) yielded 4.32 as a clear oil (285 mg, 0.757 mmol, 91%). 1H NMR (400 
MHz, CDCl3): δ 6.38 (s, 1H), 6.15 (d, J = 2.4 Hz, 1H), 6.05 (ddt, J = 17.1, 10.2, 6.2 Hz, 
1H), 5.08 (app. dd, J = 17.2, 1.8 Hz, 1H), 4.97 (app. dd, J = 10.1, 1.7 Hz, 1H), 3.85 (s, 
3H), 3.83-3.78 (m, 2H), 3.82 (s, 3H), 3.76 (s, 3H), 2.43 (d, J = 2.4 Hz, 1H), 0.91 (t, J = 
8.0 Hz, 9H), 0.61 (ddd, J = 15.2, 7.5, 2.0 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 152.9, 
152.2, 142.7, 138.1, 135.1, 120.7, 114.5, 95.5, 85.6, 72.1, 60.6, 56.4, 56.3, 55.7, 31.8, 6.6, 
4.6; IR (film) νmax 3287, 2956, 2877, 1596 cm -1; HRMS (ESI) m/z calcd. for 
C21H32NaO4Si [M+Na]+ 399.1962, found 399.1951. 
 
To a solution of 2,4-dimethoxybenzaldehyde (4.19, 20.0 g, 120 mmol, 1.0 
eq) in CH2Cl2 (401 mL) was added m-CPBA (40.5 g, 181 mmol, 1.5 eq) 
and the reaction was heated at reflux for 17 h. At RT the mixture was concentrated to an 
orange solid that was dissolved in EtOAc (400 mL) and washed with saturated aqueous 
NaHCO3 (2 x 400 mL) and brine (1 x 400 mL). The organic layer was concentrated to an 
orange oil that was dissolved in MeOH (266 mL), and to the solution was added 2 N 
aqueous KOH (132 mL) and the mixture was stirred at RT for 1 h. The mixture was 
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neutralized with 1 N aqueous HCl (300 mL) and extracted with EtOAc (4 x 200 mL), and 
the combined organic layers were washed with brine (1 x 400 mL), dried (MgSO4), 
filtered, and concentrated to provide S4.2 as a brown oil (17.5 g, 114 mmol, 95% crude). 
The material was taken directly to the next step without purification. 
 
To a solution of S4.2 (17.5 g crude, 114 mmol, 1.0 eq) in acetone (568 mL) 
was added K2CO3 (39.2 g, 284 mmol, 2.5 eq) and allyl bromide (24.0 mL, 
284 mmol, 2.5 eq) and the reaction was heated at reflux for 18 h. At RT, the 
solid was removed by filtration with acetone washes, and the filtrate was concentrated to 
a brown oil. Purification by flash column chromatography (5-10% EtOAc/hexanes) 
yielded 4.37 as a yellow oil (16.4 g, 84.4 mmol, 70% two steps). Spectral data were 
consistent with reported literature values.7 
 
4.37 (16.4 g, 84.4 mmol, 1.0 eq) was added in one-gram portions to 
microwave vials which were capped and heated via microwave 
irradiation at 200 °C for 1.25 h each. The brown oils were combined to provide S4.3 
(15.5 g, 79.7 mmol, 94%). Spectral data were consistent with reported literature values.39 
 
To a solution of S4.3 (15.5 g, 79.7 mmol, 1.0 eq) in acetone (797 mL) 
was added K2CO3 (110 g, 797 mmol, 10 eq) and MeI (49.6 mL, 797 
mmol, 10 eq) and the mixture was heated at reflux for 20 h. At RT, the solid was 
removed by filtration through a plug of Celite with acetone washes, and the filtrate was 
concentrated to a brown oil. Purification by flash column chromatography (5-10% 
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EtOAc/hexanes) yielded S4.4 as a yellow oil (14.1 g, 67.5 mmol, 85%). Spectral data 
were consistent with reported literature values.39 
 
To a solution of S4.4 (14.1 g, 67.5 mmol, 1.0 eq) in DME (225 mL) was 
added CuBr2 (30.1 g, 135 mmol, 2.0 eq) and the reaction was stirred at 
RT for 48 h. The green reaction was diluted with EtOAc (100 mL) and filtered through a 
plug of Celite with a layer of silica gel above with EtOAc washes. The filtrate was 
washed with 15% aqueous NH4OH (3 x 300 mL), and the aqueous layer was dried 
(MgSO4), filtered, and concentrated to a brown oil. Purification by flash column 
chromatography (5% EtOAc/hexanes) provided 4.35 as a yellow oil (17.7 g, 61.8 mmol, 
92%). Spectral data were consistent with reported literature values.40 
 
Freshly distilled propargyl alcohol (4.00 mL, 69.4 mmol, 1.0 eq) was added to 
DMF (8.3 mL) followed by TBSCl (12.5 g, 83.2 mmol, 1.2 eq) and imidazole 
(11.8 g, 173 mmol, 2.5 eq) and the reaction was stirred at RT for 20 h. Pentane (80 mL) 
was added and the mixture was washed with H2O (4 x 60 mL). The organic layer was 
dried (MgSO4), filtered and concentrated. Distillation (0.1 mm Hg, 24-26 °C) provided 
TBS-propargyl alcohol (S4.5) as a clear liquid (5.16 g, 30.3 mmol, 44%). Spectral data 
were consistent with reported literature values.41 
 
To a solution of pinacol (1.25 g, 10.6 mmol, 2.0 eq) in CH2Cl2 (1.0 
mL) at 0 °C was added BH3•SMe2 (10 M, 1.05 mL, 10.6 mmol, 2.0 
eq) and the mixture was stirred at 0 °C for 1 h and at RT for 3 h. To the mixture was 
OMe
MeO
OMe
Br
4.35
TBSO
S4.5
OB
O
TBSO
4.38
 224 
added a solution of TBS-propargyl alcohol (S4.5, 900 mg, 5.28 mmol, 1.0 eq) in CH2Cl2 
(500 µL) via cannula, and the reaction was sealed in a pressure tube and heated at 50 °C 
for 96 h. At RT, H2O (20 mL) was slowly and carefully added, and the mixture was 
extracted with Et2O (3 x 50 mL). The combined organic layers were dried (MgSO4), 
filtered and concentrated. Purification by flash column chromatography (2.5% and 5% 
Et2O/hexanes) yielded 4.38 as a clear oil (1.02 g, 3.42 mmol, 65%). Spectral data were 
consistent with reported literature values.13 
 
To a solution of 3.38 (500 mg, 9.02 mmol, 1.0 eq) and 4.38 (538 
mg, 1.80 mmol, 2.0 eq) in THF/H2O (9.0 mL, 8:1) was added Ag2O 
(334 mg, 1.44 mmol, 1.6 eq) and Ph3As (28.0 mg, 0.0902 mmol, 0.1 eq). The mixture 
was degassed (3x) with liquid N2, then Pd(PPh3)4 (52.0 mg, 0.0451 mmol, 0.05 eq) was 
added and the reaction was stirred at RT for 24 h. The reaction was diluted with EtOAc 
(100 mL) and washed with brine (1 x 100 mL), and the combined aqueous layers were 
extracted with EtOAc (1 x 100 mL). The combined organic layers were dried (MgSO4), 
filtered and concentrated. Purification by flash column chromatography (2.5%, 5%, 7.5% 
and 10% EtOAc/hexanes) provided 4.39 as a clear oil (356 mg, 0.595 mmol, 66%). 1H 
NMR (400 MHz, CDCl3): δ 7.98 (app. d, J = 7.4 Hz, 2H), 7.60 (app. t, J = 7.2 Hz, 1H), 
7.51-7.41 (m, 4H), 7.39-7.28 (m, 3H), 7.23-7.10 (m, 5H), 6.67 (dd, J = 11.3, 2.6 Hz, 1H), 
6.48 (dt, J = 16.1, 4.5 Hz, 1H), 6.37 (app. d, J = 15.8 Hz, 1H), 6.03 (app. d, J = 8.1 Hz, 
1H), 5.12 (d, J = 11.5 Hz, 1H), 4.90 (d, J = 11.5 Hz, 1H), 4.77 (d, J = 11.6 Hz, 1H), 4.74 
(d, J = 11.8 Hz, 1H), 4.27 (m, 2H), 4.22 (d, J = 10.6 Hz, 1H), 4.11 (dd, J = 10.5, 8.2 Hz, 
1H), 0.92 (s, 9H), 0.08 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 195.8, 165.8, 138.6, 
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137.6, 135.4, 134.9, 133.4, 129.8, 129.3, 128.4 (2C), 128.3, 128.2 (2C), 127.9, 127.7, 
121.1, 84.2, 81.4, 75.0, 74.5, 73.0, 63.4, 25.9, 25.8, 18.4, -5.3; IR (film) νmax 2954, 2928, 
2856, 1723, 1701 cm -1; HRMS (ESI) m/z calcd. for C36H42NaO6Si [M+Na]+ 621.2643, 
found 621.2633. 
 
To a solution of propargyl alcohol (9.61 mL, 165 mmol, 1.0 eq) in CH2Cl2 
(100 mL) at 0 °C was added imidazole (14.6 g, 215 mmol, 1.3 eq) and 
TMSCl (23.2 mL, 182 mmol, 1.1 eq) and a white solid precipitated from the reaction. 
The reaction was stirred at 0 °C for 1 h and at RT for 2 h, then cooled to 0 °C and 
saturated aqueous NH4Cl (50 mL) was added. The mixture was diluted with CH2Cl2 (100 
mL) and washed with H2O (3 x 100 mL), and the organic layer was dried (MgSO4), 
filtered and concentrated. Distillation (185 mm Hg, 64-66 °C) provided OTMS-propargyl 
alcohol (4.44) as a clear liquid (13.8 g, 107 mmol, 65%). Spectral data were consistent 
with reported literature values.15 
 
To a solution of pinacol (25.0 g, 212 mmol, 1.0 eq) in CH2Cl2 (24.9 mL) at 0 °C 
was added BH3•SMe2 (22.0 mL, 220 mmol, 1.0 eq) slowly. The reaction was 
stirred at 0 °C for 30 min and at RT for 3.5 h. Distillation (185 mm Hg, CH2Cl2 at 22-24 
°C, product at 50-60 °C) yielded pinacolborane (S4.6) as a clear liquid (15.6 g, 122 
mmol, 58%). Spectral data were consistent with reported literature values.15 
 
To a solution of OTMS-propargyl alcohol (4.44, 11.7 mL, 76.4 mmol, 
1.0 eq) in CH2Cl2 (38.2 mL) at 0 °C was added pinacolborane (S4.7, 
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15.6 g, 122 mmol, 1.6 eq) slowly, and the reaction was stirred at 0 °C for 2 h and at RT 
for 22 h. The reaction was concentrated to an off-white oil, and distillation (0.1 mm Hg, 
67-73 °C) provided 4.41 as a clear liquid/oil (9.94 g, 38.8 mmol, 51%). 1H NMR (400 
MHz, CDCl3): δ 6.67 (ddd, J = 17.9, 4.0, 3.9 Hz, 1H), 5.72 (ddd, J = 18.0, 2.0, 1.9 Hz, 
1H), 4.21 (dd, J = 3.9, 2.0 Hz, 2H), 1.26 (s, 12H), 0.12 (s, 9H). 
 
Method A: To a solution of 4.39 (330 mg, 0.551 mmol, 1.0 eq) in 
THF (11 mL) at 0 °C was added HF•pyridine (70%, 143 µL, 5.51 
mmol, 10 eq) and the ice bath was allowed to melt over 4 h. Additional HF•pyridine 
(70%, 40.0 µL, 1.54 mmol, 2.8 eq) was added and the reaction was stirred at RT 
overnight. To the reaction was added H2O (10 mL) and the mixture was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were washed with saturated aqueous 
NaHCO3 (1 x 20 mL) then dried (MgSO4), filtered and concentrated. Purification by flash 
column chromatography (25-55% EtOAc/hexanes) yielded 4.42 as a yellow oil (115 mg, 
0.237 mmol, 43%). 
Method B: To a solution of 3.38 (300 mg, 0.541 mmol, 1.0 eq) and 4.41 (277 mg, 1.08 
mmol, 2.0 eq) in THF/H2O (5.4 mL, 8:1) was added Ag2O (201 mg, 0.866 mmol, 1.6 eq) 
and Ph3As (17.0 mg, 0.0541 mmol, 0.1 eq). The mixture was degassed (3x) with liquid 
N2, then Pd(PPh3)4 (31.0 mg, 0.0271 mmol, 0.05 eq) was added and the reaction was 
stirred at RT for 24 h. The reaction was diluted with EtOAc (40 mL) and washed with 1 
N aqueous HCl (3 x 25 mL), and the combined aqueous layers were extracted with 
EtOAc (1 x 40 mL). The combined organic layers were dried (MgSO4), filtered and 
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concentrated. Purification by flash column chromatography (10-50% EtOAc/hexanes) 
provided 4.42 as a clear oil (188 mg, 0.388 mmol, 72%). 
[α]  –166 (c 0.17, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.97 (dd, J = 8.3, 1.2 Hz, 
2H), 7.60 (app. t, J = 7.5 Hz, 1H), 7.49-7.41 (m, 4H), 7.39-7.27 (m, 3H), 7.21-7.11 (m, 
5H), 6.70 (d, J = 2.5 Hz, 1H), 6.49 (dt, J = 16.0, 5.0 Hz, 1H), 6.38 (d, J = 16.0 Hz, 1H), 
6.02 (dd, J = 8.3, 1.9 Hz, 1H), 5.10 (d, J = 11.2 Hz, 1H), 4.90 (d, J = 11.4 Hz, 1H), 4.77 
(d, J = 11.4 Hz, 1H), 4.74 (d, J = 11.4 Hz, 1H), 4.24 (app. d, J = 4.8 Hz, 2H), 4.22 (d, J = 
10.6 Hz, 1H), 4.11 (dd, J = 10.6, 8.3 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 195.8, 
165.8, 139.1, 137.6, 137.5, 135.3, 134.3, 133.5, 129.8, 129.3, 128.5, 128.4, 128.3, 128.2 
(2C), 127.9, 127.7, 122.5, 84.1, 81.3, 75.1, 74.5, 72.9, 63.3; IR (film) νmax 3442, 3063, 
3032, 2921, 1721, 1698 cm -1; HRMS (ESI) m/z calcd. for C30H28NaO6 [M+Na]+ 
507.1778, found 507.1763. 
 
To a solution of 4.42 (115 mg, 0.237 mmol, 1.0 eq) in CH2Cl2 (20 mL) 
was added MnO2 (310 mg, 3.56 mmol, 15 eq) and the slurry was 
stirred at RT for 18 h. The reaction was diluted with CH2Cl2 (20 mL) and filtered through 
a plug of Celite with CH2Cl2 washes (3 x 20 mL). The filtrate was concentrated, and 
purification by flash column chromatography (10-50% EtOAc/hexanes) gave 4.40 as a 
white solid (63.0 mg, 0.131 mmol, 55%). MP: 131-134 °C; [α]  −162 (c 0.21, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 9.61 (d, J = 7.6 Hz, 1H), 7.97 (app. d, J = 7.2 Hz, 2H), 
7.62 (app. t, J = 7.2 Hz, 1H), 7.50-7.42 (m, 4H), 7.40-7.29 (m, 4H), 7.23-7.12 (m, 5H), 
7.05 (d, J = 2.5 Hz, 1H), 6.82 (dd, J = 16.3, 7.7 Hz, 1H), 6.09 (dd, J = 8.4, 2.4 Hz, 1H), 
5.11 (d, J = 11.4 Hz, 1H), 4.91 (d, J = 11.4 Hz, 1H), 4.81 (d, J = 11.4 Hz, 1H), 4.76 (d, J 
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= 11.5 Hz, 1H), 4.27 (d, J = 10.6 Hz, 1H), 4.18 (dd, J = 10.4, 8.3 Hz, 1H); 13C NMR (100 
MHz, CDCl3): δ 194.5, 193.5, 165.6, 145.6, 143.3, 137.3, 137.2, 133.7, 133.6, 132.8, 
129.9, 128.9, 128.5 (2C), 128.3, 128.2 (2C), 128.1, 127.8, 83.9, 80.8, 75.2, 74.6, 72.5; IR 
(film) νmax 3063, 3032, 2918, 1722, 1686, 1453 cm -1; HRMS (ESI) m/z calcd. for 
C30H26NaO6 [M+Na]+ 505.1622, found 505.1615. 
 
To a solution of 4.41 (2.48 g, 9.66 mmol, 1.0 eq) in THF (48 mL) was 
added H2O (4.8 mL) and AcOH (9.7 mL) and the reaction was stirred at 
RT for 22 h. The solvents were removed in vacuo followed by distillation (0.1 mm Hg, 
78-83 °C) yielded S4.7 as a clear oil (1.22 g, 6.60 mmol, 68%). Spectral data were 
consistent with reported literature values.15 
 
To a solution of S4.7 (50 mg, 0.272 mmol, 1.0 eq) in CH2Cl2 (750 µL) at 
0 °C was added DMP (138 mg, 0.326 mmol, 1.2 eq) and the reaction was 
stirred at RT with exclusion of light for 2 h. The reaction was concentrated, dissolved in 
petroleum ether/Et2O (55 mL, 10:1) and the solid was removed by filtration to yield 4.36 
as a light yellow oil (39 mg, 0.214 mmol, 79%). Spectral data were consistent with 
reported literature values.14 
 
To a solution of 4.35 (158 mg, 0.549 mmol, 2.0 eq) in THF (1.5 
mL) at –78 °C was added n-BuLi (2.2 M in hexanes, 262 µL, 
0.577 mmol, 2.1 eq) and the yellow mixture was stirred at –78 °C for 30 min. To the 
mixture at –78 °C was added a solution of 4.36 (50 mg, 0.275 mmol, 1.0 eq) in THF (1.2 
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mL) and the reaction was stirred at –78 °C for 30 min, at 0 °C for 30 min and at RT for 
24 h. To the reaction was added saturated aqueous NH4Cl and the mixture was extracted 
with CH2Cl2 (3 x 20 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated. Purification by flash column chromatography (15-45% EtOAc/hexanes) 
yielded 4.46 as a light yellow oil (47 mg, 0.120 mmol, 44%). 1H NMR (400 MHz, 
CDCl3): δ 6.83 (dd, J = 18.1, 4.7 Hz, 1H), 6.42 (s, 1H), 5.94 (ddt, 17.1, 10.2, 5.7 Hz, 1H), 
5.52 (dd, J = 18.1, 1.8 Hz, 1H), 5.29 (ddd, J = 10.7, 4.6, 1.5 Hz, 1H), 5.04 (ddd, J = 10.2, 
3.3, 1.7 Hz, 1H), 4.97 (ddd, J = 17.1, 3.4, 1.7 Hz, 1H), 3.85 (s, 3H), 3.85-3.81 (m, 1H), 
3.80 (s, 3H), 3.72 (s, 3H), 3.57 (ddt, 15.9, 5.7, 1.8 Hz, 1H), 3.34 (ddt, J = 15.9, 5.7, 1.8 
Hz, 1H), 1.24 (s, 12H); 13C NMR (100 MHz, CDCl3): δ 154.3, 154.2, 152.4, 141.4, 
136.6, 132.0, 121.0, 115.8, 96.3, 83.2, 72.1, 61.0, 55.9, 55.8, 30.3, 24.7; IR (film) νmax 
3533, 2977, 2937, 1637, 1597, 1485 cm -1; HRMS (ESI) m/z calcd. for C21H31BNaO6 
[M+Na]+ 413.2110, found 413.2090. 
 
To a solution of 4.46 (132 mg, 0.338 mmol, 1.0 eq) in DMF (676 
µL) was added imidazole (115 mg, 1.69 mmol, 5.0 eq) and 
DMAP (2 mg, catalytic) and the mixture was cooled to 0 °C. TESCl (170 µL, 1.01 mmol, 
3.0 eq) was added and the reaction was stirred at RT for 3 h. To the reaction was added 
saturated aqueous NH4Cl (10 mL) and the mixture was extracted with CH2Cl2 (3 x 10 
mL). The combined organic layers were dried (MgSO4), filtered and concentrated. 
Purification by flash column chromatography (5-20% EtOAc/hexanes containing 1% 
Et3N) yielded 4.47 as a clear oil (78 mg, 0.155 mmol, 46%). 1H NMR (400 MHz, 
CDCl3):  δ 6.72 (dd, J = 17.9, 3.2 Hz, 1H), 6.35 (s, 1H), 5.98 (app. t, J = 2.5 Hz, 1H), 
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5.87 (ddt, J = 16.9, 10.3, 6.1 Hz, 1H), 5.71 (dd, J = 17.9, 2.1 Hz, 1H), 4.95-4.84 (m, 2H), 
3.84 (s, 3H), 3.77 (s, 3H), 3.71 (s, 3H), 3.63 (ddt, J = 14.7, 6.4, 1.5 Hz, 1H), 3.44 (ddt, J 
= 14.7, 5.8, 1.5 Hz, 1H), 1.23 (br. s, 12H), 0.83 (t, J = 7.9 Hz, 9H), 0.50 (q, J = 7.9 Hz, 
6H); 13C NMR (100 MHz, CDCl3): δ 156.2, 152.6, 152.2, 142.5, 138.4, 135.2, 121.8, 
114.2, 95.3, 82.9, 68.0, 60.4, 56.2, 55.7, 31.3, 24.7 (2C), 6.7, 4.6; IR (film) νmax 2956, 
2877, 1637, 1595 cm -1; HRMS (ESI) m/z calcd. for C27H45BNaO6Si [M+Na]+ 527.2976, 
found 527.2956. 
 
HCl(g) was bubbled through acetone (867 mL) in a 2 L 3-necked flask for 1 
min at a medium rate then (–)-quinic acid (4.51, 50.0 g, 260 mmol, 1.0 eq) 
was added and the white slurry was stirred at RT for 22 h. The clear yellow 
reaction was cooled to 0 °C and NH3(g) was bubbled through the solution until 
neutralization. The precipitated NH4Cl was removed by filtration and the filtrate was 
concentrated to a volume of ~200 mL. To the solution was added hexanes (~200 mL) 
until crystallization initiated, and the material was stored overnight at –20 °C. The solid 
was collected by filtration with cold hexanes, and the filtrate was concentrated and dried 
on high-vac until solid. The solids were recrystallized from 1:1 CHCl3/hexanes (450 mL) 
and the insoluble solids were removed by hot filtration. The precipitated solid was 
collected by filtration to yield 4.52 as a white solid (31.8 g, 149 mmol, 57%). Spectral 
data were consistent with reported literature values.19 
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To a slurry of LAH (8.00 g, 211 mmol, 1.3 eq) in THF (448 mL) in a 2 L 3-
necked flask at 0 °C was added a solution of 4.52 (36.1 g, 169 mmol, 1.0 eq) 
in THF (181 mL) via syringe pump over 4 h with vigorous stirring while 
remaining at 0 °C. The gray slurry was heated at reflux for 22 h then cooled to 0 °C and 
H2O (8.1 mL) was carefully added dropwise, then 15% aqueous NaOH (8.1 mL) and H2O 
(24 mL). To the mixture was added Celite (90.3 g) and the slurry was stirred at RT for 3 
h. The slurry was filtered through a plug of Celite with hot CHCl3/EtOH (95:5, 1.0 L), 
and the filtrate was concentrated to ~100 mL, crystallized with hexanes (~100 mL), and 
stored at –20 °C overnight. Collection of the white crystalline solid by filtration yielded 
4.53 (20.6 g, 94.4 mmol, 56%). Spectral data were consistent with reported literature 
values.19 
 
To a solution of 4.53 (20.6 g, 94.4 mmol, 1.0 eq) in pH 7 buffer (248 mL) at 
0 °C was added NaIO4 (26.0 g, 122 mmol, 1.3 eq) slowly and the white 
slurry was stirred at RT for 1 h. The reaction mixture was extracted with 
CH2Cl2 (12 x 250 mL), and the combined organic layers were dried (MgSO4), filtered, 
and concentrated to provide 4.54 as a yellow oil (15.9 g, 85.5 mmol, 91%). Spectral data 
were consistent with reported literature values.20 
 
To a solution of 4.54 (15.9 g, 85.5 mmol, 1.0 eq) in CH2Cl2 (259 mL) at 0 °C 
was added Et3N (35.7 mL, 256 mmol, 3.0 eq) slowly then a solution of 
methanesulfonyl chloride (7.94 mL, 103 mmol, 1.2 eq) in CH2Cl2 (31 mL) via 
syringe pump over 2 h while remaining at 0 °C. The reaction was stirred at RT for 2 h 
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then washed with H2O (3 x 150 mL). The combined aqueous layers were extracted with 
Et2O (2 x 150 mL), and the combined organic layers were washed with saturated aqueous 
NaHCO3 (1 x 150 mL) and brine (1 x 150 mL) then dried (MgSO4), filtered, and 
concentrated. Immediate purification by flash column chromatography (17% and 20% 
EtOAc/hexanes) provided 4.55 as a maroon oil that solidified at 0 °C (8.37 g, 49.8 mmol, 
58%). Spectral data were consistent with reported literature values.20 
 
To a solution of 4.55 (8.37 g, 49.8 mmol, 1.0 eq) in CH2Cl2 (101 mL) at 0 °C 
was added DMAP (1.22 g, 9.95 mmol, 0.2 eq) and pyridine (50.3 mL) 
slowly. To the mixture was added a solution of I2 (31.6 g, 124 mmol, 2.5 eq) 
in CH2Cl2 (51 mL) and pyridine (51 mL) via syringe pump over 3 h while remaining at 0 
°C. The reaction was stirred at RT for 2 h, diluted with Et2O (500 mL) and washed with 
H2O (2 x 400 mL). The combined aqueous layers were extracted with Et2O (2 x 250 mL), 
and the combined organic layers were washed with 1 N aqueous HCl (4 x 400 mL), H2O 
(2 x 400 mL), 10% aqueous Na2S2O3 (2 x 400 mL), and brine (1 x 400 mL), then dried 
(MgSO4), filtered, and concentrated. Immediate purification by flash column 
chromatography (18% EtOAc/hexanes) yielded 4.50 as an orange solid (9.49 g, 32.3 
mmol, 65%). Spectral data were consistent with reported literature values.42 
 
To a solution of 4.50 (9.49 g, 32.3 mmol, 1.0 eq) in toluene (323 mL) at –78 
°C was added propyl magnesium chloride (2 M in Et2O, 48.4 mL, 96.8 mmol, 
3.0 eq) over 5 seconds and the reaction turned green then yellow/brown and 
was stirred at –78 °C for 1.5 h. To the reaction at –78 °C was added saturated aqueous 
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NH4Cl (100 mL) and at RT the mixture was added to saturated aqueous NH4Cl (500 mL) 
and H2O (200 mL) and extracted with CH2Cl2 (4 x 300 mL). The combined organic 
layers were washed with brine (1 x 250 mL), dried (MgSO4), filtered, and concentrated. 
Purification by flash column chromatography (10% EtOAc/hexanes) yielded 4.57 as an 
orange solid (7.23 g, 21.4 mmol, 66%). MP: 56-59 °C; [α]  −127 (c 0.25, CHCl3); 
1H 
NMR (400 MHz, CDCl3): δ 6.40 (dd, J = 2.6, 0.8 Hz, 1H), 4.55-4.50 (m, 1H), 4.39 (dd, J 
= 5.0, 2.8 Hz, 1H), 3.59 (s, 1H), 2.43 (dd, J = 15.1, 4.1 Hz, 1H), 2.14 (dd, J = 15.1, 2.1 
Hz, 1H), 1.61-1.54 (m, 2H), 1.47 (s, 3H), 1.36 (s, 3H), 1.23 (ddt, J = 16.3, 7.4, 7.2 Hz, 
2H), 0.96 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 138.1, 114.7, 110.3, 74.4, 
73.3, 72.0, 45.5, 32.6, 28.0, 26.6, 17.1, 14.3; IR (film) νmax 3518, 2984, 2959, 2933, 
2873, 1620, 1381 cm -1; HRMS (ESI) m/z calcd. for C12H19INaO3 [M+Na]+ 361.0271, 
found 361.0270. 
 
To a solution of 4.57 (4.00 g, 11.8 mmol, 1.0 eq) in THF (210 mL) and 
H2O (26 mL) was added 4.41 (4.55 g, 17.7 mmol, 1.5 eq), Ag2O (4.39 
g, 18.9 mmol, 1.6 eq), and Ph3As (543 mg, 1.77 mmol, 0.15 eq), and 
the mixture was degassed (3x) with liquid N2, then Pd(PPh3)4 (1.03 g, 0.887 mmol, 0.075 
eq) was added and the reaction was stirred at RT for 20 h. The reaction was diluted with 
EtOAc (350 mL) and washed with brine (2 x 250 mL). The combined aqueous layers 
were extracted with EtOAc (2 x 150 mL), and the combined organic layers were dried 
(MgSO4), filtered, and concentrated. The orange oil was dissolved in MeOH (118 mL) 
and citric acid (1.13 g, 5.90 mmol, 0.5 eq) was added and the mixture was stirred at RT 
for 30 min. The mixture was concentrated, dissolved in Et2O (300 mL) and washed with 
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saturated aqueous NaHCO3 (4 x 175 mL). The combined aqueous layers were extracted 
with Et2O (2 x 150 mL), and the combined organic layers were dried (MgSO4), filtered, 
and concentrated. Purification by flash column chromatography (40-80% 
EtOAc/hexanes) yielded 4.61 as an orange oil (2.24 g, 8.35 mmol, 71%). [α]  −50.0 (c 
0.30, CHCl3); 1H NMR (400 MHz, CDCl3): δ 6.33 (app. d, J = 15.6 Hz, 1H), 6.08 (dt, J = 
15.6, 5.7 Hz, 1H), 5.66 (app. d, J = 2.6 Hz, 1H), 4.54 (dd, J = 5.3, 2.9 Hz, 1H), 4.50-4.43 
(m, 1H), 4.21 (br. s, 2H), 3.41 (s, 1H), 2.19 (dd, J = 15.0, 4.4 Hz, 1H), 1.99 (dd, J = 14.9, 
2.5 Hz, 1H), 1.62-1.53 (m, 2H), 1.41 (s, 3H), 1.36 (s, 3H), 1.32-1.10 (m, 2H), 0.90 (t, J = 
7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 141.8, 130.6, 128.6, 122.7, 109.6, 73.1, 
72.9, 70.3, 63.6, 41.4, 34.9, 28.3, 26.6, 17.0, 14.5; IR (film) νmax 3412, 2960, 2934, 2873, 
1372, 1218 cm -1; HRMS (ESI) m/z calcd. for C15H24NaO4 [M+Na]+ 291.1567, found 
291.1558. 
 
To a solution of 4.61 (2.24 g, 8.35 mmol, 1.0 eq) in CH2Cl2 (167 mL) at 
RT was added MnO2 (10.9 g, 125 mmol, 15 eq) and the reaction was 
stirred shielded from light for 2 h. The reaction was diluted with CH2Cl2 
(100 mL) and filtered through a plug of Celite with extensive CH2Cl2 washes and the 
filtrate was concentrated to yield S4.8 as a white solid requiring no further purification 
(1.93 g, 7.23 mmol, 87%). [α]  −56.6 (c 0.33, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 
9.58 (d, J = 7.8 Hz, 1H), 7.26 (d, J = 15.9 Hz, 1H), 6.50 (dd, J = 15.8, 7.8 Hz, 1H), 5.96 
(app. s, 1H), 4.58 (app. s, 1H), 4.52 (app. s, 1H), 3.49 (s, 1H), 2.26 (dd, J = 15.1, 4.2 Hz, 
1H), 2.03 (dd, J = 15.1, 1.6 Hz, 1H), 1.60 (ddt, J = 14.0, 12.3, 5.1 Hz, 2H), 1.38 (s, 3H), 
1.37 (s, 3H), 1.33-1.19 (m, 1H), 1.18-1.04 (m, 1H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR 
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(100 MHz, CDCl3): δ 193.9, 151.4, 140.4, 131.1, 129.0, 110.0, 72.8, 72.5, 70.0, 41.6, 
34.5, 28.2, 26.4, 17.0, 14.4; IR (film) νmax 3477, 2961, 2933, 2360, 1681, 1381 cm -1; 
HRMS (ESI) m/z calcd. for C15H22NaO4 [M+Na]+ 289.1410, found 289.1396. 
 
To a solution of S4.8 (1.93 g, 7.23 mmol, 1.0 eq) in CH2Cl2 (15 mL) at 
0 °C was added Et3N (8.05 mL, 57.8 mmol, 8.0 eq) then TMSTFA 
(6.77 mL, 43.4 mmol, 6.0 eq) which caused gas evolution and the 
reaction was stirred at 0 °C for 5 min then at RT. The reaction turned dark red, and after 4 
h, was cooled to 0 °C and brine (75 mL) was carefully added. The mixture was added to 
brine (100 ml) and extracted with CH2Cl2 (4 x 75 mL). The combined organic layers 
were dried (MgSO4), filtered, and concentrated. Immediate purification by flash column 
chromatography (5-10% EtOAc/hexanes containing 1% Et3N) provided 4.62 as a yellow 
solid (1.93 g, 5.69 mmol, 79%). MP: 85-87 °C; [α]  +47.8 (c 0.28, CHCl3); 
1H NMR 
(400 MHz, C6D6): δ 9.40 (d, J = 7.5 Hz, 1H), 6.74 (d, J = 16.1 Hz, 1H), 6.61 (dd, J = 
16.1, 7.5 Hz, 1H), 5.82 (d, J = 3.8 Hz, 1H), 4.11 (dd, J = 6.5, 4.0 Hz, 1H), 4.00 (ddd, J = 
11.4, 5.8, 5.8 Hz, 1H), 2.23 (dd, J = 11.9, 5.6 Hz, 1H), 1.89 (app. t, J = 11.4 Hz, 1H), 
1.48 (s, 3H), 1.42 (dt, J = 13.0, 4.4 Hz, 1H), 1.37-1.26 (m, 1H), 1.29 (s, 3H), 1.25-1.10 
(m, 1H), 1.01 (dt, J = 13.2, 4.6 Hz, 1H), 0.77 (t, J = 7.3 Hz, 3H), 0.07 (s, 9H); 13C NMR 
(100 MHz, C6D6): δ 193.0, 149.7, 146.5, 131.9, 109.7, 77.0, 72.1, 71.2, 43.3, 39.9, 28.4, 
25.8, 17.2, 14.6, 2.1; IR (film) νmax 2960, 2874, 2721, 1687, 1622, 1373, 1253 cm -1; 
HRMS (ESI) m/z calcd. for C18H31O4Si [M+H]+ 339.1986, found 339.1982. 
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To a solution of 4.35 (600 mg, 2.09 mmol, 1.0 eq, dried by 
azeotropic removal of H2O with benzene 2x and on high-vac for 
2 h) in THF (15 mL, dried over activated 4 Å MS for 2 h) at –78 
°C was added n-BuLi (2.2 M in hexanes, 1.04 mL, 2.30 mmol, 1.1 eq) dropwise and the 
yellow mixture was stirred at –78 °C for 30 min. To the mixture at –78 °C was added a 
solution of 4.62 (778 mg, 2.30 mmol, 1.1 eq, dried by azeotropic removal of H2O with 
benzene 2x and on high-vac for 1 h) in THF (5.9 mL, dried over activated 4 Å MS for 2 
h) via cannula and the reaction was stirred at –78 °C for 30 min and at RT for 22 h. To 
the reaction was added saturated aqueous NH4Cl and the mixture was extracted with 
CH2Cl2 (4 x 40 mL). The combined organic layers were dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (10-50% EtOAc/hexanes 
containing 1% Et3N) provided 4.63 as an inseparable mixture of diastereomers as a 
yellow oil (820 mg, 1.50 mmol, 72%). IR (film) νmax 3546, 2959, 2873, 2839, 1597, 
1485, 1326, 1250 cm -1; HRMS (ESI) m/z calcd. for C30H47O7Si [M+H]+ 547.3092, found 
547.3086. 
 
To a solution of 4.63 (267 mg, 0.488 mmol, 1.0 eq) in CH2Cl2 
(9.8 mL) was added MnO2 (1.06 g, 12.2 mmol, 25 eq) and the 
black slurry was stirred at RT for 5 h. The reaction was diluted 
with CH2Cl2 (25 mL) and filtered through a plug of Celite with CH2Cl2 washes (3 x 25 
mL). The filtrate was concentrated, and purification by flash column chromatography 
(10-40% EtOAc/hexanes) yielded 4.74 as an orange oil (252 mg, 0.463 mmol, 95%). [α]
 +67.6 (c 0.71, CHCl3); 
1H NMR (400 MHz, C6D6): δ 7.34 (d, J = 16.2 Hz, 1H), 7.04 
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(d, J = 16.2 Hz, 1H), 6.15 (dddd, J = 17.0, 10.2, 6.4, 6.4 Hz, 1H), 6.09 (s, 1H), 5.99 (d, J 
= 3.8 Hz, 1H), 5.17 (dd, J = 17.1, 1.7 Hz, 1H), 5.01 (dd, J = 10.0, 1.3 Hz, 1H), 4.13 (dd, J 
= 6.5, 3.9 Hz, 1H), 4.05 (ddd, J = 17.0, 11.4, 5.8 Hz, 1H), 3.76-3.62 (m, 2H), 3.71 (s, 
3H), 3.33 (s, 3H), 3.26 (s, 3H), 2.25 (dd, J = 11.9, 5.5 Hz, 1H), 1.95 (dd, J = 11.4, 11.4 
Hz, 1H), 1.58-1.44 (m, 1H), 1.49 (s, 3H), 1.33-1.18 (m, 1H), 1.29-1.18 (m, 1H), 1.28 (s, 
3H), 1.10 (ddd, J = 13.2, 13.2, 4.5 Hz, 1H), 0.79 (t, J = 7.3 Hz, 3H), 0.09 (s, 9H); 13C 
NMR (100 MHz, C6D6): δ 195.6, 154.3, 153.6, 146.9, 142.5, 141.9, 137.5, 133.2, 131.9, 
125.3, 123.5, 115.8, 109.5, 96.3, 77.0, 72.2, 71.4, 60.5, 55.8, 55.5, 43.6, 40.2, 31.8, 28.4, 
25.8, 17.2, 14.6, 2.0; IR (film) νmax 2959, 2937, 1650, 1595, 1332, 1253 cm -1; HRMS 
(ESI) m/z calcd. for C30H45O7Si [M+H]+ 545.2929, found 545.2929. 
 
To a solution of 4.74 (113 mg, 0.207 mmol, 1.0 eq) in CH3CN 
(830 µL) was added 2 N aqueous HCl (830 µL) and the dark 
red reaction mixture was stirred at RT for 4 h. To the reaction 
was added saturated aqueous NaHCO3 (10 mL) and the mixture was extracted with 
EtOAc (3 x 10 mL). The combined organic layers were dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (5% MeOH/CH2Cl2) yielded 
4.75 as a yellow oil (75 mg, 0.173 mmol, 84%). [α]  +64.2 (c 2.5, CHCl3); 
1H NMR 
(400 MHz, CDCl3): δ 7.03 (d, J = 16.0 Hz, 1H), 6.72 (d, J = 16.0 Hz, 1H), 6.41 (s, 1H), 
5.90 (s, 1H), 5.83 (dddd, J = 15.7, 6.4, 6.4, 3.2 Hz, 1H), 4.95 (ddd, J = 6.9, 1.6, 1.6 Hz, 
1H), 4.92 (dd, J = 1.4, 1.4 Hz, 1H), 4.25 (br. m, 1H), 4.18 (br. m, 1H), 3.90 (s, 3H), 3.76 
(s, 3H), 3.75 (s, 3H), 3.40 (br. s, 1H), 3.35 (dd, J = 1.4, 1.4 Hz, 1H), 3.33 (dd, J = 1.4, 1.4 
Hz, 1H), 2.96 (br. s, 1H), 2.46 (br. s, 1H), 2.14 (dd, J = 14.5, 4.9 Hz, 1H), 1.83 (dd, J = 
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14.8, 1.7 Hz, 1H), 1.64-1.48 (m, 2H), 1.25-1.05 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 196.7, 154.1, 153.4, 143.3, 141.4, 141.1, 136.7, 132.4, 131.3, 
130.3, 121.9, 115.6, 95.4, 71.1, 69.1, 68.1, 60.9, 56.2, 55.9, 42.1, 37.4, 31.1, 17.1, 14.4; 
IR (film) νmax 3410, 2959, 2929, 1640, 1594, 1332, 1083 cm -1; HRMS (ESI) m/z calcd. 
for C24H33O7 [M+H]+ 433.2221, found 433.2218. 
 
A solution of 4.63 (113 mg, 0.207 mmol, 1.0 eq) in toluene (40 
mL) was heated at 75 °C for 48 h. At RT, the reaction was 
concentrated, and purification by flash column chromatography 
(25-45% EtOAc/hexanes) containing 1% Et3N provided S4.9 as a yellow oil (32 mg, 
0.0585 mmol, 28%). [α]  +57.0 (c 0.48, CHCl3); 
1H NMR (600 MHz, C6D6): δ 6.13 (s, 
1H), 6.05 (s, 1H), 5.10 (d, J = 3.7 Hz, 1H), 4.13 (dd, J = 9.7, 6.4 Hz, 1H), 4.05 (ddd, J = 
13.4, 5.6, 2.1 Hz, 1H), 3.71 (s, 3H), 3.44 (s, 3H), 3.29 (s, 3H), 3.18 (dd, J = 16.4, 3.6 Hz, 
1H), 2.98 (dd, J = 7.9, 6.9 Hz, 1H), 2.47 (dd, J = 12.9, 2.3 Hz, 1H), 2.38 (14.0, 8.0 Hz, 
1H), 2.26 (m, 1H), 2.21 (dd, J = 16.5, 11.9 Hz, 1H), 2.04 (dd, J = 14.1, 5.3 Hz, 1H), 1.89 
(ddd, J = 13.2, 13.2, 4.0 Hz, 1H), 1.84 (ddd, J = 10.5, 1.6, 1.6 Hz, 1H), 1.72 (ddd, J = 
12.3, 12.3, 4.6 Hz, 1H), 1.65-1.58 (m, 1H), 1.59 (s, 3H), 1.55 (ddd, J = 12.8, 12.8, 5.9 
Hz, 1H), 1.51-1.43 (m, 1H), 1.29 (s, 3H), 0.98 (t, J = 7.3 Hz, 3H), 0.19 (s, 9H); 13C NMR 
(150 MHz, C6D6): δ 154.5, 152.8, 141.4, 141.0, 132.8, 126.9, 121.4, 108.3, 95.4, 78.8, 
75.4, 73.2, 65.3, 59.8, 55.9, 55.2, 43.3 (2C), 40.7, 36.4, 32.0, 31.2, 28.5, 25.5, 24.0, 17.6, 
15.0, 2.5; IR (film) νmax 3485, 2958, 2280, 1601, 1489, 1466, 1330 cm -1; HRMS (ESI) 
m/z calcd. for C30H46NaO7Si [M+Na]+ 569.2905, found 569.2930. 
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To a solution of S4.9 (20 mg, 0.0366 mmol, 1.0 eq) in CH2Cl2 
(732 µL) at 0 °C was added DMAP (2 mg, catalytic), pyridine 
(15 µL, 0.183 mmol, 5.0 eq), and Ac2O (17 µL, 0.183 mmol, 
5.0 eq) and the reaction was stirred at 0 °C for 1 h and at RT for 21 h. To the reaction was 
added saturated aqueous NH4Cl and the mixture was extracted with CH2Cl2 (3 x 10 mL). 
The combined organic layers were dried (MgSO4), filtered, and concentrated. Purification 
by flash column chromatography (20% EtOAc/hexanes containing 1% Et3N) yielded 4.80 
as a clear oil (15 mg, 0.0255 mmol, 70%). [α]  +88.1 (c 0.60, CHCl3); 
1H NMR (600 
MHz, C6D6): δ 6.79 (d, J = 3.3 Hz, 1H), 6.23 (s, 1H), 6.11 (s, 1H), 4.10 (ddd, J = 7.9, 6.3, 
5.6 Hz, 1H), 4.04 (dd, J = 9.7, 6.6 Hz, 1H), 3.71 (s, 3H), 3.37 (s, 3H), 3.37 (s, 3H), 3.17 
(dd, J = 16.8, 4.0 Hz, 1H), 2.94 (dd, J = 7.6, 7.1 Hz, 1H), 2.40 (dd, J = 14.1, 8.2 Hz, 1H), 
2.38 (dd, J = 13.3, 2.7 Hz, 1H), 2.18 (dd, J = 16.8, 11.9 Hz, 1H), 2.14-2.06 (m, 1H), 2.11 
(dd, J = 13.8, 5.2 Hz, 1H), 1.91 (ddd, J = 11.0, 4.3, 2.0 Hz, 1H), 1.86 (ddd, J = 13.2, 13.2, 
3.7 Hz, 1H), 1.79 (s, 3H), 1.64 (ddd, J = 12.4, 12.4, 4.2 Hz, 1H), 1.61-1.54 (m, 1H), 1.59 
(s, 3H), 1.47 (ddd, J = 13.0, 13.0, 6.0 Hz, 1H), 1.35-1.27 (m, 1H), 1.31 (s, 3H), 0.97 (dd, 
J = 7.3, 7.0 Hz, 3H), 0.17 (s, 9H); 13C NMR (150 MHz, C6D6): δ 169.4, 155.2, 153.5, 
142.6, 141.0, 133.6, 125.7, 117.0, 108.5, 95.4, 78.8, 75.2, 73.3, 66.8, 59.8, 55.6, 55.5, 
43.7, 43.2, 40.8, 36.4, 31.5, 30.8, 28.4, 25.4, 24.9, 21.1, 17.8, 14.8, 2.5; IR (film) νmax 
3436, 2959, 2102, 1734, 1644, 1233 cm -1; HRMS (ESI) m/z calcd. for C32H48NaO8Si 
[M+Na]+ 611.3011, found 611.3013. 
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To a solution of 4.35 (3.60 g, 12.5 mmol, 1.0 eq) in acetone (12.5 
mL) and H2O (12.5 mL) was added NMO (1.84 g, 15.7 mmol, 1.25 
eq) and OsO4 (1 mg, catalytic) and the reaction was vigorously stirred at RT for 20 h. The 
thick slurry was diluted with EtOAc (50 mL), added to 20% aqueous Na2SO3 (250 mL) 
and extracted with EtOAc (3 x 100 mL). The combined organic layers were dried 
(MgSO4), filtered and concentrated. The white solid (S4.10) was taken forward crude, 
except for characterization, in which recrystallization (EtOAc) provided S4.10 as a 
crystalline white solid. MP: 116-120 °C; 1H NMR (400 MHz, CDCl3): δ 6.47 (s, 1H), 
4.01-3.91 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.79 (s, 3H), 3.61 (ddd, J = 11.5, 8.0, 3.1 
Hz, 1H), 3.47 (dt, J = 11.4, 5.0 Hz, 1H), 3.09 (dd, J = 13.2, 7.2 Hz, 1H), 3.02 (dd, J = 
13.2, 6.4 Hz, 1H), 2.79 (d, J = 5.9 Hz, 1H), 2.56 (dd, J = 8.0, 5.1 Hz, 1H); 13C NMR (100 
MHz, CDCl3): δ 153.0, 152.2, 141.6, 132.4, 104.8, 96.7, 71.4, 65.6, 61.0, 56.7, 56.0, 
34.1; IR (film) νmax 3301, 2965, 2361, 2341, 1579 cm -1; HRMS (ESI) m/z calcd. for 
C12H18BrO5 [M+H]+ 321.0332, found 321.0345. 
 
To a solution of crude S4.10 (3.90 g, 12.1 mmol, 1.0 eq) in MeOH (121 
mL) and pH 7 buffer (60.7 mL) was added NaIO4 (3.35 g, 15.7 mmol, 
1.3 eq) and the reaction was stirred at RT for 45 min. The thick white slurry was diluted 
with H2O (250 mL) and extracted with CH2Cl2 (4 x 175 mL), and the combined organic 
layers were washed with brine (1 x 175 mL), dried (MgSO4), filtered and concentrated. 
Purification by flash column chromatography (20-40% EtOAc/hexanes) provided 4.81 as 
a white solid (2.91 g, 10.1 mmol, 81% two steps). MP: 83-85 °C; 1H NMR (400 MHz, 
CDCl3): δ 9.70 (s, 1H), 6.53 (s, 1H), 3.94 (d, J = 1.3 Hz, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 
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3.70 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 198.4, 152.7, 152.3, 142.1, 128.2, 104.5, 
97.4, 60.9, 56.6, 56.0, 44.9; IR (film) νmax 2969, 2939, 1714, 1348 cm -1; HRMS (ESI) 
m/z calcd. for C11H14BrO4 [M+H]+ 289.0070, found 289.0068. 
 
To a solution of sodium azide (11.3 g, 173 mmol, 1.1 eq) in EtOH (64 mL) 
and H2O (32 mL) was added a hot solution (~45 °C) of toluenesulfonyl 
chloride (30.0 g, 157 mmol, 1.0 eq) in EtOH (160 mL), and the reaction precipitated 
NaCl and became slightly orange. After 3 h at RT, EtOH was removed in vacuo and the 
residue was added to H2O (190 mL) and separated. The oil was washed with H2O (2 x 20 
mL), dried (MgSO4), and filtered to yield S4.11 as a clear oil (19.5 g, 99.1 mmol, 63%). 
Spectral data were consistent with reported literature values.43 
 
To a slurry of NaH (60% in mineral oil, 1.32 g, 33.1 mmol, 1.1 eq) in THF 
(53 mL) and toluene (40 mL) at 0 °C was added neat dimethyl 2-
oxopropylphosphonate (5.00 g, 30.1 mmol, 1.0 eq) which caused gas evolution. After 5 
min, a solution of S4.11 (6.53 g, 33.1 mmol, 1.1 eq) in THF (18 mL) was added via 
cannula and the reaction was stirred at RT for 22 h. The orange slurry was diluted with 
petroleum ether (500 mL) and filtered through a plug of celite with extensive petroleum 
ether washes. Concentration of the opaque filtrate was followed by purification by flash 
colum chromatography (1:1 EtOAc/petroleum ether (1000 mL) and 1:1:0.1 
EtOAc/petroleum ether/MeOH (600 mL)) to yield the Bestmann-Ohira reagent (4.82) as 
a yellow oil (4.10 g, 21.3 mmol, 71%). Spectral data were consistent with reported 
literature values.29 
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To a solution of 4.81 (2.91 g, 10.1 mmol, 1.0 eq) in MeOH (101 mL) 
was added K2CO3 (4.17 g, 30.2 mmol, 3.0 eq) and a solution of the 
Bestmann-Ohira reagent (4.82, 2.90 g, 15.1 mmol, 1.5 eq) in MeOH (20 mL) via cannula 
and the reaction was stirred at RT for 4 h. The reaction was diluted with H2O (275 mL) 
and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with 
brine (1 x 200 mL), dried (MgSO4), filtered, and concentrated. Purification by flash 
column chromatography (10-30% EtOAc/hexanes) provided 4.83 as a white solid (2.76 g, 
9.68 mmol, 96%). MP: 91-94 °C; 1H NMR (400 MHz, CDCl3): δ 6.51 (s, 1H), 3.88 (s, 
3H), 3.88 (s, 3H), 3.86 (s, 3H), 3.77 (d, J = 2.7 Hz, 2H), 2.02 (t, J = 2.7 Hz, 1H); 13C 
NMR (100 MHz, CDCl3): δ 152.8, 152.5, 141.5, 131.7, 104.2, 97.1, 81.5, 68.4, 61.3, 
56.7, 56.1, 20.0; IR (film) νmax 3302, 2966, 2939, 2840, 2361, 2341, 1580, 1341 cm -1; 
HRMS (ESI) m/z calcd. for C12H14BrO3 [M+H]+ 285.0121, found 285.0104. 
 
To a solution of 4.83 (300 mg, 1.05 mmol, 1.0 eq) in THF (4.2 mL) 
at 0 °C was added ethyl magnesium chloride (2.0 M in THF, 3.16 
mL, 6.31 mmol, 6.0 eq) dropwise and the mixture was stirred at 0 °C for 50 min. To the 
mixture at 0 °C was added TMSCl (1.34 mL, 10.5 mmol, 10 eq) dropwise and the 
reaction was stirred at 0 °C for 1 h and at RT for 22 h. To the reaction was added 
saturated aqueous NH4Cl (15 mL) and the mixture was extracted with CH2Cl2 (4 x 15 
mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. 
Purification by flash column chromatography (20% EtOAc/hexanes) yielded 4.84 as a 
white solid (326 mg, 0.912 mmol, 87%). MP: 68-71 °C; 1H NMR (400 MHz, CDCl3): δ 
6.49 (s, 1H), 3.88 (s, 3H), 3.88 (s, 3H), 3.85 (s, 3H), 3.79 (s, 2H), 0.1 (s, 9H); 13C NMR 
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(100 MHz, CDCl3): δ 152.7, 152.4, 141.6, 132.2, 104.4, 103.8, 96.9, 84.6, 61.4, 56.7, 
56.0, 21.5, 0.0; IR (film) νmax 2959, 2840, 2175, 1581, 1480, 1341 cm -1; HRMS (ESI) 
m/z calcd. for C15H22BrO3Si [M+H]+ 357.0516, found 357.0520. 
 
To a solution of 4.83 (62 mg, 0.217 mmol, 1.0 eq) in THF (2.17 
mL) at 0 °C was added ethyl magnesium chloride (2.0 M in THF, 
761 µL, 1.52 mmol, 7.0 eq) and the mixture was stirred at 0 °C for 50 min. To the 
mixture at 0 °C was added methyl chloroformate (151 µL, 1.96 mmol, 9.0 eq) and the 
reaction was stirred at 0 °C for 1.25 h. Saturated aqueous NH4Cl (15 mL) was added and 
the mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were 
dried (MgSO4), filtered, and concentrated. Purification by flash column chromatography 
(20-25% EtOAc/hexanes) provided 4.85 as a white solid (50 mg, 0.146 mmol, 67%). MP: 
98-101 °C; 1H NMR (600 MHz, CDCl3): δ 6.51 (s, 1H), 3.91 (s, 2H), 3.88 (s, 3H), 3.87 
(s, 3H), 3.84 (s, 3H), 3.71 (s, 3H); 13C NMR (150 MHz, CDCl3): δ 154.1, 152.9, 152.5, 
141.7, 129.6, 104.2, 97.5, 86.4, 72.5, 61.4, 56.8, 56.1, 52.5, 20.3; IR (film) νmax 2944, 
2843, 2238, 1713, 1583, 1479 cm -1; HRMS (ESI) m/z calcd. for C14H15BrNaO5 [M+Na]+ 
364.9995, found 365.0012. 
 
To a solution of 4.83 (75 mg, 0.263 mmol, 1.0 eq) in acetone (2.6 mL) 
was added NBS (56 mg, 0.316 mmol, 1.2 eq) and AgNO3 (4.5 mg, 
0.0263 mmol, 0.10 eq) and the reaction was stirred at RT for 3 h. The reaction was 
diluted with CH2Cl2 (10 mL) and filtered through a plug of Celite with CH2Cl2 washes (4 
x 10 mL) and the filtrate was concentrated. Purification by flash column chromatography 
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(20% EtOAc/hexanes) yielded 4.86 as an off-white solid (90 mg, 0.247 mmol, 94%). MP: 
96-98 °C; 1H NMR (400 MHz, CDCl3): δ 6.49 (s, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.83 (s, 
3H), 3.76 (s, 2H); 13C NMR (100 MHz, CDCl3): δ 152.7, 152.4, 141.5, 131.2, 104.1, 
97.0, 77.1, 61.3, 56.7, 56.0, 38.5, 21.1; IR (film) νmax 2938, 2841, 2361, 2341, 1581, 
1475, 1343 cm -1; HRMS (ESI) m/z calcd. for C12H13Br2O3 [M+H]+ 362.9226, found 
362.9231. 
 
To a solution of 4.83 (2.27 g, 7.95 mmol, 1.3 eq, dried by 
azeotropic removal of H2O with benzene 2x and on high-vac for 
2 h) in THF (32 mL, dried over activated 4 Å MS for 2 h) at      
–100 °C was added n-BuLi (6.52 mL, 15.9 mmol, 2.5 eq) slowly, and the mixture was 
stirred at –100 °C. After 8 min, a solution of 4.62 (2.15 g, 6.36 mmol, 1.0 eq, dried by 
azeotropic removal of H2O with benzene 2x and on high-vac for 2 h) in THF (32 mL) 
was added quickly via syringe, and the red/orange reaction was stirred at –100 °C. After 
20 min, saturated aqueous NH4Cl (50 mL) was added, and at RT, the mixture was diluted 
with saturated aqueous NH4Cl (100 mL) and extracted with CH2Cl2 (3 x 75 mL). The 
combined organic layers were washed with brine (1 x 75 mL), dried (MgSO4), filtered, 
and concentrated. Purification by flash column chromatography (30% EtOAc/hexanes 
containing 1% Et3N) provided 4.90 as a yellow solid in an inconsequential 1.5:1 mixture 
of inseparable diastereomers (2.62 g, 4.81 mmol, 76%). IR (film) νmax 3539, 3308, 2959, 
2872, 2118, 1599, 1251 cm -1; HRMS (ESI) m/z calcd. for C30H44NaO7Si [M+Na]+ 
567.2749, found 567.2748. 
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To a solution of 4.90 (100 mg, 0.184 mmol, 1.0 eq) in CH2Cl2 
(9.2 mL) was added MnO2 (399 mg, 4.59 mmol, 25 eq) and the 
black slurry was stirred at RT for 5.5 h. The mixture was diluted 
with CH2Cl2 and filtered through a plug of Celite with CH2Cl2 washes. The filtrate was 
concentrated to provide 4.91 as a light yellow oil which required no purification (93 mg, 
0.171 mmol, 93%). [α]  +80.0 (c 0.25, C6D6); 
1H NMR (400 MHz, CDCl3): δ 7.43 (d, J 
= 16.2 Hz, 1H), 7.13 (d, J = 16.2 Hz, 1H), 6.05 (s, 1H), 6.01 (d, J = 3.9 Hz, 1H), 4.15 
(dd, J = 6.4, 4.0 Hz, 1H), 4.06 (ddd, J = 11.3, 11.3, 5.8 Hz, 1H), 3.84 (dd, J = 16.7, 2.7 
Hz, 1H), 3.78 (dd, J = 16.7, 2.8 Hz, 1H), 3.78 (s, 3H), 3.29 (s, 3H), 3.23 (s, 3H), 2.27 (dd, 
J = 11.8, 5.5 Hz, 1H), 1.97 (dd, J = 11.5, 11.5 Hz, 1H), 1.77 (dd, J = 2.7, 2.7 Hz, 1H), 
1.57 (ddd, J = 14.2, 14.2, 4.1 Hz, 1H), 1.49 (s, 3H), 1.47-1.34 (m, 1H), 1.28 (s, 3H), 1.26-
1.17 (m, 1H), 1.11 (ddd, J = 13.1, 13.1, 4.5 Hz, 1H), 0.78 (dd, J = 7.3, 7.3 Hz, 3H), 0.12 
(s, 9H); 13C NMR (100 MHz, C6D6): δ 195.6, 155.1, 154.5, 147.7, 142.7, 142.5, 132.4, 
131.0, 126.0, 123.7, 110.1, 97.4, 83.6, 77.7, 72.9, 72.0, 69.7, 61.3, 56.4, 56.1, 44.1, 40.7, 
29.0, 26.4, 17.7, 16.9, 15.2, 2.7; IR (film) νmax 3311, 2959, 2360, 2341, 1650, 1597, 
1334, 1252 cm -1; HRMS (ESI) m/z calcd. for C30H43O7Si [M+H]+ 543.2773, found 
543.2774. 
 
To a solution of 4.91 (146 mg, 0.269 mmol, 1.0 eq) in CH3CN 
(2.7 mL) was added aqueous 2 N HCl (2.7 mL) at RT and the 
orange reaction was stirred at RT for 3 h. To the mixture was 
added saturated aqueous NaHCO3 (10 mL) and the mixture was extracted with EtOAc (3 
x 10 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. 
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Purification by flash column chromatography (5% MeOH/CH2Cl2) yielded 4.103 as an 
orange oil (106 mg, 0.246 mmol, 92%). [α]  +113 (c 1.47, CHCl3); 
1H NMR (400 MHz, 
CDCl3): δ 7.11 (d, J = 16.0 Hz, 1H), 6.80 (d, J = 16.0 Hz, 1H), 6.44 (s, 1H), 5.93 (br. s, 
1H), 4.20 (br. s, 1H), 4.13 (br. s, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.75 (s, 3H), 3.68 (br. s, 
1H), 3.51 (s, 1H), 3.50 (s, 1H), 3.35 (br. s, 1H), 3.15 (br. s, 1H), 2.10 (dd, J = 14.8, 4.9 
Hz, 1H), 1.93 (dd, J = 2.7, 2.6 Hz, 1H), 1.80 (dd, J = 14.7, 1.3 Hz, 1H), 1.55 (dd, J = 8.7, 
8.2 Hz, 2H), 1.23-1.04 (m, 2H), 0.86 (dd, J = 7.3, 7.1 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 196.2, 154.4, 153.8, 143.6, 141.0, 140.9, 131.1, 130.8, 129.6, 121.4, 96.1, 
82.4, 71.2, 69.0, 68.9, 68.0, 61.1, 56.2, 55.9, 41.9, 37.4, 17.1, 16.1, 14.4; IR (film) νmax 
3410, 3305, 2959, 2249, 1597, 1335 cm -1; HRMS (ESI) m/z calcd. for C24H31O7 [M+H]+ 
431.2064, found 431.2063. 
 
To a solution of 4.103 (67 mg, 0.156 mmol, 1.0 eq) in CH2Cl2 
(760 µL) at 0 °C was added Et3N (108 µL, 0.778 mmol, 5.0 eq) 
then a solution of triphosgene (51 mg, 0.171 mmol, 1.1 eq) in 
CH2Cl2 (760 µL) via cannula and the reaction was stirred at 0 °C for 5 min and at RT for 
1.5 h. To the reaction was added saturated aqueous NH4Cl (15 mL) and the mixture was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated. Purification by flash column chromatography (50% 
EtOAc/hexanes) provided S4.12 as a yellow oil (51 mg, 0.112 mmol, 72%). 1H NMR 
(600 MHz, C6D6): δ 7.36 (d, J = 16.0 Hz, 1H), 7.14 (d, J = 16.1 Hz, 1H), 6.06 (s, 1H), 
5.53 (d, J = 3.5 Hz, 1H), 4.04 (dd, J = 7.3, 3.5 Hz, 1H), 3.92-3.84 (m, 2H), 3.85 (dd, J = 
5.0, 2.7 Hz, 1H), 3.75 (s, 3H), 3.31 (s, 3H), 3.29 (s, 3H), 1.86 (dd, J = 2.6, 2.6 Hz, 1H), 
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1.77 (dd, J = 13.1, 5.4 Hz, 1H), 1.71 (br. s, 1H), 1.34 (ddd, J = 13.5, 13.5, 4.1 Hz, 1H), 
1.21 (dd, J = 12.7, 10.5 Hz, 1H), 1.20-1.13 (m, 1H), 0.98 (dddd, J = 17.5, 5.3, 5.0, 4.9 
Hz, 1H), 0.87 (ddd, J = 13.6, 13.6, 4.7 Hz, 1H), 0.69 (dd, J = 7.3, 7.3 Hz, 3H); 13C NMR 
(150 MHz, C6D6): δ 194.5, 155.0, 154.5, 153.9, 148.7, 142.0, 139.4, 133.1, 130.7, 122.6, 
121.3, 96.7, 83.2, 72.6, 71.8, 71.5, 69.2, 60.8, 56.0, 55.5, 41.8, 37.4, 16.9, 16.2, 14.5; IR 
(film) νmax 3468, 3292, 2961, 2361, 1801, 1650, 1596, 1335 cm -1; HRMS (ESI) m/z 
calcd. for C25H29O8 [M+H]+ 457.1857, found 457.1871. 
 
To a solution of S4.12 (51 mg, 0.112 mmol, 1.0 eq) in CH2Cl2 
(600 µL) at 0 °C was added Et3N (124 µL, 0.894 mmol, 8.0 eq) 
then TMSTFA (105 µL, 0.670 mmol, 6.0 eq) and the reaction 
was stirred at RT for 5 h. To the reaction was added brine (10 mL) and the mixture was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated. Purification by flash column chromatography (40% 
EtOAc/hexanes containing 1% Et3N) gave 4.105 as a yellow oil (41 mg, 0.0776 mmol, 
69%). [α]  +33.3 (c 1.16, CHCl3); 
1H NMR (400 MHz, C6D6): δ 7.29 (d, J = 16.2 Hz, 
1H), 6.96 (d, J = 16.2 Hz, 1H), 6.06 (s, 1H), 5.55 (d, J = 3.7 Hz, 1H), 4.01 (dd, J = 7.7, 
3.8 Hz, 1H), 3.96-3.84 (m, 2H), 3.80 (dd, J = 8.0, 2.6 Hz, 1H), 3.77 (s, 3H), 3.30 (s, 3H), 
3.23 (s, 3H), 2.08 (dd, J = 12.2, 5.7 Hz, 1H), 1.77 (dd, J = 2.6, 2.6 Hz, 1H), 1.71 (dd, J = 
11.6, 11.6 Hz, 1H), 1.32-1.19 (m, 2H), 1.08-0.97 (m, 1H), 0.79 (ddd, J = 13.1, 13.1, 4.6 
Hz, 1H), 0.70 (dd, J = 7.2, 7.2 Hz, 3H), 0.0 (s, 9H); 13C NMR (100 MHz, C6D6): δ 194.6, 
154.8, 154.1, 153.6, 149.6, 142.2, 139.7, 132.8, 130.6, 122.6, 120.1, 96.7, 83.0, 75.1, 
72.3, 71.4, 69.1, 60.8, 55.8, 55.5, 43.7, 38.3, 17.0, 16.2, 14.4, 1.9; IR (film) νmax 3293, 
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2960, 2361, 1805, 1597, 1335 cm -1; HRMS (ESI) m/z calcd. for C28H37O8Si [M+H]+ 
529.2252, found 529.2255. 
 
To a solution of 4.90 (250 mg, 0.459 mmol, 1.0 eq) in CH2Cl2 
(1.53 mL) was added imidazole (156 mg, 2.29 mmol, 5.0 eq) 
and DMAP (2 mg, catalytic) at 0 °C. To the solution was added 
TESCl (231 µL, 1.38 mmol, 3.0 eq) and the slurry was stirred at 0 °C for 10 min. To the 
reaction was added saturated aqueous NH4Cl and the mixture was extracted with CH2Cl2 
(3 x 20 mL). The combined organic layers were dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (12% EtOAc/hexanes 
containing 1% Et3N) provided 4.108 as a yellow oil in an inconsequential 1.5:1 mixture 
of inseparable diastereomers (292 mg, 0.443 mmol, 97%). IR (film) νmax 3309, 2957, 
2877, 2118, 1597, 1463, 1244 cm -1; HRMS (ESI) m/z calcd. for C36H58NaO7Si2 [M+Na]+ 
681.3613, found 681.3629. 
 
To a solution of 4.108 (113 mg, 0.171 mmol, 1.0 eq) in THF 
(1.7 mL) at –78 °C was added n-BuLi (2.4 M in hexanes, 105 
µL, 0.257 mmol, 1.5 eq) and the mixture was stirred at –78 °C 
for 30 min. To the mixture was added Manders’ reagent (41 µL, 0.514 mmol, 3.0 eq) and 
the reaction was stirred at –78 °C for 2 h. To the reaction was added saturated aqueous 
NH4Cl (25 mL) and at RT the mixture was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were dried (MgSO4), filtered, and concentrated. Immediate 
purification by flash column chromatography (10% EtOAc/hexanes containing 1% Et3N) 
OMe
MeO
OMe
OTES
OTMS
O
O
4.108
OMe
MeO
OMe
OTES
O OMe
H
H
OTMS
O
O
4.110
 249 
provided a 4:1 mixture of uncyclized to cyclized product as 1:1 mixtures of 
diastereomers. Material was taken to next step without characterization. 
 
A solution of the previous products (4:1 mixture of products as 1:1 mixtures of 
diastereomers, 61 mg, 0.0851 mmol, 1.0 eq) in toluene (20 mL) was heated at 40 °C for 6 
h then at RT concentrated. Purification by flash column chromatography (10-20% 
EtOAc/hexanes containing 1% Et3N) provided 4.110 as a separable mixture of two 
diastereomers. 
β-OTES: (27 mg, 0.0377 mmol, 22% two steps). [α]  +57.9 (c 0.19, CHCl3); 
1H NMR 
(600 MHz, C6D6): δ 6.44 (d, J = 3.5 Hz, 1H), 6.08 (s, 1H), 5.13 (d, J = 7.0 Hz, 1H), 4.69 
(d, J = 16.0 Hz, 1H), 4.12 (dd, J = 7.8, 7.6 Hz, 1H), 3.91 (dd, J = 12.1, 6.1 Hz, 1H), 3.88 
(s, 3H), 3.59 (dd, J = 9.7, 6.1 Hz, 1H), 3.55 (s, 3H), 3.44 (ddd, J = 15.1, 11.2, 4.9 Hz, 
1H), 3.36 (s, 3H), 3.32 (s, 3H), 3.09 (d, J = 15.5 Hz, 1H), 2.41 (dd, J = 14.3, 6.3 Hz, 1H), 
1.87 (dd, J = 14.1, 5.8 Hz, 1H), 1.88-1.82 (m, 1H), 1.71-1.63 (m, 1H), 1.56 (ddd, J = 
13.3, 13.3, 4.5 Hz, 1H), 1.55 (s, 3H), 1.42-1.33 (m, 1H), 1.15 (s, 3H), 1.12 (dd, J = 8.1, 
7.9 Hz, 9H), 0.96 (dd, J = 7.3, 7.2 Hz, 3H), 0.81 (q, J = 8.0 Hz, 6H), 0.25 (s, 9H); 13C 
NMR (150 MHz, C6D6): δ 169.1, 154.8, 153.3, 140.3, 140.2, 137.9, 133.6, 126.2, 122.9, 
119.7, 108.8, 95.3, 82.1, 75.8, 74.8, 73.0, 60.3, 55.7, 54.3, 51.2, 48.7, 44.1, 40.3, 39.6, 
29.6, 27.9, 25.4, 17.2, 14.9, 7.6, 6.3, 2.3; IR (film) νmax 2956, 2877, 2279, 1726, 1599, 
1462, 1246 cm -1; HRMS (ESI) m/z calcd. for C38H61O9Si2 [M+H]+ 717.3849, found 
717.3857. 
α-OTES: (23 mg, 0.0321 mmol, 19% two steps). [α]  +50.7 (c 0.26, CHCl3); 
1H NMR 
(600 MHz, C6D6): δ 6.13 (s, 1H), 5.64 (d, J = 3.4 Hz, 1H), 5.28 (d, J = 2.2 Hz, 1H), 4.93 
€ 
D
20
€ 
D
20
 250 
(d, J = 21.4 Hz, 1H), 4.28-4.22 (m, 2H), 4.18 (dd, J = 6.9, 6.9 Hz, 1H), 3.70-3.64 (m, 
1H), 3.67 (s, 3H), 3.60 (s, 3H), 3.40 (s, 3H), 3.39 (s, 3H), 2.83 (ddd, J = 5.3, 3.5, 1.4 Hz, 
1H), 2.54 (dd, J = 14.2, 5.7 Hz, 1H), 2.06 (dd, J = 14.2, 5.2 Hz, 1H), 1.81 (ddd, J = 12.9, 
12.9, 3.3 Hz, 1H), 1.74-1.67 (m, 1H), 1.62 (s, 3H), 1.60 (ddd, J = 12.7, 12.7, 4.6 Hz, 1H), 
1.49-1.41 (m, 1H), 1.33 (s, 3H), 0.99 (dd, J = 7.3, 7.3 Hz, 3H), 0.93 (dd, J = 8.0, 7.9 Hz, 
9H), 0.64 (dd, 14.8, 7.8 Hz, 2H), 0.60 (dd, J = 16.3, 7.9 Hz, 2H), 0.56 (dd, J = 14.8, 8.0 
Hz, 2H), 0.24 (s, 9H); 13C NMR (150 MHz, C6D6): δ 169.4, 153.3, 152.7, 141.5, 140.9, 
135.1, 131.9, 122.3, 120.8, 108.7, 94.4, 82.9, 74.7, 73.2, 66.2, 59.8, 55.8, 54.5, 51.0, 45.2, 
43.5, 40.0 (2C), 28.0, 27.5, 25.6, 17.2, 14.9, 7.3, 5.4, 2.4; IR (film) νmax 2955, 2876, 
2279, 1725, 1600, 1462, 1332, 1247 cm -1; HRMS (ESI) m/z calcd. for C38H61O9Si2 
[M+H]+ 717.3849, found 717.3859. 
 
To a solution of 4.83 (1.00 g, 3.51 mmol, 1.0 eq) in THF (35.1 mL) 
at 0 °C was added ethyl magnesium chloride (2.0 M in THF, 10.5 
mL, 21.0 mmol, 6.0 eq) and the mixture was stirred at 0 °C for 1 h. To the mixture at 0 
°C was added paraformaldehyde (1.05 g, 35.1 mmol, 10 eq, dried on high-vac with P2O5 
overnight) and the reaction was stirred at RT for 22 h. To the reaction was added 
saturated aqueous NH4Cl (100 mL) and the mixture was extracted with CH2Cl2 (3 x 100 
mL). The combined organic layers were washed with brine (1 x 100 mL), dried (MgSO4), 
filtered, and concentrated. Purification by flash column chromatography (40-50% 
EtOAc/hexanes) provided 4.112 as a white solid (970 mg, 3.08 mmol, 88%). 1H NMR 
(400 MHz, CDCl3): δ 6.49 (s, 1H), 4.19 (s, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 
3.77 (t, J = 2.1 Hz, 2H), 1.83 (br. s, 1H); 13C NMR (100 MHz, CDCl3): δ 152.8, 152.5, 
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141.4, 131.9, 104.2, 97.0, 83.2, 78.5, 61.4, 56.7, 56.1, 51.3, 20.3; IR (film) νmax 3303, 
2963, 1582, 1477 cm -1; HRMS (ESI) m/z calcd. for C13H16BrO4 [M+H]+ 315.0226, found 
315.0234. 
 
To a solution of 4.112 (970 mg, 3.08 mmol, 1.0 eq) in CH2Cl2 
(10.3 mL) at 0 °C was added imidazole (419 mg, 6.16 mmol, 2.0 
eq), DMAP (2 mg, catalytic), and TESCl (775 µL, 4.62 mmol, 1.5 eq) and the white 
slurry was stirred at 0 °C for 30 min. To the reaction was added saturated aqueous NH4Cl 
(100 mL) and the mixture was extracted with CH2Cl2 (3 x 100 mL). The combined 
organic layers were dried (MgSO4), filtered, and concentrated. Purification by flash 
column chromatography (20% EtOAc/hexanes) yielded 4.113 as a clear oil (1.23 g, 2.86 
mmol, 93%). 1H NMR (400 MHz, CDCl3): δ 6.48 (s, 1H), 4.25 (t, J = 2.2 Hz, 2H), 3.87 
(s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 3.77 (t, J = 2.2 Hz, 2H), 0.91 (t, J = 8.0 Hz, 9H), 0.59 
(q, J = 7.9 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 152.7, 152.4, 141.6, 132.1, 104.4, 
97.0, 82.1, 78.7, 61.4, 56.7, 56.1, 51.6, 20.4, 6.6, 4.4; IR (film) νmax 2953, 2876, 1582, 
1475 cm -1; HRMS (ESI) m/z calcd. for C19H30BrO4Si [M+H]+ 429.1091, found 
429.1096. 
 
 To a solution of 4.113 (1.35 g, 3.13 mmol, 1.5 eq, dried by 
azeotropic removal of H2O with benzene 2x and on high-vac for 
3 h) in THF (11 mL, dried over activated 4 Å MS for 3 h) at      
–100 °C was added n-BuLi (2.5 M in hexanes, 1.44 mL, 3.55 
mmol, 1.7 eq) slowly, and the mixture was stirred at –100 °C for 12 min. To the mixture 
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at –100 °C was added a solution of 4.62 (707 mg, 2.09 mmol, 1.0 eq, dried by azeotropic 
removal of H2O with benzene 2x and on high-vac for 3 h) in THF (11 mL, dried over 
activated 4 Å MS for 3 h) via cannula quickly, and the reaction was stirred at –100 °C for 
30 min. To the reaction was added saturated aqueous NH4Cl (25 mL) and at RT the 
mixture was added to saturated aqueous NH4Cl (75 mL) and extracted with CH2Cl2 (3 x 
100 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. 
Purification by flash column chromatography (10-40% EtOAc/hexanes containing 1% 
Et3N) provided 4.114 as a yellow oil in an inseparable mixture of diastereomers (1.23 g, 
1.78 mmol, 85%). IR (film) νmax 3466, 2957, 2876, 1598, 1462, 1076 cm -1; HRMS (ESI) 
m/z calcd. for C37H60NaO8Si2 [M+Na]+ 711.3719, found 711.3729. 
 
To a solution of 4.114 (264 mg, 0.383 mmol, 1.0 eq) in CH2Cl2 
(19 mL) was added MnO2 (833 mg, 9.58 mmol, 25 eq) and the 
black slurry was stirred at RT protected from light for 2 h. The 
reaction was diluted with CH2Cl2 and filtered through a plug of 
Celite with extensive CH2Cl2 washes, and the filtrate was concentrated. Purification by 
flash column chromatography (20-30% EtOAc/hexanes containing 1% Et3N) yielded 
4.115 as a yellow oil (152 mg, 0.221 mmol, 58%). [α]  +18.6 (c 0.74, CHCl3); 
1H NMR 
(400 MHz, C6D6): δ 7.43 (d, J = 16.2 Hz, 1H), 7.15 (d, J = 16.2 Hz, 1H), 6.07 (s, 1H), 
6.05 (3.8 Hz, 1H), 4.27 (dd, J = 2.1, 2.0 Hz, 2H), 4.19 (dd, J = 6.4, 4.0 Hz, 1H), 4.07 
(ddd, J = 11.4, 11.4, 5.8 Hz, 1H), 3.88-3.84 (m, 2H), 3.85 (s, 3H), 3.30 (s, 3H), 3.24 (s, 
3H), 2.28 (dd, J = 11.8, 5.5 Hz, 1H), 1.97 (dd, J = 11.5, 11.4 Hz, 1H), 1.58 (ddd, J = 
12.6, 12.6, 4.1 Hz, 1H), 1.50 (s, 3H), 1.48-1.38 (m, 1H), 1.34-1.22 (m, 1H), 1.29 (s, 3H), 
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1.13 (ddd, J = 13.3, 13.3, 4.5 Hz, 1H), 1.01 (dd, J = 8.0, 7.9 Hz, 9H), 0.81 (dd, J = 7.4, 
7.2 Hz, 3H), 0.65 (dd, J = 15.8, 7.8 Hz, 6H), 0.14 (s, 9H); 13C NMR (100 MHz, C6D6): δ 
195.0, 154.5, 153.9, 147.3, 142.2, 142.0, 131.9, 130.8, 125.5, 123.2, 109.5, 96.8, 83.8, 
79.7, 77.1, 72.3, 71.4, 60.8, 55.9, 55.5, 52.0, 43.6, 40.2, 28.5, 25.8, 17.2, 16.9, 14.6, 7.1, 
5.0, 2.1; IR (film) νmax 2957, 2877, 1651, 1597, 1334, 1078 cm -1; HRMS (ESI) m/z 
calcd. for C37H59O8Si2 [M+H]+ 687.3743, found 687.3739. 
 
To a solution of 4.115 (186 mg, 0.271 mmol. 1.0 eq) in THF 
(2.7 mL) at 0 °C was added TBAF (1 M in THF, 1.35 mL, 1.35 
mmol, 5.0 eq) and the reaction was stirred at 0 °C. After 1 h, 
saturated aqueous NH4Cl (25 mL) was added and the mixture 
was extracted with CH2Cl2 (3 x 25 mL), and the combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (70-
90% EtOAc/hexanes) provided 4.116 as an orange oil (125 mg, 0.250 mmol, 92%). 1H 
NMR (400 MHz, CDCl3): δ 7.14 (d, J = 16.0 Hz, 1H), 6.81 (d, J = 16.0 Hz, 1H), 6.42 (s, 
1H), 5.99 (d, J = 2.8 Hz, 1H), 4.58 (dd, J = 5.2, 3.1 Hz, 1H), 4.48 (dd, J = 7.1, 4.6 Hz, 
1H), 4.07 (dd, J = 1.9, 1.8 Hz, 2H), 3.89 (s, 3H), 3.82 (s, 3H), 3.74 (s, 3H), 3.74-3.67 (m, 
1H), 3.59 (ddd, J = 16.9, 2.1, 2.0 Hz, 1H), 3.50 (ddd, J = 16.9, 2.0, 2.0 Hz, 1H), 2.60 (br. 
s, 1H), 2.16 (dd, J = 14.9, 4.7 Hz, 1H), 2.02 (dd, J = 15.0, 2.7 Hz, 1H), 1.64-1.53 (m, 
2H), 1.39 (s, 3H), 1.35 (s, 3H), 1.31-1.19 (m, 2H), 0.87 (dd, J = 7.3, 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 196.1, 154.2, 153.6, 142.8, 141.2, 140.9, 131.4, 130.0, 127.8, 
121.6, 109.8, 95.9, 83.8, 79.5, 72.7, 72.4, 70.7, 61.1, 56.1, 55.9, 50.8, 41.3, 35.2, 28.1, 
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26.3, 17.0, 16.3, 14.4; IR (film) νmax 3433, 2934, 2871, 2246, 1645, 1596, 1334, 1076 cm 
-1; HRMS (ESI) m/z calcd. for C28H36NaO8 [M+Na]+ 523.2302, found 523.2280. 
 
To a solution of 4.116 (20 mg, 0.0400 mmol, 1.0 eq) in CH2Cl2 
(500 µL) at 0 °C was added pyridine (16 µL, 0.200 mmol. 5.0 
eq) then DMP (0.3 M in CH2Cl2, 266 µL, 0.0800 mmol, 2.0 eq) 
and the reaction was stirred at 0 °C for 2 h and at RT for 30 min. 
To the reaction was added a 1:1 mixture of saturated aqueous NaHCO3 and saturated 
aqueous Na2S2O3 (10 mL) and the mixture was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were washed with 10% aqueous CuSO4 (2 x 10 mL), then dried 
(MgSO4), filtered, and concentrated. Immediate purification by flash column 
chromatography (50% EtOAc/hexanes) provided 4.117 as a yellow oil (8.0 mg, 0.0160 
mmol, 40%). 1H NMR (400 MHz, CDCl3): δ 9.07 (s, 1H), 7.18 (d, J = 16.0 Hz, 1H), 6.83 
(d, J = 16.0 Hz, 1H), 6.47 (s, 1H), 5.95 (d, J = 2.8 Hz, 1H), 4.57 (dd, J = 5.3, 2.8 Hz, 1H), 
4.49 (ddd, J = 6.9, 4.5, 1.8 Hz, 1H), 3.92 (s, 3H), 3.84 (s, 3H), 3.80-3.76 (m, 2H), 3.77 (s, 
3H), 3.44 (s, 1H), 2.19 (dd, J = 14.9, 4.8 Hz, 1H), 2.02 (dd, J = 14.9, 2.6 Hz, 1H), 1.61-
1.52 (m, 2H), 1.38 (s, 3H), 1.36 (s, 3H), 1.29-1.11 (m, 2H), 0.89 (dd, J = 7.3, 7.3 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ 195.3, 177.0, 154.5, 154.1, 143.3, 141.4, 141.2, 
130.9, 128.2, 127.6, 121.5, 109.9, 96.8, 96.4, 81.2, 72.8, 72.6, 70.4, 61.2, 56.2, 56.0, 41.5, 
35.2, 28.1, 26.4, 17.0, 16.9, 14.5; IR (film) νmax 3509, 2934, 2196, 1660, 1596, 1335, 
1233 cm -1; HRMS (ESI) m/z calcd. for C28H34NaO8 [M+Na]+ 521.2146, found 521.2152. 
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Appendix A2: 
 
Spectra Relevant to Chapter IV. 
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Figure A2.1. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.23. 
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Figure A2.2. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 4.24. 
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Figure A2.3. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.31. 
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Figure A2.4. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.32. 
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Figure A2.5. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.39. 
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Figure A2.6. 1H NMR spectrum (400 MHz, CDCl3) of compound 4.41. 
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Figure A2.7. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.42. 
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Figure A2.8. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.40. 
OBn
OBz
OBn
O
H
O
4.40
 268 
 
 
Figure A2.9. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.46. 
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Figure A2.10. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.47. 
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Figure A2.11. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.57. 
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Figure A2.12. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.61. 
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Figure A2.13. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound S4.8. 
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Figure A2.14. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (100 MHz, C6D6) of 
compound 4.62. 
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Figure A2.15. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (100 MHz, C6D6) of 
compound 4.74. 
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Figure A2.16. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.75. 
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Figure A2.17. 1H NMR spectrum (600 MHz, C6D6) and 13C NMR spectrum (150 MHz, C6D6) of 
compound S4.9. 
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Figure A2.18. 1H NMR spectrum (600 MHz, C6D6) and 13C NMR spectrum (150 MHz, C6D6) of 
compound 4.80. 
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Figure A2.19. COSY spectrum (600 MHz, C6D6) and NOESY spectrum (600 MHz, C6D6) of compound 
4.80. 
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Figure A2.20. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound S4.10. 
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Figure A2.21. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.81. 
OMe
MeO
OMe
O
Br
4.81
 281 
 
 
Figure A2.22. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.83. 
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Figure A2.23. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.84. 
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Figure A2.24. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 4.85. 
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Figure A2.25. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.86. 
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Figure A2.26. 1H NMR spectrum (400 MHz, C6D6) of compound 4.90. 
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Figure A2.27. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (100 MHz, C6D6) of 
compound 4.91. 
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Figure A2.28. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.103. 
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Figure A2.29. 1H NMR spectrum (600 MHz, C6D6) and 13C NMR spectrum (150 MHz, C6D6) of 
compound S4.12. 
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Figure A2.30. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (100 MHz, C6D6) of 
compound 4.105. 
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Figure A2.31. 1H NMR spectrum (400 MHz, C6D6) of compound 4.108. 
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Figure A2.32. 1H NMR spectrum (600 MHz, C6D6) and 13C NMR spectrum (150 MHz, C6D6) of 
compound β-4.110. 
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Figure A2.33. COSY spectrum (600 MHz, C6D6) and NOESY spectrum (600 MHz, C6D6) of compound β-
4.110. 
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Figure A2.34. 1H NMR spectrum (600 MHz, C6D6) and 13C NMR spectrum (150 MHz, C6D6) of 
compound α-4.110. 
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Figure A2.35. COSY spectrum (600 MHz, C6D6) of compound α-4.110. 
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Figure A2.36. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.112. 
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Figure A2.37. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.113. 
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Figure A2.38. 1H NMR spectrum (400 MHz, C6D6) of compound 4.114. 
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Figure A2.39. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (100 MHz, C6D6) of 
compound 4.115. 
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Figure A2.40. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.116. 
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Figure A2.41. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 4.117. 
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CHAPTER V 
 
AN INTRAMOLECULAR DIELS-ALDER-ENABLED  
DIMERIZATION APPROACH AND BEYOND 
 
A Modified D-Ring Protecting Group and Synthetic Analysis 
 
Several important pieces of information began to surface regarding the absolute 
stereochemistry of hibarimicin B (1.78) through the course of our studies. We had 
recently identified the absolute atropisomerism of HMP-Y6 (1.93) and thus 
hibarimicinone (1.96), and along with Hori and co-workers’ Mosher ester analysis of 
hibarimicione, the first total synthesis of hibarimicinone was reported in January 2012 in 
Tetrahedron Letters confirming the absolute stereochemistry.1,2,3 When considered with 
our synthetic studies, these data showed that we had serendipitously chosen to work 
toward the natural enantiomer of hibarimicinone when we changed to (–)-quinic acid as 
our starting material. To reflect this knowledge, Scheme 5.1 displays the confirmed 
absolute stereochemistry of HMP-Y1 and hibarimicinone. 
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Scheme 5.1. Retrosynthesis reflecting new stereochemical knowledge. 
 
 In light of our disappointments with synthesis of a transannular Diels-Alder 
substrate, we attempted to view our efforts in a new light and realign the necessary pieces 
to achieve our goal. We first reevaluated the tetracyclic substrate 4.12 which we still 
planned to dimerize through an oxidative homocoupling relying on the free phenol at    
C-1. However, our previous work had proposed a difficult demethylation of the C-1 
phenol in the presence of the innate C-3 and C-4 methoxy groups. Therefore, we sought 
to simplify a late-stage phenol deprotection by installing an orthogonal protecting group, 
and Shaw and co-workers’ use of an isopropyl phenol protecting group in their synthesis 
of (–)-viriditoxin, which has been shown to undergo deprotection in the presence of aryl 
methyl ethers, inspired our resynthesis of our functionalized D-ring intermediate.4 
 Thus, our route to the isopropyl-protected D-ring 5.6 was developed by Marta 
Wenzler and began by allyl ether formation with vanillin (3.4).5 Key to our route was 
implementation of a Baeyer-Villiger protocol that did not undergo competing olefin 
epoxidation, and we thus became aware of a method utilizing a simple mixture of boric 
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acid, sulfuric acid, and hydrogen peroxide which presumably involves the intermediacy 
of an aldehyde-coordinated boric acid/hydrogen peroxide complex. 6  Thus, Baeyer-
Villiger oxidation of aldehyde 5.1 provided phenol 5.2 which was protected as its 
isopropyl ether 5.3. Claisen rearrangement of the allyl ether 5.3 provided the phenol 5.4 
which was methylated under standard conditions. Finally, regioselective bromination 
with CuBr2 provided 5.6 in overall good yield. The intermediates 5.5 and 5.6 could then 
serve as building blocks for our future efforts. 
 
 
Scheme 5.2. Synthesis of an orthogonally-protected D-ring. 
 
 With our improved D-ring in hand, we revisited the crux of our approach to the 
tetracycle 4.12, a tethered Diels-Alder reaction. Chapter IV discussed our efforts toward 
the macrocyclic intermediate 4.13 for TADA cyclization and reinforced the importance 
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of the southern tether for correct C-9 stereocenter formation. But ultimately all of our 
routes utilizing initial northern tether formation failed to lead to the desired southern 
tether formation. With this in mind, we acknowledged that a southern-tethered IMDA 
approach through an intermediate such as 4.14 should correctly form the necessary C-9 
stereocenter, and a functionalized diene would allow for final C-ring closure.  
 
 
Scheme 5.3. Revisiting possible Diels-Alder-enabled routes to tetracycle 4.12. 
 
The key to this southern-tethered IMDA route would lay in our ability to 
differentiate the (–)-quinic acid-derived cis-diol for tether formation. We hoped that the 
requisite triol could be regioselectively protected to provide an intermediate such as 5.8 
which would allow for esterification with a suitably functionalized α,β-unsaturated- or 
alkynyl-acid 5.7. 
 
 
Scheme 5.4. Synthetic analysis of an IMDA approach. 
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While formation of the differentially protected A-ring 5.8 would present 
difficulties, we were confident that the remaining esterification and Suzuki coupling steps 
would allow formation of an IMDA substrate toward the tetracycle 4.12. Thus, we set out 
to synthesize the necessary building blocks toward IMDA precursor 4.14. 
 
Building Block Synthesis Toward an Alkynyl IMDA Precursor 
 
We identified our first target as an alkynyl acid containing no halide functionality 
for multiple reasons. As compared to the olefin, we decided that a terminal alkyne 
functionality would provide the largest number of options for routes to an acid for 
esterification. We also reasoned that an intramolecular C-ring closure would likely be 
difficult outside of a Nozaki-Hiyama-Kishi-type manifold, and a Friedel-Crafts-type 
closure might be more likely. Therefore, we set out to convert the terminal olefin of 5.5 
to alkyne 5.10 based on our previous three step procedure which occurred in excellent 
yield. To install the acid functionality, we first employed a standard sequence of addition 
of the methyl ester followed by saponification arriving at 5.12. However, both steps 
suffered from low yields, and we believe the hydrolysis step produced quantities of the 
undesired allene product as the remaining mass balance. Due to the low yielding two-step 
procedure, we alternately arrived at the desired alkynyl acid 5.12 in almost quantitative 
yield by alkyne deprotonation and bubbling of CO2(g) into the reaction mixture for 45 
minutes. This approach led to large quantities of the acid, and now we needed to 
determine a synthetic scheme to produce the proposed vinyl iodide 5.8 shown in Scheme 
5.4. 
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Scheme 5.5. Synthesis of the alkynyl acid D-ring building block. 
 
 Our approach to a differentially functionalized A-ring began with our previously-
synthesized vinyl iodide 4.57 which was readily converted to the requisite triol 5.13 in 
high yield. We hoped that the innate difference between the two secondary alcohols 
would provide selectivity for esterification, and thus we performed a model esterification 
reaction with 2-butynoic acid (5.14) and DCC as a coupling reagent.7 While the observed 
yield was reasonable, a 2:1 regioselectivity for the desired ester was deemed undesirable 
in the greater context of our synthesis of tetracycle 4.12, and we continued searching for 
conditions that would impart greater selectivity. 
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Scheme 5.6. Regioselectivity evaluation of a model esterification. 
 
 After much experimentation, we arrived at a sequence that, although more steps 
than desired, provided large quantities of a substrate similar to 5.8 with a free C-10 
alcohol and a functionalized C-11 alcohol in good yield. The triol 5.13 was treated with 
TBSCl which selectively silylated the allylic alcohol, and the remaining alcohol was 
easily mesylated.8 TBAF-mediated silyl ether removal finally formed our targeted A-ring 
substrate 5.19, which we believed would allow straightforward southern tether formation. 
 
 
Scheme 5.7. Synthesis of a differentially functionalized A-ring. 
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substrate such as 5.21 would allow for hydroxyl-directed epoxidation.9 From the epoxide 
5.22, we proposed, based on literature precedent, nucleophilic opening with water to 
arrive at the trans-trans triol system 5.23.10,11 Although we were unable to predict the 
regioselectivity of epoxide opening, we were hopeful that a steric argument could be 
utilized to provide the desired regioselectivity by opening at the C-11 carbon. 
 
 
Scheme 5.8. Proposed installation of trans-trans triol functionality. 
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 We now had in hand our three proposed building blocks for southern tethering, 
and we simply needed to identify proper conditions for esterification of the alkynyl acid 
5.12 with the allylic alcohol 5.19. Despite our precedent with the model system in 
Scheme 5.6, DCC provided the southern tether substrate 5.24 in very low yield.12 Thus 
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excited to be only steps away from a southern-tethered IMDA substrate and we pressed 
on using the Yamamoto conditions. 
 
 
Scheme 5.9. Formation of a southern-tethered alkynyl ester. 
 
 Once we had successfully synthesized the southern-tethered ester 5.24, we 
quickly identified conditions to arrive at an IMDA precursor. Thus, modification of our 
standard Suzuki coupling conditions involved heating a mixture of the vinyl iodide 5.24 
and the vinyl boronate 4.41 in the presence of Pd(PPh3)4 and potassium carbonate via 
microwave irradiation at 50 °C for 30 minutes which, following acidic workup, provided 
the allylic alcohol 5.26 in moderate yield.14 Finally, we arbitrarily installed an acetate 
protecting group for the purposes of the cycloaddition, and we were ecstatic to arrive at 
our long-awaited precursor 5.27 for a southern-tethered Diels-Alder. 
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Scheme 5.10. Arrival at a southern-tethered IMDA precursor. 
 
 The crux of our synthetic plans relied on a southern-tethered Diels-Alder to set 
the correct C-9 stereochemistry, and we had finally produced a substrate that met these 
criteria. For ease of reaction monitoring, the diene-yne 5.27 was heated in deuterated 
toluene in an NMR tube, and at 100 °C for 24 hours, we observed conversion to a new 
product. Extensive 1-D and 2-D NMR studies confirmed our suspicions: we had 
successfully performed an intramolecular Diels-Alder to arrive at an ABD ring system 
with the correct C-9 bridgehead stereochemistry. This proof-of-concept reaction became 
the pinnacle of our efforts, and our future work would rely on this important data. 
 
 
Scheme 5.11. A southern-tethered IMDA leads to desired C-9 stereochemistry. 
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 This success quickly became overshadowed by the reality of our route to 5.28: the 
Sc(OTf)3-mediated esterification reaction proved intractable for production of reasonable 
amounts of material due to both its yield and inconsistency. Additionally, we remained 
uncertain how to predictably utilize the tetrasubstituted C-7/C-8 olefin toward our desired 
target. Considering these issues, we reasoned that an α,β-unsaturated acid might address 
both concerns, and instead of refocusing our efforts on improving the alkynyl acid 
esterification, we turned toward synthesis of an olefinic dienophile. 
 
Toward a Southern-Tethered Alkenyl IMDA Substrate 
 
We had utilized aldehyde 5.9 previously for synthesis of the aryl alkyne 5.10, and 
we hoped this intermediate would expedite synthesis of an α,β-unsaturated acid. Horner-
Wadsworth-Emmons (HWE) reaction with methyl diethylphosphonoacetate (5.29) easily 
led to the methyl ester 5.30; however, after attempts at ester hydrolysis led to partial 
olefin isomerization, we became keenly aware of the tenuous nature of the olefin 
regiochemistry. To avoid the need for base-mediated hydrolysis, we successfully 
employed a procedure developed by Helquist involving HWE reaction with 
diethylphosphonoacetic acid (5.32) leading to the α,β-unsaturated acid 5.33 in reasonable 
yield. 15  With both coupling pieces in hand, we reverted to standard esterification 
conditions and were disappointed to observe partial olefin isomerization when employing 
DCC and almost complete isomerization with EDCI. These results implied the need to 
avoid traditional ester-forming procedures in attempting southern tethering. 
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Scheme 5.12. Attempted southern tethering of an α,β-unsaturated acid. 
 
 Our previous experience with acrylate esters prompted a completely novel 
approach to the southern tether: cross metathesis between an aryl olefin D-ring and an 
acrylate ester A-ring. These two metathesis partners seemed well-suited for coupling 
when considering Grubbs’ model for cross metathesis selectivity.16 Terminal olefins 
readily undergo homodimerization and are considered type I olefins, while acrylates 
undergo slow homodimerization and are type II olefins. Therefore, use of an excess of the 
aryl olefin with an acrylate ester A-ring should lead to the desired southern tether. 
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 We first converted the allylic alcohol 5.19 to the acrylate ester 5.36 with ease, and 
we were greatly pleased when upon heating of 3 molar equivalents of the aryl olefin 5.5 
and the acrylate ester 5.36 with Hoveyda-Grubbs second generation catalyst via 
microwave irradiation for 1.5 hours, formation of the southern-tethered α,β-unsaturated 
ester 5.37 occurred in stellar yield. At this point, we saw a straightforward path to an 
IMDA substrate that we hoped would lead to the desired ABD-ring system toward the 
tetracyclic target. 
 
 
Scheme 5.13. Cross-metathesis route to the southern tether. 
 
 Suzuki cross coupling of the vinyl iodide 5.37 under our newest optimized 
microwave conditions afforded the allylic alcohol 5.38 which was acylated with acetic 
anhydride in good yield to quickly arrive at the proposed IMDA precursor 5.39. 
Believing we had approached the tipping point in our synthesis, we were highly 
disappointed to observe only decomposition and no desired cyclization. This unexpected 
pathway began to occur at 100 °C, precisely the temperature that effected Diels-Alder 
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cyclization of the similar alkynyl ester 5.27. Although we failed to unambiguously 
determine the nature of the decomposition products, we isolated what appeared by 1H 
NMR to be a fragmented form of the D-ring and tether with no indication of the presence 
of peaks from the A-ring. And while the topic of relative reactivity of olefin vs. alkyne 
dienophiles has been explored with no true concensus, we hypothesized that a 
combination of potentially slightly lower reactivity of the α,β-unsaturated ester 5.39 
compared to the alkynyl ester 5.27 and the presence of a possibly labile mesylate group 
contributed to the decomposition of 5.39 under IMDA conditions.17  
 
 
Scheme 5.14. Failed southern-tethered IMDA. 
 
 Several issues appeared upon the failure of the α,β-unsaturated ester 5.39 IMDA 
reaction. Reconsidering the reactive rotamer effect described in Scheme 3.24, we 
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reasoned that an ester-linkage might hinder the necessary orientation for Diels-Alder 
cycloaddition and sought out other linkers with greater conformational flexibility. 
Additionally, despite the ultimate necessity of a leaving group on the C-11 secondary 
alcohol for our proposed triol installation shown in Scheme 5.8, we proposed the 
incorporation of a more robust orthogonal protecting group that would impart stability 
toward the necessary high temperatures of an IMDA reaction. 
 
Third Generation Southern-Tethered IMDA Approach 
 
We first chose to investigate replacement of the mesylate group with a  more 
robust protecting group, and a benzyl ether seemed to suit our needs. We reasoned that 
we could quickly evaluate an IMDA reaction with the benzyl series utilizing the same 
sequence previously optimized for the mesylate series. Therefore benzyl protection of the 
free secondary alcohol intermediate 5.17 was followed by TBAF-mediated desilylation 
and acrylate ester formation to provide the A-ring cross metathesis partner. 
 
 
Scheme 5.15. Synthesis of the benzyl series acrylate ester. 
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 Following the same route as previously developed, cross metathesis with an 
excess of the aryl olefin 5.5 provided the southern-tethered ester 5.44, and the 
functionalized diene was installed through microwave-mediated Suzuki cross coupling. 
Finally, acetylation of the primary alcohol capped off our rapid generation of the benzyl 
series IMDA precursor 5.46, and we were hopeful that with a more stable substrate an 
ABD-ring system product was close at hand. Therefore, we systematically heated the 
triene 5.46 in toluene with catalytic BHT, and we were severely disappointed to observe 
no conversion to the desired product. In fact, with heating at 200 °C for multiple days, 
only starting material was isolated. 
 
 
Scheme 5.16. Failed IMDA route with the benzyl series. 
 
OiPr
MeO
OMe
5.5
D
I
OH
5.43
O
OBn
O
A Hoveyda-Grubbs II
CH2Cl2, µW, 100 °C
54%
OiPr
MeO
OMe
5.44
O
O
I
OBn
OHD A
TMSO Bpin
4.41
Pd(PPh3)4, K2CO3, THF
H2O, 50 °C, µW
then 1 N HCl
43%
OiPr
MeO
OMe
5.45
O
O
OBn
OH
OH
Ac2O, DMAP
pyridine, CH2Cl2
93%
OiPr
MeO
OMe
5.46
O
O
OBn
OH
OAc
toluene, BHT, Δ
OiPr
MeO
OMe O
OBn
OH
H
OAc
O
ABD
5.47
 317 
 We were initially perplexed as to the lack of reactivity of the triene 5.46; 
however, an analysis of possible conformations led to a reasonable explanation of our 
observed results. Assuming that the cyclohexene A-ring exists in a twist-boat 
conformation, three major functionalities compete for equatorial orientations. In 
conformation 5.48, the ester dienophile inhabits the desired pseudo-equatorial orientation 
that appears necessary for orbital overlap in the Diels-Alder transition state and the 
propyl group also is shown as pseudo-equatorial. However, the adjacent O-benzyl group 
is then required to exist in a pseudo-axial orientation. Conversely in conformation 5.49, 
the O-benzyl group is shown as pseudo-equatorial and the remaining ester and propyl 
groups occupy pseudo-axial orientations. We reasoned that conformation 5.49 must 
predominate considering the unreactivity of 5.46 where the ester dienophile points away 
from the diene. Thus, the large size of the benzyl protecting group apparently imparts a 
large effect on the solution conformation of the molecule and rendered it unreactive even 
upon heating at high temperatures. This information points to a situation in which the 
mesylate group allowed population of the necessary 5.48 orientation but was too unstable 
to allow cycloaddition with the inferred higher LUMO energy acrylate ester dienophile 
when compared to the alkynyl dienophile. 
 
 
Scheme 5.17. Conformational analysis of the benzyl series IMDA substrate. 
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 In light of the undesirable results with the ester dienophile, we pursued other 
linking elements such as sulfur and silicon which we reasoned could provide greater 
conformational flexibility as well as simplify their removal following cycloaddition. 
Therefore, formation of the vinyl sulfonate 5.51 and vinyl siloxane 5.53 proceeded 
smoothly, and we then attempted cross metathesis with these substrates. Grubbs’ model 
for cross metathesis selectivity implied that both 5.51 and 5.53 should be considered type 
III olefins that do not undergo homodimerization; however, when applying our standard 
cross metathesis conditions, we observed no desired product and only homodimerization 
of the aryl olefin 5.5.16 These results were not completely surprising, as only few reports 
address the cross metathesis of vinyl siloxanes and none to our knowledge exist for the 
cross metathesis of vinyl sulfonates.18 Nevertheless, we were disappointed considering 
both functional groups have been successfully applied in the IMDA framework.19,20 
Finally, we set out to determine whether functionality present on the diene and/or 
dienophile was partly responsible for the observed lack of reactivity of our synthesized 
IMDA substrates. 
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Scheme 5.18. Unsuccessful cross metatheses of alternate vinyl A-ring substrates. 
 
 Our unsuccessful IMDA reactions prompted a closer look as to causative factors. 
We reasoned that independently truncating both the diene and dienophile might provide 
some insight into this issue, and based on our previously synthesized substrates, access to 
these intermediates required a minimal number of steps. Thus, we first synthesized the 
diene-truncated IMDA precursor 5.56 by substituting the cyclic vinyl boronate 3.20 into 
our recently optimized Suzuki cross coupling conditions. Unfortunately, heating 5.56 at 
temperatures up to 200 °C for multiple days resulted only in isolation of starting material, 
and we concluded that the substitution off of the diene did not appear to directly affect 
the cycloaddition. 
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Scheme 5.19. An attempted diene-truncated IMDA. 
 
 Truncation of the dienophile required Suzuki cross coupling utilizing the vinyl 
iodide 5.43 which occurred in modest yield. Acetylation then led to the dienophile-
truncated IMDA precursor 5.59 which was heated in toluene with catalytic BHT. Upon 
heating to 150 °C, we began to observe conversion to a more polar product, and full 
conversion occurred after heating for 4 days. Isolation of the new product indicated the 
desired cycloadduct 5.60 with the correct C-9 stereochemistry as would be predicted by a 
southern-tethered Diels-Alder. With this data, we became more perplexed as to the 
factors involved in rendering a southern-tethere IMDA substrate reactive within the 
benzyl series. Clearly our conformational analysis shown in Scheme 5.17 was not the 
only contributor, and we reasoned that the additional dienophile functionality donated 
significant electron density causing raising of the dienophile LUMO energy. This logic 
could begin to account for the lack of reactivity observed with the fully functionalized 
benzyl series IMDA shown in Scheme 5.16.  
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Scheme 5.20. Successful dienophile-truncated IMDA. 
 
 We had thus answered questions regarding the reactivity of a southern-tethered 
IMDA motif, but we remained unsatisfied as the IMDA product 5.60 did not immediately 
provide a reasonable route to the proposed tetracycle 4.12. However, we had learned 
much from the developed reactions for synthesis of the southern-tethered series, and we 
began to re-envision potential within the TADA mode that we hoped would overcome 
issues with Diels-Alder reactivity. 
 
Revisiting Synthesis of a TADA Substrate 
 
Despite our failures with an IMDA approach, we had added an extensive array of 
knowledge and reactions to our toolbox, and this experience allowed a fresh viewpoint 
for our original TADA strategy. First, we remained concerned regarding Diels-Alder 
reactivity, and we believed that formation of a macrocyclic precursor could lower the 
transition state energy based on a Diels-Alder proximity effect.21 Next, our work toward 
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previous TADA substrates never allowed formation of an α,β-unsaturated acid for 
southern tethering; however, we had since developed conditions for cross metathesis with 
an aryl olefin that we were confident could deliver a desirable substrate for southern 
tethering. Finally, our past experience with the TADA substrates had provided a highly 
reliable method for northern tether formation on large scale. Therefore, we sought to 
combine our most successful methods toward a greatly improved route to a macrocyclic 
TADA precursor. 
Considering this information, our newly proposed synthetic strategy involved 
ultimate synthesis of the macrocycle 5.61. We proposed ring closure through a 
macrolactonization of a requisite acid triol such as 5.62. We planned to arrive at the acid 
functionality through cross metathesis with a suitably protected acrylate ester reagent, 
and the northern tether would be formed through our well-established nucleophilic 
addition of the aryl lithiate of 5.6 with aldehyde 4.62. 
 
 
Scheme 5.21. An improved TADA synthetic analysis. 
 
 Brimming with confidence, we performed our tried and true northern tethering 
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cycloadditions, we then deactivated the diene by MnO2-mediated oxidation while 
effectively converging two diastereomers to arrive at the ketone 5.64. With this substrate, 
we believed that cross metathesis would provide a functionalized olefin to be utilized in 
macrolactonization. Thus, we first chose acrolein diethyl acetal as our cross metathesis 
partner for numerous reasons. Based on our previous studies with base-mediated 
hydrolysis of α,β-unsaturated methyl esters as shown in Scheme 5.12, we reasoned that 
incorporation of functionality at a lower oxidation state than necessary would avoid 
potential olefin isomerization. Additionally, we sought an acid-labile protected form of 
acrolein that, upon treatment with acid, would effect not only deprotection of the 
aldehyde functionality but also the acetonide moiety. Thus, acrolein diethyl acetal fit 
these parameters, and we applied it in a cross metathesis reaction with the terminal olefin 
substrate 5.64. While we did isolate desired product 5.66, we were disappointed by its 
mass recovery, and we quickly determined that the remaining mass balance existed in the 
formation of the naphthalene product 5.67. While ultimately this undesired reaction 
pathway was not completely surprising, it did complicate our efforts at arriving at an acid 
triol substrate for macrolactonization. 
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Scheme 5.22. Northern tethering and first generation cross metathesis. 
 
 Formation of the CD-naphthalene 5.67 is generated from the same ruthenium 
intermediate 5.68 that leads to the desired product 5.66. The two pathways diverge 
through the differences between cross metathesis and ring closing metathesis, where 
cross metathesis leads to 5.66 while RCM with the enone olefin leads to the naphthalene 
product 5.67. This understanding highlighted the concentration dependence of product 
formation where low concentration of the cross metathesis partner should favor the 
intramolecular RCM reaction (leading to 5.67) over the intermolecular reaction (leading 
to 5.66). However, increasing the concentration of the cross metathesis partner could 
improve the ratio of formed products by improving the rate of intermolecular reaction as 
compared to the rate of intramolecular RCM. 
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Scheme 5.23. Diverging metathesis pathways. 
 
 We forged ahead with the desired diethyl acetal 5.66 hoping to effect selective 
deprotection of both the acetonide and diethyl acetal groups. Our most successful 
conditions for these transformations involved removal of the diethyl acetal moiety with 
BF3•OEt2 at low temperature to provide the α,β-unsaturated aldehyde 5.71. 
Unfortunately, all attempts at subsequent acetonide removal failed likely due to the 
instability of the aldehyde group under the acidic reaction conditions necessary.  
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Scheme 5.24. Unsuccessful deprotection to an aldehyde triol intermediate. 
 
 We had targeted the aldehyde triol 5.72 partly due to precedent set by Kozmin 
and co-workers in their synthesis of leucascandrolide A where a spontaneous 
macrolactolization reaction led to the desired macrocycle 5.75.22 As shown in Scheme 
5.25, the triol 5.73 was treated with Pb(OAc)4 to effect oxidative cleavage to the 
intermediate aldehyde 5.74 which slowly cyclized to the lactol 5.75 in high yield. 
Similarly, we hoped that the aldehyde triol 5.72 might spontaneously cyclize, but much 
higher macrocyclic strain in our system likely would preclude this type of lactol 
formation. 
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Scheme 5.25. Kozmin’s spontaneous macrolactolization. 
 
 Instead of continuing with acrolein diethyl acetal cross metathesis, we elected to 
pursue a different cross metathesis partner that we hoped would simplify the two 
necessary deprotection steps. We still planned to avoid hydrolysis of an ester to arrive at 
the targeted acid triol for macrolactonization, and thus we realized that an acid-labile 
carboxylic acid protecting group could lead to a one-pot protocol for unmasking. 
Therefore, we chose tert-butyl acrylate (5.76) as our new cross metathesis partner while 
cognizant of the necessary concentration to favor cross metathesis over RCM (Scheme 
5.23). 
 We first probed cross metathesis between terminal olefin 5.64 and 50 equivalents 
of tert-butyl acrylate (5.76), and we first began by employing CH2Cl2 as solvent at high 
concentrations. On small scale, reaching concentrations higher than 0.4 M proved 
difficult, and we isolated desired t-butyl ester 5.77 in 46% yield with the remainder of the 
mass balance being an inseparable mixture of starting material and naphthalene 5.67. 
However, we were pleased to observe improved yield when we utilized the same number 
of molar equivalents of tert-butyl acrylate (5.76) as the reaction solvent, we isolated 5.77 
in 64% yield.. These results confirmed the schematic shown in Scheme 5.23 in which the 
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intermolecular pathway predominates under a high concentration of cross metathesis 
partner. From the desired product 5.77 we moved to find acidic conditions that would 
effect ester and acetonide deprotection. Disappointingly, our best conditions only formed 
the triol 5.78, and all attempts at removing the t-butyl ester failed to provide the desired 
product. 
 
 
Scheme 5.26. Tert-butyl acrylate cross metathesis and attempted deprotection. 
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to varying levels of decomposition. Additionally, much of the remaining mass balance 
from the hydrolysis step went to olefin isomerization but was easily separable by flash 
column chromatography. 
 
 
Scheme 5.27. Synthesis of a macrolactonization precursor. 
 
 Synthesis of the acid triol 5.83 marks the pinnacle of our studies thus far, and our 
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closure. Macrocycle formation and subsequent transannular Diels-Alder would open a 
wide door toward our ultimate goal of synthesizing a tetracyclic monomer 4.12 for 
dimerization and elaboration to HMP-Y1 (1.94) and hibarimicinone (1.96). Our ongoing 
studies have continually stood on the shoulders of previous routes, and the synthetic 
sequence involved in arriving at 5.83 combines our most successful methods identified to 
date. 
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Future Directions 
 
Our synthetic studies have encompassed a significant range of approaches that 
have all culminated in the proposed macrolactonization of acid triol 5.83 and subsequent 
transannular Diels-Alder. This strategy relies upon knowledge that a southern-tethered 
Diels-Alder reaction is necessary for correct C-9 stereocenter formation and hopes to take 
advantage of a proximity effect in the macrocycle for promotion of the cycloaddition. 
Thus, upon identification of appropriate lactonization conditions, of which we plan to 
investigate Yamaguchi and other well-established protocols, we hope to observe 
formation of the ABCD tetracycle 5.85 upon controlled heating. 
 
 
Scheme 5.28. Remaining steps to the ABCD tetracycle. 
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C14/C15 olefin regiochemistry as the necessary α-hydroxyketone functionality will arise 
from the requisite olefin. Nevertheless, the enone 5.86 could be imagined to derive from 
isomerization into conjugation with the ketone at C-16. Additionally, if a double olefin 
transposition were to occur, the phenol 5.89 which is saturated at the C14/C15 carbons, 
could arise from tautomerization as observed in Scheme 5.26. These two possible 
products would ultimately thwart attempts to install the hydroxyketone functionality; 
however, aromatization without olefin isomerization to provide phenol 5.88 could be 
highly desirable. 
 
 
Scheme 5.29. Possible base-promoted pathways for TADA product 5.85. 
 
 Despite these alternate pathways, we continue to operate on the presumed stability 
of TADA product 5.85 to ketohydroxylation conditions. Thus we plan to arrive at the 
hydroxyketone 5.90 as the first transformation of the newly formed tetracycle 5.85 so as 
to avoid issues regarding olefin isomerization. However, protection of the remaining 
secondary alcohol will be required, possibly prior to TADA cyclization, to avoid 
OiPr
MeO
OMe
OH
H
OH
OH
O
O
ABCD
5.85
OiPr
MeO
OMe
O
H
OH
OH
O
O
5.86
base
OiPr
MeO
OMe
O
H
OH
OH
O
O
5.87
OiPr
MeO
OMe
H
OH
OH
O
O
5.88
OH OiPr
MeO
OMe
H
OH
OH
O
O
5.89
OH
base
14
15
14
15
16
15
14
15
 332 
unwanted oxidation. This juncture may prove to be the correct time to install the 
necessary leaving group in preparation for the sequence proposed in Scheme 5.8. Next on 
our list is C-ring oxidation to the requisite phenol. Prior work in our laboratory has 
demonstrated the feasibility of this transformation, and phenol 5.91 will constitute 
synthesis of the isopropyl-protected CD ring system.1 
 
 
Scheme 5.30. Proposed B- and C-ring oxidation sequence. 
 
 Two major transformations will then remain, and as previously detailed in 
Scheme 5.8, we have proposed a three-step sequence for the first purpose. With a proper 
leaving group in place, elimination to the olefin 5.93 can be followed by hydroxyl-
directed epoxidation. Water-promoted epoxide opening of 5.94 will finally install the 
final oxygen functionality, and the regioselectivity of epoxide opening can be predicted 
to occur at the less hindered site to provide 5.95. 
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Scheme 5.31. Proposed installation of the A-ring trans-trans triol system. 
 
 Completion of the tetracyclic monomer synthesis will finally require removal of 
the tethering carbon utilized for TADA stereoselectivity. Mootoo and co-workers have 
previously addressed the issue with a highly similar AB-ring system substrate, and their 
approach appears to we well-suited for our needs. 23  Therefore, as noted in their 
publication, isomerization of the lactone conformation was necessary. Formation of the 
lactol 5.97 appears to be a tenuous step considering the presence of the C-15 ketone 
functionality, and if necessary, we could alter the order of operations to reflect this 
complication. The lactol can then be reacted with phenyliodonium diacetate to effect 
radical-mediated C-C bond cleavage and trapping with iodine, and the iodo-functionality 
5.98 can be removed under alternate radical conditions. Finally, removal of the formate 
functionality should provide a fully functionalized and protected tetracyclic monomer 
5.99. 
 
OiPr
MeO
OMe
OH
H
OH
O
O
O
O
OH
5.92
DBU
OH
H
OH
O
A
m-CPBA
or
VO(acac)2
TBHP
OH
H
OH
O
A O
H2O
Δ
OH
H
OH
O
A
OH
OH
5.93 5.94 5.95
LG
A
 334 
 
Scheme 5.32. Completion of the protected tetracyclic monomer 5.99. 
 
 Fortunately, work in our laboratory has demonstrated the potential for oxidative 
dimerization. With the model system 5.100, which possesses two sites of potential 
dimerization as well as hetero-coupling, we subverted these undesired pathways by use of 
a silyl linker which efficiently formed the desired symmetrical silyl-linked bi-phenol 
5.101. And although over-oxidation to the biquinone 5.102 was observed, we remain 
optimistic that careful optimization can lead to the dimerized bis-phenol. 
 
 
Scheme 5.33. Romaine’s preliminary work toward oxidative dimerization. 
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 For the purposes of oxidative dimerization, we will need to unmask the isopropyl-
protected phenol at C-1 which we proposed upon its installation that mild Lewis-acidic 
conditions should impart selectivity for the isopropyl ether over the two other methyl 
ethers. In analogy to the oxidative dimerization model study shown in Scheme 5.33, the 
free phenolic tetracycle 5.103 contains two locations for possible oxidative dimerization 
which we intend to direct through formation of a bridged silaketal 5.104. Careful 
determination of oxidation conditions should provide the protected racemic HMP-Y1 
(1.94), which upon deprotection and deracemization with O’Brien’s diamine will finally 
arrive at the biosynthetic intermediate aR HMP-Y1 (1.94). 
 
 
Scheme 5.34. Endgame strategy for completion of aR HMP-Y1. 
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 All that will remain once we have successfully employed our biomimetic route to  
aR HMP-Y1 will be conversion to hibarimicinone. Mono-oxidation of the C2-symmetric 
HMP-Y1 to the quinone 5.105 will set up for a key transformation. From the beginning of 
our synthetic studies, we have proposed a transformative Michael addition of the C-13’ 
tertiary alcohol into a proximate quinone methide intermediate 5.106 to form the bridging 
furan moiety found in hibarimicinone. We believe that the resulting intermediate 
hydroquinone 5.107 will undergo air oxidation to the quinone 5.108, and upon 
tautomerization will provide our final target, aS hibarimicinone (1.96). 
 
 
Scheme 5.35. Proposed completion of hibarimicinone. 
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Conclusion 
 
An IMDA approach to the proposed tetracyclic monomer was evaluated within 
alkyne and alkene dienophile motifs and both ultimately failed due to a low-yieldeing 
esterification step and unforeseen complications in the Diels-Alder cyclization 
respectively. The lessons learned in these forays were relayed into an improved approach 
to a TADA precursor, and we currently stand tantalizingly close to the crux of our efforts. 
Only two steps stand in front of formation of one of the most important intermediates 
originally proposed toward our total syntheses. 
Overall, extensive investigations into the total synthesis of HMP-Y1 and 
hibarimicinone have been detailed in the preceding chapters which have encompassed 
both two-directional and dimerization strategies. Additionally, attempted synthesis of a 
tetracyclic monomer has involved evaluation of both TADA and IMDA routes, and 
generally, the Diels-Alder reaction has played an integral part in these studies. Despite 
two recent syntheses of hibarimicinone, we continue to believe that our biomimetic 
dimerization approach constitutes a novel and superior strategy toward these complicated 
natural products. Ultimately, only time will serve as the judge of these questions, and we 
remain confident that our efforts will not have been in vain. 
 
Experimental Methods 
 
General Procedure. All non-aqueous reactions were performed under an argon 
atmosphere in flame-dried glassware. Stainless steel syringes or cannula were used to 
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transfer air- and moisture-sensitive liquids. Reaction temperatures were controlled using 
a thermocouple thermometer and analog hotplate stirrer. Reactions were conducted at 
room temperature (RT, approximately 23 °C) unless otherwise noted. Analytical thin-
layer chromatography was performed on E. Merck pre-coated silica gel 60 F254 plates 
and visualized using UV, ceric ammonium molybdate (CAM) and potassium 
permanganate (KMnO4) stains. Flash column chromatography was conducted as 
described by Still et. al. using indicated solvents and Dynamic Adsorbents silica gel 60 
(230-240 mesh).24 Where necessary, silica gel was neutralized by treatment of the silica 
gel prior to chromatography with the eluent containing 1% triethylamine (Et3N). Where 
necessary, silica gel was treated prior to chromatography with the eluent containing 1% 
glacial acetic acid (AcOH). Yields were reported as isolated, spectrocopically pure 
compounds. 
 
Materials. Reagents were purchased at the highest commercial quality and used without 
further purification unless otherwise stated. When necessary, intermediates were dried by 
azeotropic removal of water by evaporation from benzene (three iterations) and further 
dried on high-vacuum for the indicated amount of time. Toluene and dichloromethane 
(CH2Cl2) were obtained by passing commercially available solvents through activated 
alumina columns (MBraun MB-SPS solvent system). Tetrahydrofuran (THF) was 
purified by distillation from sodium metal with benzophenone indicator, and when 
necessary, was further dried over activated 4 Å molecular sieves under an atmosphere of 
argon. Triethylamine (Et3N) was distilled from calcium hydride and stored over sodium 
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hydroxide. The molarity of commercial n-butyllithium solutions was determined by 
titration using diphenylacetic acid as an indicator (average of three determinations). 
 
Instrumentation. Optical rotations were obtained using a Perkin Elmer 341 polarimeter 
and zeroed with the pure solvent, spectrophotometric-grade chloroform. 1H NMR spectra 
were recorded on Bruker 300, 400, 500, or 600 MHz spectrometers and are reported 
relative to deuterated solvent signals (CDCl3: 7.26; C6D6: 7.16). Data for 1H NMR 
spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sept. = septet, m = multiplet, br = broad, app = 
apparent), coupling constants (Hz), and integration. 13C NMR spectra were recorded at 
100, 125, or 150 MHz and are reported relative to deuterated solvent signals (CDCl3: 
77.0; C6D6: 128.1). Infrared spectra were obtained as thin films on NaCl plates using a 
Thermo Electron IR100 series instrument and are reported in terms of frequency of 
absorption (cm-1). High-resolution mass spectra were obtained from the Department of 
Chemistry and Biochemistry, University of Notre Dame using either a JEOL AX505HA 
or JEOL LMS-GCmate mass spectrometer. 
 
Preparative Procedures 
 
To a solution of vanillin (3.4, 10.0 g, 65.7 mmol, 1.0 eq) in DMF (33 mL) 
was added K2CO3 (22.7 g, 164 mmol, 2.5 eq) then allyl bromide (11.4 mL, 
131 mmol, 2.0 eq) and the thick slurry was stirred at RT for 22 h. The reaction was 
diluted with H2O (100 mL) and extracted with CH2Cl2 (3 x 100 mL). The combined 
CHO
MeO
O5.1
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organic layers were washed with H2O (4 x 100 mL), dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (10-40% EtOAc/hexanes) 
provided 5.1 as a yellow oil (12.5 g, 64.8 mmol, 99%). Spectral data were consistent with 
reported literature values. 
 
To a mixture of boric acid (19.7 g, 318 mmol, 5.0 eq) in THF (182 mL) was 
added H2O2 (30% in H2O, 21.2 mL) then concentrated H2SO4 (9.23 mL) and 
the mixture was stirred at RT for 30 min. A solution of 5.1 (12.2 g, 63.7 mmol, 1.0 eq) in 
THF (64 mL) was added via dropping funnel over 15 min, and the reaction was stirred at 
RT for 5 h. The orange reaction mixture was filtered through a Büchner funnel with 
EtOAc washes, and the filtrate was neutralized with saturated aqueous NaHCO3 (4 x 100 
mL) which caused vigorous bubbling and the aqueous layers turned red. The combined 
aqueous layers were extracted with EtOAc (3 x 100 mL), and the combined organic 
layers were washed with brine (1 x 100 mL), dried (MgSO4), filtered, and concentrated to 
provide 5.2 as a thick, dark brown oil that was immediately taken forward crude. 
 
To a solution of crude 5.2 (11.5 g, 63.7 mmol, 1.0 eq) in acetone (64 mL) was added 
K2CO3 (17.6 g, 127 mmol, 2.0 eq) then TBAI (1.18 mg, 3.18 mmol, 0.05 eq). To the 
mixture was added isopropyl bromide (20.9 mL, 223 mmol, 3.5 eq) and the reaction was 
heated at reflux for 24 h. At RT, the reaction was concentrated, diluted with H2O (100 
mL) and extracted with CH2Cl2 (4 x 100 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (10-
40% EtOAc/hexanes) yielded 5.3 as a yellow oil (7.39 g, 33.3 mmol, 52% two steps). 1H 
OiPr
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O5.3
 341 
NMR (400 MHz, CDCl3): δ 6.79 (d, J = 8.7 Hz, 1H), 6.50 (d, J = 2.7 Hz, 1H), 6.37 (dd, J 
= 8.7, 2.7 Hz, 1H), 6.07 (dddd, J = 16.1, 10.8, 5.5, 5.5 Hz, 1H), 5.37 (dd, J = 17.3, 1.3 
Hz, 1H), 5.25 (dd, J = 10.5, 0.8 Hz, 1H), 4.54 (d, J = 5.5 Hz, 2H), 4.45 (sept., J = 6.1 Hz, 
1H), 3.84 (s, 3H), 1.32 (s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 152.7, 
150.6, 142.2, 133.8, 117.7, 114.8, 105.8, 102.5, 70.8, 70.5, 55.8, 22.1; IR (film) νmax 
2976, 2934, 1596, 1264 cm -1; HRMS (ESI) m/z calcd. for C13H19O3 [M+H]+ 223.1329, 
found 223.1339. 
 
To three 5 mL microwave vials was added 5.3 (7.39 g, 33.3 mmol, 1.0 
eq) and the vials were capped and heated via microwave irradiation at 
200 °C for 2 h each. The material had turned red/orange, and the vials were combined 
and concentrated. Product (5.4) was taken forward crude, except for characterization 
purposes, in which purification by flash column chromatography (5-15% 
EtOAc/hexanes) yielded 5.4 as a light yellow oil. 1H NMR (400 MHz, CDCl3): δ 6.37 (d, 
J = 2.7 Hz, 1H), 6.30 (d, J = 2.6 Hz, 1H), 5.98 (dddd, J = 17.0, 10.2, 6.6, 6.6 Hz, 1H), 
5.28 (s, 1H), 5.12-5.02 (m, 2H), 4.41 (sept., J = 6.1 Hz, 1H), 3.84 (s, 3H), 3.38 (br. s, 
1H), 3.37 (br. s, 1H), 1.30 (s, 3H), 1.29 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 150.8, 
146.7, 137.4, 136.5, 125.6, 115.4, 108.6, 99.4, 70.7, 55.9, 33.9, 22.0; IR (film) νmax 3534, 
3077, 2976, 2935, 1610, 1495, 1225 cm -1; HRMS (ESI) m/z calcd. for C13H19O3 [M+H]+ 
223.1329, found 223.1343. 
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To a solution of 5.4 (7.45 g, 33.5 mmol, 1.0 eq) in DMF (52 mL) was 
added methyl iodide (6.26 mL, 101 mmol, 3.0 eq) then K2CO3 (13.9 g, 
101 mmol, 3.0 eq) and the reaction was stirred at RT for 22 h. The thick orange slurry 
was diluted with H2O (100 mL) and extracted with CH2Cl2 (3 x 100 mL). The combined 
organic layers were washed with H2O (5 x 100 mL), dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (5-10% EtOAc/hexanes) 
provided 5.5 as a yellow oil (6.45 g, 27.3 mmol, 81% two steps). 1H NMR (400 MHz, 
CDCl3): δ 6.36 (d, J = 2.8 Hz, 1H), 6.28 (d, J = 2.8 Hz, 1H), 5.96 (dddd, J = 16.9, 10.2, 
6.6, 5.6 Hz, 1H), 5.08 (dd, J = 11.5, 1.6 Hz, 1H), 5.04 (dd, J = 4.1, 1.6 Hz, 1H), 4.47 
(sept., J = 6.1 Hz, 1H), 3.82 (s, 3H), 3.75 (s, 3H), 3.38 (d, J = 6.5 Hz, 2H), 1.32 (s, 3H), 
1.31 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 154.1, 153.3, 140.8, 137.2, 133.9, 115.6, 
107.3, 100.0, 70.1, 60.8, 55.6, 34.1, 22.0; IR (film) νmax 2975, 2934, 1595, 1488, 1223 
cm -1; HRMS (ESI) m/z calcd. for C14H21O3 [M+H]+ 237.1485, found 237.1514. 
 
To a solution of 5.5 (1.00 g, 4.23 mmol, 1.0 eq) in DME (14 mL) was 
added CuBr2 (1.89 g, 8.46 mmol, 2.0 eq) and the green reaction was 
stirred at RT for 48 h. The reaction was diluted with EtOAc (100 mL) and filtered 
through a plug of Celite with a layer of silica on top, and the plug was washed with 
EtOAc until the eluting filtrate was mostly clear. The filtrate was washed with 15% 
NH4OH (4 x 100 mL), and the orange organic layer was dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (5% EtOAc/hexanes) 
provided 5.6 as a light yellow oil (911 mg, 2.89 mmol, 68%). 1H NMR (600 MHz, 
CDCl3): δ 6.49 (s, 1H), 5.95 (dddd, J = 17.1, 6.3, 6.0, 2.7 Hz, 1H), 5.03 (dd, J = 1.4, 1.2 
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Hz, 1H), 5.00 (ddd, J = 6.8, 3.2, 1.4 Hz, 1H), 4.44 (sept., J = 6.1 Hz, 1H), 3.83 (s, 3H), 
3.76 (s, 3H), 3.60 (ddd, J = 6.1, 1.4, 1.2 Hz, 2H), 1.36 (s, 3H), 1.35 (s, 3H); ); 13C NMR 
(150 MHz, CDCl3): δ 152.1, 151.1, 142.3, 134.3, 115.5, 107.7, 100.9, 73.3, 61.1, 55.9, 
34.4, 22.1; IR (film) νmax 2977, 2935, 2837, 1580, 1327, 1232  cm -1; HRMS (ESI) m/z 
calcd. for C14H20BrO3 [M+H]+ 315.0590, found 315.0576. 
 
To a solution of 5.5 (3.60 g, 12.5 mmol, 1.0 eq) in acetone (13 mL) and 
H2O (13 mL) was added NMO (1.84 g, 15.7 mmol, 1.3 eq) then 1 crystal 
of OsO4 (catalytic) and the reaction was stirred at RT for 22 h. The reaction was diluted 
with EtOAc (100 mL), added to 20% Na2SO3 (250 mL), and extracted with EtOAc (3 x 
100 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated to 
provide S5.1 as a light yellow solid. The material was taken forward crude. 
 
To a solution of S5.1 (3.80 g, 11.8 mmol, 1.0 eq) in MeOH (118 mL) open to the air was 
added pH 7 buffer (59 mL) then NaIO4 (3.26 g, 15.3 mmol, 1.3 eq) and the reaction was 
stirred at RT for 45 min. The reaction was diluted with H2O (250 mL) and extracted with 
CH2Cl2 (4 x 175 mL). The combined organic layers were washed with brine (1 x 175 
mL) then dried (MgSO4), filtered, and concentrated to yield 5.9 as a white solid. The 
material was taken forward crude. 
 
To a solution of 5.9 (3.03 g, 10.5 mmol, 1.0 eq) in MeOH (105 mL) was added K2CO3 
(4.35 g, 31.4 mmol, 3.0 eq) then a solution of the Bestmann-Ohira reagent (4.82, 3.02 g, 
15.7 mmol, 1.5 eq) in MeOH (25 mL) via cannula and the reaction was stirred at RT for  
OiPr
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4 h over which time the reaction turned light green. The reaction was diluted with H2O 
(275 mL) and extracted with EtOAc (3 x 175 mL), and the combined organic layers were 
washed with brine (1 x 175 mL), dried (MgSO4), filtered, and concentrated. Purification 
by flash column chromatography (10-35% EtOAc/hexanes) provided 5.10 as a white 
solid (2.84 g, 9.97 mmol, 80% three steps). 1H NMR (400 MHz, CDCl3): δ 6.60 (d, J = 
2.7 Hz, 1H), 6.38 (d, J = 2.7 Hz, 1H), 4.49 (sept., 6.0 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 
3.57 (d, J  = 2.6 Hz, 2H), 2.13 (dd, J = 2.7, 2.7 Hz, 1H), 1.32 (s, 3H), 1.30 (s, 3H); 13C 
NMR (100 MHz, CDCl3): δ 154.1, 153.1, 140.2, 130.0, 106.3, 100.6, 82.0, 70.1, 70.0, 
60.4, 55.6, 21.9, 19.2; IR (film) νmax 3290, 2976, 2936, 2119, 1597, 1491, 1329 cm -1; 
HRMS (ESI) m/z calcd. for C14H19O3 [M+H]+ 235.1329, found 235.1332. 
 
To a solution of 5.10 (589 mg, 2.51 mmol, 1.0 eq) in THF (25.1 
mL) at 0 °C was added ethyl magnesium chloride (2.0 M in THF, 
7.54 mL, 15.1 mmol, 6.0 eq) and the mixture was stirred at 0 °C for 1 h. CO2 (g) was 
bubbled into the mixture at 0 °C while slowly warming to RT for 45 min, and the 
reaction was diluted with EtOAc (50 mL), added to 1 N HCl (50 mL), and extracted with 
EtOAc (3 x 50 mL). The combined organic layers were dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (30-50% EtOAc/hexanes 
containing 1% AcOH) yielded 5.12 as a yellow oil (671 mg, 2.41 mmol, 96%). MP: 73-
76 °C; 1H NMR (400 MHz, CDCl3): δ 10.63 (br. s, 1H), 6.48 (d, J = 2.7 Hz, 1H), 6.41 (d, 
J = 2.7 Hz, 1H), 4.49 (sept., J = 6.0 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 3H), 3.71 (br. s, 2H), 
1.33 (s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 157.6, 154.3, 153.3, 140.4, 
127.8, 106.6, 101.3, 89.3, 73.8, 70.4, 60.8, 55.7, 22.0, 19.7; IR (film) νmax 3475, 2978, 
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2625, 2239, 1708, 1598, 1493, 1226 cm -1; HRMS (ESI) m/z calcd. for C15H19O5 [M+H]+ 
279.1227, found 279.1232. 
 
To a solution of 4.57 (2.50 g, 7.39 mmol, 1.0 eq) in CH3CN (37.0 mL) was 
added 2 N aqueous HCl (37.0 mL) slowly and the reaction was stirred at RT 
for 2.75 h. To the reaction was carefully added saturated aqueous NaHCO3 
(100 mL) and the mixture was extracted with EtOAc (3 x 75 mL). The combined organic 
layers were dried (MgSO4), filtered, and concentrated. Purification by flash column 
chromatography (50-70% EtOAc/hexanes) provided 5.13 as an orange oil (1.92 g, 6.44 
mmol, 87%). [α]  –6.9 (c 0.33, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 6.39 (s, 1H), 
4.15 (br. s, 1H), 4.09 (br. s, 1H), 4.02 (d, J = 3.8 Hz, 1H), 3.85 (s, 1H), 3.83 (br. s, 1H), 
2.27 (dd, J = 14.6, 5.1 Hz, 1H), 1.99 (dd, J = 14.5, 1.5 Hz, 1H), 1.55 (ddddd, J = 16.9, 
13.7, 6.9, 6.8, 6.2 Hz, 2H), 1.21 (ddd, J = 14.4, 14.4, 7.1 Hz, 2H), 0.94 (dd, J = 7.4, 7.2 
Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 140.1, 113.3, 73.5, 70.5, 67.8, 45.4, 35.1, 17.0, 
14.3; IR (film) νmax 3371, 2958, 2932, 2872, 1620, 1396 cm -1; HRMS (ESI) m/z calcd. 
for C9H15IO3 [M+H]+ 299.0145, found 299.0139. 
 
To a solution of 5.13 (36 mg, 0.121 mmol, 1.1 eq) in CH2Cl2 (1.1 mL) at 
0 °C was added 2-butynoic acid (5.14, 9.0 mg, 0.110 mmol, 1.0 eq), 
DMAP (2 mg, catalytic), and DCC (23 mg, 0.110 mmol, 1.0 eq) and the 
reaction was stirred at 0 °C for 2 h and at RT for 20 h. The reaction was diluted with H2O 
(10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (40-
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60% EtOAc/hexanes) yielded 5.15 as clear oil (20 mg, 0.0549 mmol, 50%), and the 
undesired regioisomer was discarded. 1H NMR (600 MHz, CDCl3): δ 6.28 (dd, J = 1.8, 
1.7 Hz, 1H), 5.24 (dd, J = 3.5, 2.2 Hz, 1H), 4.34 (br. m, 1H), 3.54 (s, 1H), 2.64 (br. s, 
1H), 2.34 (dd, J = 14.8, 5.2 Hz, 1H), 2.06-1.99 (m, 1H), 2.02 (s, 3H), 1.65-1.52 (m, 2H), 
1.29-1.18 (m, 2H), 0.95 (dd, J = 7.4, 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 152.4, 
134.1, 116.0, 87.8, 74.0, 73.0, 71.7, 66.4, 45.1, 34.8, 16.9, 14.3, 3.9. 
 
To a solution of 5.13 (1.16 g, 3.89 mmol, 1.0 eq) in CH2Cl2 (3.3 mL) at 0 
°C was added imidazole (398 mg, 5.84 mmol, 1.5 eq) then TBSCl (587 mg, 
3.89 mmol, 1.0 eq) and the light yellow slurry was stirred at RT for 22 h. 
To the reaction was added saturated aqueous NH4Cl (50 mL) and the mixture was 
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated. Purification by flash column chromatography (5-20% 
EtOAc/hexanes) yielded 5.17 as a light yellow solid (1.15 g, 2.80 mmol, 72%). MP: 32-
35 °C; [α]  +29.8 (c 0.50, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 6.15 (dd, J = 1.4, 1,4 
Hz, 1H), 4.13 (dd, J = 3.8, 1.9 Hz, 1H), 4.07 (dd, J = 5.5, 3.7 Hz, 1H), 3.98 (s, 1H), 2.91 
(d, J = 1.7 Hz, 1H), 2.31 (dd, J = 14.7, 4.6 Hz, 1H), 1.90 (ddd, J = 14.8, 1.6, 1.5 Hz, 1H), 
1.52 (ddddd, J = 14.5, 7.8, 7.7, 5.9, 5.3, 2H), 1.21 (ddd, J = 15.0, 15.0, 7.2 Hz, 2H), 0.92 
(dd, J = 7.4, 7.2 Hz, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 138.7, 114.1, 72.3, 71.2, 68.5, 45.0, 34.4, 25.6, 18.0, 16.9, 14.2, –4.8, –5.0; IR 
(film) νmax 3501, 2933, 2860, 1620, 1395, 1256 cm -1; HRMS (ESI) m/z calcd. for 
C15H29INaO3Si [M+Na]+ 435.0823, found 435.0848. 
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To a flask under argon containing 5.17 (1.15 g, 2.80 mmol, 1.0 eq) at 0 °C 
was added pyridine (14 mL) then MsCl (325 µL, 4.19 mmol, 1.5 eq) 
dropwise and the yellow reaction was stirred at 0 °C for 10 min and at RT 
for 1 h, over which time the reaction became lighter yellow. The reaction was diluted 
with CH2Cl2 (50 mL) and washed with 1 N aqueous HCl (4 x 50 mL), and the combined 
aqueous layers were extracted with CH2Cl2 (3 x 50 mL). The combined organic layers 
were dried (MgSO4), filtered, and concentrated. Purification by flash column 
chromatography (10-40% EtOAc/hexanes) provided 5.18 as a clear oil (1.10 g, 2.24 
mmol, 80%). [α]  +40.0 (c 0.85, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 6.30 (dd, J = 
2.9, 0.6 Hz, 1H), 4.93 (ddd, J = 5.3, 5.3, 1.9 Hz, 1H), 4.18 (dd, J = 3.2, 3.2 Hz, 1H), 3.06 
(s, 3H), 2.46 (dd, J = 14.6, 6.8 Hz, 1H), 2.45 (br. s, 1H), 2.18 (dd, J = 14.6, 1.9 Hz, 1H), 
1.65-1.48 (m, 2H), 1.31-1.19 (m, 2H), 0.93 (dd, J = 7.4, 7.2 Hz, 3H), 0.90 (s, 9H), 0.11 
(s, 6H); 13C NMR (125 MHz, CDCl3): δ 139.1, 114.3, 77.8, 73.0, 69.4, 44.3, 39.0, 34.7, 
25.7, 18.2, 16.7, 14.2, –4.8, –4.9; IR (film) νmax 3582, 3523, 2933, 2253, 1619, 1358, 
1115 cm -1; HRMS (ESI) m/z calcd. for C16H31INaO5SSi [M+Na]+ 513.0598, found 
513.0622. 
 
To a solution of 5.18 (1.10 g, 2.24 mmol, 1.0 eq) in THF (11.2 mL) at 0 °C 
was added TBAF (4.49 mL, 4.49 mmol, 2.0 eq)  and the reaction was stirred 
at 0 °C for 1 h. To the reaction was added saturated aqueous NH4Cl (50 mL) 
and the mixture was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers 
were dried (MgSO4), filtered, and concentrated. Purification by flash column 
chromatography (50-90% EtOAc/hexanes) yielded 5.19 as a white solid (739 mg, 1.96 
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mmol, 88%). MP: 100-103 °C; [α]  +10.7 (c 0.24, CHCl3); 
1H NMR (400 MHz, 
CDCl3): δ 6.46 (d, J = 3.1 Hz, 1H), 5.03 (ddd, J = 6.4, 6.4, 2.9 Hz, 1H), 4.27 (ddd, J = 
7.2, 7.2, 3.4 Hz, 1H), 3.14 (s, 3H), 2.49 (dd, J = 14.5, 7.2 Hz, 1H), 2.41 (d, J = 7.6 Hz, 
1H), 2.28 (s, 1H), 2.23 (dd, J = 14.5, 2.4 Hz, 1H), 1.70-1.50 (m, 2H), 1.35-1.22 (m, 2H), 
0.96 (dd, J = 7.3, 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 138.1, 115.7, 77.5, 73.2, 
68.3, 44.5, 39.1, 34.1, 16.8, 14.2; IR (film) νmax 3519, 2961, 1338, 1172 cm -1; HRMS 
(ESI) m/z calcd. for C10H17INaO5S [M+Na]+ 398.9734, found 398.9753. 
 
To a solution of 5.12 (70 mg, 0.253 mmol, 1.2 eq) and 5.19 (79 
mg, 0.211 mmol, 1.0 eq) in a 5:1 mixture of MeNO2 and 
MeCN (dried over activated 4 Å MS overnight, 2.1 mL) was 
added p-nitrobenzoic anhydride (5.25, 100 mg, 0.316 mmol, 1.5 eq) and Sc(OTf)3 (21 
mg, 0.0422 mmol, 0.2 eq) and the reaction was stirred at RT for 22 h. To the reaction was 
added saturated aqueous NaHCO3 (25 mL) and the mixture was extracted with EtOAc (3 
x 20 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. 
Purification by flash column chromatography (10-50% EtOAc/hexanes) provided 5.24 as 
an orange oil (35 mg, 0.0550 mmol, 26%). [α]  +13.8 (c 0.83, CHCl3); 
1H NMR (400 
MHz, CDCl3): δ 6.44 (d, J = 2.7 Hz, 1H), 6.41 (d, J = 2.7 Hz, 1H), 6.37 (d, J = 3.1 Hz, 
1H), 5.32 (dd, J = 3.4, 3.4 Hz, 1H), 5.11 (ddd, J = 6.0, 6.0, 2.2 Hz, 1H), 4.49 (sept., J = 
6.0 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.75 (d, J = 5.2 Hz, 1H), 3.71 (s, 2H), 3.06 (s, 
3H), 2.49 (dd, J = 14.7, 7.4 Hz, 1H), 2.31 (dd, J = 14.5, 2.1 Hz, 1H), 1.71-1.51 (m, 2H), 
1.33 (s, 3H), 1.32 (s, 3H), 1.30-1.22 (m, 2H), 0.95 (dd, J = 7.3, 7.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ 154.3, 153.3, 152.2, 140.4, 133.3, 127.7, 117.8, 106.7, 101.2, 89.6, 
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74.3, 73.2, 73.1, 70.4, 70.1, 60.8, 55.7, 44.2, 38.8, 34.8, 22.0, 19.8, 16.7, 14.2; IR (film) 
νmax 3508, 2968, 2236, 1715, 1351, 1243 cm -1; HRMS (ESI) m/z calcd. for 
C25H33INaO9S [M+Na]+ 659.0782, found 659.0788. 
 
To a microwave vial was added a solution of 5.24 (21 mg, 
0.0330 mmol, 1.0 eq) in THF (550 µL) then H2O (110 µL), 
K2CO3 (14 mg, 0.0990 mmol, 3.0 eq), 4.41 (17 mg, 0.0660 
mmol, 2.0 eq) and Pd(PPh3)4 (8.0 mg, 6.60 µmol, 0.2 eq), and the reaction was heated via 
microwave irradiation at 50 °C for 30 min. The reaction was diluted with EtOAc (10 mL) 
and washed with 1 N HCl (3 x 10 mL). The combined aqueous layers were extracted with 
EtOAc (2 x 10 mL), and the combined organic layers were dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (30-90% EtOAc/hexanes) 
yielded 5.26 as an orange oil (11 mg, 0.0194 mmol, 59%). [α]  +33.5 (c 0.47, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 6.45 (d, J = 2.7 Hz, 1H), 6.41 (d, J = 2.7 Hz, 1H), 6.32 (d, 
J = 15.8 Hz, 1H), 6.20 (ddd, J = 15.6, 5.0, 5.0 Hz, 1H), 5.68 (d, J = 2.9 Hz, 1H), 5.48 (dd, 
J = 3.3, 3.2 Hz, 1H), 5.10 (ddd, J = 5.9, 5.9, 2.3 Hz, 1H), 4.49 (sept., J = 6.1 Hz, 1H), 
4.22 (d, J = 4.9 Hz, 2H), 3.83 (s, 3H), 3.79 (s, 3H), 3.75 (d, J = 5.8 Hz, 1H), 3.71 (s, 2H), 
3.05 (s, 3H), 2.35 (br. s, 1H), 2.33 (dd, J = 14.8, 7.2 Hz, 1H), 2.17 (dd, J = 14.7, 2.1 Hz, 
1H), 1.66 (ddd, J = 13.7, 13.7, 4.8 Hz, 1H), 1.54 (ddd, J = 11.9, 11.9, 5.0 Hz, 1H), 1.33 
(s, 3H), 1.33-1.29 (m, 2H), 1.32 (s, 3H), 0.91 (dd, J = 7.4, 7.3 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ 154.4, 153.4, 152.6, 145.1, 140.5, 132.3, 127.8, 126.7, 118.5, 106.8, 
101.2, 89.1, 75.4, 73.4, 71.5, 70.4, 69.7, 63.4, 60.8, 55.8, 41.7, 38.8, 37.6, 22.1, 19.8, 
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16.8, 14.4; IR (film) νmax 3410, 2964, 2934, 2237, 1712, 1493, 1355, 1247, 1176 cm -1; 
HRMS (ESI) m/z calcd. for C28H38NaO10S [M+Na]+ 589.2078, found 589.2057. 
 
To a solution of 5.26 (10 mg, 0.0176 mmol, 1.0 eq) in CH2Cl2 
(250 µL) at 0 °C was added DMAP (catalytic, 2 mg) then 
Ac2O (3 µL, 0.0353 mmol, 2.0 eq) and pyridine (3 µL, 0.0353 
mmol, 2.0 eq) and the reaction was stirred at 0 °C for 1 h. To the reaction was added 
saturated aqueous NH4Cl (5 mL) and the mixture was extracted with CH2Cl2 (3 x 5 mL). 
The combined organic layers were dried (MgSO4), filtered, and concentrated. Purification 
by flash column chromatography (30-50% EtOAc/hexanes) provided 5.27 as a yellow oil 
(5.0 mg, 8.21 µmol, 47%). 1H NMR indicated desired product which was unstable when 
concentrated and was taken immediately to the next step. 1H NMR (400 MHz, CDCl3): δ 
6.45 (d, J = 2.7 Hz, 1H), 6.42 (d, J = 2.8 Hz, 1H), 6.35 (d, J = 15.7 Hz, 1H), 6.12 (ddd, J 
= 15.8, 6.1, 6.1 Hz, 1H), 5.69 (d, J = 2.5 Hz, 1H), 5.47 (dd, J = 3.1, 3.0 Hz, 1H), 5.12 (dd, 
J = 3.6, 3.2 Hz, 1H), 4.62 (d, J = 6.1 Hz, 2H), 4.49 (sept., J = 6.0 Hz, 1H), 3.83 (s, 3H), 
3.79 (s, 3H), 3.71 (s, 2H), 3.05 (s, 3H), 2.33 (dd, J = 14.8, 6.9 Hz, 1H), 2.17 (dd, J = 15.0, 
2.1 Hz, 1H), 2.10 (s, 1H), 2.08 (s, 3H), 1.70-1.48 (m, 2H), 1.34 (s, 3H), 1.32 (s, 3H), 
1.30-1.15 (m, 2H), 0.91 (dd, J = 7.3, 7.2 Hz, 3H). 
 
A solution of 5.27 (5.0 mg, 8.21 µmol, 1.0 eq) in toluene (4 
mL) was heated in a sealed tube at 80 °C for 72 h. At RT, the 
reaction was concentrated, and purification by flash column 
chromatography (40-70% EtOAc/hexanes) yielded 5.28 as a clear oil (4.0 mg, 6.57 µmol, 
OiPr
MeO
OMe O
O
OMs
OH
OAc
5.27
OiPr
MeO
OMe O
O
OMs
OH
OAc
H
5.28
 351 
80%). [α]  –10.6 (c 0.08, CHCl3); 
1H NMR (600 MHz, CDCl3): δ 6.37 (d, J = 2.8 Hz, 
1H), 6.21 (d, J = 2.6 Hz, 1H), 5.86 (dd, J = 2.7, 1.5 Hz, 1H), 5.15 (dd, J = 5.7, 2.7 Hz, 
1H), 4.85 (d, J = 14.9 Hz, 1H), 4.70 (dd, J = 9.7, 2.9 Hz, 1H), 4.49 (dd, J = 11.5, 3.9 Hz, 
1H), 4.42 (sept., J = 6.0 Hz, 1H), 4.38 (dd, J = 11.5, 4.9 Hz, 1H), 3.83 (s, 3H), 3.77 (s, 
3H), 3.70 (d, J = 15.3 Hz, 1H), 3.52 (dd, J = 11.1, 10.9 Hz, 1H), 3.12 (ddd, J = 12.4, 3.6, 
3.6 Hz, 1H), 2.97 (s, 3H), 2.52 (dd, J = 16.6, 3.8 Hz, 1H), 2.29 (s, 1H), 2.12 (dd, J = 16.5, 
2.2 Hz, 1H), 2.01 (s, 3H), 1.64 (ddd, J = 12.1, 4.7, 4.7 Hz, 1H), 1.51 (dd, J = 13.4, 4.6, 
4.6 Hz, 1H), 1.34-1.21 (m, 2H), 1.30 (d, J = 6.1 Hz, 3H), 1.28 (d, J = 6.2 Hz, 3H), 0.91 
(dd, J = 7.3, 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 171.0, 167.7, 154.3, 153.5, 
151.7, 141.7, 140.9, 131.7, 128.3, 123.7, 122.6, 107.6, 100.0, 78.0, 74.1, 71.9, 70.4, 63.7, 
60.8, 55.8, 46.2, 42.3, 41.3, 38.6, 29.7, 26.8, 22.1, 20.7, 16.9, 14.2; IR (film) νmax 3542, 
2930, 1743, 1594, 1354, 1231, 1176 cm -1; HRMS (ESI) m/z calcd. for C30H40NaO11S 
[M+Na]+ 631.2184, found 631.2188. 
 
To a solution of methyl diethylphosphonoacetate (5.29, 77 µL, 
0.420 mmol, 2.0 eq) in THF (2.1 mL) at 0 °C was added NaH 
(60% in mineral oil, 16 mg, 0.399 mmol, 1.9 eq) and the mixture was stirred at 0 °C for 
10 min. To the mixture was added 5.9 (50 mg, 0.210 mmol, 1.0 eq) and the reaction was 
stirred at RT for 3 h. To the reaction was added saturated aqueous NH4Cl (15 mL) and 
the mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were 
dried (MgSO4), filtered, and concentrated. Purification by flash column chromatography 
(20-30% EtOAc/hexanes) provided 5.30 as a clear oil (57 mg, 0.194 mmol, 92%). 1H 
NMR (400 MHz, CDCl3): δ 7.08 (ddd, J = 15.5, 6.7, 6.6 Hz, 1H), 6.38 (d, J = 2.7 Hz, 
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1H), 6.21 (d, J = 2.7 Hz, 1H), 5.80 (d, J = 15.6, Hz, 1H), 4.44 (sept., 6.0 Hz, 1H), 3.81 (s, 
3H), 3.73 (s, 3H), 3.69 (s, 3H), 3.49 (dd, J = 6.6, 1.0 Hz, 2H), 1.31 (s, 3H), 1.29 (s, 3H);  
13C NMR (100 MHz, CDCl3): δ 166.9, 154.2, 153.4, 147.6, 140.9, 131.4, 121.6, 107.4, 
100.6, 70.2, 60.8, 55.6, 51.3, 32.7, 22.0; IR (film) νmax 2975, 2834, 2010, 1723, 1491, 
1194 cm -1; HRMS (ESI) m/z calcd. for C16H23O5 [M+H]+ 295.1540, found 295.1535. 
 
To a solution of Zn(OTf)2 (306 mg, 0.840 mmol, 2.2 eq) in THF 
(2.0 mL) was added diethylphosphonoacetic acid (62 µL, 0.382 
mmol, 1.0 eq), TMEDA (68 µL, 0.458 mmol, 1.2 eq), DBU (228 µL, 1.53 mmol, 4.0 eq), 
and 5.9 (100 mg, 0.420 mmol, 1.1 eq) and the reaction was stirred at RT for 22 h. To the 
reaction was added 1 N aqueous HCl (20 mL) and the mixture was extracted with EtOAc 
(3 x 15 mL). The combined aqueous layers were dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (20-50% EtOAc/hexanes) 
yielded 5.33 as a brown oil (68 mg, 0.243 mmol, 64%). HRMS (ESI) m/z calcd. for 
C15H21O5 [M+H]+ 281.1384, found 281.1377. 
 
To a solution of 5.19 (100 mg, 0.266 mmol, 1.0 eq) in CH2Cl2 (1.1 mL) at 
–78 °C was added DIPEA (351 µL, 2.13 mmol, 8.0 eq) then acryloyl 
chloride (129 µL, 1.59 mmol, 6.0 eq) dropwise and the reaction was stirred 
at –78 °C for 30 min then at 0 °C for 1.5 h. To the reaction was added saturated aqueous 
NH4Cl (20 mL) and the mixture was extracted with CH2Cl2 (3 x 15 mL). The combined 
organic layers were dried (MgSO4), filtered, and concentrated. Purification by flash 
column chromatography (30-50% EtOAc/hexanes) provided 5.36 as a clear oil (100 mg, 
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0.232 mmol, 87%). [α]  +58.9 (c 0.21, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 6.47 
(dd, J = 17.2, 0.5 Hz, 1H), 6.37 (d, J = 3.2 Hz, 1H), 6.11 (dd, J = 17.3, 10.5 Hz, 1H), 5.91 
(dd, J = 10.5, 0.7 Hz, 1H), 5.33 (dd, J = 3.5, 3.4 Hz, 1H), 5.10 (ddd, J = 6.5, 6.5, 2.7 Hz, 
1H), 3.02 (s, 3H), 2.62 (br. s, 1H), 2.46 (dd, J = 14.6, 7.3 Hz, 1H), 2.32 (dd, J = 14.6, 2.2 
Hz, 1H), 1.68-1.49 (m, 2H), 1.33-1.16 (m, 2H), 0.93 (dd, J = 7.4, 7.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ 164.8, 134.1, 132.6, 127.2, 117.1, 74.5, 73.1, 68.9, 44.2, 38.8, 34.7, 
14.1, 14.0; IR (film) νmax 3512, 2962, 2936, 1726, 1356, 1179 cm -1; HRMS (ESI) m/z 
calcd. for C13H19INaO6S [M+Na]+ 452.9839, found 452.9845. 
 
To a solution of 5.36 (100 mg, 0.232 mmol, 1.0 eq) in 
CH2Cl2 (3.9 mL) was added 5.5 (165 mg, 0.697 mmol, 
3.0 eq) then Hoveyda-Grubbs second generation catalyst (15 mg, 0.0232 mmol, 0.1 eq) 
and the mixture was heated via microwave irradiation at 100 °C for 1.5 h. The reaction 
was concentrated, and purification by flash column chromatography (30-50% 
EtOAc/hexanes) provided 5.37 as a yellow oil (112 mg, 0.175 mmol, 76%). [α]  +31.3 
(c 0.61, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.15 (ddd, J = 15.5, 6.6, 6.6 Hz, 1H), 
6.36 (d, J = 2.6 Hz, 1H), 6.34 (d, J = 3.1 Hz, 1H), 6.18 (d, J = 2.7 Hz, 1H), 5.77 (d, J = 
15.7 Hz, 1H), 5.29 (dd, J = 3.4, 3.4 Hz, 1H), 5.07 (ddd, J = 9.7, 6.1, 2.5 Hz, 1H), 4.43 
(sept., J = 6.1 Hz, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 3.48 (d, J = 6.4 Hz, 2H), 2.97 (s, 3H), 
2.54 (s, 1H), 2.44 (dd, J = 14.6, 7.3 Hz, 1H), 2.29 (dd, J = 14.5, 1.9 Hz, 1H), 1.67-1.48 
(m, 2H), 1.30-1.25 (m, 2H), 1.29 (s, 3H), 1.27 (s, 3H), 0.92 (dd, J = 7.4, 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 165.1, 154.2, 153.4, 149.8, 140.8, 134.4, 130.9, 120.6, 116.8, 
107.4, 100.7, 74.7, 73.1, 70.2, 68.6, 60.7, 55.6, 44.2, 38.7, 34.8, 33.0, 22.0, 16.6, 14.1; IR 
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(film) νmax 3504, 2963, 2874, 2252, 1722, 1357, 1178 cm -1; HRMS (ESI) m/z calcd. for 
C25H36IO9S [M+H]+ 639.1119, found 639.1106. 
 
To a solution of 5.37 (112 mg, 0.175 mmol, 1.0 eq) in 
THF (2.9 mL) was added H2O (585 µL), K2CO3•1.5H2O 
(87 mg, 0.526 mmol, 3.0 eq), 4.41 (90 mg, 0.351 mmol, 
2.0 eq) and Pd(PPh3)4 (41 mg, 0.0351 mmol, 0.2 eq) and the reaction was heated via 
microwave irradiation at 50 °C for 1 h. The reaction was diluted with EtOAc (10 mL), 
added to 1 N aqueous HCl (20 mL) and extracted with EtOAc (3 x 10 mL). The 
combined organic layers were dried (MgSO4), filtered, and concentrated. Purification by 
flash column chromatography (50-90% EtOAc/hexanes) yielded 5.38 as a yellow oil (60 
mg, 0.106 mmol, 60%). [α]  +57.4 (c 1.89, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 
7.17 (ddd, J = 15.5, 6.6, 6.6 Hz, 1H), 6.39 (d, J = 2.7 Hz, 1H), 6.31 (d, J = 15.9 Hz, 1H), 
6.21 (d, J = 2.5 Hz, 1H), 6.18 (ddd, J = 15.8 Hz, 5.3, 5.3 Hz, 1H), 5.81 (d, J = 15.6 Hz, 
1H), 5.68 (d, J = 2.8 Hz, 1H), 5.46 (dd, J = 3.2, 3.0 Hz, 1H), 5.09 (ddd, J = 6.0, 6.0, 2.6 
Hz, 1H), 4.46 (sept., J = 6.0 Hz, 1H), 4.20 (d, J = 4.8 Hz, 2H), 3.82 (s, 3H), 3.73 (s, 3H), 
3.50 (d, J = 6.3 Hz, 2H), 2.97 (s, 3H), 2.32 (dd, J = 14.7, 7.1 Hz, 1H), 2.17 (dd, J = 14.7, 
2.0 Hz, 1H), 1.65 (ddd, J = 12.2, 12.2, 4.7 Hz, 1H), 1.55 (ddd, J = 11.9, 11.9, 5.1 Hz, 
1H), 1.31 (s, 3H), 1.30 (s, 3H), 1.29-1.17 (m, 2H), 0.90 (dd, J = 7.3, 7.3 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 165.5, 154.3, 153.5, 149.4, 144.2, 140.9, 132.0, 131.1, 126.9, 
121.0, 119.7, 107.6, 100.7, 75.9, 71.5, 70.3, 68.0, 63.4, 60.9, 55.7, 41.8, 38.7, 37.6, 33.1, 
22.1, 16.8, 14.4; IR (film) νmax 3419, 2965, 2936, 1717, 1597, 1356, 1176 cm -1; HRMS 
(ESI) m/z calcd. for C28H40NaO10S [M+Na]+ 591.2234, found 591.2244. 
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To a solution of 5.38 (25 mg, 0.0440 mmol, 1.0 eq) in 
CH2Cl2 (879 µL) at 0 °C was added DMAP (catalytic, 2 
mg) then Ac2O (6 µL, 0.0659 mmol, 1.5 eq) and pyridine 
(5 µL, 0.0659 mmol, 1.5 eq) and the reaction was stirred at 0 °C for 15 min. To the 
reaction was added saturated aqueous NH4Cl (10 mL) and the mixture was extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers were dried (MgSO4), filtered, and 
concentrated, and purification by flash column chromatography (40-60% 
EtOAc/hexanes) provided 5.39 as a light yellow oil (20 mg, 0.0327 mmol, 74%). [α]  
+98.0 (c 0.15, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.17 (ddd, J = 15.6, 6.7, 6.6 Hz, 
1H), 6.39 (d, J = 2.8 Hz, 1H), 6.34 (d, J = 15.8 Hz, 1H), 6.21 (d, J = 2.7 Hz, 1H), 6.10 
(ddd, J = 15.7, 6.1, 6.1 Hz, 1H), 5.81 (d, J = 15.6 Hz, 1H), 5.69 (d, J = 2.5 Hz, 1H), 5.45 
(dd, J = 3.1, 3.0 Hz, 1H), 5.10 (dd, J = 3.4, 3.2 Hz, 1H), 4.60 (d, J = 5.9 Hz, 2H), 4.46 
(sept., J = 6.1 Hz, 1H), 3.82 (s, 3H), 3.73 (s, 3H), 3.50 (d, J = 6.3 Hz, 2H), 2.97 (s, 3H), 
2.32 (dd, J = 14.8, 6.7 Hz, 1H), 2.16 (dd, J = 14.8, 1.8 Hz, 1H), 2.07 (s, 3H), 1.64 (ddd, J 
= 12.2, 12.2, 4.7 Hz, 1H), 1.54 (ddd, J = 12.0, 12.0, 5.0 Hz, 1H), 1.39-1.12 (m, 2H), 1.31 
(s, 3H), 1.30 (s, 3H), 0.90 (dd, J = 7.3, 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 
170.7, 165.5, 154.3, 153.5, 149.5, 143.7, 140.9, 131.1, 130.0, 126.6, 120.9, 120.6, 107.6, 
100.7, 75.9, 71.3, 70.3, 68.1, 64.7, 60.8, 55.7, 41.7, 38.7, 37.7, 33.1, 22.1, 20.9, 16.8, 
14.3; IR (film) νmax 3500, 2963, 2936, 1724, 1651, 1596, 1358, 1177 cm -1; HRMS (ESI) 
m/z calcd. for C30H42NaO11S [M+Na]+ 633.2340, found 633.2319. 
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To a slurry of NaH (60% in mineral oil, 405 mg, 10.1 mmol, 2.2 eq) in THF 
(12 mL) at 0 °C was added a solution of 5.17 (1.90 g, 4.61 mmol, 1.0 eq) in 
THF (11 mL) via cannula causing vigorous gas evolution. After gas 
evolution had ceased (~15 min), BnBr (603 µL, 5.07 mmol, 1.1 eq) was added dropwise 
and the reaction was stirred at 0 °C for 20 min and at RT for 4.25 h. To the reaction was 
added saturated aqueous NH4Cl (100 mL) and the mixture was extracted with CH2Cl2 (3 
x 75 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. 
Purification by flash column chromatography (3-6% EtOAc/hexanes) yielded 5.41 as a 
clear oil that solidified at 0 °C (1.54 g, 3.06 mmol, 66%). MP: 41-45 °C; [α]  +31.6 (c 
0.26, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.40-7.28 (m, 5H), 6.32 (dd, J = 1.4, 1.3 
Hz, 1H), 4.92 (d, J = 12.0 Hz, 1H), 4.65 (d, J = 12.1 Hz, 1H), 4.23 (dd, J = 3.3, 1.8 Hz, 
1H), 3.94-3.88 (m, 2H), 2.26 (dd, J = 14.4, 4.8 Hz, 1H), 1.91 (dd, J = 14.3, 1.0 Hz, 1H), 
1.58-1.50 (m, 2H), 1.29-1.15 (m, 2H), 0.94 (dd, J = 7.4, 7.0 Hz, 3H), 0.94 (s, 9H), 0.11 
(s, 6H); 13C NMR (100 MHz, CDCl3): δ 140.7, 137.9, 128.3, 127.6 (2C), 112.6, 76.1, 
73.6, 72.9, 72.7, 44.7, 34.4, 25.7, 18.1, 16.9, 14.2, –4.8, –4.9; IR (film) νmax 3506, 2954, 
2859, 1463, 1364, 1255, 1113 cm -1; HRMS (ESI) m/z calcd. for C22H35INaO3Si [M+Na]+ 
525.1292, found 525.1287. 
 
To a solution of 5.41 (1.54 g, 3.06 mmol, 1.0 eq) in THF (15 mL) at 0 °C 
was added TBAF (6.13 mL, 6.13 mmol, 2.0 eq) and the reaction was stirred 
at 0 °C for 1 h. To the reaction was added saturated aqueous NH4Cl (50 mL) 
and the mixture was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers 
were dried (MgSO4), filtered, and concentrated. Purification by flash column 
€ 
D
20
OTBS
OBn
I
OH
5.41
OH
OBn
I
OH
5.42
 357 
chromatography (20-50% EtOAc/hexanes) yielded 5.42 as a light yellow oil (962 mg, 
2.48 mmol, 81%). [α]  –6.1 (c 0.34, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 7.44-7.29 
(m, 5H), 6.41 (dd, J = 1.9, 0.9 Hz, 1H), 4.76 (d, J = 11.1 Hz, 1H), 4.57 (d, J = 11.1 Hz, 
1H), 4.09 (br. s, 1H), 3.98 (dd, J = 4.5, 4.4 Hz, 1H), 3.34 (br. s, 1H), 2.64 (br. s, 1H), 2.40 
(dd, J = 14.8, 4.9 Hz, 1H), 1.93 (dd, J = 14.7, 1.5 Hz, 1H), 1.60-1.51 (m, 2H), 1.29-1.16 
(m, 2H), 0.95 (dd, J = 7.3, 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 140.7, 136.7, 
128.8, 128.5, 128.4, 113.5, 75.7, 73.0, 72.8, 69.9, 44.9, 32.8, 17.0, 14.3; IR (film) νmax 
3429, 2958, 2931, 2871, 1619, 1455, 1389, 1099 cm -1; HRMS (ESI) m/z calcd. for 
C16H21INaO3 [M+Na]+ 411.0428, found 411.0414. 
 
To a solution of 5.42 (100 mg, 0.266 mmol, 1.0 eq) in CH2Cl2 (1.1 mL) at 
–78 °C was added DIPEA (351 µL, 2.13 mmol, 8.0 eq) then acryloyl 
chloride (129 µL, 1.59 mmol, 6.0 eq) and the reaction was stirred at –78 °C 
for 30 min and at 0 °C for 1.5 h. To the reaction was added saturated aqueous NH4Cl (15 
mL) and the mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic 
layers were dried (MgSO4), filtered, and concentrated. Purification by flash column 
chromatography (30-50% EtOAc/hexanes) provided 5.43 as a clear oil (100 mg, 0.232 
mmol, 87%). [α]  +40.0 (c 0.34, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 7.38-7.26 (m, 
5H), 6.47 (dd, J = 17.3, 1.0 Hz, 1H), 6.36 (dd, J = 1.4, 1.4 Hz, 1H), 6.17 (dd, J = 17.3, 
10.4 Hz, 1H), 5.92 (dd, J = 10.4, 1.0 Hz, 1H), 5.31 (dd, J = 3.5, 2.6 Hz, 1H), 4.69 (d, J = 
11.8 Hz, 1H), 4.58 (d, J = 11.8 Hz, 1H), 4.12 (ddd, J = 3.8, 3.8, 1.7 Hz, 1H), 3.60 (br. s, 
1H), 2.32 (dd, J = 14.5, 5.5 Hz, 1H), 2.04 (dd, J = 14.5, 1.6 Hz, 1H), 1.61-1.52 (m, 2H), 
1.30-1.15 (m, 2H), 0.94 (dd, J = 7.4, 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 165.3, 
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137.3, 135.6, 132.1, 128.6, 128.1, 127.9, 127.8, 115.4, 73.3 (2C), 73.2, 72.4, 44.6, 34.1, 
16.9, 14.3; IR (film) νmax 3485, 2959, 1723, 1405, 1188 cm -1; HRMS (ESI) m/z calcd. for 
C19H23INaO4 [M+Na]+ 465.0533, found 465.0559. 
 
To a solution of 5.43 (96 mg, 0.217 mmol, 1.0 eq) in 
CH2Cl2 (3.6 mL) was added 5.5 (154 mg, 0.651 mmol, 
3.0 eq) and Hoveyda-Grubbs second generation catalyst (14 mg, 0.0217 mmol, 0.1 eq) 
and the reaction was heated via microwave irradiation at 100 °C for 1.5 h. The reaction 
mixture was concentrated, and purification by flash column chromatography (10-25% 
EtOAc/hexanes) yielded 5.44 as a yellow oil (76 mg, 0.117 mmol, 54%). [α]  +21.9 (c 
2.13, CHCl3); 1H NMR (600 MHz, CDCl3): δ 7.34-7.22 (m, 5H), 7.17 (ddd, J = 15.5, 6.6, 
6.5 Hz, 1H), 6.41 (d, J = 2.7 Hz, 1H), 6.33 (dd, J = 1.5, 1.1 Hz, 1H), 6.24 (d, J = 2.7 Hz, 
1H), 5.85 (d, J = 15.6 Hz, 1H), 5.28 (dd, J = 3.4, 2.5 Hz, 1H), 4.67 (d, J = 11.9 Hz, 1H), 
4.56 (d, J = 11.8 Hz, 1H), 4.45 (sept., J = 6.1 Hz, 1H), 4.10 (ddd, J = 3.4, 3.4, 1.8 Hz, 
1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.62 (s, 1H), 3.53 (d, J = 6.2 Hz, 2H), 2.29 (dd, J = 14.5, 
5.5 Hz, 1H), 2.02 (dd, J = 14.5, 1.1 Hz, 1H), 1.59-1.51 (m, 2H), 1.31 (s, 3H), 1.30 (s, 
3H), 1.25-1.16 (m, 2H), 0.94 (dd, J = 7.3, 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 
165.6, 154.3, 153.5, 149.2, 141.0, 137.3, 135.8, 131.1, 128.5, 128.0, 127.8, 121.2, 115.1, 
107.6, 100.7, 73.3, 73.2, 73.1, 72.1, 70.2, 60.8, 55.7, 44.6, 34.1, 33.0, 22.1, 16.9, 14.3; IR 
(film) νmax 3503, 2963, 2934, 2873, 1717, 1596, 1492, 1265, 1150 cm -1; HRMS (ESI) 
m/z calcd. for C31H39INaO7 [M+Na]+ 673.1633, found 673.1658. 
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To a solution of 5.44 (76 mg, 0.117 mmol, 1.0 eq) in THF 
(2.0 mL) was added H2O (389 µL), K2CO3•1.5H2O (58 
mg, 0.350 mmol, 3.0 eq), 4.41 (60 mg, 0.234 mmol, 2.0 
eq) and Pd(PPh3)4 (27 mg, 0.0234 mmol, 0.2 eq) and the reaction was heated via 
microwave irradiation at 50 °C for 30 min. The reaction was diluted with EtOAc (10 mL) 
and washed with 1 N aqueous HCl (3 x 10 mL). The combined aqueous layers were 
extracted with EtOAc (2 x 10 mL), and the combined organic layers were dried (MgSO4), 
filtered, and concentrated. Purification by flash column chromatography (30-60% 
EtOAc/hexanes) provided 5.45 as a yellow oil (29 mg, 0.0499 mmol, 43%). [α]  +42.3 
(c 0.79, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.33-7.22 (m, 5H), 7.16 (ddd, J = 15.6, 
6.6, 6.6 Hz, 1H), 6.40 (d, J = 2.8 Hz, 1H), 6.30 (d, J = 15.6 Hz, 1H), 6.24 (d, J = 2.8 Hz, 
1H), 6.12 (ddd, J = 15.8, 5.7, 5.6 Hz, 1H), 5.86 (d, J = 15.5 Hz, 1H), 5.65 (s, 1H), 5.40 (s, 
1H), 4.66 (d, J = 11.8 Hz, 1H), 4.56 (d, J = 11.8 Hz, 1H), 4.45 (sept., J = 6.0 Hz, 1H), 
4.18 (d, J = 5.5 Hz, 2H), 4.06 (ddd, J = 5.0, 5.0, 1.9 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 
3.52 (dd, J = 6.6, 0.9 Hz, 2H), 3.51 (s, 1H), 2.12 (dd, J = 14.7, 5.5 Hz, 1H), 1.87 (dd, J = 
14.5, 1.0 Hz, 1H), 1.55 (ddd, J = 10.4, 10.4, 5.0 Hz, 2H), 1.31 (s, 3H), 1.29 (s, 3H), 1.22-
1.06 (m, 2H), 0.88 (dd, J = 7.4, 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 166.0, 
154.3, 153.5, 148.7, 143.2, 141.0, 137.7, 131.3, 130.5, 128.4, 128.2, 127.8 (2C), 121.6, 
121.3, 107.6, 100.7, 73.7, 73.0, 71.6, 71.4, 70.3, 63.7, 60.9, 55.7, 41.4, 36.4, 33.0, 24.8, 
22.1, 16.9, 14.5; IR (film) νmax 3423, 2964, 1713, 1650, 1596, 1492, 1268, 1151 cm -1; 
HRMS (ESI) m/z calcd. for C34H44NaO8 [M+Na]+ 603.2928, found 603.2928. 
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To a solution of 5.45 (7 mg, 0.0121 mmol, 1.0 eq) in 
CH2Cl2 (241 µL) at 0 °C was added DMAP (catalytic, 2 
mg), Ac2O (2 µL, 0.0181 mmol, 1.5 eq) and pyridine (1 
µL, 0.0181 mmol, 1.5 eq) and the reaction was stirred at 0 °C for 1 h and at RT for 3 h. 
To the reaction was added saturated aqueous NH4Cl (5 mL), and the mixture was 
extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated. Purification by flash column chromatography (30-50% 
EtOAc/hexanes) yielded 5.46 as a clear oil (7 mg, 0.0112 mmol, 93%). [α]  +46.5 (c 
0.28, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.34-7.22 (m, 5H), 7.16 (ddd, J = 15.6, 6.6, 
6.6 Hz, 1H), 6.40 (d, J = 2.8 Hz, 1H), 6.34 (d, J = 15.8 Hz, 1H), 6.24 (d, J = 2.8 Hz, 1H), 
6.03 (ddd, J = 15.8, 6.3, 6.3 Hz, 1H), 5.86 (d, J = 15.7 Hz, 1H), 5.66 (s, 1H), 5.39 (s, 1H), 
4.66 (d, J = 11.8 Hz, 1H), 4.62-4.53 (m, 3H), 4.45 (sept., J = 6.0 Hz, 1H), 4.07 (ddd, J = 
4.1, 4.1, 1.7 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 3.52 (dd, J = 5.2, 1.1 Hz, 2H), 2.12 (dd, J 
= 14.6, 5.4  Hz, 1H), 2.06 (s, 3H), 1.86 (d, J = 13.9 Hz, 1H), 1.54 (ddd, J = 15.9, 10.4, 4.5 
Hz, 1H), 1.31 (s, 3H), 1.29 (s, 3H), 1.27-1.05 (m, 3H), 0.88 (dd, J = 7.3, 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 170.8, 166.0, 154.3, 153.5, 148.8, 142.9, 141.0, 137.6, 131.3, 
131.2, 128.5, 127.9, 127.8, 125.2, 122.0, 121.6, 107.6, 100.7, 73.7, 73.1, 71.6, 71.2, 70.3, 
64.9, 60.9, 55.7, 41.4, 36.4, 33.0, 22.1, 21.0, 16.9, 14.5; IR (film) νmax 3613, 3541, 2962, 
1717, 1596, 1492, 1227, 1024 cm -1; HRMS (ESI) m/z calcd. for C36H46NaO9 [M+Na]+ 
645.3034, found 645.3037. 
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To a solution of 5.19 (30 mg, 0.0797 mmol, 1.0 eq) in CH2Cl2 (797 µL) at 
–78 °C was added vinylsulfonyl chloride (15 µL, 0.159 mmol, 2.0 eq) then 
DIPEA (53 µL, 0.319 mmol, 4.0 eq) and the reaction was stirred at –78 °C 
for 1.5 h. To the reaction was added saturated aqueous NH4Cl (10 mL), and at RT, the 
mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (30-
50% EtOAc/hexanes) yielded 5.51 as a clear oil (29 mg, 0.0622 mmol, 78%). 1H NMR 
(400 MHz, CDCl3): δ 6.64 (dd, J = 16.6, 9.8 Hz, 1H), 6.49 (s, 1H), 6.43 (dd, J = 4.2, 3.7 
Hz, 1H), 5.05 (ddd, J = 8.3, 3.3, 3.1 Hz, 1H), 4.90 (dd, J = 3.8, 3.7 Hz, 1H), 3.13 (s, 3H), 
2.46 (dd, J = 14.3, 8.5 Hz, 1H), 2.33 (dd, J = 14.4, 2.5 Hz, 1H), 2.17 (br. s, 1H), 1.67 
(ddd, J = 12.2, 12.2, 5.0 Hz, 1H), 1.54 (ddd, J = 11.7, 11.7, 5.0 Hz, 1H), 1.39-1.24 (m, 
2H), 0.96 (dd, J = 7.3, 7.3 Hz, 3H). 
 
To a solution of 5.42 (187 mg, 0.482 mmol, 1.0 eq) in CH2Cl2 (2.4 mL) 
and DMAP (2 mg, catalytic) at –78 °C was added DIPEA (119 µL, 0.722 
mmol, 1.5 eq) then vinyldiphenylchlorosilane (128 µL, 0.578 mmol, 1.2 
eq) dropwise, and the reaction was stirred at –78 °C for 10 min. To the mixture was 
added saturated aqueous NH4Cl (20 mL), and at RT, the mixture was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried (MgSO4), filtered, and 
concentrated. Purification by flash column chromatography (5-15% EtOAc/hexanes) 
provided 5.53 as a clear oil (241 mg, 0.404 mmol, 84%). [α]  +28.4 (c 1.19, CHCl3); 
1H 
NMR (400 MHz, CDCl3): δ 7.62 (dd, J = 8.0, 7.2 Hz, 5H), 7.51-7.44 (m, 2H), 7.43-7.36 
(m, 3H), 7.32-7.23 (m, 5H), 6.50 (dd, J = 20.2, 14.9 Hz, 1H), 6.40 (br. s, 1H), 6.33 (dd, J € 
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= 14.9, 3.7 Hz, 1H), 5.92 (dd, J = 20.2, 3.7 Hz, 1H), 4.83 (d, J = 11.9 Hz, 1H), 4.62 (d, J 
= 11.9 Hz, 1H), 4.40 (dd, J = 3.4, 2.2 Hz, 1H), 3.85 (dd, J = 4.3, 3.6 Hz, 1H), 3.82 (s, 
1H), 2.22 (dd, J = 14.5, 5.1 Hz, 1H), 1.83 (app. d, J = 14.0 Hz, 1H), 1.56-1.46 (m, 2H), 
1.16 (ddd, J = 14.8, 14.8, 7.3 Hz, 2H), 0.92 (dd, J = 7.4, 7.2 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ 140.2, 138.1, 137.9, 135.0, 133.1, 130.3, 128.4, 128.0 (2C), 127.8, 
127.7, 113.2, 75.7, 73.3, 73.1, 72.8, 44.7, 34.2, 16.9, 14.3; IR (film) νmax 3502, 3050, 
2958, 2871, 1428, 1114 cm -1; HRMS (ESI) m/z calcd. for C30H33INaO3Si [M+Na]+ 
619.1136, found 619.1152. 
 
To a solution of 5.44 (15 mg, 0.0231 mmol, 1.0 eq) in 
THF (417 µL) was added H2O (83 µL), K2CO3•1.5H2O 
(11 mg, 0.0692 mmol, 3.0 eq), 3.20 (4 mg, 0.0173 mmol, 
0.75 eq) and Pd(PPh3)4 (3 mg, 2.31 µmol, 0.1 eq) and the reaction mixture was heated via 
microwave irradiation at 50 °C for 30 min. The reaction was diluted with EtOAc (10 
mL), added to saturated aqueous NH4Cl (10 mL), and extracted with EtOAc (3 x 10 mL). 
The combined organic layers were dried (MgSO4), filtered, and concentrated. Purification 
by flash column chromatography (10-25% EtOAc/hexanes) provided 5.56 as a yellow oil 
(5.0 mg, 9.08 µmol, 39%). [α]  +51.8 (c 0.19, CHCl3); 
1H NMR (400 MHz, CDCl3): δ 
7.33-7.23 (m, 5H), 7.16 (ddd, J = 15.5, 6.7, 6.6 Hz, 1H), 6.41 (dd, J = 17.4, 11.0 Hz, 1H), 
6.40 (d, J = 2.5 Hz, 1H), 5.87 (d, J = 15.7 Hz, 1H), 5.66 (s, 1H), 5.47 (d, J = 16.5 Hz, 
1H), 5.40 (s, 1H), 5.09 (dd, J = 10.9, 1.0 Hz, 1H), 4.66 (d, J = 11.9 Hz, 1H), 4.57 (d, J = 
11.9 Hz, 1H), 4.45 (sept., J = 6.1 Hz, 1H), 4.07 (dd, J = 4.1, 3.8 Hz, 1H), 3.83 (s, 3H), 
3.74 (s, 3H), 3.55-3.49 (m, 3H), 2.12 (dd, J = 14.6, 5.2 Hz, 1H), 1.86 (d, J = 13.9 Hz, 
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1H), 1.35-1.07 (m, 4H), 1.31 (s, 3H), 1.29 (s, 3H), 0.87 (dd, J = 7.4, 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 166.0, 154.3, 153.5, 148.7, 144.3, 141.0, 137.7, 134.4, 131.3, 
128.5, 127.9, 127.8, 121.7, 120.9, 115.8, 107.6, 100.7, 73.8, 73.0, 71.7, 71.2, 70.3, 60.9, 
55.7, 41.4, 36.3, 33.0, 22.1, 16.9, 14.5; IR (film) νmax 3512, 2963, 2934, 1715, 1596, 
1492, 1151 cm -1; HRMS (ESI) m/z calcd. for C33H42NaO7 [M+Na]+ 573.2823, found 
573.2845. 
 
To a solution of 5.43 (287 mg, 0.649 mmol, 1.0 eq) in THF (10.8 mL) 
was added H2O (2.2 mL) then K2CO3•1.5H2O (322 mg, 1.95 mmol, 
3.0 eq), 4.41 (333 mg, 1.30 mmol, 2.0 eq) and Pd(PPh3)4 (75 mg, 
0.0649 mmol, 0.1 eq) and the reaction was heated via microwave irradiation at 50 °C for 
1 h. The reaction was diluted with CH2Cl2 (50 mL), added to 1 N aqueous HCl (50 mL) 
and extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (20-
80% EtOAc/hexanes) yielded 5.58 as an orange oil (114 mg, 0.306 mmol, 47%). [α]  
+76.6 (c 0.24, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.36-7.24 (m, 5H), 6.47 (dd, J = 
17.3, 0.7 Hz, 1H), 6.32 (d, J = 15.7 Hz, 1H), 6.18 (dd, J = 17.5, 10.4 Hz, 1H), 6.14 (ddd, 
J = 15.7, 5.8, 5.5 Hz, 1H), 5.90 (dd, J = 10.5, 0.7 Hz, 1H), 5.68 (s, 1H), 5.45 (s, 1H), 4.69 
(d, J = 11.9 Hz, 1H), 4.59 (d, J = 11.9 Hz, 1H), 4.23-4.15 (m, 2H), 4.11-4.05 (m, 1H), 
3.51 (s, 1H), 2.15 (dd, J = 14.4, 5.5 Hz, 1H), 1.89 (dd, J = 14.5, 1.4 Hz, 1H), 1.61-1.49 
(m, 2H), 1.21-1.08 (m, 2H), 0.88 (dd, J = 7.3, 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): 
δ 165.7, 143.4, 137.6, 131.6, 130.7, 128.5, 128.2, 128.1, 127.9, 127.8, 120.9, 73.6, 72.9, 
71.8, 71.4, 63.6, 41.4, 36.3, 24.8, 16.9, 14.5; IR (film) νmax 3415, 2963, 2873, 1720, 
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1406, 1195 cm -1; HRMS (ESI) m/z calcd. for C22H28NaO5 [M+Na]+ 395.1829, found 
395.1825. 
 
To a solution of 5.58 (13 mg, 0.0349 mmol, 1.0 eq) in CH2Cl2 (698 
µL) at 0 °C was added Ac2O (7 µL, 0.0698 mmol, 2.0 eq) and 
pyridine (6 µL, 0.0698 mmol, 2.0 eq) and the reaction was stirred at 
0 °C for 1 h. To the reaction was added saturated aqueous NH4Cl (10 mL) and the 
mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (10-
40% EtOAc/hexanes) provided 5.59 as a clear oil (10 mg, 0.0241 mmol, 69%). [α]  
+89.0 (c 0.38, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.36-7.27 (m, 5H), 6.47 (dd, J = 
17.3, 1.0 Hz, 1H), 6.36 (d, J = 15.7 Hz, 1H), 6.18 (dd, J = 17.3, 10.5 Hz, 1H), 6.05 (ddd, 
J = 15.8, 6.3, 6.1 Hz, 1H), 5.91 (dd, J = 10.4, 1.0 Hz, 1H), 5.69 (s, 1H), 5.44 (s, 1H), 4.69 
(d, J = 11.9 Hz, 1H), 4.63-4.56 (m, 3H), 4.10 (dd, J = 4.6, 2.3 Hz, 1H), 3.55 (br. s, 1H), 
2.15 (dd, J = 14.6, 5.3 Hz, 1H), 2.06 (s, 3H), 1.88 (dd, J = 14.7, 1.4 Hz, 1H), 1.63-1.48 
(m, 2H), 1.22-1.05 (m, 2H), 0.89 (dd, J = 7.3, 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): 
δ 170.8, 165.7, 143.1, 137.6, 131.6, 131.2, 128.5, 128.2, 128.0, 127.8, 125.3, 121.7, 73.6, 
73.1, 71.9, 71.3, 64.9, 41.5, 36.6, 21.0, 16.9, 14.4; IR (film) νmax 3507, 2959, 2873, 1729, 
1233, 1193 cm -1; HRMS (ESI) m/z calcd. for C24H30NaO6 [M+Na]+ 437.1935, found 
437.1927. 
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To a solution of 5.59 (8.0 mg, 0.0193 mmol, 1.0 eq) in toluene (1.0 mL) 
was added BHT (3 mg, catalytic) and the mixture was heated at 150 °C 
in a sealed tube for 96 h. At RT, the mixture was concentrated, and 
purification by flash column chromatography (10-50% EtOAc/hexanes) provided 5.60 as 
a light yellow oil (3.0 mg, 7.24 µmol, 38%). [α]  +18.5 (c 0.07, CHCl3); 
1H NMR (600 
MHz, CDCl3): δ 7.37-7.23 (m, 5H), 5.68 (dd, J = 2.5, 2.5 Hz, 1H), 4.64 (d, J = 11.8 Hz, 
1H), 4.62 (d, J = 11.7 Hz, 1H), 4.41 (dd, J = 9.1, 3.1 Hz, 1H), 4.20 (ddd, J = 4.4, 4.4, 2.0 
Hz, 1H), 4.01 (dd, J = 10.8, 5.8 Hz, 1H), 3.94 (dd, J = 10.8, 7.2 Hz, 1H), 2.86-2.80 (m, 
1H), 2.80 (dd, J = 12.7, 4.4 Hz, 1H), 2.72 (dddd, J = 12.9, 11.7, 2.5, 2.5 Hz, 1H), 2.45 
(br. s, 1H), 2.25 (dd, J = 15.6, 4.6 Hz, 1H), 1.96 (ddd, J = 13.3, 4.4, 2.0 Hz, 1H), 1.94 (s, 
3H), 1.84 (ddd, J = 12.8, 12.8, 9.3 Hz, 1H), 1.72 (dd, J = 15.6, 1.7 Hz, 1H), 1.60-1.52 (m, 
2H), 1.37-1.23 (m, 2H), 0.91 (dd, J = 7.3, 7.2 Hz, 3H); 13C NMR (150 MHz, CDCl3): δ 
176.2, 171.1, 148.4, 137.4, 128.7, 128.1, 127.5, 123.5, 78.2, 75.1, 73.2, 72.2, 67.4, 46.0, 
43.2, 40.4, 39.4, 35.3, 24.6, 20.8, 17.4, 14.3; IR (film) νmax 3403, 2956, 1780, 1737, 
1244, 1090 cm -1; HRMS (ESI) m/z calcd. for C24H30NaO6 [M+Na]+ 437.1935, found 
437.1911. 
 
To a solution of 5.6 (736 mg, 2.34 mmol, 1.1 eq, dried by 
azeotropic removal of H2O with benzene 2x and on high-vac 
overnight) in THF (5.3 mL, dried over activated 4 Å MS 
overnight) at –78 °C was added n-BuLi (2.5 M in hexanes, 1.04 mL, 2.55 mmol, 1.2 eq) 
dropwise and the yellow mixture was stirred at –78 °C for 30 min. To the mixture at –78 
°C was added a solution of 4.62 (719 mg, 2.12 mmol, 1.0 eq, dried by azeotropic removal 
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of H2O with benzene 2x and on high-vac for 2 h) in THF (5.3 mL, dried over activated 4 
Å MS overnight) via cannula and the reaction was stirred at –78 °C for 30 min and at      
0 °C for 1.5 h. To the reaction was added saturated aqueous NH4Cl (40 mL) and the 
mixture was extracted with CH2Cl2 (3 x 40 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (10-
40% EtOAc/hexanes) provided 5.63 as an inseparable mixture of diastereomers as a 
yellow oil (992 mg, 1.73 mmol, 81%). The material was taken forward without 
characterization. 
 
To a solution of 5.63 (992 mg, 1.73 mmol, 1.0 eq) in CH2Cl2 (35 mL) was added MnO2 
(3.00 g, 34.5 mmol, 20 eq) and the black slurry was stirred at RT for 6 h. The reaction 
was diluted with CH2Cl2 (50 mL) and filtered through a plug of Celite with CH2Cl2 
washes. The filtrate was concentrated, and purification by flash column chromatography 
(10-30% EtOAc/hexanes) provided 5.64 as a yellow oil (860 mg, 1.50 mmol. 87%). [α]  
+73.9 (c 0.22, CDCl3); 1H NMR (400 MHz, C6D6): δ 7.39 (d, J = 16.2 Hz, 1H), 7.09 (d, J 
= 16.2 Hz, 1H), 6.26 (s, 1H), 6.15 (dddd, J = 17.0, 10.1, 6.4, 6.4 Hz, 1H), 6.00 (d, J = 3.9 
Hz, 1H), 5.18 (ddd, J = 17.0, 3.3, 1.5 Hz, 1H), 5.01 (ddd, J = 10.0, 1.8, 1.2 Hz, 1H), 4.17-
4.08 (m, 2H), 4.05 (sept., J = 5.6 Hz, 1H), 3.77-3.64 (m, 2H), 3.71 (s, 3H), 3.34 (s, 3H), 
2.27 (dd, J = 11.8, 5.5 Hz, 1H), 1.97 (dd, J = 11.5, 11.4 Hz, 1H), 1.57 (ddd, J = 12.8, 
12.8, 4.1 Hz, 1H), 1.49 (s, 3H), 1.46-1.32 (m, 2H), 1.32-1.24 (m, 1H), 1.29 (s, 3H), 1.11 
(d, J = 6.1 Hz, 3H), 1.08 (d, J = 6.1 Hz, 3H), 0.81 (dd, J = 7.3, 7.3 Hz, 3H), 0.12 (s, 9H); 
13C NMR (150 MHz, C6D6): δ 195.9, 154.3, 152.1, 147.2, 142.8, 141.6, 137.6, 133.1, 
132.0, 125.3, 115.8, 109.5, 99.9, 77.1, 72.4, 72.3, 71.4, 60.6, 55.6, 43.5, 40.0, 31.8, 28.5, 
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25.9, 22.3, 22.2, 17.2, 14.6, 2.1; IR (film) νmax 2962, 2874, 2279, 1653, 1593, 1323, 1255 
cm -1; HRMS (ESI) m/z calcd. for C32H49O7Si [M+H]+ 573.3242, found 573.3266. 
 
To a solution of 5.64 (26 mg, 0.0454 mmol, 1.0 eq) in CH2Cl2 
(454 µL) was added acrolein diethyl acetal (5.65, 173 µL, 1.13 
mmol, 25 eq) and Hoveyda-Grubbs second generation catalyst 
(3.0 mg, 4.54 µmol, 0.1 eq) and the reaction was heated via 
microwave irradiation at 50 °C for 1 h. The reaction mixture was concentrated, and 
purification by flash column chromatography (10-40% EtOAc/hexanes) yielded 5.66 as a 
yellow oil (11 mg, 0.0163 mmol, 36%). [α]  +51.0 (c 0.78, CDCl3); 
1H NMR (400 
MHz, C6D6): δ 7.40 (d, J = 16.2 Hz, 1H), 7.08 (d, J = 16.2 Hz, 1H), 6.28 (ddd, J = 15.9, 
7.1, 6.6 Hz, 1H), 6.24 (s, 1H), 6.02 (d, J = 3.8 Hz, 1H), 5.83 (dd, J = 15.6, 5.0 Hz, 1H), 
4.92 (d, J = 5.0 Hz, 1H), 4.17 (dd, J = 6.4, 4.0 Hz, 1H), 4.15-4.03 (m, 2H), 3.75 (s, 3H), 
3.71-3.55 (m, 4H), 3.41 (ddd, J = 16.4, 7.1, 1.5 Hz, 2H), 3.32 (s, 3H), 2.27 (dd, J = 11.8, 
5.4 Hz, 1H), 1.96 (dd, J = 11.4, 11.4 Hz, 1H), 1.56 (ddd, J = 12.9, 12.9, 4.4 Hz, 1H), 1.49 
(s, 3H), 1.45-1.35 (m, 2H), 1.28 (s, 6H), 1.23-1.16 (m, 1H), 1.15-1.04 (m, 9H), 0.82 (dd, 
J = 7.3, 7.2 Hz, 3H), 0.13 (s, 9H); 13C NMR (100 MHz, C6D6): δ 195.8, 154.3, 152.0, 
147.0, 143.0, 141.6, 133.0, 132.9, 131.9, 129.9, 125.5, 125.2, 109.5, 101.6, 100.1, 77.1, 
72.5, 72.3, 71.5, 60.6, 60.5, 55.5, 43.6, 40.2, 30.6, 28.5, 25.8, 22.2, 17.2, 15.6, 14.6, 2.2; 
IR (film) νmax 2970, 2935, 2874, 1653, 1594, 1254, 1050 cm -1; HRMS (ESI) m/z calcd. 
for C37H58NaO9Si [M+Na]+ 697.3742, found 697.3773. 
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From the above reaction, 5.67 was formed (7 mg, 0.0267 mmol, 59%). 1H 
NMR (400 MHz, CDCl3): δ 9.64 (s, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.33 
(dd, J = 8.0, 8.0 Hz, 1H), 6.73 (d, J = 7.6 Hz, 1H), 6.64 (s, 1H), 4.81 (sept., J = 6.1 Hz, 
1H), 3.97 (s, 3H), 3.90 (s, 3H), 1.51 (s, 3H), 1.50 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
154.9, 150.8, 147.9, 137.8, 131.7, 128.0, 112.2 (2C), 108.4, 98.1, 73.5, 61.0, 57.3, 22.0; 
IR (film) νmax 3370, 2978, 2935, 1611, 1387, 1108 cm -1; HRMS (ESI) m/z calcd. for 
C15H19O4 [M+H]+ 263.1278, found 263.1256. 
 
To a solution of 5.66 (10 mg, 0.0148 mmol, 1.0 eq) in CH2Cl2 
(500 µL) at –78 °C was added BF3•OEt2 (9 µL, 0.0741 mmol, 
5.0 eq) and the reaction was stirred at –78 °C for 45 min. To the 
reaction was added saturated aqueous NaHCO3 (5 mL) and the 
mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (20-
50% EtOAc/hexanes) provided 5.71 as a yellow oil (4.0 mg, 6.66 µmol, 45%). [α]  +2.1 
(c 0.23, CDCl3); 1H NMR (400 MHz, CDCl3): δ 9.43 (d, J = 7.9 Hz, 1H), 7.00 (d, J = 
16.1 Hz, 1H), 6.89 (ddd, J = 15.6, 6.6, 6.4 Hz, 1H), 6.85 (d, J = 16.0 Hz, 1H), 6.46 (s, 
1H), 6.09 (d, J = 3.8 Hz, 1H), 6.02 (dd, J = 15.5, 7.9 Hz, 1H), 4.53 (dd, J = 6.6, 3.9 Hz, 
1H), 4.42 (sept., J = 6.1 Hz, 1H), 4.29 (ddd, J = 12.0, 12.0, 6.0 Hz, 1H), 3.88 (s, 3H), 
3.76 (s, 3H), 3.57 (ddd, J = 15.5, 7.8, 1.1 Hz, 1H), 3.50 (ddd, J = 15.6, 6.3, 1.3 Hz, 1H), 
2.24 (dd, J = 11.9, 5.5 Hz, 1H), 1.74 (dd, J = 11.7, 11.4 Hz, 1H), 1.47 (s, 3H), 1.42-1.31 
(m, 2H), 1.37 (s, 3H), 1.30-1.18 (m, 2H), 0.87 (dd, J = 7.1, 7.1 Hz, 3H), 0.02 (s, 9H); 13C 
NMR (150 MHz, CDCl3): δ 196.7, 193.9, 156.5, 154.0, 152.0, 147.2, 143.1, 141.6, 133.4, 
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131.0, 129.5, 125.8, 123.5, 109.6, 99.1, 72.1, 72.0, 71.0, 60.9, 55.9, 43.1, 39.3, 30.7, 29.7, 
28.0, 25.6, 22.2, 16.8, 14.3, 2.0; IR (film) νmax 3386, 2931, 1690, 1593, 1453, 1250, 1048 
cm -1; HRMS (ESI) m/z calcd. for C33H48NaO8Si [M+Na]+ 623.3011, found 623.3023. 
 
To 5.64 (41 mg, 0.0716 mmol, 1.0 eq) at RT was added t-butyl 
acrylate (5.76, 524 µL, 3.58 mmol, 50 eq) then Hoveyda-
Grubbs second generation catalyst (7.16 µmol, 0.1 eq) and the 
reaction was stirred at RT for 5 h. The reaction was loaded 
directly onto a silica gel column, and purification by flash column chromatography (10-
30% EtOAc/hexanes) yielded 5.77 as a yellow oil (31 mg, 0.0461 mmol, 64%). [α]  
+50.0 (c 0.45, CDCl3); 1H NMR (400 MHz, C6D6): δ 7.39 (d, J = 16.4 Hz, 1H), 7.32 
(ddd, J = 15.6, 6.5, 6.5 Hz, 1H), 7.09 (d, J = 16.1 Hz, 1H), 6.22 (s, 1H), 6.05-5.97 (m, 
2H), 4.20 (dd, J = 6.3, 4.0 Hz, 1H), 4.13-4.03 (m, 2H), 3.67-3.58 (m, 2H), 3.63 (s, 3H), 
3.28 (s, 3H), 2.29 (dd, J = 11.8, 5.4 Hz, 1H), 1.97 (dd, J = 11.5, 11.4 Hz, 1H), 1.69-1.54 
(m, 2H), 1.49 (s, 3H), 1.37 (s, 9H), 1.32-1.13 (m, 2H), 1.29 (s, 3H), 1.09 (d, J = 6.0 Hz, 
3H), 1.06 (d, J = 6.1 Hz, 3H), 0.85 (dd, J = 7.3, 7.2 Hz, 3H), 0.15 (s, 9H); 13C NMR (100 
MHz, C6D6): δ 195.4, 165.7, 154.3, 152.2, 147.2, 146.1, 142.9, 141.9, 131.8, 131.3, 
125.7, 125.5, 124.6, 109.5, 100.4, 79.4, 77.1, 72.6, 72.3, 71.5, 60.5, 55.5, 43.5, 40.1, 30.2, 
28.5, 28.2 (2C), 25.8, 22.2, 17.3, 14.6, 2.2; IR (film) νmax 2964, 1712, 1653, 1593, 1453, 
1254, 1150 cm -1; HRMS (ESI) m/z calcd. for C37H57O9Si [M+H]+ 673.3766, found 
673.3758. 
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To a solution of 5.77 (12 mg, 0.0178 mmol, 1.0 eq) in THF 
(400 µL) at 0 °C was added H2O (100 µL) then TFA (27 µL, 
0.357 mmol, 20 eq) and the reaction was stirred at 0 °C for 15 
min and at RT for 48 h. To the reaction was added EtOAc (10 
mL) and the mixture was washed with saturated aqueous NaHCO3 (2 x 10 mL). The 
combined aqueous layers were extracted with EtOAc (2 x 10 mL), and the combined 
organic layers were washed with saturated aqueous NH4Cl (1 x 10 mL), then dried 
(MgSO4), filtered, and concentrated. Purification by flash column chromatography (40-
100% EtOAc/hexanes) provided 5.78 as a yellow oil (6.0 mg, 0.0107 mmol, 60%). [α]  
+24.0 (c 0.30, CDCl3); 1H NMR (600 MHz, CDCl3): δ 7.01 (d, J = 16.0 Hz, 1H), 6.84 
(ddd, J = 15.6, 6.7, 6.7 Hz, 1H), 6.76 (d, J = 16.0 Hz, 1H), 6.43 (s, 1H), 5.88 (s, 1H), 5.57 
(d, J = 15.4 Hz, 1H), 4.42 (sept., J = 6.1 Hz, 1H), 4.20 (br. m, 1H), 4.14 (br. m, 1H), 3.88 
(s, 3H), 3.77 (s, 3H), 3.71 (s, 1H), 3.62 (br. s, 1H), 3.44 (ddd, J = 15.4, 6.5, 1.5 Hz, 1H), 
3.37 (ddd, J = 15.2, 7.1, 0.9 Hz, 1H), 3.06 (br. s, 1H), 2.13 (dd, J = 14.8, 5.0 Hz, 1H), 
1.81 (dd, J = 14.7, 1.5 Hz, 1H), 1.61-1.53 (m, 2H), 1.46-1.35 (m, 2H), 1.42 (s, 9H), 1.26 
(d, J = 6.1 Hz, 3H), 1.24 (d, J = 6.2 Hz, 3H), 0.87 (dd, J = 7.3, 7.2 Hz, 3H); 13C NMR 
(150 MHz, CDCl3): δ 196.7, 166.5, 153.9, 151.7, 145.8, 144.5, 141.5, 141.3, 131.2, 
131.0, 130.0, 124.0, 123.5, 98.8, 80.6, 71.8, 71.1, 69.0, 67.9, 60.9, 55.8, 42.1, 37.3, 29.8, 
28.1, 22.2, 22.0, 17.1, 14.4; IR (film) νmax 3424, 2930, 1710, 1652, 1592, 1324, 1152 cm -
1; HRMS (ESI) m/z calcd. for C31H44NaO9 [M+Na]+ 583.2878, found 583.2886. 
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To 5.64 (149 mg, 0.260 mmol, 1.0 eq) was added methl acrylate 
(5.80, 1.17 mL, 13.0 mmol, 50 eq) and Hoveyda-Grubbs second 
generation catalyst (16 mg, 0.0260 mmol, 0.1 eq) and the 
reaction was stirred at RT for 22 h. The reaction mixture was 
added directly to silica gel column, and purification by flash column chromatography 
(10-40% EtOAc/hexanes) provided 5.81 as a yellow oil (129 mg, 0.204 mmol, 79%). [α]
 +52.7 (c 0.61, CDCl3); 
1H NMR (400 MHz, CDCl3): δ 6.98 (ddd, J = 15.8, 7.0, 6.0 Hz, 
2H), 6.82 (d, J = 16.2 Hz, 1H), 6.43 (s, 1H), 6.07 (d, J = 3.8 Hz, 1H), 5.69 (d, J = 15.7 
Hz, 1H), 4.51 (dd, J = 6.5, 3.9 Hz, 1H), 4.40 (sept., J = 6.1 Hz, 1H), 4.28 (ddd, J = 11.6, 
11.6, 5.9 Hz, 1H), 3.87 (s, 3H), 3.75 (s, 3H), 3.63 (s, 3H), 3.42 (d, J = 6.4 Hz, 2H), 2.23 
(dd, J = 11.8, 5.6 Hz, 1H), 1.73 (dd, J = 11.6, 11.4 Hz, 1H), 1.54 (ddd, J = 13.1, 13.1, 4.8 
Hz, 1H), 1.46 (s, 3H), 1.36 (s, 3H), 1.34-1.25 (m, 3H), 1.25 (d, J = 6.0 Hz, 3H), 1.23 (d, J 
= 6.0 Hz, 3H), 0.86 (dd, J = 7.5, 7.1 Hz, 3H), 0.01 (s, 9H); 13C NMR (100 MHz, CDCl3): 
δ 196.7, 166.8, 153.9, 151.8, 147.3, 147.1, 143.0, 141.6, 131.2, 130.0, 125.6, 123.7, 
121.8, 109.5, 99.0, 76.6, 72.0 (2C), 71.0, 60.9, 55.9, 51.2, 43.1, 39.3, 29.9, 28.0, 25.6, 
22.1 (2C), 16.8, 14.3, 1.9; IR (film) νmax 2960, 2874, 1724, 1654, 1594, 1452, 1267, 1048 
cm -1; HRMS (ESI) m/z calcd. for C34H51O9Si [M+H]+ 631.3297, found 631.3270. 
 
To 5.81 (116 mg, 0.184 mmol, 1.0 eq) at RT was added H2O 
(2.8 mL) then AcOH (6.4 mL) and the mixture was stirred at 
RT for 22 h. The mixture was diluted with EtOAc (30 mL) and 
carefully washed with saturated aqueous NaHCO3 (3 x 25 mL). 
The combined aqueous layers were extracted with EtOAc (1 x 25 mL), and the combined 
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organic layers were dried (MgSO4), filtered, and concentrated. The material was taken 
forward crude except for characterization purposes, for which purification by flash 
column chromatography (60-100% EtOAc/hexanes) provided 5.82 as a yellow oil. [α]  
+77.0 (c 1.19, CDCl3); 1H NMR (400 MHz, CDCl3): δ 6.99 (d, J = 16.3 Hz, 1H), 6.95 
(ddd, J = 15.6, 6.6, 6.4 Hz, 1H), 6.74 (d, J = 16.0 Hz, 1H), 6.43 (s, 1H), 5.84 (s, 1H), 5.65 
(ddd, J = 15.6, 1.5, 1.3 Hz, 1H), 4.41 (sept., J = 6.1 Hz, 1H), 4.18 (br. m, 1H), 4.12 (br. 
m, 1H), 3.87 (s, 3H), 3.75 (s, 3H), 3.63 (s, 3H), 3.47 (ddd, J = 15.6, 6.3, 1.6 Hz, 1H), 3.39 
(ddd, J = 15.5, 6.8, 1.4 Hz, 1H), 3.21 (br. s, 1H), 2.10 (dd, J = 14.7, 5.0 Hz, 1H), 1.79 
(dd, J = 14.7, 1.5 Hz, 1H), 1.58-1.50 (m, 2H), 1.24 (d, J = 6.1 Hz, 3H), 1.23 (d, J = 6.1 
Hz, 3H), 1.19-1.03 (m, 2H), 0.84 (dd, J = 7.3, 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): 
δ 196.7, 167.4, 153.9, 151.8, 147.5, 144.3, 141.4, 141.2, 131.2, 130.9, 129.8, 123.5, 
121.8, 98.9, 71.8, 71.1, 69.0, 67.9, 60.9, 55.8, 51.5, 41.9, 37.4, 29.8, 22.2, 22.0, 17.0, 
14.4; IR (film) νmax 3425, 2961, 1719, 1652, 1593, 1451, 1274 cm -1; HRMS (ESI) m/z 
calcd. for C28H38NaO9 [M+Na]+ 541.2408, found 541.2403. 
 
To a solution of 5.82 (95 mg crude, 0.184 mmol, 1.0 eq) in THF 
(6.9 mL) at 4 °C was added a solution of LiOH (44 mg, 1.84 
mmol, 10 eq) in H2O (2.3 mL) and the reaction was stirred at 4 
°C for 22 h. The reaction was added directly to a silica gel 
column, and purification by flash column chromatography (5-15% MeOH/CH2Cl2) 
yielded 5.83 as a brown oil (53 mg, 0.105 mmol, 57% two steps). IR (film) νmax 3411, 
2934, 2250, 1703, 1652, 1592, 1323, 1235, 1113 cm -1; HRMS (ESI) m/z calcd. for 
C27H37O9 [M+H]+ 505.2432, found 505.2447. 
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Figure A3.1. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.3. 
OiPr
MeO
O5.3
 378 
 
 
Figure A3.2. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.4. 
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Figure A3.3. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.5. 
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Figure A3.4. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 5.6. 
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Figure A3.5. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.10. 
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Figure A3.6. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.12. 
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Figure A3.7. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.13. 
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Figure A3.8. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 5.15. 
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Figure A3.9. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.17. 
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Figure A3.10. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (125 MHz, CDCl3) of 
compound 5.18. 
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Figure A3.11. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.19. 
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Figure A3.12. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.24. 
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Figure A3.13. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.26. 
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Figure A3.14. 1H NMR spectrum (400 MHz, CDCl3) of compound 5.27. 
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Figure A3.15. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 5.28. 
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Figure A3.16. COSY spectrum (600 MHz, CDCl3) and NOESY spectrum (600 MHz, CDCl3) of compound 
5.28. 
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Figure A3.17. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.30. 
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Figure A3.18. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.36. 
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Figure A3.19. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.37. 
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Figure A3.20. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.38. 
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Figure A3.21. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.39. 
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Figure A3.22. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.41. 
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Figure A3.23. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.42. 
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Figure A3.24. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.43. 
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Figure A3.25. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 5.44. 
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Figure A3.26. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.45. 
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Figure A3.27. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.46. 
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Figure A3.28. 1H NMR spectrum (400 MHz, CDCl3) of compound 5.51. 
 
 
 
 
 
 
 
 
 
 
 
O
OMs
I
OH
S
O O
5.51
 405 
 
 
Figure A3.29. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.53. 
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Figure A3.30. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.56. 
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Figure A3.31. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.58. 
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Figure A3.32. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.59. 
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Figure A3.33. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 5.60. 
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Figure A3.34. COSY spectrum (600 MHz, CDCl3) and NOESY spectrum (600 MHz, CDCl3) of compound 
5.60. 
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Figure A3.35. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (150 MHz, C6D6) of 
compound 5.64. 
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Figure A3.36. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (100 MHz, C6D6) of 
compound 5.66. 
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Figure A3.37. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.67. 
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Figure A3.38. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 5.71. 
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Figure A3.39. 1H NMR spectrum (400 MHz, C6D6) and 13C NMR spectrum (100 MHz, C6D6) of 
compound 5.77. 
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Figure A3.40. 1H NMR spectrum (600 MHz, CDCl3) and 13C NMR spectrum (150 MHz, CDCl3) of 
compound 5.78. 
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Figure A3.41. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.81. 
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Figure A3.42. 1H NMR spectrum (400 MHz, CDCl3) and 13C NMR spectrum (100 MHz, CDCl3) of 
compound 5.82. 
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